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ABSTRACT 
Kevin M. Watt: Physiologically-based Pharmacokinetics in Critically Ill Children 
(Under the direction of Kim L.R. Brouwer) 
 
Extracorporeal membrane oxygenation (ECMO) is used to support 
cardiorespiratory failure in critically ill infants, children, and adults. In these 
vulnerable populations, the effect of ECMO on drug disposition leaves clinicians with 
uncertainty about dosing. The goal of this dissertation research was to develop a 
physiologically-based pharmacokinetic (PBPK) modeling approach that translated 
results from ex vivo ECMO studies to bedside dosing recommendations. To 
determine optimal dosing, the impact of the ECMO circuit on antifungal disposition 
was first assessed in isolation through ex vivo studies of three antifungal drugs.  
These experiments showed variable degrees of extraction by the ECMO circuit with 
micafungin highly extracted and fluconazole and amphotericin B deoxycholate with 
limited extraction. These results were then used to parameterize drug-specific 
ECMO compartments in the PBPK models. Model building followed an established 
workflow whereby a PBPK model was developed in adults and scaled to children. 
Once the Pediatric PBPK Model met acceptance criteria, an ECMO compartment 
was added to the Pediatric PBPK Model to form the ECMO PBPK Model. The 
fluconazole ECMO PBPK Model over-predicted exposure (1.13 fold error) but was 
within the pre-specified acceptance criteria of 0.7-1.3 fold error. PBPK-predicted 
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dosing recommendations showed good agreement with recommendations based on 
the Fluconazole ECMO PK Trial. The micafungin ECMO PBPK Model also over-
predicted exposure (1.16 fold error), but, again, dosing recommendations were in 
close agreement with recommendations determined from the trial. The two clinical 
PK trials of fluconazole and micafungin in children on ECMO were performed in 
parallel with the PBPK model building. Both the Fluconazole and Micafungin ECMO 
PK Trials showed that exposure was significantly lower in children on ECMO 
compared to children not on ECMO. Although determining optimal dosing for these 
two commonly used drugs in children on ECMO was important, more importantly, 
the PBPK modeling developed in this dissertation demonstrated the utility of this 
approach to understand and quantify the physiologic alterations driving drug 
disposition in critically ill children. A more precise, refined, integrated approach for 
drug dosing in this pediatric sub-population will improve both the safety and efficacy 
of drug therapy in children supported with ECMO.  
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CHAPTER 1. INTRODUCTION: ALTERED PHARMACOKINETICS DUE TO 
EXTRACORPOREAL LIFE SUPPORT 
Extracorporeal membrane oxygenation (ECMO) is life-saving in patients with 
cardiorespiratory failure. ECMO is a cardiopulmonary bypass device that provides 
complete respiratory and cardiac support (Figure 1.1). Mechanically, blood is drained 
from the venous system, pumped through an artificial lung membrane, and then 
returned to either the venous or arterial circulation. ECMO was first used successfully in 
1972 to support an adult with respiratory failure and three years later was used 
successfully in an infant.1,2 Early controlled studies showed a clear mortality benefit in 
infants with respiratory failure, and ECMO is now standard of care in this population.3-5 
However, early trials of ECMO in adults showed no survival benefit over standard of 
care, and use in adults was limited until 2009.6,7 In 2009, ECMO was used successfully 
as rescue therapy for adults with H1N1 influenza.8,9 Multiple observational studies 
showed improved survival associated with ECMO support, and adult ECMO programs 
were scaled up worldwide.10-16 While pediatric ECMO support has remained steady with 
~2000 cases per year, ECMO use in adults has increased from <500 cases in 2008 to 
nearly 3000 cases in 2014.17 
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The ECMO Circuit 
ECMO support comes in two forms: veno-venous (VV) and veno-arterial (VA). 
VV ECMO provides pulmonary support and VA ECMO provides both pulmonary and 
cardiac support. In VV ECMO, deoxygenated blood is drained from the venous system, 
pumped through the oxygenator where oxygen is added and carbon dioxide removed, 
and then returned to the venous system. From the venous circulation, this oxygenated 
blood then drains into the heart where native cardiac function distributes it to the arterial 
circulation. In VA ECMO, deoxygenated blood is also drained from the venous system 
and pumped through the oxygenator but returned to the arterial circulation, completely 
bypassing the heart and lungs. Oxygenated blood is distributed to the arterial circulation 
via non-pulsatile flow by the ECMO pump. 
Regardless of whether the ECMO circuit is configured for VV or VA ECMO, the 
components are the same: tubing, pump, and oxygenator. In some cases a hemofilter is 
added to function as an artificial kidney. Most of the tubing used in ECMO circuits is 
polyvinylchloride (PVC). However, when blood comes into contact with an extrinsic 
surface such as PVC, various cellular mechanisms are activated that trigger clotting and 
inflammatory cascades.18,19 To limit these interactions, different coatings have been 
applied to ECMO tubing, hemofilters, and oxygenators.20-22 The Maquet Quadrox iD 
Oxygenator® used in the experiments in this dissertation has a proprietary coating 
(Bioline®) consisting of albumin adsorbed to the PVC and covered by covalently bound 
heparin.  
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ECMO oxygenators employ a gas-permeable membrane with a countercurrent 
gas mixture (sweep gas) flowing on one side of the membrane and the patient’s blood 
on the other.23 Gas diffuses down a concentration gradient with oxygen crossing the 
membrane into the blood and carbon dioxide diffusing from blood into the sweep gas. 
Early oxygenators had a silicone membrane, but high resistance to permeating gases 
necessitated a large surface area to ensure adequate oxygenation and ventilation. To 
enhance gas transfer, microporous hollow-fiber membranes were developed.  However, 
these membranes were plagued by plasma leakage across the membrane that resulted 
in an oxygenator lifespan of 2-3 days. Oxygenators in use today employ a non-
microporous, hollow-fiber, polymethylpentane membrane. These devices are low 
resistance, require much smaller surface area, do not suffer from plasma leakage, and 
have a lifespan measured in weeks. The type and amount of material to which the blood 
is exposed can have a substantial impact on drug interaction with the ECMO circuit. 
 
Pharmacokinetic changes during ECMO support 
While ECMO allows for the survival of a very critically ill subset of patients, it also 
presents new challenges related to their management. One of these challenges is 
understanding and appropriately compensating for the effect of ECMO on drug 
pharmacokinetics (PK). This topic has been studied since the late 1980’s in neonates 
and isolated ex vivo ECMO circuits, and more recently, data from older children and 
adults have been published. In general, ECMO has been shown to impact PK in three 
primary ways, as discussed below. 
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Direct extraction by the circuit 
Drug extraction by the ECMO circuit is a well-recognized contributor to PK 
alterations across all patient populations that depends on both the circuit component 
materials and the drug physicochemical properties. The interaction between the drug 
and the ECMO circuit has been studied primarily in ex vivo experiments in which drug is 
administered to isolated ECMO circuits.24-33 Because there is no human attached to the 
circuit, any change in concentration over time is due to extraction by the circuit or drug 
degradation. In general, ex vivo studies have demonstrated increased extraction of 
highly lipophilic and protein bound drugs.28,31,32  
However, the degree of extraction, even for the same drug, can be markedly 
affected by circuit materials. A study of fentanyl (LogP 4, protein binding 80%) in an 
ECMO circuit using a silicone membrane oxygenator showed >99% fentanyl loss in 180 
minutes.28 When the same experiment was repeated in a microporous, hollow-fiber 
polypropylene oxygenator, fentanyl loss was only 66% at 180 minutes.28 Another study 
compared the effect of six different coatings on drug extraction by the PVC tubing by 
administering fentanyl to circuits constructed with only a pump and tubing (no 
oxygenator).34,35 In the uncoated circuit, fentanyl loss at 120 minutes was 80%.34 In the 
coated tubing, fentanyl loss at 120 minutes ranged from 40-75%.35 
Drug extraction by the circuit is likely due to non-specific adsorption,33-37 
Adsorption is a function of 1) interactions between the drug and the material surface, 2) 
the maximal amount of binding per unit of surface area, and 3) the affinity of the drug for 
the surface. The process of adsorption is driven primarily by electrostatic and 
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hydrophobic interactions. Interactions with polymers such as those used in ECMO 
circuit equipment tend to be due to hydrophobic adsorption (i.e., hydrophobic drugs 
adsorb to hydrophobic alkyl groups on polymers). Electrostatic interactions tend to 
dominate when surface coatings are applied to ECMO circuit components. As noted 
above, surface coatings are applied to ECMO circuit components to minimize the 
inflammatory response triggered when blood comes into contact with a foreign 
material,20-22 but coatings also can change the nature of interaction between the drug 
and material surface. When the drug and surface are oppositely charged, the degree of 
ionization driven by blood pH and drug pKa can influence the degree of adsorption. 
The extent and irreversibility of adsorption depend on the number of binding sites 
on the material surface and the affinity of the drug for the surface. In the ECMO system 
data are conflicting as to whether binding is saturable.  Two ex vivo studies have 
attempted to answer this question by comparing extraction in freshly primed circuits 
versus circuits that were used clinically and exposed to multiple drugs during their 
clinical use. Dagan et al. showed that morphine extraction in the freshly primed circuit 
was 36% after four hours but only 16% in a circuit that had been in clinical use for five 
days.25 In contrast, Wildschut et al. showed no significant difference in morphine 
extraction at three hours between fresh and used circuits (76% vs 70%, respectively).28 
The higher absolute extraction of morphine in Wildschut et al. was likely due to 
differences in equipment and flow rates. While both studies used uncoated tubing with 
silicone membrane oxygenators, the oxygenators used by Wildschut et al. had twice the 
surface area of the oxygenators used by Dagan et al.28,38 In addition, the blood flow rate 
was 10% higher in the Wildschut et al. study. The discrepancy in saturation between the 
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two studies is less clear, but may be related to one of three factors: 1) the dose of 
morphine administered to the circuit; 2) other drugs administered with morphine during 
the experiment, or 3) drugs administered to the used circuit while it was in use clinically.  
Dagan et al dosed morphine to achieve a concentration of 0.008 mg/L while Wildschut 
et al achieved an initial concentration over 200x higher (~1.7 mg/L). It is possible that 
the higher dose in the Wildschut et al study saturated binding sites for the new circuit as 
well as the old circuit. Secondly, both sets of experiments were designed to measure 
extraction of multiple drugs in a single circuit. The co-administered drugs were different 
between studies, and it is possible that co-administered drugs confounded the results 
by competing for binding sites. Finally, the drugs that were administered to the 
patient/circuit prior to the ex vivo experiment were neither controlled nor reported, and 
differences in clinical drug administration between the two studies could impact 
morphine extraction.  More work is needed to determine if drug extraction by the ECMO 
circuit is saturable. Further, it is unknown whether extraction is reversible. While the 
volume of distribution (V) may be increased as drug is extracted, clearance (CL) may be 
decreased if drug is slowly released back into the systemic circulation. 
 
Increased volume of distribution 
ECMO support can increase V via multiple mechanisms: 1) drug extraction via 
direct interaction with the circuit as mentioned above; 2) hemodilution; and 3) 
physiologic changes related to ECMO support and critical illness. Hemodilution occurs 
due to the large volume of exogenous blood required to prime the circuit, frequent 
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transfusions of blood products, and administration of crystalloid to maintain circuit flows. 
Hemodilution has the largest effect on drugs whose distribution is limited to the plasma 
compartment (i.e. low V drugs). Drugs with a large V may be less impacted because 
drug extracted by the circuit may be replaced by drug stored in the tissue. The impact of 
hemodilution is likely inversely related to age. For a 3kg infant, the circuit prime volume 
(250-400mL) might exceed the infant’s native blood volume (~250mL), while in a 70kg 
adolescent, the prime volume is ~8% of the child’s blood volume (~5L). Ongoing 
hemolysis and the need to maintain hemostasis results in frequent transfusions of blood 
products, often totaling 6-8L over the course of an ECMO run.39 Additionally, on 
occasion ECMO circuits fail and need to be replaced with a freshly primed circuit, which 
can further increase the amount of exogenous fluid administered. 
The disease state can also impact V. Exposure to the ECMO circuit results in an 
inflammatory response.18,19,40 Inflammation often results in capillary leak and edema, 
which can increase V.18,41,42 In addition, patients on ECMO can have altered blood pH, 
which can affect a drug’s ionization and distribution into tissues. Finally, the renin-
angiotensin system in the kidney can be upregulated, possibly related to non-pulsatile 
blood flow seen in VA EMCO.43 Upregulation of the renin-angiotensin system alters 
handling of fluids and can change the ratio of fluids in the body fluid compartments. 
Our understanding of the impact of ECMO on V is limited by the fact that most 
studies were done in infants or an ex vivo system. Although ex vivo studies are useful in 
understanding how drugs interact with an ECMO circuit in isolation, direct translation of 
those results into humans is challenging. Translating results from infant studies is 
challenging because infants differ from older children and adults in important ways. In 
8 
 
addition to the different ratio of exogenous to native blood volume described above, 
infants have a higher proportion of body water and lower protein binding, both of which 
can impact V.44-46 For these reasons, extrapolation of infant ECMO data to older 
children and adults must be done with caution. 
 
Altered clearance 
ECMO alters the PK of certain drugs by the effect it has on various organ 
systems. Renal dysfunction is common in patients on ECMO, occurring in >30% of 
ECMO patients.17 Reasons for the renal dysfunction are not entirely clear but appear to 
be multifactorial. Hypoxia and poor organ perfusion prior to ECMO support likely 
contributes. Non-pulsatile blood flow seen with VA ECMO is associated with decreased 
glomerular filtration rate (GFR).43 Of note, in VV ECMO where blood flow is pulsatile, 
the incidence of renal dysfunction (32%) is almost as high as that observed in VA 
ECMO (47%).17 Altered renal function can substantially increase exposure of renally-
cleared drugs and places patients at risk for toxicity. The effect is exacerbated if 
hemofiltration or dialysis are combined with ECMO support.47  
The impact of ECMO on metabolic capacity is not well described. It is postulated 
that decreased regional flow to the liver could result in decreased metabolism of 
hepatically-cleared drugs, especially those where extraction is blood-flow dependent.48 
Further, ECMO causes inflammation and that inflammation tends to decrease the 
expression and function of drug metabolizing enzymes.40,49 Of the enzymes that are 
relevant for this dissertation, the Cytochrome P450 (CYP) enzymes and UDP 
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glucuronosyltransferase 2B7 (UGT2B7) are down regulated, likely mediated by 
inflammatory cytokines.50-53 On the other hand, rat models of liver disease show 
upregulation of arylsulfatase activity. 54,55 There are no data describing the impact of 
ECMO on drug transporters. Transporters also are impacted by inflammation, so it is 
reasonable to assume that ECMO could also impact disposition of drugs that rely on 
transporters.56-58  
Because patients on ECMO are exposed to multiple drugs, it is important to 
understand the impact of ECMO support on drug PK. Such PK alterations are complex 
and challenging to investigate, arguing for a targeted approach based on the frequency 
of use of the drug, medical need, delayed clinical effect, and expected PK changes on 
ECMO. Some drugs have a readily apparent clinical effect and are easily titrated (e.g., 
epinephrine). Easily titratable drugs can be dosed clinically and dedicated PK studies 
are less necessary. However, many drugs have effects that are not easily measured. 
Antimicrobials are a good example, and multiple studies have been conducted to 
describe the effect of ECMO on the PK of antibiotics.24,59-68 However, an important 
category of antimicrobial agents that have not been investigated extensively are the 
antifungal drugs. 
 
Fungal infection on ECMO 
Candida is the most common cause of ECMO-related nosocomial infection in 
adults and children and the second most common cause in neonates.69 Incidence varies 
by center and rates as high as 10% have been reported.69,70 Candida infections cause 
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substantial morbidity and mortality70 and are difficult to eradicate due to the organism’s 
ability to adhere to indwelling catheters. For this reason, routine management for 
candidiasis consists not only of antifungal agents but also removal of catheters.71 
Catheter removal for patients on ECMO is often impossible, because the ECMO 
cannulas connect the patient to the ECMO circuit. Therefore, therapy on ECMO relies 
on either prevention of invasive candidiasis or optimal therapeutic dosing in children 
with infection. Optimal dosing for prevention or treatment of candidiasis in children on 
ECMO is unknown due to the PK changes induced by the ECMO circuit.  
Fluconazole and micafungin are first-line agents for prevention and treatment of 
candidiasis in children. 72,73 Amphotericin B deoxycholate is used less frequently 
because of its renal toxicity and safer alternatives, but remains a mainstay of treatment 
for serious invasive fungal infections. Each of these antifungal drugs has potential 
strengths and limitations in the ECMO system.72-77 Fluconazole penetrates tissue well, 
and its hydrophilicity, neutral charge, and low binding to plasma proteins may protect it 
from adsorption by the ECMO circuit.32,74 However, fluconazole is eliminated primarily 
by the kidneys, which may prolong its half-life and alter dosing in this patient population 
that frequently develops renal insufficiency.74,78 Amphotericin B deoxycholate is a 
fungicidal against many clinically important species of fungi and undergoes renal 
clearance similar to fluconazole. Amphotericin is a slightly lipophilic (LogP 0.8) 
zwitterion that is 90% protein bound; it is unknown how these physicochemical 
properties will impact extraction by the ECMO circuit. Micafungin, an echinocandin, is 
active against both Candida spp. and Aspergillus spp., has few known drug-drug 
interactions, and most importantly has the ability to penetrate Candida biofilms.73,79 
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These biofilms can form in the different components of the ECMO circuit, which makes 
micafungin a promising antifungal drug in this setting. However, micafungin is more than 
99% protein-bound and negatively charged at physiologic pH, which may result in high 
adsorption by the ECMO circuit and significantly decrease exposure. 
 
Approaches to determining drug dosing on ECMO 
Dosing recommendations are frequently derived by conducting PK trials and 
analyzing the data with traditional PK modeling and simulation. Traditional PK models 
(e.g., noncompartmental, compartmental, and population PK analyses) are built by 
fitting a model to drug concentration-time data from individuals or populations. This 
approach is well accepted by regulatory agencies and employs simplified models (e.g., 
1-compartment model) with well-defined validation criteria. However, this approach is 
costly and time-consuming as it depends on collecting data from a trial, and care must 
be taken when extrapolating results to a population that is different from the population 
used to build the model. As an example, in this dissertation the results from a PK trial of 
fluconazole in 21 children on ECMO are reported. This study was performed under a 
Food and Drug Administration (FDA) investigational new drug (IND) application. Dosing 
recommendations submitted to the FDA were determined using nonlinear mixed effects 
population PK modeling. From the time of study design to FDA submission was six 
years for a single drug. Additionally, there is concern that if new ECMO technology is 
adopted in the future, the drug may interact differently with the new equipment. If true, 
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the dosing recommendations based on the old ECMO equipment would no longer be 
valid and a new trial would be necessary. 
Physiologically-based pharmacokinetics (PBPK) offers an alternative modeling 
platform with greater flexibility, efficiency, and the ability to account for the complex 
physiology of critically ill children. PBPK models expand on traditional compartmental 
models by incorporating the key physiological, biochemical, and physicochemical 
determinants of drug disposition. The models are parameterized using a physiologic 
structure (Figure 1.2) with mathematical equations that describe the volume of the 
compartments, flows into and out of the compartments, and drug disposition within the 
compartments. These models can account for the effect that physiologic changes have 
on organ function (e.g., decreased renal perfusion) and provide a mechanistic 
understanding of drug disposition. Understanding the mechanism(s) of drug disposition 
enables more accurate dose predictions and optimization of trial design for different 
disease states.  
In children on ECMO, an ECMO compartment can be added to the PBPK model 
to account for the effect of ECMO on drug disposition. The ECMO compartment is 
assigned a volume based on the volume of blood required to prime the ECMO circuit, 
and assigned an equal blood flow into and out of the compartment. Drug interaction 
(e.g. adsorption) within the ECMO compartment is informed by administering a drug of 
interest to an isolated ex vivo ECMO circuit. Drug extraction by the ECMO circuit can be 
described mathematically with a disposition function that is added to the ECMO 
compartment to predict dosing. While the model predictions will still need to be validated 
with PK data from children on ECMO, the number of children required will be less and 
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the trial design more efficient. Further, if ECMO technology changes, the ex vivo 
experiment can be repeated with the new circuit to understand whether the drug 
interaction is different. Based on the interaction with the new circuit, parameterization of 
the ECMO compartment can be updated in the PBPK model and new predictions of 
drug disposition can be generated. While the critically ill child, especially with 
extracorporeal support (e.g., ECMO, dialysis), represents an ideal population for the use 
of PBPK modeling, this approach has never been applied in this population. 
 
The hypothesis of this proposal is that PBPK modeling can be combined with ex 
vivo ECMO experiments to mechanistically understand drug disposition and provide 
evidence-based dosing recommendations in children on ECMO.  
 
Specific Aim 1: Evaluate the ECMO circuit extraction of three antifungal drugs ex 
vivo.  
Hypothesis 1: Fluconazole and amphotericin B deoxycholate will undergo limited 
extraction due to their physicochemical properties (low lipophilicity, neutral or 
zwitterionic charge), while micafungin will be highly extracted because of its high degree 
of protein binding.  
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Specific Aim 2: Develop PBPK models of fluconazole and micafungin in critically 
ill children. 
Hypothesis 2: PBPK models will predict drug exposure of fluconazole and micafungin as 
measured by area under the concentration time curve (AUC) within 0.7-1.3 fold of 
observed exposure in critically ill children and can be adapted to different physiologic 
states including ECMO. 
 
Specific Aim 3: Prospectively evaluate through clinical trials PBPK models of 
fluconazole and micafungin in children on ECMO. 
Hypothesis 3: Addition of the ECMO compartment into PBPK models will predict drug 
exposure of fluconazole and micafungin as measured by AUC within 0.7-1.3 fold of 
observed exposure in children on ECMO. 
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Figure 1.1. ECMO Circuit Schematic. An ECMO circuit has at least three components: tubing, 
pump, and oxygenator. Some circuits will also employ a hemofilter that can remove fluid and 
perform dialysis. Ex vivo ECMO experiments would replace the child in this schematic with a 
reservoir.  
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Figure 1.2. PBPK Model Structure. Each organ compartment is assigned a volume and flow 
based on the age, weight, and height of the individual or population. Drug-specific information 
such as physicochemical properties and clearance pathways determine drug disposition within 
each compartment. In children on ECMO, an ECMO compartment can be added.  
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CHAPTER 2. ANTIFUNGAL EXTRACTION BY THE EXTRACOPOREAL MEMBRANE 
OXYGENATION (ECMO) CIRCUIT EX VIVO 
INTRODUCTION 
Extracorporeal membrane oxygenation (ECMO) is a cardiopulmonary bypass 
device used to support patients with refractory respiratory and/or cardiac failure. 
Patients supported with ECMO are critically ill and, thus, exposed to multiple drugs. 
Optimal dosing of drugs in this setting is unknown because ECMO can alter drug 
pharmacokinetics (PK). Studies of antimicrobials (e.g., vancomycin,1-4 gentamicin5-8) 
and sedatives (e.g., opiates,9-12 benzodiazepines13,14) generally show an increased 
volume of distribution (V) and decreased clearance (CL). These alterations in PK are 
caused by multi-organ dysfunction, the large volume of exogenous blood required to 
prime the ECMO circuit, and drug extraction by the circuit.  
Drug extraction by the ECMO circuit is thought to be due to non-specific binding 
by the components of the circuit.15-19 While supported by ECMO, nearly all of a patient’s 
blood is drained from the venous system via a large bore cannula and pumped through 
tubing to an artificial lung (oxygenator) before being returned to the patient. In some 
cases the ECMO circuit also contains a hemofilter that can provide hemofiltration or 
dialysis for patients with renal injury. As drugs transit the ECMO circuit they come in 
contact with the various components of the circuit (e.g., tubing, pump, oxygenator, 
hemofilter) and are vulnerable to extraction. The extent of drug extraction by the ECMO 
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circuit depends on the materials in the circuit and the physicochemical properties of the 
drug. Non-specific binding of drugs occurs via two primary mechanisms: 1) hydrophobic 
interactions and 2) ionic interactions.20 Hydrophobic binding can occur between 
hydrophobic drugs and a hydrophobic surface, while ionic binding occurs when the drug 
and surface are oppositely charged. Non-specific binding of drugs can significantly 
decrease exposure and lead to therapeutic failure. 
Circuit-drug interactions have been investigated using ex vivo ECMO 
experiments in which drug is administered to an isolated ECMO circuit.13,15,21-29 
Because there is no corporeal metabolism or elimination in this system, decreases in 
drug concentration are due to either extraction by the circuit or drug degradation. In 
general, highly lipophilic (e.g., fentanyl) and highly protein bound (e.g., caspofungin) 
drugs are extensively extracted by the circuit.23,30 However, this relationship is not 
always predictable. Ciprofloxacin is lipophilic with low protein binding but not extracted, 
while meropenem is hydrophilic with low protein binding and extensively extracted.22,23 
This suggests that other factors such as ionic binding may play a role. Additionally, the 
site(s) of extraction within the circuit is not known. 
  In the present study, the extent of extraction by the ECMO circuit was 
determined for selected antifungal drugs in an ex vivo ECMO system. Antifungal drugs 
were chosen because fungal infections are common in children on ECMO and 
treatment depends on optimal dosing.31 The contribution of each component of the 
ECMO circuit to overall extraction was determined by comparing extraction in three 
circuit configurations with different component combinations.  
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METHODS 
Drug selection 
Three antifungal drugs were selected for evaluation: fluconazole, micafungin, and 
amphotericin B dexoycholate. These drugs were selected based on their frequency of 
use in clinical practice and range of physicochemical properties (Table 2.1, Figure 2.1).  
 
Circuit configuration 
In order to determine the impact of each component on drug extraction, the 
experiment was designed with three circuit configurations (Figure 2.2). The Complete 
Circuit contained tubing, a pump, an oxygenator, and a hemofilter (Table 2.2). The 
Oxygenator Circuit was identical to the Complete Circuit except that the hemofilter was 
removed. The Pump Circuit was identical to the Oxygenator Circuit except that the 
oxygenator was removed. Any difference in extraction between the Complete and 
Oxygenator Circuits was due to the hemofilter. Similarly, any difference in extraction 
between the Oxygenator and Pump Circuits was due to the Oxygenator (Figure 2.2).  
 
Circuit setup 
Circuits were assembled according to the standard practice for Duke University 
Children’s Hospital. Circuits were primed with a solution of 1 unit of packed red blood 
cells (~350mL), 0.5 unit of fresh frozen plasma (~175mL), and plasmalyte crystalloid 
(500mL). In addition, the following were added to each circuit to complete the prime 
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solution: heparin sulfate (0.1 units), sodium bicarbonate (30mEq), and calcium 
gluconate (6.5mg). Additional sodium bicarbonate and/or carbon dioxide were added to 
the system to maintain physiologic pH. To be consistent with standard practice at Duke, 
albumin was not routinely added to the circuit, and albumin concentrations were low 
(≤1.0 mg/dL). However, if a drug showed extraction in any of the circuit configurations, 
subsequent experiments were performed and human serum albumin was added to 
achieve two additional concentration levels: low-physiologic (2.2-2.8 mg/dL; typical for a 
child on ECMO) and physiologic (3.5-3.8 mg/dL). In order to examine the impact of 
albumin on extraction, extraction was compared between circuits with low, low-
physiologic, and physiologic albumin concentrations. 
Because there was no human connected to the circuit, the circuit was completed 
via a reservoir (plasmalyte IV bag). An ECMO heat exchanger was used to maintain a 
constant temperature of 36˚ C throughout the study. ECMO flow was set to 1L/min to 
simulate the clinical scenario for a 10kg child.  
 
Control 
In order to determine the amount of drug degradation over time, at least three 
clear, polyvinylchloride plastic tubes per drug were filled with 30mL of the prime solution 
drawn from the ECMO circuit. The prime solution was collected from the ECMO circuit 
after ≥5 minutes of circulation and before drug administration. The control tubes were 
tightly capped in a 36˚ C static, water bath. 
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Drug administration and sample collection 
Drug was introduced into the circuit via a port downstream of the sampling port at 
time=0 and dosed to achieve a therapeutic concentration. Drug was dosed to achieve a 
comparable concentration in the control samples at time -5 minutes, sealed with a tight 
cap, and then gently mixed for 5 minutes until time=0. At time=0, the controls were 
returned to the water bath where they remained for the duration of the experiment, 
except at times of sample collection. Immediately prior to control sample collection, 
control tubes were removed from the water bath and gently inverted five times to ensure 
adequate mixing. In the initial set of experiments, samples were collected from the 
circuits and controls for 4 hours at the following time points: 1, 5, 15, and 30min, 1, 2, 3, 
and 4h. In order to better understand drug disposition over an entire dosing interval, 
subsequent experiments measured concentrations up to 24 hours by collecting 
additional samples at 8, 12, and 24h. 
 
Analysis 
Drug concentrations were measured using assays that were developed and 
validated according to FDA guidance.32 Fluconazole concentrations were measured at 
OpAns Laboratory (Durham, NC) using HPLC/MS-MS.  Plasma samples were acidified 
with formic acid and precipitated with acetonitrile. Samples were centrifuged and diluted 
with water containing 0.2% (v/v) acetic acid prior to injection into the HPLC system. 
Separation was achieved with a Poroshell 120 EC-C18 Column. Fluconazole was 
quantified using an electrospray ionization source in the positive mode and under the 
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following conditions: gas temperature 300ºC, gas flow 10 L/min, nebulizer pressure 50 
psi, sheath gas temperature 345 ºC, sheath gas flow 11 L/min, capillary voltage 3500 V, 
nozzle voltage 500 V, Dynamic MRM scan type. The lower limit of quantification (LLOQ) 
was 0.01 mg/L with a calibration curve range of 0.01 to 10 mg/L. Intraday and interday 
precision (%CV) ranged from 1.4% to 8.5% and 2.8% to 5.8%, respectively. Micafungin 
concentrations were measured at the University of Texas Health System Fungal Testing 
Laboratory using HPLC with fluorescence detection. Plasma samples were acidified 
with phosphoric acid and precipitated with acetonitrile. Samples were centrifuged and 
diluted with 10mM ammonium acetate prior to injection into the HPLC system. Injection 
into the HPLC occurred under the following conditions: mobile phase with 10mM 
ammonium acetate/acetonitrile 60:40 v/v at a flow rate of 1.0 mL/min. Separation was 
achieved with a Phenomenex-Luna 5µ C18 Column. Micafungin was quantified by 
fluorescence. Fluorescence detector excitation and emission wavelengths were 273nm 
and 464nm, respectively. The LLOQ was 0.05 mg/L. The calibration curve ranged from 
0.05 to 25 mg/L. Intraday precision ranged from 1.19% to 7.35% except at the LLOQ 
where the range was 12.0% to 21.6%. Interday precision ranged from 4.88% to 10.3%. 
Amphotericin B deoxycholate also was measured at the Fungal Testing Laboratory 
using HPLC. Plasma samples were deproteinated and precipitated with acetonitrile, 
centrifuged and injected into the HPLC system. Injection into the HPLC occurred under 
the following conditions: mobile phase with 0.01M TEMED buffer/acetonitrile 65:35 v/v 
at a flow rate of 0.8 mL/min. Separation was achieved with a Phenomenex Luna 5u 
C18(2) 150 X 4.6 mm column. UV detection was at 406nm. The LLOQ was 0.05 mg/L; 
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intraday and interday precision ranged from 0% to 11.8% and 3.23 to 5.65%, 
respectively. 
Drug recovery in circuits and controls was calculated at each sample time using 
the following equation: 
ܴ݁ܿ݋ݒ݁ݎݕ	ሺ%ሻ ൌ ܥ௧ܥ௜ ∗ 100 
where Ct is the concentration at time t and Ci is the initial concentration measured at 
time=1 minute.  Data are reported as the mean and 95% confidence interval.   
 
Ethics 
The Duke University Medical Center Institutional Review Board provided a waiver 
of review because the protocol met the definition of research not involving human 
subjects.  
 
RESULTS 
The total number of circuits studied, by configuration, are summarized for each 
drug in Table 2.3. 
 
Fluconazole 
Fluconazole was not extracted by the ECMO circuit (Figure 2.3.a). In three 
Complete Circuits, the mean (95% confidence interval) recovery of fluconazole was 
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97.8% (96.3, 99.3) at 4 hours. In the two Complete Circuits that were run for 24 hours, 
95.2% (89.6, 100.9) of the initial concentration was recovered. When the hemofilter was 
removed to create the Oxygenator Circuit, 92.3% (83.1 101.5) of the initial fluconazole 
concentration was recovered at 4 hours (n=4). One Oxygenator Circuit was run for 24 
hours and 98.4% of the initial concentration was recovered at 24 hours. When 
fluconazole was administered to the Pump Circuit (n=1), 105.8% was recovered after 4 
hours. Because no extraction was observed in the Complete or Oxygenator Circuits, 
additional Pump Circuits were not run. In the control samples, 100.2% (95.5, 104.9) of 
the initial fluconazole concentration was recovered at 4 hours (n=4) and 100.6% (98.5, 
102.8) at 24 hours (n=3).  
 
Micafungin 
In the Complete Circuit (n=10), micafungin recovery was low at 4h (46.3% [35.3, 
57.3]). However, when the hemofilter was removed (Oxygenator Circuit, n=4), 
micafungin recovery at 4 hours was 91.1% (85.2, 97.0) (Figure 2.3.b). Similarly, in the 
Pump Circuit (n=1) and Control (n=4) 98.1% and 90.9% (86.8, 95.0), respectively, were 
recovered at 4 hours. By 24 hours, however, recovery of micafungin was low in the 
Complete (26.0% [15.0, 37.0]; n=9) and Oxygenator Circuits (42.6% [31.3, 53.9]; n=3) 
as well as in the Control samples (56.8% [49.2, 64.4]; n=3).  
Micafungin extraction during the first 4 hours was dependent on albumin 
concentration (Figure 2.4). At low albumin concentrations (≤ 1.0 g/dL; n=4) in a 
Complete Circuit, 29.0% (19.7, 38.4) and 16.1% (1.7, 30.5) of the initial micafungin 
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concentrations were recovered at 4 and 24 hours, respectively. At low physiologic 
albumin concentrations (2.2-2.8 g/dL; n=3) recovery was 58.4% (53.5, 63.3) and 35.7% 
(24.7, 46.7) at 4 and 24 hours, respectively. Similarly, when albumin concentrations 
were in the normal range (3.5-3.8 g/dL; n=3), micafungin recovery was 57.2% (54.8, 
59.5) and 26.1% (20.4, 31.9) at 4 and 24 hours, respectively. 
Because the hemofilter was responsible for micafungin extraction in the first 4 
hours, micafungin concentrations were measured in the hemofiltrate for one circuit to 
determine if micafungin passively crossed the hemofilter membrane (hemofilter was 
only in-line and not actively filtering). Concentrations in the hemofiltrate at 1min, 1h, 2h, 
and 24h were only 0.07, 0.06, 0.21 and 0.16 mg/L, respectively. Concentrations in the 
plasma samples from the ECMO circuit at the same times were 15.5, 13.1, 11.6, and 
8.1 mg/L, respectively. Concentrations in the hemofiltrate were <2% of concentrations in 
the circuit suggesting that micafungin does not cross the hemofilter membrane.  
 
Amphotericin 
Three amphotericin B deoxycholate Complete Circuits and Controls were run for 
24 hours. The three circuits showed virtually no loss of amphotericin at 4 hours or 12 
hours, with recovery of 98.9% (88.7, 109.1) and 99.2% (88.5, 110.1), respectively 
(Figure 2.3.c). Results after 12 hours were unable to be reported because the circuits 
and controls developed substantial hemolysis after 12 hours. Hemolysis interferes with 
the amphotericin assay resulting in unreliable concentration measurements. Because 
amphotericin was not extracted in the Complete Circuit, extraction by the Oxygenator or 
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Pump Circuits would not be expected. Therefore, additional circuit configurations were 
not evaluated for amphotericin. Of note, the concentrations of amphotericin in the 
control samples increased over the first 4 hours so that recovery was 143.8% (137.5, 
150.1) of the initial concentration. Between 4 hours and 12 hours concentrations 
remained constant with recovery of 145.3% (140.4, 150.3) at 12 hours. 
 
DISCUSSION 
ECMO can alter drug pharmacokinetics (PK) directly and indirectly through a 
variety of mechanisms. Direct effects include 1) increased volume of distribution due to 
the addition of the large volume of exogenous blood required to prime the ECMO circuit, 
2) hemofiltration, which is common in patients on ECMO, and 3) extraction of drug by 
components of the circuit.33 Ex vivo ECMO experiments such as those performed in this 
study provide insight into extraction via circuit-drug interactions. The degree of 
interaction with the ECMO circuit is drug-dependent and likely influenced by the 
physicochemical properties of the drug and circuit components (e.g., oxygenator, 
hemofilter).23,30 Results of the present study demonstrate important differences in 
antifungal drug extraction by the ECMO circuit that can affect dosing recommendations 
in clinical practice. 
Micafungin was highly extracted in the first 4 hours in a Complete Circuit but not 
in the other circuit configurations. This suggests that extraction was due to the 
hemofilter.  Three possible mechanisms may explain extraction by the hemofilter: 1) 
diffusion across the hemofilter membrane; 2) areas of stasis in the hemofilter that 
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“trapped” the drug; or 3) direct adsorption by the hemofilter. Micafungin would not be 
expected to diffuse across the hemofilter membrane due to its high degree of protein 
binding (>99%) and the fact that the hemofilter was not actively filtering during the 
experiments. This was confirmed by collecting samples of hemofiltrate, which contained 
virtually undetectable concentrations of micafungin. Although areas of low flow can 
occur around the hemofilter, inconsistency in the degree of “trapping” and more 
variability in recovery would be expected if this were the mechanism. Adsorption by the 
hemofilter appears to be the most likely explanation. This is supported by greater 
extraction at low albumin concentrations suggesting that the unbound fraction is 
adsorbed by the hemofilter membrane. However, the polyethersulfone membrane used 
in these experiments was hydrophobic and had no net charge, making it less likely to 
interact with a hydrophilic anion such as micafungin. Further studies to understand the 
mechanism of drug loss to the hemofilter are needed. 
These results are in contrast to studies of micafungin in continuous venovenous 
hemofiltration (CVVH) using similar hemofilters that showed no loss when micafungin 
concentrations were measured pre- and post-hemofilter.34,35  However, several 
important differences were noted between our ECMO ex vivo system and the CVVH 
studies that could explain this apparent discrepancy: 1) the CVVH studies were PK trials 
in critically ill adults so other unmeasured factors inherent to clinical trials may have 
influenced drug concentrations; 2) flow rates were higher in the ECMO experiments 
compared to CVVH and for drugs where extraction is perfusion limited, increased flow 
results in higher extraction; and 3) the CVVH studies were actively filtering and by 
removing plasma water but not drug, micafungin was functionally concentrating in the 
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plasma. Differences in protein binding between the in vivo and ex vivo studies could 
also account for the differences. Albumin concentrations were higher in the in vivo 
CVVH studies. Because micafungin is highly protein bound, small changes in binding 
can substantially alter the amount of unbound drug available to be absorbed by the 
hemofilter. 
More important than the hemofilter-related decrease in concentration over four 
hours was the observation that micafungin concentrations decreased over a 24 hour 
dosing interval in all circuit configurations and the controls. Non-specific binding to 
circuit materials should occur quickly (i.e., <4 hours).16,18-20 The continued extraction of 
micafungin over 24 hours in both circuits and controls suggests that drug degradation or 
plasma metabolism may have occurred. Micafungin is known to degrade in light.36 It is 
possible that light penetration of the ECMO tubing and control tubes caused sample 
degradation throughout the study. Clinically, ECMO circuits are exposed to light so that 
clinicians operating the circuit can monitor for clot accumulation in the components. As 
a result, a substantial amount of blood is exposed to light at any given time during 
ECMO support, and this may have important dosing implications for light-sensitive 
drugs. Alternatively, metabolism by plasma peptidases could result in continuous loss of 
micafungin. Although plasma metabolism is not described for micafungin, peptidases 
are a major elimination pathway for both caspofungin and anidulafungin, echinocandins 
with similar structure. Experiments are ongoing to determine the mechanism of 
continued drug loss. Regardless of the mechanism, the fact that mean micafungin 
recovery ranged from 26-57% at 24 hours suggests that micafungin dosing may need to 
be increased in patients on ECMO. 
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In the present study, fluconazole was not extracted by the ECMO circuit. The 
fluconazole results are consistent with a recent ECMO ex vivo study where fluconazole 
recovery at 24 hours in a system similar to the Oxygenator Circuit and Control used in 
this study were 96% and 102%, respectively.23 Based on physicochemical properties, 
fluconazole would not be expected to interact with the ECMO circuit. It is only slightly 
lipophilic (LogP 0.4) and should not undergo extensive hydrophobic binding to 
polymers. The present findings also are supported by an ECMO ex vivo study that 
demonstrated minimal extraction of linezolid, a drug with similar physicochemical 
properties (LogP of 0.9, protein binding of 30%).23 Additionally, fluconazole has a 
neutral charge at physiologic pH so it would not be expected to undergo extensive ionic 
binding.  
Amphotericin B deoxycholate also was not extracted by the ECMO circuit. There 
are no prior studies of amphotericin in ECMO. Amphotericin is slightly lipophilic, similar 
to fluconazole, and would not be expected to undergo extensive hydrophobic binding. 
More importantly, amphotericin is a zwitterion. Zwitterions would not be expected to 
adsorb to hydrophobic or charged surfaces because they tend to be well hydrated with 
both positive and negative groups, but have no net charge. In fact, zwitterions have 
been used as a surface coating on polymers to prevent adsorption of drugs.37 The 
increase in amphotericin concentrations in the control samples over the first four hours 
was unexpected. Hemolysis was observed in control and circuit samples and can cause 
elevations in plasma concentrations when drug that is sequestered in the red blood cell 
is released into the extracellular space. A study of amphotericin B lipid complex showed 
that the amphotericin blood:plasma ratio was 1.5:1.38 This degree of partitioning is not 
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likely to explain the observed increase in concentration as most hemolysis occurred 
after four hours and a concomitant increase would have been expected in the circuit 
samples, as well. It is more likely that amphotericin did not distribute evenly in the 
control sample solution leading to sampling error. The deoxycholic acid component of 
amphotericin disperses very rapidly in plasma. In vitro studies show that amphotericin 
solubility is time dependent, and amphotericin is not completely solubilized even at one 
hour.39 It is possible that the amphotericin precipitated and was concentrated near the 
bottom of the control tubes. If samples were not adequately mixed, this could result in 
increasing concentrations until solubilization was complete. This phenomenon would be 
less likely in the ECMO circuit because it was flowing continuously. More work is 
necessary to understand the disposition of amphotericin B deoxycholate in this system. 
Additionally, studies should be conducted to characterize the circuit interactions with 
other, more commonly used amphotericin forumulations (e.g. liposomal, lipid 
complexed) that may result in interaction with the ECMO circuit. 
 In summary, it is clear that a single physicochemical property (e.g., lipophilicity) is 
unable to predict which and to what extent drugs are extracted by the ECMO circuit. 
Even if older circuits with uncoated, hydrophobic polymers were used, differences in the 
materials and residuals in the matrix such as plasticizers would likely require an empiric 
correction factor to accurately describe the extent of adsorption.20 The circuit-drug 
interactions are even more complicated when surface coatings are applied. Although 
surface coatings are added primarily to increase biocompatibility, the impact on 
adsorption can be substantial. Studies comparing the adsorption of drugs between 
tubing with different surface coatings showed significant differences in drug recovery 
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both between coated and uncoated materials, and also between the different types of 
surface coatings.16,17 Many knowledge gaps remain. It is unknown if surface coatings on 
ECMO circuits change over time. Further, it is unknown to what extent endogenous 
materials (e.g., plasma proteins, platelets) compete for binding sites on circuit 
components. Future work should explore high-throughput systems to evaluate the 
interaction between ECMO circuit components and different drugs. Until that time, ex 
vivo experiments remain the best way to define specific circuit-drug interactions. The 
results from the present ex vivo experiments will be used to inform the ECMO 
compartment of the fluconazole and micafungin PBPK models and translate those 
circuit-drug interactions into dosing recommendations in children on ECMO. 
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Table 2.1. Antifungal drug physicochemical properties and clearance pathways 
 
Antifungal 
 
Charge 
 
LogP 
Plasma Protein 
Binding (%)a 
Molecular 
Weight (g/mol) 
Primary Metabolic 
Pathway 
Amphotericin Zwitterion 0.8 90 924 Renal 
Fluconazole Neutral 0.4 11% 306 Renal 
Micafungin Negative -0.4 99% 1270 Hepatic 
aAmphotericin binds to plasma lipoproteins, albumin, and alpha-1-acid glycoprotein.40,41 Fluconazole 
binds primarily to alpha-1acid-glycoprotein.42,43 Micafungin binds primarily to albumin.44 
 
Table 2.2. ECMO circuit components 
Component Manufacturer Model Material 
Oxygenator Maquet Adult/Pediatric Quadrox iDa Polymethylpentane hollow fibers with Biolineb coating 
Hemofilter Sorin DHF0.2 Polyethersulfone 
Pump Sorin Revolution Centrifugal Polycarbonate 
Tubing Sorin Smart Tubing Phosphorylcholine coated polyvinylchloride
a Adult and pediatric oxygenators only differed in surface area (1.8m2 for adult and 0.8m2 for pediatric). 
Because the oxygenator was not responsible for clinically significant extraction, and no difference was 
observed between adult and pediatric oxygenator circuits, adult and pediatric oxygenators were assumed 
to be equivalent for the purposes of these experiments. 
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Table 2.3. Number of circuits by configuration and drug 
Configuration  Fluconazole Micafungin Amphotericin 
A. Complete Circuit  
(hemofilter, oxygenator, pump, tubing) 3
a 10d 3g 
B. Oxygenator Circuit  
(oxygenator, pump, tubing) 4
b 4e - 
C. Pump Circuit  
(pump, tubing) 1 1 - 
D. Control 4
c 4f 3g 
a 1 circuit run for 4 hours; 2 circuits run for 24 hours 
b 3 circuits run for 4 hours; 1 circuit run for 24 hours 
c 4 controls sampled for 4 hours; 3 controls sampled for 24 hours 
d 10 circuits stratified by albumin level (g/dL): low (≤ 1; N=4), low physiologic (2.2-2.8; N=3); physiologic 
(3.5-3.8; N=3). 1 circuit run for 4 hours (low albumin); 9 circuits run for 24 hours 
e 2 circuits run for 4 hours; 2 circuits run for 24 hours 
f 1 control sampled for 4 hours; 3 controls sampled for 24 hours 
g All 3 circuits and controls sampled for 24 hours 
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Figure 2.1. Molecular Structure of Antifungals 
Fluconazole45 Micafungin46 Amphotericin B deoxycholate47 
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Figure 2.2. ECMO circuit configurations. A. Complete Circuit; B. Oxygenator Circuit; C. Pump Circuit 
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Figure 2.3. Recovery (mean [95% confidence interval]) by circuit configuration for each drug.  
 
A Fluconazole – 4h Fluconazole – 24h 
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B Micafungin – 4h Micafungin – 24h 
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C Amphotericin B deoxycholate – 4h Amphotericin B deoxycholate – 12h 
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Figure 2.4. Micafungin recovery stratified by albumin concentration. Values are mean (95% 
confidence interval). 
 
 
 
 
  
Control
Physiologic albumin (3.5-3.8 g/dL)
Low physiologic albumin (2.2-2.8 g/dL)
Low albumin (<1.0 g/dL)
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CHAPTER 3: PHARMACOKINETICS OF FLUCONAZOLE IN CHILDREN 
SUPPORTED WITH EXTRACORPOREAL MEMBRANE OXYGENATION 
 
PART1:  Pharmacokinetics and Safety of Fluconazole in Young Infants Supported 
with Extracorporeal Membrane Oxygenation1 
 
INTRODUCTION 
Extracorporeal membrane oxygenation (ECMO) is a cardiopulmonary bypass 
device used in the pediatric critical care setting that is life-saving for infants with 
refractory cardiorespiratory failure. Blood is drained from the central venous system via 
a surgically placed cannula, pumped through an artificial lung (oxygenator) where 
oxygen is added and carbon dioxide is removed, and then oxygenated blood is returned 
to either the venous or arterial circulation. ECMO has been used successfully in multiple 
disease states including meconium aspiration syndrome, persistent pulmonary 
hypertension of the newborn, fulminant myocarditis, and sepsis.2 Despite these 
successes, infants supported with ECMO are at high risk for ECMO-related 
complications, including nosocomial infections.3 
Invasive candidiasis is the second most common nosocomial infection in infants 
on ECMO and is often fatal.3,4 The incidence of fungal infections in patients on ECMO 
varies by center, with reports ranging from 0.7-10%.3,4 Standard treatment for invasive
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candidiasis in many patient populations consists of antifungal agents (e.g., fluconazole) 
and removal or replacement of intravascular catheters due to the organism’s ability to 
adhere to indwelling catheters.5 Catheter removal for infants on EMO is impossible if the 
infant cannot be disconnected from the ECMO circuit; therefore, successful treatment of 
invasive candidiasis in infants on ECMO relies upon optimal antifungal drug therapy. 
 Optimal antifungal management for patients on ECMO depends on dosing that 
has not been previously described and can differ greatly from other populations due to 
the pharmacokinetic (PK) changes induced by the ECMO circuit. PK changes attributed 
to the ECMO circuit include increased volume of distribution and decreased clearance, 
but these vary by drug.6-9 This study describes the ECMO-related PK changes of 
fluconazole and their impact on pharmacodynamic (PD) targets for fungal prophylaxis 
and treatment of invasive candidiasis. 
 
MATERIALS AND METHODS 
 This was a prospective, single-center, open-label PK and safety trial of 
fluconazole in infants supported with ECMO at Duke University Medical Center. Infants 
<120 postnatal days and supported with ECMO were enrolled. Infants were excluded if 
they had a history of hypersensitivity or severe vasomotor reaction to any triazole or had 
previously participated in the study. Infants received either prophylactic fluconazole per 
study protocol (25 mg/kg administered intravenously over 2 hours) or fluconazole per 
standard of care (12 mg/kg administered intravenously over 1 hour) if the child had a 
known or suspected fungal infection. Infants on prophylactic fluconazole continued to 
receive fluconazole 25 mg/kg once weekly for the duration of their ECMO course. 
   
52 
 
Duration of treatment for infants with suspected or culture-proven fungal infection was at 
the discretion of the treating physician. This trial was approved by the institutional 
review board of Duke University Medical Center, registered with clinicaltrials.gov 
(NCT01169402), and conducted under a Food and Drug Administration investigational 
new drug application (#108314). Written informed consent was obtained from the legal 
guardian of each infant.  
 
Sample Collection and Preparation 
 Up to 12 paired samples (200 μL whole blood per sample) were collected from 
the infant via an arterial catheter (Cout) and the ECMO circuit just before the oxygenator 
(Cin) for each infant at dose 1 and dose 2. Sampling times for all enrolled infants 
included a trough level 0–4 hours prior to the start of infusion and serial samples after 
the end of the infusion: 15 minutes (+/– 15 minutes), 3 hours (+/– 1 hour), 9 hours (+/– 3 
hours), 23 hours (+/– 1 hour), and 47 hours (+/– 1 hour). Samples were collected in 
ethylenediaminetetraacetic acid (EDTA) microcontainers and taken from a different site 
than the site used for fluconazole administration. Samples were processed immediately 
or placed on ice until processing. Plasma was separated via centrifugation (3000 g for 
10 minutes at 4o C), manually aspirated, and transferred to polypropylene tubes. Plasma 
samples were frozen at –80o C until analysis. 
 Fluconazole extraction by the ECMO oxygenator was calculated using the paired 
samples collected from the ECMO circuit just prior to the oxygenator (Cin) and from the 
patient (Cout) using the equation: [(Cin – Cout) / Cin] * 100. Any extraction levels greater 
than 3 standard deviations above or below the mean extraction were considered outliers 
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and were excluded from the analysis. Venous (Cin) samples were used for all PK 
analyses. 
 
ECMO Circuit Configuration 
 The ECMO circuit configuration was consistent across all infants and included 
tubing (Sorin Smart®, Sorin Group, Denver, CO), a centrifugal pump (Sorin Revolution®, 
Sorin Group, Denver, CO), and a hollow fiber membrane oxygenator (Quadrox-iD 
Adult® or Quadrox-iD Pediatric®, MAQUET Cardiovascular, Wayne, NJ). A hemofilter 
(Sorin DHFO.2®, Sorin Group, Denver, CO) was used if the infant required 
hemofiltration or hemodialysis. The circuit prime volume was 450 mL for the Quadrox-iD 
Adult® oxygenator (infants 2, 3, 5, 7, 9, 10) and 250 mL for the Quadrox-iD Pediatric® 
oxygenator (infants 1, 4, 6, 8). 
 
Analytic Procedures and Analyses 
 Plasma fluconazole concentrations were determined using a validated liquid 
chromatography-tandem mass spectrometry assay.10 The lower limit of quantification 
was 0.01 mg/L; intraday and interday precision ranged from 2.84% to 10.8% and 5.27% 
to 11.5%, respectively, within the concentration range of the standard curve (0.01 to 10 
mg/L). 
 The primary outcomes were the fluconazole PK indices in infants on ECMO 
(clearance, volume of distribution) and the number of infants achieving the proposed PD 
target for fungal prophylaxis (fluconazole time above the minimum inhibitory 
concentration [tMIC; 4 mg/L] for >50% of the dosing interval).11 In addition, the proportion 
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of infants achieving the surrogate PD target for treatment (area under the curve from 0–
24 hours [AUC0–24] > 400 mg*h/L)12 of invasive candidiasis was calculated. This was 
performed because the dose evaluated in this study has previously been evaluated for 
treatment of candidiasis.13 The secondary outcome was fluconazole extraction by the 
ECMO circuit. The PK indices of fluconazole were examined with descriptive statistics.  
 PK data were analyzed by nonlinear regression with the most appropriate model 
using WinNonlin v. 6.2 (Pharsight Co., St. Louis, MO). The model fit was evaluated 
using successful minimization, diagnostic plots, goodness of fit as assessed by the 
Akaike Information Criterion, and precision of the parameter estimates. AUC0–24 was 
computed by the linear trapezoidal method using simulated data predicted from the 1-
compartment model. The tMIC was estimated and expressed as a percentage of the 
dose interval using the following equation: 
Clast = MIC * e-k(tlast-tMIC) 
where Clast is last simulated fluconazole concentration from the terminal elimination 
phase using the predicted data from the 1-compartment model; MIC is the minimum 
inhibitory concentration (4 mg/L); k is the elimination rate constant derived from the 1-
compartment model; tlast is time of last fluconazole concentration using the predicted 
data from the 1-compartment model; and tMIC is estimated time above the MIC. For an 
infant on standard-of-care fluconazole (12 mg/kg daily), AUC0–24 and tMIC were 
calculated using the simulated data after administration of a 25 mg/kg dose using the 
clearance and volume of distribution estimates from the 1-compartment model.  
 The relationships between fluconazole clearance and serum creatinine on the 
day of dose, as well as the fluconazole volume of distribution and the ECMO prime 
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volume were explored with scatter plots. Differences in PK indices between doses were 
evaluated using Wilcoxon signed-rank test. Correlation between ECMO circuit 
extraction and time was measured with Spearman’s rank correlation coefficient. The 
sample size was based on the ability to provide reasonable estimates for safety. It was 
determined a priori that, with a sample size of 8, the 95% confidence interval (CI) for an 
adverse event (AE) in 1 infant within the patient population was 0–53%. STATA 11 
(College Station, TX) was used to perform the statistical analyses. In all cases, a P 
value of <0.05 was considered statistically significant. 
 
Safety 
 The safety of fluconazole was assessed by monitoring the frequency, intensity, 
and relationship to study drug of AEs while on study drug and for 7 days after the last 
dose. The results of clinical laboratory tests performed within 72 hours of study drug 
administration and weekly throughout the monitoring period were recorded. The primary 
AE of interest was liver toxicity assessed by the evaluation of aspartate 
aminotransferase (AST) and alanine aminotransferase (ALT) values measured at least 
weekly during study drug administration. AEs were graded according to the National 
Cancer Institute’s Common Terminology Criteria and reported as mild (grade 1), 
moderate (grade 2), severe (grade 3), life-threatening (grade 4), or fatal (grade 5). 
Causality (unrelated and possibly, probably and definitely related) of AEs and study 
drug was determined by the principal investigator and the treating physician. AEs 
determined to be probably or definitely related to study drug were followed until 
resolution. The safety data were summarized descriptively. 
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RESULTS 
 Between August 2010 and July 2011, 10 infants with a median age of 19 days 
(range 1–113 days) supported with ECMO were enrolled in the study, received at least 
1 dose of fluconazole, and were included in the safety analysis (Table 3.1.1). Nine 
infants received prophylactic intravenous fluconazole (25 mg/kg weekly infused over 2 
hours), and 1 infant (#7) was treated for presumed fungal infection with standard-of-care 
fluconazole (12 mg/kg intravenously daily infused over 1 hour). PK samples were 
collected from the 9 infants on prophylaxis around the first dose, and the 6 infants who 
remained on ECMO for more than 1 week were also sampled around the second dose. 
Infant #7, who received fluconazole 12 mg/kg/day, had PK samples collected around 
the final seventh dose. Thirty percent of infants were female, 60% were white, and 10% 
were Hispanic. Three infants were born pre-term. At time of cannulation, median 
corrected age was 41 weeks (range 36–53 weeks). Hemofiltration and/or continuous 
veno-venous hemodialysis (CVVHD) was used in 3 infants. Overall serum creatinine 
was similar between first dose and multiple dose evaluations, although 2 infants 
receiving hemofiltration or CVVHD had a 3-fold increase in their serum creatinine 
between dose 1 and 2. The renal dysfunction in infant #3 was multifactorial, while that in 
infant #6 was due to intrinsic renal dysfunction following cardiac arrest. In both cases, 
renal dysfunction occurred prior to initiation of hemofiltration.   
 
Pharmacokinetics  
 PK data were evaluated from 62 plasma samples around the first dose and 47 
samples after multiple doses. The plasma concentrations after the first dose and after 
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multiple doses are shown in Figure 3.1.1. The PK indices after first and multiple doses 
are presented in Table 3.1.2. A 1-compartment model with zero-order infusion 
appropriately described the data, and PK indices were estimated with high precision as 
evidenced by median clearance coefficient of variation of 10.2% (range 2.0–25.8%) and 
median volume of distribution coefficient of variation of 5.7% (range 1.4–16.1%). After 
the first dose, the median (interquartile range [IQR]) clearance was 17 mL/kg/h (14, 22), 
the median volume of distribution was 1.5 L/kg (1.3, 1.7), and the median AUC0–24 was 
322 mg*h/L (307, 343). After multiple doses, the median (IQR) clearance was 22 
mL/kg/h (11, 33), the median volume of distribution was 1.9 L/kg (1.4, 2.2), and the 
AUC0–24 was 352 mg*h/L (344, 399). Fluconazole clearance was inversely related to 
serum creatinine (Figure 3.1.2). Neither fluconazole clearance (P=0.92) nor serum 
creatinine (P=0.67) was significantly different between the first and multiple doses. 
There was no relationship between the fluconazole volume of distribution and amount of 
the volume of exogenous blood needed to prime the ECMO circuit (data not shown). A 
relationship between postnatal age and clearance and gestational age and clearance 
was not observed during visual inspection of scatter plots (data not shown). The volume 
of distribution of fluconazole did not differ significantly between dose 1 and multiple 
doses (P=0.14). The median fluconazole trough concentration before dose 2 was 1.8 
mg/L (range 0.2–5.4). 
 
Pharmacodynamic Targets 
 After the first dose, 7 out of 9 infants (78%) achieved the prophylaxis target of 
tMIC (4 mg/L) for >84 hours, which was 50% of the dosing interval.10 Only 1 infant (11%) 
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achieved the therapeutic target for treatment of invasive candidiasis of AUC0–24 > 400 
h*mg/L (Figure 3.1.3).11 After multiple doses of fluconazole, 5 out of 7 infants (71%) 
achieved the prophylaxis target, and none achieved the therapeutic target. None of the 
infants developed a fungal infection while enrolled in the study. 
 
ECMO Circuit Extraction 
 A total of 210 samples were included in the extraction analysis after 2 paired 
samples (1.9%) were identified as outliers and excluded from the analysis. Mean 
fluconazole extraction across the oxygenator was –2.0% (standard deviation 15.0), but 
there was wide dispersion around the mean. Extraction by the oxygenator did not 
correlate with the age of the ECMO circuit (rho= –0.05).  
 
Safety 
 There were 11 AEs in 6 infants, including 3 deaths. None of the AEs were 
probably or definitely related to study drug (Table 3.1.3). Three infants had elevated 
AST or ALT levels. In all 3 cases, the transaminase levels were elevated prior to 
initiation of study fluconazole and declined to normal levels while on study drug. Of the 
3 infants who died, 2 of the deaths were attributed to severe congenital heart disease, 
and 1 death was attributed to intracranial hemorrhage.  
 
DISCUSSION 
 Invasive candidiasis can be a devastating complication of ECMO. Invasive 
candidiasis is difficult to treat in this setting and is associated with higher mortality 
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compared with infants on ECMO without invasive candidiasis.3,4 Infants on ECMO with 
invasive disease require optimal dosing of antifungal drugs and may benefit from fungal 
prophylaxis. To prevent or treat invasive infection, the first step is to determine exposure 
of a candidate drug. This requires at least 1 PK and safety study in infants supported by 
ECMO because the ECMO circuit can substantially alter the PK of drugs through the 
addition of large volumes of exogenous blood to prime the ECMO circuit, adhesion of 
drug to components of the ECMO circuit, and renal insufficiency common in infants on 
ECMO.14  
 The complexity of the ECMO circuit and its impact on dosing have been 
observed for drugs that require therapeutic drug monitoring such as gentamicin7,15–17 
and vancomycin.9,18,19 PK data of antifungals in ECMO, however, are extremely scarce. 
Two case reports suggested that voriconazole and caspofungin may be extracted by the 
ECMO circuit, resulting initially in subtherapeutic exposure with standard dosing, 
although voriconazole concentrations became supra-therapeutic over time, consistent 
with decreased clearance.20,21 The voriconazole data were supported by an ex vivo 
ECMO model indicating that 71% of a voriconazole dose was adsorbed by the ECMO 
circuit within 3 hours of administration.22 
 In this PK trial of fluconazole in infants on ECMO, volume of distribution was 50–
90% higher and clearance was similar in infants on ECMO compared with a similar 
cohort of critically ill infants not on ECMO,13 resulting in lower fluconazole exposure 
(AUC0–24) (Table 3.1.4). The increased volume of distribution in infants on ECMO is 
consistent with physiology: infants have a total blood volume of ~80 mL/kg (estimated 
range for our cohort 160–500 mL), and 250–450 mL of blood are required to prime the 
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ECMO circuit. Thus, the circuit effectively doubles the native blood volume of these 
infants. Clearance was inversely related to serum creatinine. This relationship was also 
expected as the kidneys constitute the primary fluconazole elimination pathway. 
Therefore, renal function should be considered when dosing fluconazole in this 
population. However, fluconazole clearance can be affected by the concurrent use of 
hemofiltration or CVVHD. In adults supported with CVVHD, higher doses of fluconazole 
were required to maintain adequate exposure due to effective drug removal by the 
CVVHD system.23 Three of the infants enrolled in the present study received 
hemofiltration, and 1 received CVVHD. While the small sample size limits generalization 
of results (these 3 infants had the lowest, median, and highest fluconazole clearances, 
respectively), infant #3 who was supported with both hemofiltration and CVVHD had a 
threefold rise in serum creatinine between the start of dose 1 and start of dose 2, the 
lowest clearance, and the highest volume of distribution. This pattern of renal 
insufficiency is common in children on ECMO and supports the hypothesis that, for 
renally cleared drugs, a larger dose administered less frequently is appropriate. 
 Fluconazole undergoes minimal extraction by the ECMO circuit, and that 
extraction is not influenced by the age of the ECMO circuit. This finding is consistent 
with the low lipophilicity of fluconazole. Prior studies of drugs administered during 
ECMO have shown that increased lipophilicity is associated with increased adsorption 
by the circuit.24 Therefore, the findings from this study should not be extrapolated to 
other antifungal agents within and outside of class. Echinocandins have excellent 
activity against Candida species and penetrate biofilms, an appealing quality in a 
population for whom catheter removal is impossible. However, as a class, they are 
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nearly 100% protein-bound and highly lipophilic, which may predispose them to high 
adhesion to the ECMO circuit. 
 PK/PD indices for fluconazole prophylaxis are not well defined. Dosing for 
fluconazole prophylaxis in immuno-compromised adults ranges from 50–200 mg/day, 
targeting an AUC0–24 of 50–200 mg*h/L, though with these strategies some resistance to 
fluconazole has developed. In premature infants, doses of 3–6 mg/kg given twice per 
week have been shown to decrease the incidence of invasive candidiasis without 
concurrent development of resistance, though the power to detect differences in 
resistance in these studies was low.25–27 A murine model of invasive candidiasis showed 
that resistance could be prevented if fluconazole serum concentrations were kept above 
the MIC for >50% of the dosing interval.11 The typical MIC of Candida species in 
children ranges from 0.25 to 4 mg/L.25–28 
 In this trial of fluconazole prophylaxis of infants on ECMO, fluconazole 25 mg/kg 
weekly resulted in exposures comparable to those seen in prophylaxis trials in adults 
and children with malignancy29 and premature infants.25–27 Further, at this dose, 
fluconazole serum concentrations were kept above the MIC of 4 mg/L for 50% of the 
dosing interval in over 70% of infants on ECMO. Fluconazole 25 mg/kg weekly should 
be adequate to prevent invasive candidiasis in infants supported with ECMO and 
prevent development of resistance.  
 However, a fluconazole dose of 25 mg/kg did not achieve the necessary 
exposure to treat invasive candidiasis (AUC0–24 >400 mg*h/L) in this population on 
ECMO. This is in contrast to a cohort of critically ill children not on ECMO, in whom this 
therapeutic target was achieved in 70% of infants who received a fluconazole loading 
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dose of 25 mg/kg.13 Fluconazole PK is linear up to 40 mg/kg;30,31 thus, a fluconazole 
loading dose of 30–40 mg/kg would be needed to achieve an AUC0–24 effective to treat 
Candida infection in infants on ECMO. Only 1 infant in this study received daily 
fluconazole treatment doses (12 mg/kg/day), which limits the assessment of exposures 
achieved after repeat daily dosing. A fluconazole therapeutic regimen should be 
prospectively evaluated.  
 The decision to use fluconazole prophylaxis in children on ECMO should be 
based on individual risk factors and center-specific incidence of fungal infection. The 
overall rate of fungal infection for all ECMO centers is relatively low at 2 per 1000 
ECMO days.3 Prophylaxis for a low-prevalence infection must be weighed against the 
devastating consequences of and difficulty treating a fungal infection in this population.4 
A multi-center trial evaluating the epidemiology of fungal infection and efficacy of 
antifungal prophylaxis in children on ECMO is urgently needed.  
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Table 3.1.1. Demographics 
 
Weight Gestational Postnatal Age 
 
Serum Creatinine (mg/dL) Hemofiltration/ 
Infant (kg) Age (weeks) (days) Diagnosis Dose 1 Dose 2 CVVHD 
1 2.7 36 1 CHD 1 0.9 N/N 
2 3.2 37 7 PPHN 0.5 0.5 N/N 
3 3.9 41 7 MecAsp 0.6 1.8 Y/Y 
4 2.0 38 18 CHD 1.6 - N/N 
5 3.3 40 18 CDH 0.1 0.1 N/N 
6 3.4 39 20 Sepsis 0.4 1.5 Y/N 
7 3.2 38 24 PPHN - 0.6 N/N 
8 2.4 34 32 CHD 0.7 - N/N 
9 2.5 30 96 CHD 0.3 0.2 Y/N 
10 6.2 37 113 CHD 0.6  - N/N 
Median 3.2 37 19 
 
0.6 0.7 
 
IQR 2.6, 3.4 36, 39 9, 30 
 
0.4, 0.7 0.3, 1.4 
 
Gestational age refers to time elapsed between conception and delivery. Weight and postnatal age were calculated at time of 
enrollment, which was within 24 hours of first dose of study fluconazole for all infants except #7. Infant #7 was on standard-of-care 
fluconazole, and enrollment occurred between doses 6 and 7.  
Serum creatinine refers to the concentration measured closest to the dose. 
CHD indicates congenital heart disease; PPHN, persistent pulmonary hypertension; MecAsp, meconium aspiration; CVVHD, 
continuous veno-venous hemodialysis; IQR, interquartile range. 
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Table 3.1.2. Pharmacokinetic Indices 
  First Dose Multiple Doses 
 Dose CL V t1/2 tMIC AUC0–24 Dose CL V t1/2 tMIC AUC0–24 
ID (mg/kg) (mL/h/kg) (L/kg) (h) (%) (h*mg/L) (mg/kg) (mL/h/kg) (L/kg) (h) (%) (h*mg/L)
1 25 19 1.3 47 63 367 25 22 1.5 46 61 385 
2 25 22 1.7 55 61 288 25 19 1.9 68 83 352 
3 25 10 1.7 116 132 324 25 9 2.3 189 233 399 
4 25 17 1.5 60 75 343 - - - - - - 
5 25 33 1.4 29 39 322 25 33 1.4 29 38 347 
6 25 16 1.7 75 85 307 25 11 1.9 115 152 424 
7* - - - - - -  12 22 2.2 56 438 299† 
8 25 14 1.7 79 91 316 - - - - - - 
9 25 44 1.3 21 28 303 25 35 1.4 27 39 344 
10 25 11 1.2 76 106 423 - - -  - - - 
Median  17 1.5 60 75 322  22 1.9 56 83 352 
IQR  14, 22 1.3, 1.7 47, 76 61, 91 307, 343  11, 33 1.4, 2.2 37, 92 39, 233 344, 399 
*Infant 7 was on fluconazole per standard of care (12 mg/kg IV daily), and PK sampling occurred after the final (seventh) dose. All 
other multiple-dose data were obtained during the infants’ second dose. 
†tMIC and AUC0–24 for infant 7 were obtained by simulating exposure after a dose of 25 mg/kg using clearance and volume of 
distribution derived from the 1-compartment model. 
CL indicates clearance; V, volume of distribution; t1/2, half-life; tMIC, percentage of the dosing interval that fluconazole concentration 
was above the minimum inhibitory concentration of 4 mg/L (PD target was 50% of dosing interval); AUC0–24, area under the curve 
from 0–24 hours (PD target 400 h*mg/L); IQR, interquartile range. 
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Table 3.1.3. Adverse Events 
Infant Adverse Event Intensity Causality 
1 
Cardiac arrest due to cardiac anatomy Death Unrelated 
Renal hemorrhage Severe Unrelated 
Conjugated hyperbilirubinemia Moderate Unlikely 
3 Transaminitis Mild Unrelated 
5 Supraventricular tachycardia Moderate Unrelated 
6 
Adenovirus sepsis Life-threatening Unrelated 
Cardiac arrest due to myocarditis Life-threatening Unrelated 
Cerebral hemorrhage Death Unrelated 
Transaminitis Mild Unrelated 
7 Transaminitis Mild Unrelated 
8 Cardiac arrest due to cardiac anatomy Death Unrelated 
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Table 3.1.4. Pharmacokinetic Indices in Infants on ECMO after the First Dose of Intravenous 
Fluconazole 25 mg/kg Compared with Historical Controls not on ECMO who Received 1 Dose 
of Intravenous Fluconazole 25 mg/kg13 
 ECMO Non-ECMO P 
V (L/kg) 1.5 (1.3, 1.7) 1.0 (0.8, 1.4) 0.02 
CL (ml/h/kg) 17 (14, 22) 18 (14, 22) 0.57 
t1/2 (h) 60 (47, 76) 39 (24, 79) 0.49 
AUC0–24 (h*mg/L) 322 (307, 343) 476 (366, 492) 0.01 
Data for historical controls were extracted from Piper et al.13 minus their infant on ECMO and 
compared using Wilcoxon signed-rank test. 
ECMO indicates extracorporeal membrane oxygenation; V, volume of distribution; CL, 
clearance; t1/2, half-life; AUC0–24, area under the curve from 0–24 hours. All values are median 
(interquartile range).  
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FIGURE 3.1.1. Fluconazole concentration time profiles. A. Dose 1: Plasma concentration-time 
profiles in young infants (n=9) after receiving first dose of intravenous fluconazole 25 mg/kg. 
Concentrations at time=0 hours are concentrations prior to first dose. Pharmacodynamic (PD) 
target for prevention of fungal infection is serum concentration > minimum inhibitory 
concentration (MIC) (4 mg/L) for 84 hours (50% of the dosing interval). B. Dose 2: Plasma 
concentration-time profiles in young infants after receiving second dose of intravenous 
fluconazole 25 mg/kg (n=6). Infant #7 who received treatment fluconazole (12 mg/kg daily) is 
not represented in this figure. Concentrations at time=0 hours are trough concentrations prior to 
the second dose. PD target for prevention of fungal infection is serum concentration >MIC (4 
mg/L) for 50% of the dosing interval, which was 84 hours for the once-weekly 25 mg/kg dose. 
A. 
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B. 
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Figure 3.1.2. Serum creatinine versus clearance 
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Figure 3.1.3. Median (interquartile range) fluconazole exposure in the first 24 hours (AUC0–24) 
after dose 1 and multiple doses. Pharmacodynamic target for therapy is AUC0–24 >400 h*mg/L. 
AUC0–24 indicates area under the curve from 0–24 hours. 
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PART 2:  Fluconzole Population Pharmacokinetics and Dosing for the Prevention 
and Treatment of Invasive Candidiasis in Children Supported with Extracorporeal 
Membrane Oxygenation1 
 
INTRODUCTION 
Extracorporeal membrane oxygenation (ECMO) is life-saving in children with 
cardiorespiratory failure. ECMO is a cardiopulmonary bypass device that provides 
complete respiratory and cardiac support. Mechanically, blood is drained from the 
venous system, pumped through an artificial lung membrane where oxygen is added 
and carbon dioxide removed, and then returned to either the venous or arterial 
circulation. ECMO has been used successfully to support children with multiple disease 
processes including meconium aspiration syndrome, fulminant myocarditis, and sepsis.2 
Despite these successes, children supported with ECMO are at high risk for ECMO-
related complications, especially nosocomial infections.3 
Invasive candidiasis is common and fatal in children on ECMO. In this 
population, Candida species are the most common infectious organism.3 Incidence 
varies by center and rates as high as 10% have been reported.3,4 Candida infections 
cause substantial morbidity and mortality4 and are difficult to eradicate due to the 
organism’s ability to adhere to indwelling catheters. For this reason, routine 
management for candidiasis consists not only of antifungal agents but also removal of 
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catheters.5 Catheter removal for children on ECMO is often impossible, because the 
ECMO cannulas connect the child to the ECMO circuit. Therefore, therapy on ECMO 
relies on either prevention of invasive candidiasis or optimal therapeutic dosing in 
children with infection. Optimal dosing for prevention or treatment of candidiasis in 
children on ECMO can differ greatly from other populations due to the pharmacokinetic 
(PK) changes induced by the ECMO circuit. PK changes attributed to ECMO support 
include increased volume of distribution and decreased clearance, but these vary by 
drug and are not consistently predicted using drug physicochemical properties.6-9 This 
study describes the population PK of fluconazole in children supported with ECMO and 
provides rational dosing recommendations for the prevention and treatment of invasive 
candidiasis in this vulnerable population. 
 
METHODS 
Study Design 
Fluconazole samples were obtained from three prospective trials: Study 1 was a 
single-center, open-label PK study of fluconazole in children on ECMO (n=20);10 Study 
2 was a single center PK study of a fluconazole loading dose in critically ill children 
(n=12);11 and Study 3 was a multi-center PK study of fluconazole in infants (n=8).12 The 
study designs are described in detail elsewhere.10-12 In brief, Study 1 included critically 
ill children <18 years of age supported with ECMO who received intravenous (IV) 
fluconazole (25 mg/kg once weekly for prophylaxis or standard of care dosing for 
presumed fungal infection) for prevention or treatment of fungal infection. Study 2 
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included critically ill infants <1 year of age, one of whom was supported by ECMO, who 
received a fluconazole loading dose (25 mg/kg IV once) followed by daily maintenance 
therapy (12 mg/kg IV). Study 3 enrolled infants 23- to 42-week gestational age at birth, 
who were <120 days of age and were receiving IV fluconazole for prevention or 
treatment of candidiasis. We only included children from Study 3 who were > 36 weeks 
gestation to limit the PK variability introduced by prematurity.  These trials were 
approved by the respective institutional review boards and written informed consent was 
obtained from the legal guardian of each child. 
The following clinical variables were collected for all studies: postnatal age 
(PNA), weight, race, sex, presence of ECMO support, use of hemofiltration or dialysis, 
and serum creatinine (SCR). Serum albumin, aspartate aminotransferase (AST), and 
serum alanine aminotransferase (ALT) were collected for Study 1 and Study 2. PNA 
and weight were calculated on the day of first dose of study drug and those values 
imputed forward. For children with multiple measurements of SCR, albumin, AST, or 
ALT, values were allowed to change with time. For children without albumin, AST, or 
ALT measurements during the study period, values were set to the population medians 
(2.7 g/dL, 35 U/L, and 19 U/L, respectively). Comparison of covariate values between 
children on ECMO and those not on ECMO was done using Wilcoxon rank sum test in 
STATA 12 (College Station, TX). 
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PK Sample Collection 
Children in Study 1 had up to 12 plasma samples (200 μL) collected around dose 
1 and 2. Sampling windows at each dose included: 0–4 hours prior to the start of 
infusion and serial samples after the end of the infusion: 15 minutes (+/– 15 minutes), 3 
hours (+/– 1 hour), 9 hours (+/– 3 hours), 23 hours (+/– 1 hour), and 47 hours (+/– 1 
hour). Children in Study 2 had 6 to 8 plasma samples (200 μL) after the loading dose at 
the following time points after the end of the infusion: 15 minutes (+/– 15 minutes), 3 
hours (+/– 1 hour), 9 hours (+/– 3 hours), 21 hours (+/– 3 hours); and multi-dose 
sampling after doses 3 and 5 (0 to 4 hours before dose and 2 to 6 hours after dose). 
Infants enrolled in Study 3 were sampled pre-infusion, at the end of infusion, and 1, 7 
(+/- 1) or 11 (+/- 1), 24, and 48 h post-infusion. Samples were collected in 
ethylenediaminetetraacetic acid (EDTA) microcontainers and taken from a different site 
than the site used for fluconazole administration. Samples were processed immediately 
or placed on ice until processing. Plasma was separated via centrifugation (3000 g for 
10 minutes at 4o C), manually aspirated, and transferred to polypropylene tubes. 
Plasma samples were frozen at –80oC until analysis. To supplement these PK samples, 
plasma from leftover clinical samples collected per standard of care (EDTA 
Microtainers) was collected up to 72 h after sample collection. Fluconazole scavenge 
samples have been shown previously to be stable for up to 72 hours.12  
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Analytic Procedures 
Plasma fluconazole concentrations were determined using a validated liquid 
chromatography-tandem mass spectrometry assay.13 The lower limit of quantification 
was 0.01 mg/L; intraday and interday precision ranged from 2.84% to 10.8% and 5.27% 
to 11.5%, respectively, within the concentration range of the standard curve (0.01 to 10 
mg/L). 
 
Population PK Analysis 
PK data were analyzed with a nonlinear mixed effect modeling approach using 
NONMEM v7.2 (Icon Development Solutions, Ellicott City, MD) in conjunction with Perl 
speaks NONMEM v3.6.2.14 Run management was performed using Pirana v2.8.0.15 
Model analysis was summarized with STATA 12 (College Station, TX). A first order 
conditional estimation with interaction was used for all models. One and two-
compartment PK structural models were evaluated. Inter-individual random effects were 
evaluated on CL and V, and both diagonal and block Omega matrices for covariance 
were explored. An exponential model for inter-individual variance was used. ETA 
shrinkage was assessed to determine if the PK dataset was informative to adequately 
estimate inter-individual variability in PK parameter estimates. Proportional and additive 
plus proportional error models of residual variability were assessed. Body weight was 
incorporated into the base model before evaluation of other covariates due to multi-
collinearity with other clinical covariates. Both linear and allometric scaling of weight 
was assessed for clearance. For volume and intercompartmental clearance parameters, 
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size-based scaling was incorporated using a linear relationship with body weight. The 
impact of physiologically plausible covariates was evaluated if a relationship was 
suggested by visual inspection of scatter and box plots (continuous and categorical 
variables, respectively) of individual Bayesian estimates of CL and V obtained from the 
base model against covariates. The following covariates were evaluated: ECMO 
support; volume of blood required to prime the ECMO circuit; ratio of blood prime 
volume to a child’s estimated native blood volume; hemofiltration; use of continuous 
venovenous hemodialysis (CVVHD); SCR; albumin; AST; and ALT; PNA; sex; and race. 
All continuous variables were centered using the median value. Covariate testing was 
performed via standard stepwise forward addition backward elimination methods. 
Covariates were included in the multivariable analysis if the decrease in the objective 
function value relative to the base model was at least 3.84 (p<0.05). Covariates were 
retained in the final model if their removal from the multivariable model caused an 
increase in the objective function value of at least 6.635 (p<0.01). Empirical Bayesian 
estimates of individual PK parameters were generated from the final model using the 
post hoc subroutine. 
 
Model Evaluation 
Models were evaluated based on the successful minimization, goodness of fit 
plots, objective function values, plausibility of parameter estimates, and precision of 
parameter estimates. The precision of the final model was evaluated through 
bootstrapping with 1000 replicate datasets to generate median and 95% confidence 
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intervals for the PK parameter estimates. In addition, visual predictive check was used 
to evaluate model predictability by simulating 1000 datasets based on the final 
parameter estimates and their associated variance. The dosing and covariate values 
used to generate the predictions in the standardized visual predictive check were the 
same as those used in the study population. Simulated results were compared with 
results observed in the study and the number of observed concentrations outside of the 
90% prediction interval was quantified.  
 
Assessment of Dose-Exposure Relationship 
Fluconazole exhibits time-dependent fungistatic activity with a prolonged post-
antibiotic effect and efficacy is most closely associated with an area under the 
concentration time curve: minimum inhibitory concentration (AUC/MIC) ratio > 50.16-18 
For treatment, we chose to target a minimum AUC0-24 of 400 mg*h/L in 90% of children. 
The AUC0-24  of 400 mg*h/L achieves the target AUC/MIC ratio assuming a MIC of 8 
mg/L, the clinical laboratory standards institute (CLSI) sensitivity breakpoint for all 
Candida species.19 There are no established pharmacodynamic targets for prophylaxis; 
so we chose an AUC0-24 of 200 mg*h/L in 90% of simulated children to match the 
exposure seen in adults on 200-400 mg daily for prophylaxis.20-22  For prophylaxis it is 
important to minimize development of Candida resistance. The risk of developing 
resistance increases when fluconazole concentrations are below MIC for <50% of the 
dosing interval.23 Therefore, for prophylaxis, we also evaluated as a secondary endpoint 
the percentage of the dosing interval that concentrations were above MIC (%tMIC).  
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Monte Carlo simulations using parameter estimates from the final model were 
used to explore dose-exposure relationships using these targets. We explored a variety 
of dosing regimens based on current IDSA guidelines20 and our previous work 
describing fluconazole exposure in children on ECMO.10 We simulated 100 PK profiles 
for each child in the dataset based on the parameter estimates and variability derived 
from the final model to measure target attainment rates in the first 24 hours and at 
steady state. We stratified children by presence or absence of ECMO support. Using 
parameter estimates from the final model, we calculated the maximum (Cmax) and 
minimum (Cmin) fluconazole concentrations for each of 14 simulated dosing intervals 
using the equation for an intermittent infusion. We then used the Cmax and Cmin values to 
calculate AUC0-24 for each dosing interval using the linear-up log-down trapezoidal 
approach. 
 
 RESULTS 
Study infants and PK specimens 
PK samples were collected from 40 children who received intravenous (IV) 
fluconazole. The median (range) age of the children was 22 days (1 day, 17 years; 
Table 3.2.1). While some children were born prematurely, the median postmenstrual 
age for children less than 1 year of age was 41 weeks (35, 76). Data from 360 plasma 
PK samples with a median of 8 samples per child (1, 22) were included in the 
population PK analysis. Fifty-five (15%) of the PK samples were scavenge samples 
(Study 1 n=32; Study 2 n=6; Study 3 n=17). Twenty-one (53%) children were supported 
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by ECMO. Five of the children on ECMO had concomitant hemofiltration during PK 
sample collection and two of those children subsequently required CVVHD. The median 
number of SCR samples collected during the study period per child was 10 (1, 23). All 
children had a SCR sample at time of first dose. The median SCR value at the time of 
first dose was 0.4 mg/dL (0.1, 1.3) and the maximum SCR during the PK sampling 
period was 0.6 mg/dL (0.1, 3.2). The initial SCR was not significantly different between 
children on ECMO and those not on ECMO (0.5 vs 0.3 mg/dL, p=0.13). However, 
children on ECMO had a higher maximum SCR than children not on ECMO (0.7 vs 0.5 
mg/dL, p=0.03). Albumin and AST/ALT lab values were available for all children on 
ECMO but only half of those not on ECMO. Median albumin levels were low at 2.7 
whereas AST/ALT were within normal limits (Table 3.2.1). No children developed 
culture-confirmed invasive candidiasis while on study. 
 
Population PK model development 
A summary of the model building process is shown in Table 3.2.2. Based on 
goodness of fit criteria, a one compartment model best described the data. Weight was 
included in the base model for CL and V. CL and V were not correlated and use of a 
covariance term between CL and V did not improve model fit. ETA shrinkage of the 
base model was low for both CL (4.6%) and V (7.0%), allowing us to reliably estimate 
inter-individual variability for both parameters. Similarly the EPS shrinkage was low at 
9.6% suggesting that our model was not over-parameterized. Residual variability was 
best described by a proportional error model. While a proportional plus additive error 
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model resulted in a significant drop in the objective function, we were unable to 
precisely estimate the additive error component. Because goodness of fit plots and 
estimates were virtually identical between the two error models, we used the 
proportional error model in the final model. Allometric scaling of weight (3/4 power) on 
CL did not improve model fit and increased the objective function value by 9.7 points. 
Similarly, use of a sigmoidal Emax maturation relationship between postmenstrual age 
and CL resulted in an increase in the objective function value by 4.8 points. 
Consequently weight was scaled to the power of 1 for both CL and V. The residual 
unexplained inter-individual variability in CL was visually associated with SCR, 
hemofiltration, CVVHD, and albumin; while ECMO support, hemofiltration, and CVVHD 
were associated with inter-individual variability in V. During the univariable analysis, 
SCR and hemofiltration on CL, and ECMO and hemofiltration on V, resulted in a 
significant drop in the objective function and were included in the multivariable analysis. 
Neither ECMO prime volume nor the ratio of prime volume to native blood volume 
improved the model fit on V better than presence of ECMO support. Because these 
covariates are collinear with ECMO, we only included the effect of ECMO on V in the 
multivariable analysis. In the multivariable analysis, during the forward addition step, the 
addition of SCR and hemofiltration to CL, and ECMO support and hemofiltration to V, 
resulted in a significant drop in the objective function. However, during backward 
elimination, hemofiltration on CL and V did not improve the model goodness of fit nor 
did it significantly decrease the objective function value. The final model included the 
effect of SCR on CL, and ECMO on V. 
CL (L/h) = 0.019 * Weight * (SCR/0.5)-0.29 * exp(ηCL)  
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V (L) = 0.93 * Weight * 1.4ECMO * exp(ηV) 
Where ηCL and ηV refer to the interindividual variability on CL and V, respectively. 
ECMO=1 if ECMO is present and 0 if ECMO is not present. 
 
Model Evaluation and Validation 
The final model had good precision as evidenced by relative standard errors 
around the parameter point estimates for fixed effects (5.6-9.9%) and random effects 
(13.1-28.6%) and by 95% confidence intervals generated by bootstrapping (N = 1000 
simulated trials, 999 successful runs) (Table 3.2.3). Goodness-of-fit diagnostic plots for 
the final model are shown in Figure 3.2.1. The visual predictive check demonstrated a 
good fit between observed and predicted fluconazole concentrations (Figure 3.2.2). 
Only 4% (13/360) of observed concentrations were outside the 90% prediction interval, 
with 10 observations greater than the prediction interval and 3 observations below. Of 
the 3 subjects with observed data greater than the prediction interval, one had the 
highest dose in the cohort (27 mg/kg load followed by 12 mg/kg daily) and the other two 
received a high loading dose (25 mg/kg and 23 mg/kg, respectively, followed by 12 
mg/kg daily) in the context of mild to moderate renal dysfunction. The subject with 3 
observations below the prediction interval received the lowest dose of the cohort. None 
of these children were on ECMO and all were less than 2 years of age. 
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Empirical Bayesian Estimates of CL and V 
The median (range) empirical Bayesian estimates for CL and V in children not on 
ECMO were 0.018 L/h/kg (0.008, 0.042) and 0.93 L/kg (0.55, 1.37), respectively (Table 
3.2.4). Children on ECMO had ~45% higher V (median 1.35 L/kg, range 0.81, 1.81) but 
similar CL (median 0.018 L/h/kg, range 0.011, 0.043) compared to children not on 
ECMO. We saw a trend toward decreased impact of ECMO support on V with increased 
age, likely reflecting the changing relationship of ECMO prime volume (250-400mL) to a 
child’s native blood volume (~250-5000mL depending on age).   
 
Dose-Exposure Relationship 
Monte Carlo simulations showed that children, both supported and not supported 
by ECMO, who received the Infectious Disease Society of America (IDSA) 
recommended treatment dose of 12 mg/kg daily20 achieved the therapeutic target of  an 
AUC0-24   of 400 mg*h/L in 90% of simulated children (Table 3.2.5). However, the time to 
reach therapeutic concentrations varied markedly based on the loading dose. No 
children on ECMO receiving 12 mg/kg as the initial dose achieved the target of AUC0-24 
> 400 mg*h/L in the first 24 hours, and it took 10 days before 90% of simulated children 
had AUC0-24  of at least 400  mg*h/L. A loading dose of 25 mg/kg achieved the 
therapeutic target within 24 hours in 77.1% of simulated children not on ECMO; but only 
34.0% of children on ECMO reached the therapeutic target in the first 24 hours with this 
loading dose. A loading dose of 35 mg/kg was required to achieve AUC0-24 > 400 
mg*h/L in 87.7% of children on ECMO in the first 24 hours and 90% of children 
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achieved the target by day 2. Providing either a 40 mg/kg loading dose or 25 mg/kg 
every 12 hours in the first day of therapy achieved an AUC0-24 > 400 mg*h/L in 95.4% 
and 90.8% of children, respectively, in the first 24 hours. However, the maximum 
simulated concentrations after the 40 mg/kg loading dose and the second 25 mg/kg 
dose were considerably higher (62.1 and 68.0 mg/L, respectively) than after a single 
loading dose of 35 mg/kg (54.6 mg/L) raising concerns for toxicity (Table 3.2.5, Figure 
3.2.3). 
For prophylaxis children on ECMO who received 6 mg/kg daily per current IDSA 
guidelines did not achieve therapeutic exposure (AUC0-24 > 200 mg*h/L in 90% of 
children) until day 7 of therapy (Table 3.2.5). If children on ECMO receive a prophylactic 
loading dose of 12 mg/kg followed by 6 mg/kg daily, most (68.9%) children will reach an 
AUC0-24 >200 mg*h/L by day 2, and 90.0% of children will achieve the therapeutic AUC0-
24 by day 5 of therapy. We also simulated exposure using the prophylactic dose 
evaluated in the ECMO Fluconazole Study (25 mg/kg once weekly) and found that this 
dosing regimen achieved the target exposure during the first two days of the dosing 
interval, but on days 3-7, only 65.9%, 33.8%, 14.5%, 5.8%, and 2.2% of children, 
respectively, achieved an AUC0-24 > 200 mg*h/L. We simulated 12 mg/kg every 72 
hours and found that even after 4 doses (12 days), there were zero days when 90% of 
children on ECMO had an AUC0-24 > 200 mg*h/L. 
Because of the wide range of age and weight among study subjects, the same 
treatment and prophylaxis simulations were performed in children <2 years of age (data 
not shown). Results from these simulations were within 5% of the results above. 
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DISCUSSION 
Current treatment recommendations for invasive candidiasis are inadequate for 
treatment in children supported with ECMO. For the treatment of invasive candidiasis, 
we chose to target exposures observed in critically ill adults taking fluconazole 800 mg 
per day. A dose of 12 mg/kg per day achieved therapeutic exposure in children on 
ECMO but it took 10 days to reach those concentrations. In a critically ill child, this delay 
is unacceptable. Loading doses are routinely used in adults and in a prior analysis of 
one of the trials included in the current study, a fluconazole loading dose of 25 mg/kg 
appeared safe and achieved pharmacodynamic targets in 90% of a small cohort of 
children.11 Because of the increased V observed in children on ECMO, a higher loading 
dose (35 mg/kg) was required to achieve comparable exposure. Clinicians must 
balance the risk of subtherapeutic exposure against the risk of toxicity. In adults, a dose 
of 1600 mg per day and serum concentrations less than 80 mg/L were well tolerated.24 
The simulated 90th percentile concentration following a loading dose of 35 mg/kg was 
34.2 mg/L, and after 12 mg/kg maintenance therapy was 51.8 mg/L at steady state. 
While loading doses of 40 mg/kg and 25 mg/kg q12 in the first 24 hours also achieved 
therapeutic exposure in children on ECMO, the simulated 90th percentile concentration 
was closer to 80 mg/L leading us to choose 35 mg/kg as the optimum loading dose.  
The safety of this loading dose should be prospectively evaluated in children. 
Because invasive candidiasis is so difficult to treat in children on ECMO, this 
population might benefit from antifungal prophylaxis. Pharmacodynamic targets are not 
well defined for prophylaxis but IDSA guidelines recommend 200-400 mg per day in 
immunocompromised and critically ill adults, equating to an AUC0-24 of 200-400 mg*h/L. 
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In addition to achieving appropriate prophylactic exposure, consideration must be given 
to limiting development of resistance to fluconazole. In vitro studies suggest that 
maintaining plasma concentrations above the MIC for 50% of the dosing interval limits 
resistance, but it is unclear if the length of the dosing interval impacts this assumption. 
The ECMO fluconazole prophylaxis study included in this population analysis evaluated 
a dose of 25 mg/kg given once weekly. While almost all of these children maintained a 
fluconazole concentration above an MIC of 4 mg/L for 50% of the dosing interval, many 
were below the MIC for the remainder of the dosing interval (3.5 days). Considering the 
uncertainty regarding how long fluconazole concentrations can remain below the MIC 
before the risk of resistance increases, we also simulated multiple daily regimens. Given 
the devastating results of invasive candidiasis in children on ECMO and the safety 
profile of fluconazole, we recommend routine fluconazole prophylaxis of 12 mg/kg on 
day 1, and 6 mg/kg/d while on ECMO in centers with a high incidence of Candida 
infection. SCR should be monitored closely during fluconazole administration given the 
propensity of children on ECMO to develop renal dysfunction. 
The difference in fluconazole exposure in children on ECMO compared to those 
not on ECMO is related to the increased V seen in children on ECMO. Increased V is 
expected due to the large volume of exogenous blood required to prime the circuit and 
the physiology associated with critical illness (e.g., inflammation). Our data suggest that 
as children age, the impact of ECMO support on V decreases, likely reflecting the 
volume of the ECMO prime in relation to the child’s native blood volume. For a 3kg 
infant, the circuit prime volume (250-400mL) might exceed the infant’s native blood 
volume (~250mL), while in a 70kg adolescent, the prime volume is ~8% of the child’s 
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blood volume (~5L). Our data are limited by the fact that only five of the 40 children 
were over the age of 2 years and all of these were on ECMO. Empirical Bayesian 
estimates of V in these five children (median 1.1 L/kg [range 0.8, 1.5]) were slightly 
higher compared to estimates of V reported in children ages 2-12 years (0.95 L/kg)25 
and critically ill adults (0.6-0.7 L/kg).22 Given the severity of illness seen in our children 
and the contribution of the ECMO prime, our estimates are reasonable. However, 
because very few children in this study were over the age of 2 years, we recommend 
caution in extrapolating our results to this older population. Further study of the impact 
of ECMO on fluconazole V is warranted in children over 2 years of age. ECMO also can 
increase V through adsorption of drug by the ECMO circuit; this is well described for 
other drugs.9, 26 However, a previous analysis evaluating fluconazole extraction by the 
ECMO circuit showed that fluconazole undergoes minimal adsorption by the circuit and 
is unlikely to contribute to increased V.10  
In our model, CL decreased with increasing SCR. This relationship also was 
expected as fluconazole is primarily excreted by the kidneys. Renal insufficiency is 
common in children supported with ECMO;2 but ECMO support itself was not 
significantly associated with changes in CL. When combined with the observation that 
neither CL nor SCR were significantly different between children on ECMO and those 
not on ECMO, these results suggest that dosing modification in children with renal 
insufficiency should adhere to label guidelines regardless of ECMO support. The 
possible exception to this conclusion is when ECMO is combined with hemofiltration or 
CVVHD. Studies in adults show that fluconazole CL increases in the presence of 
hemofiltration and CVVHD.27-30 Only 5 children received hemofiltration and two received 
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CVVHD, limiting our ability to draw conclusions about their impact on CL. We 
recommend caution in extrapolating our results to children on concomitant ECMO and 
hemofiltration or CVVHD. 
 
CONCLUSIONS 
Fluconazole V is increased in children supported with ECMO. As a result, 
children on ECMO who develop invasive candidiasis require a fluconazole loading dose 
of 35 mg/kg followed by a daily maintenance dose of 12 mg/kg to achieve exposures 
similar to children not on ECMO who are loaded with 25 mg/kg and maintained on 12 
mg/kg daily. Children on ECMO may benefit from antifungal prophylaxis and in this 
population a loading dose of 12 mg/kg followed by 6 mg/kg daily is reasonable based on 
adult exposures after 200-400 mg per day. Children over two years of age are 
underrepresented in this study and results of the present study should be extrapolated 
to this population with caution. In addition, these results are based on simulated clinical 
trials. Confirmatory, prospective trials of fluconazole exposure, safety, and efficacy in 
this population are needed. 
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Table 3.2.1. Clinical Data 
 Total ECMO Support Non-ECMO 
n 40 (100) 21 (53) 19 (47) 
Body weight (kg) 3.4 (1.9, 77) 4.2 (2.0, 77) 3.2 (1.9, 8.0) 
Postnatal age (days) 22 (1, 6498) 113 (1, 6498) 13 (1, 262) 
Gestational age (weeks)* 38 (24, 41) 38 (30, 41) 37 (24, 40) 
Postmenstrual Age (weeks) 41 (35, 76) 42 (36, 63) 39 (35, 76) 
Female 
Race 
White  
African American 
Other 
14 (35) 
 
17 (43) 
18 (45) 
5 (12) 
7 (33) 
 
9 (43) 
10 (48) 
2 (9) 
7 (37) 
 
8 (42) 
8 (42) 
3 (16) 
Indication 
Prophylaxis 
Treatment 
 
23 (57) 
17 (43) 
 
17 (81) 
4 (19) 
 
6 (32) 
13 (68) 
First dose (mg/kg) 25 (2.7, 26.5) 25.0 (10.4, 25.7) 17.4 (2.7, 26.5) 
PK sample collection period (days)‡ 5.5 (2.0, 34.0) 8.8 (2.1, 21.3) 4.2 (2.0, 34.0) 
PK samples per child 8 (1, 22) 11 (5, 22) 8 (1,14) 
Serum creatinine (mg/dL) 
Initial§ 
Maximum 
 
0.4 (0.1, 1.3) 
0.6 (0.1, 3.2) 
 
0.5 (0.1, 1.2) 
0.7 (0.3, 3.2) 
 
0.3 (0.1, 1.3) 
0.5 (0.1, 1.3) 
Albumin (g/dL) 
Aspartate Aminotransferase (U/L) 
Alanine Aminotransferase (U/L) 
2.7 (1.1, 4.0) 
35 (15, 673) 
19 (8, 127) 
2.8 (2.0, 4.0) 
39 (23, 673) 
16 (8, 127) 
2.7 (1.1, 3.1) 
35 (15, 159) 
19 (8, 126) 
Values are medians (range) for continuous variables and counts (%) for categorical variables. 
*Gestational age is only reported for infants < 1 year of age (n=33) 
‡ Sample collection period is the time between first dose of study drug and collection of last PK sample 
§ Initial serum creatinine collected +/- 24 hours of first dose 
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Table 3.2.2. Population PK model development  
Model description Population model OFV ∆OFV 
Base model and univariable analysis*   
Volume of distribution (L) V = θV * WT  1022.74  
ECMO V = θV * WT * 1.41 ECMO (=1 or 0)  1008.22 -14.52 
Hemofiltration V = θV * WT * 1.54 HMFLTR (=1 or 0)  1012.13 -10.61 
Clearance (L /h) CL = θCL * WT  1022.74  
Creatinine CL = θCL * WT * (creatinine/0.4)-0.29  950.84 -71.91 
Hemofiltration CL = θCL * WT * 0.66 HMFLTR 1019.18 -3.56 
Multivariable analysis    
CL= f(SCR), V=f(ECMO) V = θV * WT * 1.39 ECMO 
CL = θCL * WT * (creatinine/0.4)-0.29 
936.95 -13.89† 
CL = f(SCR), V = f(ECMO,HMFLTR) V = θV * WT * 1.30 ECMO * 1.34 HMFLTR 
CL = θCL * WT * (creatinine/0.4)-0.29 
930.70 -6.25‡ 
CL= f(SCR, HMFLTR), V = f(ECMO, HMFLTR) V = θV * WT * 1.30 ECMO * 1.34 HMFLTR
CL = θCL * WT * (creatinine/0.4)-0.29 * 0.90 HMFLTR 
930.33 -0.37‡ 
Final model    
V = f(ECMO) V = θV * WT * 1.39 ECMO   
CL= f(SCR) CL = θCL * WT * (creatinine/0.4)-0.29 936.95 -13.89† 
OFV – objective function value; V – volume of distribution; CL – Clearance; WT – weight; SCR – serum creatinine, HMFLTR – 
hemofiltration; All coefficients in the models above are estimated parameters from the respective model 
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* Only models of covariates that significantly improved OFV are shown in the unvariable analysis. For full list of covariates tested 
see Methods. 
† ∆OFV calculated relative to CL~Creatinine model (950.84) 
‡ ∆OFV calculated relative to preceding model 
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 Table 3.2.3. Final population PK model parameter estimates 
   Bootstrap CI 
Parameter Point 
estimate 
% RSE 2.5% Median 97.5% 
Fixed Effects 
V (L/kg) 0.93 5.8 0.83 0.93 1.06 
CL (L/h/kg) 0.019 5.6 0.017 0.019 0.021 
Coefficient for ECMO on V 1.39 7.8 1.17 1.39 1.63 
Exponent for creatinine on CL -0.29 9.9 -0.41 -0.29 -0.24 
Random Effects      
V interindividual variability (CV%) 22.2 28.6 14.7 21.5 27.7 
CL interindividual variability (CV%) 33.2 21.3 25.0 32.6 39.2 
Residual proportional error (CV%) 15.3 13.1 13.0 15.2 16.9 
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 Table 3.2.4. Bayesian estimates of V and CL based on ECMO support 
 
ECMO 
 
no ECMO 
V (L/kg)   
0-30d 1.5 (1.3, 1.8) 0.96 (0.55, 1.4) 
31d-2y 1.2 (0.91, 1.6) 0.83 (0.72, 1.0) 
>2y-17y 1.1 (0.81, 1.5) - 
All 1.3 (0.81, 1.8) 0.93 (0.55, 1.4) 
CL (L/h/kg)   
0-30d 0.018 (0.013, 0.043) 0.018 (0.008, 0.042) 
31d-2y 0.022 (0.011, 0.039) 0.017 (0.008, 0.029) 
>2y-17y 0.014 (0.013, 0.029) - 
All 0.018 (0.011, 0.043) 0.018 (0.008, 0.042) 
Values are median (range)  
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Table 3.2.5. Exposure in children on ECMO after different simulated dosing regimens 
Indication Loading Dose 
Maintenance 
Dose 
Dosing 
Interval
PD Target† 
achieved in 
first 24h 
Time to 
therapeutic 
exposure† 
 (mg/kg) (mg/kg) (h) (% of children) (days) 
Treatment 
- 12 q24 0 10  
25 12 q24 34.0 8 
35 12 q24 87.7 2 
40 12 q24 95.4 1 
25 q12h 12 q24 90.8 1 
Prophylaxis
- 6 q24 0 7 
12 6 q24 27.8 5 
- 12 q72 27.8 * 
- 25 q168 99.9 * 
PD – pharmacodynamics 
† PD target for treatment/therapeutic exposure is AUC0-24 > 400 mg*h/L in 90% of simulated children; PD target for prophylaxis is 
AUC0-24 > 200 mg*h/L in 90% of simulated children.  
* For q72h and q168h dosing we set the target as AUC0-24 > 200 mg*h/L in 90% of simulated children for each 24h period during the 
dosing interval. Using this approach, 90% of simulated children never maintained an AUC0-24 > 200 mg*h/L for each 24h period.  
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Figure 3.2.1.  Final population PK model diagnostic plots: observed versus population 
prediction (A) and individual prediction (B), weighted residuals versus population predictions 
(C), and time (D). A, B, The line of identity is included as a reference. For conditional weighted 
residuals (CWRES), a solid line at y = 0 is included as a reference 
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Figure 3.2.2. Visual predictive check. Shaded area represents the 95% prediction interval. 
Circles are observed data. Solid line represents the median of the observed data and dashed 
line the median of the predicted data. 
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Figure 3.2.3.  Simulated fluconazole plasma concentrations and exposure.  
Figures A and B depict treatment doses and C-F depict prophylactic doses. A. Simulated fluconazole plasma concentrations in 
children on ECMO (35 mg/kg load) compared to children not on ECMO (25 mg/kg load). Both cohorts received 12 mg/kg daily as 
maintenance. B. Simulated fluconazole exposure in children on ECMO after different loading doses. Lines for individual dosing 
regimens represent 10th percentile of exposure (i.e., 90% of simulated children above the line). Horizontal dashed line represents 
target AUC for therapy. Simulated fluconazole plasma concentrations (C) and exposure (D) in children on ECMO receiving 12 mg/kg 
load then 6 mg/kg daily. Simulated fluconazole plasma concentrations (E) and exposure (F) in children on ECMO receiving 25 mg/kg 
once weekly. Solid line is the median and shaded regions represent the 90% prediction interval. Dashed lines in C and E represent 
MIC 4 mg/L. Dashed lines in D and F represent target AUC for prophylaxis. AUC is calculated for a 24 hour period for all figures.
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CHAPTER 4. PHYSIOLOGICALLY-BASED PHARMACOKINETICS OF 
FLUCONAZOLE IN CHILDREN ON ECMO 
INTRODUCTION 
Fluconazole is a triazole antifungal drug available in both intravenous (IV) and 
oral formulations that is rapidly absorbed from the gastrointestinal tract with high oral 
availability (~92% bioavailability).1 Fluconazole is not bound extensively to plasma 
proteins (11%, alpha-1-acid glycoprotein [AAG]2,3), and exhibits excellent penetration 
into the cerebrospinal fluid with concentrations approximating 80% of those measured in 
plasma.1 Penetration into other body tissues also approximates or exceed 
concentrations found in the plasma; the urine:plasma concentration ratio is 10:1.1 Mass 
balance studies in humans show that fluconazole is eliminated primarily by the kidneys 
with 80% of the dose excreted as unchanged drug, and 11% recovered as 
metabolites.4,5 Fluconazole is metabolized primarily by UDP-Glucuronosyltransferase-
2B7 (UGT2B7).6 The triazoles inhibit the enzyme responsible for converting lanosterol 
to ergosterol, a key component of fungal cell membranes, resulting in cell lysis and 
death.7-9 Fluconazole has excellent activity against Candida, and is labeled for 
treatment of invasive candidiasis in infants and children.1 Although it is a first-line drug 
for treatment of invasive candidiasis in the pediatric intensive care unit, fluconazole 
pharmacokinetics (PK) and dosing may be affected by the altered physiology observed 
in critically ill children.10-18   
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 Critical illness can affect PK by altering absorption, distribution, metabolism, and 
excretion (ADME) of drugs. Absorption can be both decreased (e.g., intestinal 
hypoperfusion, decreased absorptive capacity),19-21 and increased (e.g., intestinal 
hypomotility).22 Drug distribution typically is increased due to inflammation and capillary 
leak that results in edema and increased volume of distribution (V), and 
hypoalbuminemia, which commonly occurs in critical illness.23-28 However, AAG is an 
acute phase reactant protein that often is elevated in critical illness. Some data suggest 
that the elevated AAG concentrations in critical illness increase the amount of protein 
available for binding and consequently increase the fraction of bound drug.2,3 Hepatic 
metabolism typically is decreased due to decreased expression and function of drug 
metabolizing enzymes.29-32 Renal clearance can be affected by the competing 
phenomena of augmented renal clearance and acute kidney injury that both occur in 
critical illness.33-35 The impact of critical illness on hepatic transporter function and biliary 
elimination is not well described. However, inflammation, which is common in critical 
illness, is known to impact transporter expression and function in animal models.36-38 
The impact of critical illness on drug disposition is exacerbated in the setting of 
extracorporeal membrane oxygenation (ECMO). In addition to direct interaction 
between the drug and ECMO circuit, ECMO support results in altered blood flow and 
increased inflammation, edema, hemolysis, and renal dysfunction.39-44 
Physiologically-based pharmacokinetic (PBPK) modeling is ideally suited to 
describe the PK in critically ill children supported with ECMO. PBPK models are 
structured to represent physiologically relevant spaces (Figure 4.1). Each virtual “organ” 
is parameterized with mass-balance differential equations describing the disposition of 
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drug within the compartment. Because PBPK models are mechanistic, age-related 
processes of drug disposition can be incorporated into the model to predict exposure 
across the pediatric age spectrum. Further, the model parameters can be adjusted to 
account for the altered physiology associated with critical illness (e.g., decreased renal 
blood flow). In order to model drug exposure in children on ECMO, an ECMO “organ” 
can be linked to the PBPK model and parameterized using data from ex vivo studies 
(Chapter 2). By defining the volume, blood flows, and drug clearance of the ECMO 
compartment, the impact of ECMO on drug disposition can be predicted in vivo, and the 
ECMO PBPK model can be used to determine optimal dosing in this vulnerable 
population.  
 
METHODS 
Model Building Workflow 
 The model building process followed an established workflow (Figure 4.2).45-47 A 
PBPK model was developed in adults (Adult PBPK Model) to gain confidence in the 
model structure using robust adult data before proceeding with pediatric model 
development. After model validation, the Adult PBPK Model was scaled to children 
(Pediatric PBPK Model). Once the Pediatric PBPK Model met acceptance criteria (see 
PBPK Model Acceptance Criteria below), an ECMO compartment was added to the 
Pediatric PBPK Model to form the ECMO PBPK Model. 
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Adult PBPK Model 
The whole-body PBPK model was structured with 15 organ compartments using 
mass balance differential equations describing drug entering and exiting the 
compartments (Figure 4.1). The link between physiologic spaces was the blood 
circulation. The model assumed a 30-year-old Caucasian male with a mean body 
weight of 73kg and height of 176cm based on population-level data from the National 
Health and Nutrition Examination Survey (NHANES) dataset.48 Based on these 
anthropometric measurements, organ weights, volumes, and blood flows were 
generated using the International Commission on Radiological Protection (ICRP) 
database.49  
 The distribution model assumed each organ consisted of 4 sub-compartments: 
plasma, red blood cells (together forming the vascular space), interstitial fluid, and 
cellular space. A permeation barrier exists between the vascular space and the 
interstitial fluid, and between the interstitial fluid and the cellular space. The organ-to-
plasma partition coefficients and cellular permeabilities were determined using drug 
physicochemical properties based on methods described by Willmann et al.50,51 For 
fluconazole, a perfusion–rate-limited model was assumed where each tissue or organ 
represented a well-stirred compartment.52 This implied that drug reaching the tissue or 
organ was distributed instantaneously in the whole volume of the physiological space. 
Other distribution models (e.g., permeation limited) were included if they improved 
model predictions. 
 Drug-specific information from the literature included physicochemical properties 
and clearance pathways of the drug (Table 4.1). Mass balance studies with radiolabeled 
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IV fluconazole indicated that 91% of fluconazole was eliminated in the urine, with 80% 
as unchanged drug, 2% was eliminated in the feces, and 7% was not recovered.53 
Because biliary elimination was a small fraction of total elimination, this process was not 
included in the model. As a result, the model assumed 15% of the plasma clearance of 
fluconazole was due to hepatic metabolism and 85% to renal elimination. Metabolism 
was attributed to glucuronidation via UGT2B7, and unbound intrinsic clearance (CLI’) 
was calculated using hepatic clearance (CLH).6 CLH was assumed to be 15% of total 
empiric clearance. Fluconazole is highly reabsorbed in the renal tubule, so renal 
clearance (CLR) was adjusted by calculating the glomerular filtration rate (GFR) fraction 
as follows: 
 
ܩܨܴ	ܨݎܽܿݐ݅݋݊ ൌ ܧ݉݌݅ݎ݅ܿ ܥܮோܧݔ݌݁ܿݐ݁݀ ܥܮோ 
(eq. 1)
 
where Empiric CLR equals the renal clearance reported in the literature.54 Expected CLR 
is the clearance expected due to GFR if there was no reabsorption or tubular secretion 
(Expected CLR = fraction unbound*GFR = fu *110 ml/min). A summary of the 
assumptions used in the model building process is included in Table 4.2  Plasma 
concentration vs. time profiles were generated using the initial model and compared 
with observed data from the literature (Table 4.3, Adult Development Datasets). Model 
parameters were optimized based on the observed data using the Nelder-Mead 
algorithm in the MoBi® Toolbox for Matlab.55 The optimized model was used to 
generate population predictions of plasma concentration vs. time profiles for a virtual 
population of healthy adults (n=1000) created using the PK-Sim® population module.56 
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Inter-individual variability of UGT2B7 expression was assumed to have log-normal 
distribution with a geometric standard deviation of 1.34.57 Fluconazole’s unbound 
fraction (fu) was assumed to have a normal distribution with an arithmetic standard 
deviation of 7%.2,3 Optimized model predictions for the virtual population were 
compared first with the observed data from the Adult Development Datasets to 
determine if the model met acceptance criteria (see PBPK Model Acceptance Criteria 
below). In order to evaluate the model performance, the optimized model predictions 
were then compared with observed data from the literature that were not used in the 
model building process (Adult Validation Datasets, Table 4.3). After acceptance criteria 
were met, the model was scaled to children. 
 
Pediatric PBPK Model 
Age-dependencies in physiological parameters (e.g., body weight, organ weight, 
blood flow) were included to scale the Adult PBPK Model to children according to the 
methods described by Edginton et al.45 In short, parameters were assigned for each 
simulated individual: age, race, gender, mean body weight and height.49 Based on body 
weight and height, organ weights and volumes were obtained from the ICRP 
database.49 Age-dependent blood flows for some organs were available in the 
literature.58-71 For the organs in which no data were available, the same percentage of 
cardiac output in adults was assumed.49,72  
The mechanistic drug clearance method was used to scale adult plasma 
clearance to children using 1) adult clearance, 2) the proportion of total clearance (CLT) 
attributed to each clearance process (e.g., renal versus hepatic), 3) the fraction of 
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unbound drug and major protein responsible for binding, and 4) the age of the child.73 
CLT was assumed to be the sum of CLR and CLH. CLR was attributed to GFR and 
passive reabsorption. GFR was scaled to children by calculating the percentage of adult 
GFR expected in a child of a specific age, and adjusted for fu(child): 
 
ܥܮீிோሺ௖௛௜௟ௗሻ ൌ
ܩܨܴሺ௖௛௜௟ௗሻ
ܩܨܴሺ௔ௗ௨௟௧ሻ ൈ
௨݂ ሺ௖௛௜௟ௗሻ
௨݂ ሺ௔ௗ௨௟௧ሻ
ൈ ܥܮீிோ ሺ௔ௗ௨௟௧ሻ (eq. 2)
 
Where CLGFR(child) is the child’s clearance due to GFR, GFR(child) is the estimated GFR of 
the child, GFR(adult) is the GFR in adults (assumed to be 110 mL/min73), and CLGFR(adult) 
is the clearance due to GFR  in adults. The GFR(child) was calculated using a 
postmenstrual age model,74 and fu (child) was estimated using an age-specific model 
considering plasma protein concentrations in children and the affinity of drugs for 
binding proteins.73,75 Reabsorption (GFR Fraction) was assumed to have no ontogeny. 
To scale CLH to children, the adult plasma clearance was converted to hepatic 
unbound intrinsic clearance (CLI’); 
 
ܥܮூ′ ൌ ܥܮு ൈ ܳுܳு െ ܥܮு ൈ
1
௨݂
 (eq. 3)
 
Where QH is hepatic blood flow. Adult CLI’ was then scaled to children using age- and 
enzyme-specific percent of adult activity (ontogeny); 
 
ܥܮூ	′௎ீ்ଶ஻଻ሺ௖௛௜௟ௗ	௚	௟௜௩௘௥ሻ ൌ ܱܵܨ௎ீ்ଶ஻଻ ൈ ܥܮூ′௎ீ்ଶ஻଻ሺ௔ௗ௨௟௧ ௚ ௟௜௩௘௥ሻ (eq. 4)
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Where CLI’UGT2B7(child g liver) is the scaled CLI’ due to UGT2B7 per gram of liver, OSFUGT2B7 
is the ontogeny scaling factor for UGT2B7,73 and CLI’UGT2B7(adult g liver) is the adult CLI’ due 
to UGT2B7.  
Finally, the child CLI’ was converted back to child plasma CL using pediatric body 
weight, liver weight, and blood flow.  
 
ܥܮூ′ሺ௖௛௜௟ௗ	௧௢௧௔௟	௟௜௩௘௥ሻ ൌ ܥܮூ′௎ீ்ଶ஻଻ሺ௖௛௜௟ௗ ௚ ௟௜௩௘௥ሻ ൈ ܮ ௖ܹ௛௜௟ௗ (eq. 5)
ܥܮு	ሺ௖௛௜௟ௗሻ ൌ
ܳு	ሺ௖௛௜௟ௗሻ ൈ	 ௨݂ ሺ௖௛௜௟ௗሻ ௧௢௧௔௟ ௟௜௩௘௥ ൈ ܥܮூ′ ሺ௖௛௜௟ௗሻ௧௢௧௔௟ ௟௜௩௘௥
ܳு	ሺ௖௛௜௟ௗሻ ൅ ሺ ௨݂	ሺ௖௛௜௟ௗሻ	 ൈ ܥܮூ′ሺ௖௛௜௟ௗሻ௧௢௧௔௟	௟௜௩௘௥ሻ/ܤܲሺ௖௛௜௟ௗሻ
 
(eq. 6)
 
Where LWchild is the liver weight of the child and B/P(child) is the blood/plasma ratio. 
Previously described ontogeny models were used for the hepatic enzyme of interest 
(UGT2B7) to calculate the percent of adult activity at specific ages.73 The mechanistic 
pediatric scaling information was included in software databases. In order to evaluate 
the performance of the Pediatric PBPK Model, model predictions were generated using 
a simulated population of infants (N=1000) created with the PK-Sim® population 
module56 and compared with raw data from a PK study of fluconazole in critically ill 
infants (Pediatric Validation Dataset, Table 4.3).  The median (5th, 95th %ile) area under 
the concentration time curve for 0-24 hours (AUC0-24) for these 13 children was 485 
mg*h/L (350, 664) and was calculated using compartmental methods as described in 
Piper et. al 2011.76 
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ECMO PBPK Model 
The Pediatric PBPK Model was exported into MoBi® where a new compartment 
reflecting the ECMO circuit was added (Figure 4.1). Flow into and out of the ECMO 
compartment was assigned by partitioning pulmonary blood, with 80% assigned to the 
ECMO compartment and 20% assigned to the lungs. The ECMO compartment was 
assigned a volume of 400mL to reflect the standard volume of blood required to prime 
the ECMO circuit. Because the ex vivo results from Chapter 2 showed that fluconazole 
was not extracted by the circuit, no additional clearance function was added to the 
ECMO compartment. As children on ECMO develop severe edema secondary to 
capillary leak syndrome, edema was added to the model by increasing the child’s body 
weight by 50%, and assigning the resulting increase in volume to the interstitial space of 
all organ compartments.44,77 The ECMO PBPK Model with edema was then exported 
back into PK-Sim® to perform population simulations. The population simulations were 
evaluated by comparing model predictions with observed data from the Fluconazole 
ECMO Trial described in Chapter 3. To determine the optimal loading dose that 
achieves target exposures for fluconazole in children on ECMO, new simulations were 
performed using the ECMO PBPK Model with distinct dosing regimens for different age 
groups. 78,79 
 
Assessment of Dose-Exposure Relationship 
Fluconazole is fungistatic and has a prolonged post-antibiotic effect. Efficacy is 
associated with an AUC to minimum inhibitory concentration ratio (AUC/MIC) ≥ 50.80-82 
Assuming a MIC of 8 mg/L, based on the Clinical and Laboratory Standards Institute’s 
   
114 
 
guideline sensitivity breakpoint for all Candida species, an AUC0-24 of 400 mg*h/L 
achieves the target AUC/MIC ratio.83 For treatment, a target minimum AUC0-24 of 400 
mg*h/L in 90% of children was chosen. The AUC0-24 was calculated for the PBPK model 
simulations using the linear-up log-down trapezoidal approach. The AUC0-24 for the 
observed data was calculated using the final population PK model from Chapter 3 and 
Monte Carlo simulations, also using the linear-up log-down trapezoidal approach (see 
Chapter 3 Methods). In order to balance efficacy and safety, predicted exposures also 
were compared with maximum tolerated AUC0-24 (1600 mg*h/L) and concentration (Cmax 
70 mg/L).84 
 
PBPK Model Acceptance Criteria 
The population predictability was assessed by generating a prediction interval 
(5th to 95th percentile) of drug concentrations for the population, and quantifying the 
number of observed concentrations that fell outside of the prediction interval. Because 
the goal of this model was to determine dosing, and because dosing is based on AUC, 
minimal bias in AUC estimates was desired. Model precision was assessed by 
calculating the fold error between PBPK predicted AUC and observed AUC. 
 
ܨ݋݈݀	ܧݎݎ݋ݎ ൌ ܣܷܥ଴ିଶସܲܤܲܭܣܷܥ଴ିଶସܱܾݏ݁ݎݒ݁݀ 
(eq. 7)
 
Parameters with 0.7-1.3 fold error were considered as reasonable predictions.45  
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RESULTS 
Adult PBPK Model 
Mean GFR fraction, LogP, and adult CLI’ were optimized to 0.16, 0.2, and 0.007 
L/min, respectively (Table 4.1). Optimized Adult PBPK Model predictions versus dose-
normalized observed data from the two Model Development Datasets showed good 
agreement. Based on visual inspection of the plots, approximately 85% of the observed 
data fell within the 90% prediction interval of the simulated population concentrations 
(Figure 4.3). Observed data in the initial phase of distribution (5-15 minutes) were over 
predicted by the model; however, subsequent data were well described. The predicted 
AUC was within 16% of observed AUC (Table 4.4). 
When optimized model predictions were compared with observed data from Adult 
Validation Datasets (i.e., data not used to build the model), over 90% of the observed 
data fell within the 90% prediction interval of the model and predicted AUC was within 
10% of observed (Figure 4.4, Table 4.4). Based on the excellent predictive power of the 
optimized model, the Adult PBPK Model was scaled to children. 
 
Scaling to Children 
Pediatric simulations evaluating the recommended loading dose of 25mg/kg76,85 
showed good agreement between observed versus predicted concentrations. Based on 
visual inspection of the plots, 70% (30/43) of the observed data fell within the 90% 
prediction interval of the simulated population concentrations (Figure 4.5). If 
concentrations from infants with renal dysfunction or severe edema were excluded 
(n=10), the model captured 89% (28/32) of the observed data. The observed AUC0-24 
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estimate using compartmental modeling was 485 mg*h/L, and 84% of the individuals 
were above the target AUC0-24 of 400 mg*h/L. The Pediatric PBPK Model predicted an 
AUC0-24 of 507 mg*h/L (Fold Error 1.05) with 95% of simulated individuals achieving the 
target AUC0-24 of 400 mg*h/L (Figure 4.6).  
 
ECMO PBPK Model 
When the observed data from the Fluconazole ECMO Trial were compared to the 
model predictions from the Pediatric PBPK Model, only 26% of the observed data fell 
within the 90% prediction interval (Figure 4.7.1). Compared to the observed AUC0-24  
(371 mg*h/L) reported in Chapter 3, the AUC0-24 was over-predicted (520mg*h/L; 1.40 
fold error). Adding the ECMO compartment to the Pediatric PBPK Model modestly 
improved predictions, although still only 26% of the observed data fell within the 90% 
prediction interval (Figure 4.7.2). The AUC0-24 was still over-predicted, but to a lesser 
extent (502 mg*h/L; 1.35 fold error). After adding the Edema disease state, 71% (30/42) 
of the observed data fell within the 90% model prediction interval (Figure 4.7.3). The 
PBPK predicted AUC0-24 for a loading dose of 25 mg/kg for the ECMO PBPK Model was 
420 mg*h/L, which equated to a 1.13 fold error compared to the observed AUC0-24 of 
371 mg*h/L that was estimated using the final population PK model described in 
Chapter 3 (Figure 4.8).  
Based on the precision of AUC estimates, the ECMO PBPK Model was used to 
simulate multiple dosing regimens and identify the optimal loading dose for each age 
group. The following age-dependent loading doses were found to achieve the target 
AUC0-24 in ≥ 90% of simulated children on ECMO in the first 24 hours of therapy: 
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neonates (0-29d) 35 mg/kg, infants (30d-<2y) 30 mg/kg, children (2y-<6y) 25 mg/kg, 
school-age children (6y-<12y) 25 mg/kg, and adolescents 20 mg/kg (Figure 4.9).  
Because complicated dosing regimens are often difficult to implement, the ECMO 
PBPK Model also was used to simulate exposures after a loading dose of 35 mg/kg for 
all age cohorts (Figure 4.10). This approach achieved the target AUC0-24 in ≥ 90% of 
simulated children on ECMO in the first 24 hours of therapy and no simulated child had 
an AUC0-24 (701 [307, 1036]) or Cmax (50.5 [12.3, 65.4]) greater than the safety 
threshold values of 1600 mg*h/L and 70 mg/L, respectively. 
 
DISCUSSION 
The critically ill child, especially with extracorporeal support, represents an ideal 
population for the use of PBPK modeling. Surprisingly, this approach has never been 
used in this population. In the present study, an established workflow for PBPK-based 
scaling from adults to children was employed, and then the ECMO device and disease 
state effects (i.e., edema) were added to successfully predict exposure in children on 
ECMO. The Adult PBPK Model provided an excellent description of the data, except for 
the early distribution phase. Over-prediction in the early phase may be attributed to the 
assumption in the model that initial mixing and distribution is instantaneous. This 
assumption fails to account for the lag time between drug administration to a peripheral 
site and distribution to the systemic circulation.86 Although drug binding to the IV 
catheter used to administer fluconazole also could account for model over-prediction, 
this is unlikely based on the ex vivo results detailed in Chapter 2 that demonstrate 
limited interaction of fluconazole with circuit materials. Given that 1) model over-
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prediction was limited to the early distribution phase, 2) the AUC0-24 between observed 
and predicted data showed good agreement, and 3) external validation with other 
datasets showed good agreement, the model performance was deemed to be 
acceptable for scaling to children. 
The healthy adult model was scaled to children, and then the healthy infant 
model was used to predict exposures in critically ill infants. In the process of scaling to 
children, drug-specific inputs used in the optimized Adult PBPK Model were held 
constant, and system-specific inputs were scaled to the population of interest. The 
Pediatric PBPK Model only captured 70% of the observed data for critically ill infants, 
but this was expected because the model was based on healthy infants. PBPK model-
predicted exposures were compared with exposures from critically ill children. Critically 
ill children have more variability in exposure due to disease. An examination of the data 
that fell below the 90% prediction interval revealed that 8 of the 10 observations (80%) 
were from children who had just undergone cardiac surgery and had substantial edema 
and inflammation, which would result in a higher V and lower initial fluconazole 
exposure.44,87,88 Similarly, of the 3 concentrations that were greater than the 90% 
prediction interval, one (33%) came from an infant with decreased GFR. Decreased 
GFR for fluconazole, which undergoes renal clearance, resulted in decreased CL and 
higher than expected exposures. Adjustments in the model depend on the purpose of 
the model. For example, if the purpose is to predict dosing in children after cardiac 
surgery, then an edema disease state should be added to better describe the altered 
physiology in that population. The purpose of the Pediatric PBPK Model was to build the 
ECMO PBPK Model and predict dosing in children on ECMO. Before adding an ECMO 
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compartment, confidence in the scaling process from adults to children needed to be 
established. The Pediatric PBPK Model was deemed acceptable for developing the 
ECMO PBPK Model as it explained the majority of concentrations that fell outside the 
90% prediction interval, and because observed AUC0-24 and PBPK-predicted AUC0-24 
showed close agreement. 
Observed data from the Fluconazole ECMO Trial showed that exposures were 
substantially lower in infants on ECMO compared to critically ill infants not on ECMO. 
As a result, the Pediatric PBPK Model over-predicted exposure in children on ECMO. 
Adding the ECMO compartment only lowered exposure by ~5%. This is not surprising 
as the only direct impact of ECMO was the addition of 400mL of blood required to prime 
the ECMO circuit. The impact of the ECMO prime volume was decreased because of 
fluconazole distribution from the plasma into other body tissues. The ECMO PBPK 
Model suggests that the bigger impact on fluconazole exposure may be attributed to 
edema common in infants on ECMO. ECMO support results in inflammation and 
subsequent capillary leak and edema.44,87,88 In addition, ongoing fluid resuscitation can 
result in a substantial increase in interstitial fluid volume.44 When the interstitial fluid 
volume in the ECMO PBPK Model was increased, predicted exposure showed good 
agreement with the observed data. The remaining over-prediction based on the model 
was likely due to other factors that increase V but were not captured in the model (e.g., 
ongoing fluid resuscitation, repeated blood product transfusions).  
The edema disease state was based on the assumption that edema caused a 
50% increase in body weight, and that the increase in volume was added to the 
interstitial compartment of each organ. A 50% increase in body weight is on the upper 
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end of what would be expected.44,87,88 The model predictions were sensitive to the 
extent of edema. If a 10% increase in body weight was assumed, the model-predicted 
AUC increased by 14%. In order to improve accuracy of this parameter, future studies 
should capture both the extent of edema in each individual and the other factors such 
as ongoing fluid resuscitation that can lead to altered PK.  
 Overall the ECMO PBPK Model showed good agreement with observed data, 
and was used to predict the loading dose for different age groups. Based on 
simulations, the loading dose required for >90% of children to achieve the therapeutic 
target (AUC0-24 >400 mg*h/L), decreased with age. This is in part a function of the 
decreasing impact of ECMO on fluconazole exposure in older children with increased 
body size. Because the direct impact of ECMO on fluconazole exposure is due to the 
prime volume of the circuit (400mL), that impact is decreased as the ratio of prime 
volume to native blood volume decreases from neonates (400mL:250mL) to 
adolescents (400mL:5L).  
 One of the advantages of PBPK modeling is the ability to predict dosing across 
the pediatric age spectrum. However, this must be balanced with clinical feasibility. The 
age-specific dosing regimen predicted with the ECMO PBPK model is optimized for 
each age group but is likely too complicated for clinical implementation. Choosing a 
single weight-based dose for all children involves balancing the consequences of 
underexposure with the risk of toxicity due to overexposure. Fluconazole is safe up to a 
Cmax of 70 mg/L and a maximum AUC0-24 of 1600 mg*h/L.84 Based on the wide 
therapeutic index and because the consequences of an inadequately treated fungal 
infection in a child on ECMO are devastating, dosing should target a higher exposure to 
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ensure all children are adequately treated. A dosing regimen of 35 mg/kg for all children 
achieves the therapeutic exposure in over 99% of simulated children while no simulated 
children exceed the known safety thresholds. Based on this, a fluconazole loading dose 
of 35 mg/kg is recommended for all children with suspected or confirmed fungal 
infection who are supported with ECMO. 
In conclusion, an Adult PBPK Model of fluconazole was developed, and scaled to 
children. By adding an ECMO compartment and the impact of ECMO-related changes 
in physiology, the modified model successfully predicted exposure (PBPK AUC within 
0.7-1.3 fold error of observed AUC) in infants on ECMO. The dosing recommendations 
derived for neonates and infants are comparable to the dosing recommendations 
developed from the population PK model in Chapter 3. More importantly, because the 
PBPK model is mechanistic in nature, and able to take into account developmental 
changes in size and ADME processes, dosing was predicted in pediatric populations 
that have not been studied previously. In addition, when new ECMO technology is 
introduced, ex vivo ECMO experiments could be performed to determine the interaction 
of fluconazole with the new circuit. Information generated based on the fluconazole-
circuit interactions could then be incorporated into the ECMO compartment of the 
ECMO PBPK Model and new dosing recommendations developed, thereby 
circumventing the need to repeat a large PK trial. While these recommendations will still 
need to be prospectively validated, the validation trial should be smaller and more 
efficient. 
   
122 
 
 
 
Table 4.1. Fluconazole physicochemical properties and elimination pathways 
Parameter Reported value Optimized value 
Physicochemical properties 
Lipophilicity (LogP) 0.489 0.2 
Protein binding partner Alpha-1 acid glycoprotein2,3  
Fraction unbound (%) 8990  
Molecular weight (g/mol) 306.2789  
Compound type/pKa Weak base/2.5689  
Charge Neutral89  
Blood/Plasma ratio 1.053  
Metabolism and elimination 
GFR fraction 0.16 (0.15-0.18)53,54 0.16 
UGT2B7 CLI’ (L/min) 0.0052 (0.0031-0.0073)53,54 0.007 
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Table 4.2. Assumptions used in the model building process 
Factor Assumption Reference 
Mass balance Because biliary clearance plays only a minor role (2.3%), total 
clearance was partitioned between CLR (85%) and CLH (15%; 
UGT2B7). 
Brammer et al. 199153 
Renal clearance via GFR Fluconazole is highly reabsorbed. 84% reabsorption was assumed 
based on eq. 1 using a CLR of 17.6 ml/min from the literature. 
Brammer et al. 199153 
Debruyne 199354 
Metabolism via UGT2B7 Fluconazole has at least two metabolites, but only UGT2B7 has been 
identified as a metabolizing enzyme.  
Bourcier et al. 20106 
UGT2B7 interindividual variability Interindividual variability of UGT2B7 was assumed to have log-normal 
distribution with a geometric SD of 1.34. 
Sim et al. 199157 
UGT2B7 ontogeny UGT2B7 reaches adult concentrations and function by 1 year of age. Edginton et al. 2006 45 
Edema Body weight in children on ECMO can be increased by >50% due to 
edema. 
Anderson et. al 199291 
Protein binding Protein binding is variable in critical illness; fu = 89% with standard 
deviation = 7% was assumed. 
Arredondo et al. 19943 
Arredondo et al. 19952 
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Table 4.3. Studies used in model development and evaluation 
Population N Age Dosing interval Dose Reference 
Adult Development Datasets      
Healthy volunteers 10 27y (SD 4) Single dose 100mg Yeates et al. 199492 
Healthy volunteers 8 21.1y (range 21, 22) Single dose 50mg Shiba et al. 199093 
 8 21.1y (range 21, 22) Single dose 25mg Shiba et al. 199093 
Adult Validation Datasets      
Healthy volunteers 10 NR Single dose 50mg Brammer et al. 199094 
Healthy volunteers 10 NR q24 hours 50mg Brammer et al. 198795 
Healthy volunteers 10 NR q24 hours 100mg Foulds et al. 198896 
Pediatric Validation Dataset      
Critically ill infants 13 36d (range 6-262d) q24 hours 25mg/kg Piper et al. 201576 
ECMO Validation Dataset      
Critically ill infants on ECMO 11 24d (range 1-165d) q24-168 hoursa 25mg/kg Watt et al. 201597 
aThe dosing interval for the Fluconazole ECMO Trial was variable based on indication, so only data from the first 24 hours was used.  
 
NR – not reported
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Table 4.4. Observed versus PBPK Predicted AUCs for adult studies used in model 
development and validation. 
Population N Dose 
Observed 
AUC (mg*h/L) 
PBPK Predicted AUC 
(mg*h/L) 
Fold Error 
Adult Development Datasets      
Healthy volunteers92 10 100mg 73a 85 1.16 
Healthy volunteers93 8 50mg 34b 36 1.06 
 25mg 17b 19 1.12 
Adult Validation Datasets      
Healthy volunteers95 10 50mg 39c 41 1.05 
Healthy volunteers96 10 100mg 32d 34 1.06 
AUC time intervals reported in the Adult Development and Validation Datasets varied by study, so 
PBPK model generated a corresponding AUC for each study: a AUC0-∞ after a single dose; b AUC0-72 
after a single dose; c AUC0-∞ after a single dose; d AUC0-24 after a single dose. One of the adult 
validation datasets94 did not report AUC and was not included in this table.. 
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Figure 4.1. PBPK model structure.  
Standard model structure Model structure with ECMO compartment 
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Figure 4.2. PBPK workflow 
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Figure 4.3. Adult optimized model. PBPK model predictions for a dose of 1mg versus dose-normalized observed concentrations from 
the Adult Development Datasets. Solid black line represents the median predicted concentration; grey shaded area represents the 
90% prediction interval; observed data (mean +/- 90% confidence interval) are represented by symbols. 
  
 
Shiba et al. 1990 (25mg)
Shiba et al. 1990 (50mg)
Yeates et al. 1994 (100mg)
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Figure 4.4. Adult model validation. PBPK predicted exposures versus observed data from 
Adult Validation Datasets. Solid black line is median predicted concentration; grey shaded 
area represents the 90% prediction interval; observed data (mean +/- 90% confidence 
interval when reported) are represented by symbols. 
Brammer et al. 199094; 50mg single dose 
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Brammer et al.198795; 50mg q24 hours 
 
 
Foulds et al. 198896; 100mg q24 hours 
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Figure 4.5. Pediatric PBPK Model predictions versus observed data from critically ill infants. All infants received a single 25 mg/kg 
loading dose. Solid black line is median predicted concentration; grey shaded area represents the 90% prediction interval; observed 
data are represented by symbols.  
 
No edema, normal renal function 
Edema 
Renal dysfunction 
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Figure 4.6. Pediatric PBPK Model AUC0-24 predicted versus observeda following a 25 mg/kg 
loading dose. Solid black horizontal line is median, box represents interquartile range and 
whiskers are 90% confidence interval. Dashed blue horizontal line represents target AUC0-24. 
Median AUC0-24 and percentage of children achieving target AUC0-24 shown below each plot. 
AUC0-24 485 mg*h/L 
84% ≥ 400 mg*h/L 
AUC0-24 507 mg*h/L 
95% ≥ 400 mg*h/L 
 
aObserved AUC0-24 was calculated using compartmental modeling described in Chapter 3.  
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Figure 4.7. ECMO PBPK Model development. Model predictions and observed data were 
based on a loading dose of 25 mg/kg in infants. 
1. Base PBPK model: Pediatric PBPK Model predictions versus observed 
concentrations in infants on ECMO 
 
AUC0-24 520 mg*h/L 
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2. Addition of ECMO compartment to the Pediatric PBPK Model 
 
AUC0-24 502 mg*h/L 
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3. Addition of the ECMO compartment and incorporation of Edema to the Pediatric 
PBPK Model 
 
AUC0-24 420 mg*h/L 
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Figure 4.8. ECMO PBPK Model AUC0-24 predicted versus observeda following a 25 mg/kg 
loading dose. Solid black horizontal line is median, box represents interquartile range, and 
whiskers are 90% confidence interval. Dashed blue horizontal line represents target AUC0-24. 
Median AUC0-24 and percentage of children achieving target AUC shown below each plot. 
 
                       AUC0-24 371 mg*h/L 
                                35% ≥ 400 
                  AUC0-24 420 mg*h/L 
                         67% ≥ 400 
 
aObserved AUC0-24 was calculated using the final population PK model and Monte 
Carlo simulations described in Chapter 3.  
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Figure 4.9. ECMO PBPK Model-predicted optimized fluconazole dosing and exposure in 
children on ECMO across the pediatric age spectrum.  Solid line represents the median, box 
represents interquartile range, and whiskers represent 90% prediction interval.  Dosing 
achieved the target AUC0-24 (>400 mg*h/L, blue dashed line) in ≥ 90% of simulated children on 
ECMO in the first 24 hours of therapy. 
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Figure 4.10. ECMO PBPK Model-predicted fluconazole exposure after a loading dose of 35 
mg/kg in children on ECMO across the pediatric age spectrum.  Solid line represents the 
median, box represents interquartile range, and whiskers represent 90% prediction interval.  
Dosing achieved the target AUC0-24 (>400 mg*h/L, blue dashed line) in ≥ 99% of simulated 
children on ECMO in the first 24 hours of therapy. 
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CHAPTER 5: PHARMACOKINETICS AND SAFETY OF MICAFUNGIN IN INFANTS 
SUPPORTED WITH EXTRACORPOREAL MEMBRANE OXYGENATION1 
 
INTRODUCTION 
Extracorporeal membrane oxygenation (ECMO) provides respiratory and cardiac 
support in critically ill infants when conventional modes of life-support fail.2 Although 
potentially life-saving, ECMO support is associated with a high risk of nosocomial 
infections in children (8-16%).3 The most common cause of ECMO-related nosocomial 
infection in infants and children and the second most common cause in neonates is 
invasive candidiasis.3 Invasive candidiasis causes high rates of morbidity and mortality 
and is difficult to treat because of the organism’s ability to form biofilms on indwelling 
catheters.4 For this reason, recommended treatment of invasive candidiasis consists of 
both antifungal therapy and removal of indwelling catheters.5,6 However, catheter 
removal for children on ECMO is impossible; therefore, therapy relies upon optimal 
dosing of antifungal agents.  
Micafungin is an attractive antifungal drug in infants on ECMO because it is 
fungicidal against a broad spectrum of Candida spp, and can penetrate biofilms.7-9 
However, the optimal dosing of micafungin remains to be established in the setting of 
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ECMO because ECMO support can alter drug pharmacokinetics (PK).10,11 In infants on 
ECMO, the volume of distribution (V) of drugs typically increases due to the large 
volume of blood required to prime the ECMO circuit, disease state (e.g., inflammation, 
anasarca), and drug adsorption by the ECMO circuit itself.10-14 Clearance (CL) of drugs 
can be affected by the organ dysfunction commonly observed in infants on ECMO, as 
well as non-specific drug extraction by the circuit itself. Micafungin may be more 
vulnerable to adsorption by the circuit because it is highly protein bound (>99%).15 
Therefore, it is likely that current micafungin dosing recommendations for treatment (2-3 
mg/kg every 24h) are inadequate for infants on ECMO.16 In this open-label PK trial, we 
determined micafungin PK in infants on ECMO and compared the resulting micafungin 
exposure to adult exposures known to be effective against invasive candidiasis.  
 
MATERIALS AND METHODS 
Design and study population 
This was a prospective, open-label, PK and safety study of micafungin conducted 
at Duke University Medical Center. We enrolled infants (0-2y) supported with ECMO, 
excluding those with a history of echinocandin allergy. Infants without fungal infection 
were enrolled in the prophylaxis arm and received intravenous (IV) micafungin per study 
protocol (4 mg/kg every 24h, infused over 1h). Infants with suspected or confirmed 
fungal infections who were prescribed micafungin per standard of care, were enrolled in 
the treatment arm and dosing was adjusted per study protocol to 8 mg/kg every 24h, 
infused over 1h. Duration of micafungin prophylaxis was up to 8 days, whereas duration 
of therapy in the treatment arm was determined by the treating physician. Because 
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micafungin is light-sensitive, drug vials and infusion bags were protected from light.17 
However, the ECMO circuit is not protected from light, so it is possible that micafungin 
in the blood was exposed to light while transiting the ECMO circuit. This trial was 
approved by the institutional review board of Duke University Medical Center, registered 
with clinicaltrials.gov (NCT01666769), and conducted under a Food and Drug 
Administration investigational new drug application (No.115255). Written informed 
consent was obtained from the legal guardian of each infant. 
 
PK sampling 
We collected up to 14 plasma PK samples (200 µL of whole blood per sample) 
around dose 1 and 4 via a peripheral arterial catheter. The protocol did not allow 
drawing PK samples from site of administration. Sampling intervals were as follows (1 
sample per interval): 0-4h before the start of infusion, and 0-30 min, 60-90 min, 2-4h, 8-
10h, 12-16h, and 22-24h after the end of micafungin infusion. Samples were collected in 
ethylenediaminetetraacetic acid microcontainers and processed immediately or placed 
on ice (<30 minutes) until processing. Plasma was separated via centrifugation (3000g 
for 10 minutes at 4°C), manually aspirated and transferred to polypropylene tubes. 
Plasma samples were frozen at –20°C for a maximum of 24h, and stored at -80°C until 
analysis. PK samples were protected from light when stored in the freezer. No special 
precautions were undertaken during processing of samples because reconstituted 
micafungin was shown to be stable up to 24 hours at room temperature when exposed 
to light, as suggested in the drug label.17  
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ECMO Circuit Configuration  
Two types of ECMO circuits were used; S3 and CardioHelp (Figure 5.1). A 
hemofilter (Sorin DHFO.2, Sorin Group, Milan, Italy) was used in infants requiring 
hemofiltration. The prime volume for each circuit was 450mL and included packed red 
blood cells (350mL), fresh frozen plasma (50mL), Plasmalyte® crystalloid (50mL), 
sodium bicarbonate (25mEq), and heparin (100units).  
 
PK analysis 
Plasma micafungin concentrations were determined using a validated high 
performance liquid chromatography assay with fluorescent detection.18 The lower limit 
of quantification was 0.05 mg/L. Intraday precision ranged from 1.28% for the highest 
concentration of the standard curve (25.00 mg/L) to 17.90% for the lowest concentration 
(0.05 mg/L). Interday precision ranged from 3.27% to 14.41% within the concentration 
range of the standard curve (0.05–25.00 mg/L). 
Primary outcomes were micafungin CL and V. PK data were analyzed by 
nonlinear regression with the most appropriate model using Winonlin v6.3 (Pharsight 
Co., St. Louis, MO). The model fit was evaluated using successful minimization, 
diagnostic plots, goodness of fit as assessed by the Akaike Information Criterion and 
precision of the parameter estimates. We assessed systemic exposure by estimating 
area under the concentration-time curve from 0 to 24h (AUC0–24) after the 1st and the 4th 
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dose. AUC0–24 was computed by the linear up log down trapezoidal method using 
observed data. We assessed the relationship between PK parameters and covariates 
potentially affecting micafungin disposition (age, serum albumin, aspartate 
aminotransferase, total bilirubin, and duration of ECMO support) by visual inspection of 
scatter plots.19-21 Finally, we explored the relationship between PK parameters and the 
number of doses (single vs multiple doses), and the presence of the hemofilter in the 
ECMO circuit, using a Wilcoxon rank-sum test. 
 
Assessment of dose-exposure relationship 
For a target efficacy exposure, we used an AUC0-24 range of 75-139 mg*h/L as a 
surrogate pharmacodynamic (PD) endpoint.20,22 This endpoint matches the micafungin 
exposure achieved by adult participants who cleared their fungal infection in the large, 
phase III efficacy trial.23  There is no established target exposure for Candida 
prophylaxis, however, IV micafungin 50 mg (1 mg/kg in children) daily was proven 
effective in preventing fungal infections in 882 adults and children undergoing 
hematopoietic stem cell transplantation.24 Because micafungin PK is linear in this dosing 
range, the prophylactic exposure target was set to 50% of the therapeutic target (37.5-
69.5 mg*h/L).20,22,25  
In order to characterize micafungin exposure, we simulated a variety of dosing 
regimens and measured the proportion of infants in our population who achieved the 
therapy and prophylaxis exposure targets after the 1st and 4th micafungin dose. 
Simulations were performed by estimating the maximum (Cmax) and minimum (Cmin) 
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micafungin concentrations for each individual for the first dosing interval and at steady 
state using the equation for an intermittent infusion with the individual parameter 
estimates from the final model. We then used the predicted Cmax and Cmin values to 
calculate the AUC for the dosing interval from 0 to 24h and at steady state using the 
equations for the linear-up log-down trapezoidal approach.  
 
Safety  
The secondary outcome was the proportion of infants experiencing adverse 
events (AEs). AEs were defined as any untoward medical occurrence whether or not 
considered drug-related during the conduct of the clinical trial. AEs were recorded while 
on study drug and for 7 days after the last study dose of micafungin. Liver toxicity and 
hypokalemia were the AEs of special interest because they were described previously 
in 3% and 2% of infants and children, respectively, receiving micafungin.22 Levels of 
serum aspartate aminotransferase, alanine aminotransferase and potassium were 
therefore measured at baseline (within 72h prior to the first study dose), and at the end 
of the study (within 72h after the last study dose). Other laboratory determinations were 
recorded from consent through 72h after the last study dose, if performed per standard 
of care. Other laboratory determinations included albumin, blood urea nitrogen, serum 
creatinine, sodium, complete blood count and microbiology culture results. The safety 
data were summarized descriptively. We used STATA 13 (College Station, TX) to 
perform the statistical analyses. 
   
152 
 
RESULTS 
We enrolled 12 infants on ECMO support with a median (range) postnatal age of 
59 days (0, 574) (Table 5.1). Two infants were born preterm (27 and 34 weeks of 
gestational age [GA]) and were 122 and 187 days postnatal age at time of enrollment, 
respectively. Infants were supported by ECMO for a median time of 4 days (2, 10) 
before the first micafungin dose. Of the 12 infants, 11 (92%) received prophylactic 
intravenous (IV) micafungin (4 mg/kg every 24h) for 4 (2, 8) days. One infant (ID # 2) 
was treated for presumed fungal infection with IV micafungin (8 mg/kg every 24h) for 6 
days. Site of drug administration included central venous catheter (n=7) and ECMO 
circuit, post-oxygenator (n=1). Site of drug administration was not listed for 4 infants. All 
11 infants from the prophylactic group had PK samples collected around dose 1, and 
5/11 (45%) of these infants remained on micafungin long enough to complete sampling 
around dose 4. The one infant in the therapeutic group had PK samples collected 
around doses 2 and 5. PK samples were collected from a peripheral arterial line in all 
infants but one for whom site of PK sampling was not listed. Hemofiltration was used in 
4/12 (33%) infants (Table 5.2). 
 
Pharmacokinetics  
We collected a total of 124 plasma samples, with a median of 11 (6, 14) samples 
per infant. Plasma concentration-time profiles are shown in Figure 5.2. A 1-
compartment model with zero-order infusion appropriately fit the data (Table 5.2). PK 
parameters were estimated with high precision as evidenced by median CL and V 
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coefficient of variation of 6% (5, 14) and 11% (8, 14), respectively. Three/124 (2%) PK 
samples were excluded from the analysis; one concentration was below the lower limit 
of quantification (subject ID#5), and 2 plasma samples lacked confirmation of sampling 
time (Subject ID#12). PK parameter estimates did not change when these 3 
concentrations were removed from the analysis. Median [95% confidence interval] CL 
decreased over the study period from 0.04 L/kg/h [0.03, 0.05], to 0.02 L/kg/h [0.02, 0.03] 
after single and multiple doses, respectively. Median [95% CI] V was 0.62 L/kg [0.53, 
0.73) and 0.52 L/kg [0.31, 0.67] after a single and multiple doses, respectively.  
We did not observe a significant difference in CL between infants with and 
without a hemofilter in the circuit (median [range] CL of 0.04 L/kg/h [0.03, 0.04] vs 0.04 
L/kg/h [0.03, 0.06], respectively, p=0.50) nor did we observe a significant relationship 
between V and the presence of a hemofilter (0.54 L/kg [0.46, 0.75] and 0.67 L/kg [0.44, 
0.98] in infants with and without a hemofilter, respectively; p=0.17). In evaluating other 
covariates of interest, we observed an inverse correlation between CL and age, with 
older infants demonstrating lower CL per kg of bodyweight (Figure 5.3A). The same 
relationship also was observed for V and age where older infants had lower V per kg of 
bodyweight (Figure 5.3B). An inverse relationship also was observed between CL and 
serum albumin; subjects with low serum albumin had higher CL (Figure 5.3C). However, 
no relationship was observed between V and serum albumin (Figure 5.3D), or between 
CL and the following covariates: AST, serum creatinine, or total bilirubin (data not 
shown). Finally, no relationship was observed between duration of ECMO support and 
CL or V (data not shown). 
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Dose-exposure relationship  
Prophylactic arm (4 mg/kg IV every 24h) 
Median AUC0-24 were 74 mg*h/L (53, 106) and 117 mg*h/L (84, 187) after dose 1 
and 4, respectively (Figure 5.4). After a single dose, all infants were at or higher than 
the prophylaxis range (Figure 5.4). After dose 4, all infants sampled (5/5) exceeded the 
prophylactic range. Although infants in the prophylactic arm were not treated for active 
fungal infection, 5/11 (45%) achieved the therapeutic exposure target (75-139 mg*h/L) 
after a single dose, while the remaining infants were below the lower limit of the 
therapeutic exposure target (Figure 5.4). Among the 5 infants who were sampled 
around dose 4, 3/5 (60%) were within the therapeutic range, and 2 were 
supratherapeutic. Four infants had a hemofilter in line (Table 5.2). When a hemofilter 
was in line, all infants (4/4) achieved AUC0-24 within or above the prophylactic target 
range after dose 1 and 4. Two/4 (50%) infants with a hemofilter achieved AUC0-24 within 
or above the therapeutic target range after dose 1 and 4. 
Treatment arm (8 mg/kg IV every 24h) 
The one infant (ID#2) who received micafungin for suspected Candida infection 
had AUC0-24 of 213 and 178 mg*h/L after doses 2 and 5, respectively. This infant 
achieved an AUC0-24 that exceeded both prophylactic and therapeutic target ranges 
after doses 2 and 5 (Figure 5.4). 
Dose-exposure simulations 
A daily dose of 2.5 mg/kg infused over 1 h achieved the prophylactic target 
(AUC0-24 of 37.5 - 69.5 mg*h/L) within 24 h in 100% of the cohort. At steady state all 
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children achieved an AUC0-24 of at least 37.5 mg*h/L, with 3 (25%) above the target 
range (AUC0-24 of 84, 88, 94 mg*h/L).  
A daily dose of 5 mg/kg infused over 1 h achieved the therapeutic target range 
(AUC0-24 of 75 - 139 mg*h/L) within 24 h in 100% of the cohort. At steady state all 
children achieved an AUC0-24 of at least 75 mg*h/L, with 3 (25%) above the target range 
(AUC0-24 of 169, 177, 189 mg*h/L). 
 
Safety  
Five infants died during the study period. None of the deaths were considered 
related to micafungin. Two infants died following severe intracranial hemorrhage in the 
setting of systemic anticoagulation with heparin while on ECMO, and 1 died of refractory 
pulmonary hypertension after ECMO decannulation. Three additional AEs, unrelated to 
micafungin, were observed in 2 infants; 1 infant had severe intracranial hemorrhage but 
survived, and another had necrotizing enterocolitis likely related to prematurity and 
anticoagulation resulting in mild gastrointestinal bleeding. 
 
DISCUSSION 
This is the first PK trial of micafungin in infants supported with ECMO. Infants on 
ECMO had altered PK requiring higher doses to achieve the same exposure as 
historical controls not on ECMO.16,20,25-27 We suggest an alternate dosing regimen of 2.5 
and 5 mg/kg/day for prophylaxis and treatment of invasive candidiasis, respectively.  
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However, preterm neonates at high risk for hematogenous Candida 
meningoencephalitis should be excluded from this recommendation because we did not 
evaluate the higher dosages (e.g., 10mg/kg) usually recommended in this 
populations.28,29 
The V of micafungin in our cohort was 20-90% higher than that reported in 
infants not on ECMO (0.34 – 0.54 L/kg).16,26 There are three probable explanations for 
the increased V: 1) the large volume of blood required to prime the ECMO circuit 
(~450mL) relative to an infant’s native blood volume (80 mL/kg); 2) direct adsorption of 
micafungin by components of the ECMO circuit,13-15 and 3) altered physiology (e.g., 
anasarca, inflammation) commonly seen in critically ill infants. The impact of the ECMO 
prime volume is most pronounced in smaller infants where an infant’s circulating blood 
volume may be doubled or even tripled. Because the impact of prime volume is directly 
related to the ratio between prime volume and native blood volume, our results should 
not be extrapolated to older children where the ratio of exogenous (450 mL) to native 
blood volume (~2000-5000 mL) is much lower. Our findings are consistent with previous 
literature reporting increased V due to the ECMO prime volume in infants on 
fluconazole, vancomycin and gentamicin.11,19,21,30-33  
Drug adsorption to the ECMO circuit itself, which is well described in ex vivo 
studies, is also likely to contribute to the increase in V. Drug characteristics including 
lipophilicity and high protein binding are key factors driving adsorption.14,15 While 
micafungin is not lipophilic (logP -1.5), it is >99% protein bound.34 Other drugs with 
comparable protein binding and logP such as caspofungin were substantially adsorbed 
(56%) in an isolated ex vivo ECMO circuit.15 Preliminary results from a micafungin 
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ECMO ex vivo study conducted by our group showed that micafungin concentrations 
dropped by 58% over 24h (Watt unpublished data). In summary, our study was not 
designed to isolate the source of altered V, but the increase in V was probably due to a 
combination of circuit prime volume, circuit adsorption of drug, and patient disease 
state.  
In the current study, total CL after the first dose (0.041 L/kg/h [0.026, 0.062]) was 
in the upper range of previously reported values for infants not supported by ECMO 
(0.020-0.039 L/kg/h).20,25-27 The increase in CL may be explained by altered drug 
metabolism. Micafungin is excreted primarily unchanged into bile and feces (71%) via 
hepatic transporter proteins.35 Limited metabolism also occurs in the liver by 
arylsulfatase and catechol-O-methyltransferase into metabolites with little or no 
antifungal activity.16 While the impact of ECMO on renal dysfunction is well described,36 
the effect of ECMO on hepatic transporters and metabolic capacity is unknown. 
Micafungin PK studies in adults with severe hepatic dysfunction, revealed lower 
micafungin exposure and higher CL compared with healthy controls.37,38 This 
phenomenon was attributed to lower albumin concentrations in adults with hepatic 
dysfunction, resulting in higher availability of the unbound fraction to be cleared. In our 
cohort, no subjects had hepatic dysfunction, but critically ill infants on ECMO typically 
have serum albumin concentrations in the lower range of normal. In our study, we did 
observe an inverse relationship between clearance and serum albumin (Figure 5.3C), 
with a higher micafungin CL in infants who had low serum albumin. Finally, we did not 
find a relationship between PK parameters and serum creatinine. This is consistent with 
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previous literature and the product label that states no adjustment is necessary for renal 
dysfunction.16,37 
Higher apparent micafungin elimination with ECMO may also be due to non-
specific and irreversible drug adsorption by the circuit if adsorption is an ongoing 
process.13-15 As described above,  substantial extraction was observed over 24h in ex 
vivo circuits (58%).13. The origin of this loss is still under investigation but could be due 
to circuit adsorption. It could also be explained by micafungin degradation due to light 
exposure, because the ECMO circuit is not protected from light, as opposed to drug 
vials and infusion bags.  
The type of ECMO support could also impact micafungin disposition. Veno-
venous ECMO, in which blood is drained and returned to the venous system via a 
single, double lumen cannula, is subject to a recirculation phenomenon. In recirculation, 
a portion of the oxygenated blood returned to the venous system is immediately taken 
back into the ECMO circuit via the drainage lumen of the cannula.39 The impact of 
recirculation on drug PK is unknown. However, this phenomenon increases the time 
drug spends in the circuit; and for drugs that are adsorbed by the circuit, this could 
decrease exposure (AUC). In our cohort, only 1 infant (ID #6) was on VV ECMO and 
had a high CL and a low AUC0-24h compared to the rest of the cohort. In veno-arterial 
(VA) ECMO deoxygenated blood is drained from the venous system and pumped 
directly to the arterial circulation, completely bypassing the heart and lungs. The return 
flow is non-pulsatile. Non-pulsatile blood flow may be associated with reduced renal 
function, but its impact on a drug cleared by transporters in the liver such as micafungin 
is unknown.40  
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PK changes described above translated into micafungin exposure within or 
above the prophylaxis target range for infants who received 4 mg/kg/day. Thus, a dose 
4 mg/kg/day may be too high for prophylaxis. However, assuming linear micafungin PK, 
standard prophylaxis dosing (1 mg/kg/day) recommended for older children would likely 
result in underexposure in infants on ECMO.16,22,24,25 Based on the dose-exposure 
simulations in our cohort, a dose of 2.5 mg/kg/day appears to be the most appropriate 
dose for Candida prophylaxis. Although simulations showed that some children will 
likely become supratherapeutic on 2.5 mg/kg/day, we believe that it is better to err on 
the higher side of exposure for two reasons: 1) invasive candidiasis is exceedingly 
difficult to treat in this population and 2) the highest simulated exposure on 2.5 
mg/kg/day (94 mg*h/L) was well below the mean (standard deviation) exposure of 438 
mg*h/L (99) that was deemed safe in a neonatal trial of 15 mg/kg/day.27 This dosing 
regimen needs to be prospectively evaluated. 
The one infant who received micafungin 8 mg/kg/day for suspected Candida 
infection achieved AUC0-24 above the therapeutic target range, and survived until 
hospital discharge Based on these findings, and on dose-exposure simulations 
performed in all infants of the cohort, we recommend a dose of 5 mg/kg/day for invasive 
candidiasis therapy. Dose-exposure simulations were performed in all infants because 
PK is linear in this dosing range.22,41 On 5 mg/kg/day some children may achieve 
exposures exceeding the target range. Similar to the prophylactic regimen, we feel it is 
better to target higher exposure because these exposures are still in a “safe” range; and 
higher exposures may be needed to treat through potential fungal biofilms. Moreover, 
target exposure used in this study, was derived from a phase III efficacy study in which 
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>85% of adults had their central catheter removed during candidemia treatment.23 In the 
setting of ECMO, removal of catheter is impossible and therefore, micafungin exposure 
required to clear the infection may be higher. This dosing regimen also needs 
prospective validation.  
Although dosing in the current study was higher than recommended in term 
infants not on ECMO, micafungin had a favorable safety profile without any observed 
drug-related AEs. This is consistent with previous literature describing the safe use of 
micafungin up to 15 mg/kg/day in young preterm infants.27 Safety assessment is 
however limited by our small sample size. 
Our study is the first PK trial of micafungin in infants supported by ECMO. 
Because our study population includes vulnerable infants, enrollment was challenging 
and resulted in a limited sample size. In spite of the small sample size and critical illness 
of our population, interindividual variability in PK parameters was as expected. Other 
factors may affect micafungin PK in this population, including transfusion of blood 
products which we did not collect. Our data were also limited by the lack of 
documentation of site of drug administration in 4 infants. However, the effect of site of 
drug administration on PK is unknown, and PK parameters of those 4 infants (ID #5; 8-
10) were similar to those with complete documentation. Site of PK sampling was also 
lacking in 1 infant (ID #5), but our protocol did not allow drawing PK samples from site 
of drug administration. Therefore we do not expect any significant impact on PK results.  
Finally, our assessment of the ECMO impact on micafungin PK was limited by the lack 
of controls.  
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CONCLUSION 
In this cohort of infants supported by ECMO, micafungin was well tolerated and 
the PK model indicated that V was higher and CL was in the upper range of what had 
been described previously in infants not on ECMO. In order to match exposure 
observed in adults, we recommend dosing of 2.5 and 5 mg/kg/day for prophylaxis and 
treatment of invasive candidiasis, respectively. These dosing regimens need 
prospective validation. 
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Table 5.1. Clinical Characteristics* 
 N=12 
Age (days) 59 (0.0, 574) 
Gestational age (weeks) 39 (27, 39) 
Weight (kg) 3.7 (2.9, 9.6) 
Birth weight (kg) 3 (2.4, 4.3) 
Male, n (%) 5 (42) 
Race, n (%)                                       
White
African American
 
6 (50) 
6 (50) 
Diagnosis, n (%) 
Cardiomyopathy
Pulmonary hypertension
Congenital heart disease
Congenital diaphragmatic hernia
Respiratory failure
 
4 (34) 
3 (25) 
3 (25) 
1 (8) 
1 (8) 
Serum creatinine (mg/dL) 0.5 (0.2, 1.6) 
ECMO support, n (%) 
Veno-arterial
Veno-venous
 
11 (92) 
1 (8) 
ECMO circuit configuration, n (%) 
S3
 
8 (67) 
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Cardiohelp 4 (33) 
Micafungin indication n (%) 
Prophylaxis
Therapy
 
11 (92) 
1 (8) 
Micafungin dosing (mg/kg/day) 4 (4, 8) 
Duration of therapy (days) 4 (2, 8) 
Duration of ECMO support at time of first 
micafungin dosing (days) 
4 (2, 10) 
Number of PK samples per infant 11 (6, 14) 
PK samples obtained around, n (%)  
Dose 1-2
Dose 4-5
 
12 (100) 
6 (50) 
 
*Results are expressed as median (range) unless otherwise specified 
  Median serum creatinine for each subject over the study period.   
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Table 5.2. Pharmacokinetic Parameters 
ID Age 
(days) 
Clearance 
(L/kg/h) 
Volume of 
distribution (L/kg) 
Half-life   
(h) 
Dose 
(mg/kg/day) 
AUC (mg*h/L) Albumin* 
(g/dL) 
0-24h 72-96h 
1 0 0.036 0.98 19 4 69 117 3.1 
2 1 0.040 0.76 13 8 213§ 178† 3.6 
3 1 0.046 0.64 10 4 72 - 2.5 
4 4 0.042 0.75 12 4 68 - 2.8 
5 16 0.062 0.91 10 4 53 - 2.5 
6 44 0.058 0.65 8 4 59 - 2.1 
7 74 0.026 0.56 15 4 93 163 4.2 
8 108 0.043 0.53 9 4 74 109 2.5 
9 122 0.044 0.69 11 4 77 84 2.7 
10 135 0.030 0.44 10 4 105 - 3.1 
11 187 0.040 0.46 8 4 84 - 3.8 
12 574 0.028 0.61 15 4 89 187** 3.7 
Median  59 0.041 0.64 11 4 74‡ 117‡ 3.0 
Clearance and volume of distribution estimates were determined using a one-compartmental model fitting micafungin concentrations 
after both dose 1 and 4; AUC: area under the concentration-time curve;  Hemofilter in line; *Median serum albumin value over the 
study period (from 72h prior to first study dose through 72h after last study dose); §AUC 24-48h; †AUC 96-120h; **AUC 79-103h 
‡Summary statistics do not include AUC values from subject #2 
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Figure 5.1. Extracorporeal membrane oxygenation (ECMO) circuit configuration 
 
 
 
 
 
 
 
 
 
 
 
 
1Softline coating: biopassive polymer 
2Bioline coating: heparin + recombinant human albumin 
3Smart coating: Silicone/caprolactam copolymer 
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Figure 5.2. Micafungin Concentration-Time Profiles. All subjects received IV micafungin 4 
mg/kg every 24h, except for subject ID #2 who received 8 mg/kg every 24h. Subject ID # 2 PK 
samples were collected around dose 2 and 5. Subject ID # 12 the fourth dose was given 79h 
after the first dose, instead of 72h.   
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Figure 5.3. Micafungin Exposure 
 AUC: Area under the concentration-time curve 0-24h
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Figure 5.4. Pharmacokinetic parameters vs covariates 
 
 
 
 
 
 
 
 
 
A: Clearance vs age; B: Volume of distribution vs age; C: Clearance vs serum albumin; D: 
Volume of distribution vs serum albumin 
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CHAPTER 6. PHYSIOLOGICALLY-BASED PHARMACOKINETICS OF MICAFUNGIN 
IN CHILDREN ON ECMO 
INTRODUCTION 
Micafungin is an echinocandin antifungal drug with a broad spectrum of activity 
against Candida and Aspergillus species.1,2   Micafungin inhibits the synthesis of 1,3-
beta-D-glucan, an essential component of the fungal cell wall. In children older than 4 
months, micafungin is labeled by the FDA for the prophylaxis and treatment of invasive 
candidiasis. Candida is a common pathogen in children supported with ECMO. In this 
population, Candida is difficult to treat due to the organism’s ability to adhere to vascular 
catheters and form biofilms. Micafungin can penetrate biofilms, making it an attractive 
drug for use in children on ECMO.3-5 Unfortunately, ECMO can alter drug 
pharmacokinetics (PK), thus requiring important dosing modifications. Optimal dosing 
on ECMO can be affected by 1) multi-organ dysfunction; 2) the large volume of 
exogenous blood required to prime the ECMO circuit; and 3) drug extraction by the 
circuit.  The extent of interaction with the ECMO circuit depends, in part, on the 
physicochemical properties of the drug, circuit components (e.g., oxygenator, 
hemofilter), and drug clearance mechanisms. 
The oral bioavailability of micafungin is extremely low due to its physicochemical 
properties (high molecular weight, hydrophilicity); thus, micafungin is only administered 
intravenously. Following intravenous administration of radiolabeled 14C-micafungin in 
humans, approximately 90% of the dose was recovered in feces with <10% in urine.6 
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The membrane transport protein organic anion-transporting polypeptide (OATP) 
OATP1B1 is primarily responsible for hepatic uptake of micafungin.7 Within the 
hepatocyte, micafungin is metabolized to M-1 (catechol form) by arylsulfatase, with 
subsequent metabolism to M-2 (methoxy form) by catechol-O-methyltransferase.8 M-5 
formation is catalyzed by cytochrome P450 (CYP) isozymes and occurs by 
hydroxylation at the omega-1 position.6 Although M-1 and M-2 have some in vitro 
antifungal activity, they are unlikely to play a role in the in vivo antifungal activity of 
micafungin given their low plasma concentrations (~1/20th of parent).8 Micafungin 
undergoes biliary elimination via efflux transporters on the cannalicular membrane.7 
However, recovery in feces of parent drug and metabolites is low in the first 6 hours 
relative to the rapid decline in plasma concentrations during that time period.8,9 This 
suggests that initial plasma clearance is due primarily to distribution rather than 
elimination. Insight into the mechanism of this process can be found with caspofungin, 
an echinocandin with a very similar structure, physicochemical properties, and 
elimination pathways. In human and animal studies, caspofungin rapidly distributed into 
extracellular space before slower uptake into the liver via OATP1B1.10,11 Studies of 
caspofungin in in situ rat livers suggests that the two-step uptake process involves an 
initial adsorption to the cell surface followed by slower transport across the cell 
membrane.12  
Knowledge of micafungin physicochemical properties and clearance pathways 
can be combined with system specific inputs (e.g., organ weights and blood flows) for 
the population of interest to build a physiologically-based pharmacokinetic (PBPK) 
model of micafungin. PBPK models differ from traditional compartmental models in that 
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they are structured in a physiologically relevant manner with multiple compartments 
reflecting the various organs in the body (Figure 6.1). Because PBPK models are 
mechanistic in nature, model parameters can be modified based on age (i.e., adding 
ontogeny to system specific inputs) and disease state (e.g., adjusting renal function) to 
predict dosing in special populations. Importantly for children on ECMO, an ECMO 
compartment can be added to the model to adjust for the factors that alter micafungin 
PK during ECMO support. The objective of this study was to develop a PBPK model of 
micafungin in adults, scale it to children, and add an ECMO compartment in order to 
predict optimal dosing in children supported with ECMO. 
 
METHODS 
Model Building Workflow 
 The model building workflow is described in Figure 6.2. The model was first 
constructed in adults (Adult PBPK Model) and then scaled to children (Pediatric PBPK 
Model). An ECMO compartment was then added to the Pediatric PBPK Model to form 
the ECMO PBPK Model. 
  
Adult PBPK Model  
The whole-body PBPK model was structured with 15 compartments representing 
physiologic organ spaces linked by blood flow. The blood flow into and out of the 
compartments and disposition within the compartments was parameterized using 
differential equations. Each organ consisted of 4 sub-compartments: plasma and red 
blood cells making up the vascular space, interstitial fluid, and cellular space. The 
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organ-to-plasma unbound partition coefficients (Kpu) were estimated using drug 
physicochemical properties based on the method described by Rogers and 
Rowland.13,14 All PBPK simulations were performed using PK Sim® and MoBi® (v6.03, 
Bayer Technology Services, Leverkusen, Germany).  
A PBPK model was first developed in adults in order determine the most 
appropriate model structure using robust adult data (Figure 6.2).15-17 Drug 
physicochemical properties and clearance pathways for micafungin were extracted from 
the literature in order to inform the drug-specific model inputs (Table 6.1). The system-
specific inputs were based on the average 30 year-old, healthy, Caucasian male using 
population datasets.18 Based on a weight of 74kg and a height of 173cm, organ weights, 
volumes, and blood flows were assigned based on mean values reported in the 
International Commission on Radiological Protection (ICRP) database.19   
Because micafungin disposition is mediated by both passive and active 
processes and data are lacking for some of these processes, the following assumptions 
were made when parameterizing the model. 1) Micafungin was assumed to distribute 
rapidly from plasma based on the fact that micafungin is cleared rapidly from the plasma 
(pronounced α–distribution)20-22 and is not quickly eliminated in feces or urine 
suggesting that the rapid plasma clearance is due to distribution rather than elimination 
processes.8,9 2) Micafungin was assumed to reside preferentially in the interstitial space 
and not readily cross back into the vascular space because of binding to the cellular 
membrane. Relatively slow uptake into tissues suggests that micafungin first undergoes 
rapid distribution into interstitial space.9 Micafungin is highly protein bound, and binds to 
multiple proteins, presumably including those in the interstitial space.23 In vitro studies of 
   
176 
 
caspofungin showed distribution into interstitial space and reversible adsorption to the 
cell wall prior to uptake by OATP1B1.11,12  3) Micafungin is actively transported from the 
interstitial space into the hepatocyte via OATP1B1 where it undergoes metabolism via 
arylsulfatase, catechol-O-methyltransferase, and CYP3A4.7,8 4) The majority of 
micafungin is excreted into bile via an efflux transporter on the canalicular membrane.6,7 
A summary of model assumptions is listed in Table 6.3. 
With these assumptions, the model was anchored in the following known 
parameters: 1) the mass balance data (fraction eliminated in feces and urine),6 2) the 
hepatic uptake by OATP1B1,7 and 3) empiric liver tissue concentrations that showed 
concentrations in the liver exceeded those in plasma by 6h.8,9 Renal clearance (CLR) 
represents a minor route of micafungin elimination (<10%), and CLR was included in the 
base model with an assumed glomerular filtration rate (GFR) of 110 ml/min. CLR was 
based on the following equation because there was no evidence of tubular secretion or 
reabsorption:6 
ܥܮோ ൌ ௨݂ݔ ܩܨܴ (eq. 1)
where fu is the fraction of unbound drug. Adult model development then proceeded 
according to the following steps: 
 
Step 1. Rapid Equilibrium Compartment – rapid distribution into the interstitial space 
was adjusted to describe the observed data (Adult Development Dataset) by increasing 
the Interstitial:Plasma Kpu and decreasing endothelial permeability to account for 
distribution out of the vascular space and binding to the cellular membrane, 
respectively.24,25  
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Step 2. OATP1B1 uptake was added to the basolateral membrane of the hepatocyte. 
Uptake Vmax from the literature was scaled from milligrams of protein to grams of liver in 
order to generate a liver Vmax via the following equation;  
௠ܸ௔௫	ሺ݈݅ݒ݁ݎ	ݐ݅ݏݏݑ݁ሻ ൌ ௠ܸ௔௫ሺ݉݅ܿݎ݋ݏ݋݉݁ሻݔܯܲܲܩܮ (eq. 2)
Where MPPGL represents the microsomal protein per gram of liver and was assumed 
to be 45 mg protein/g of liver.26 A specific Vmax was calculated from intrinsic liver Vmax 
normalized to the organ weight based on the following; 
௠ܸ௔௫ ൌ ௠ܸ௔௫ሺ݈݅ݒ݁ݎ	ݐ݅ݏݏݑ݁ሻ ∗ ௜݂௡௧ ൅ ௖݂௘௟௟௖݂௘௟௟  
(eq. 3)
where fint and fcell are the fraction of the liver that make up the interstitial and cellular 
sub-compartments, respectively. Km was obtained from the literature.7 
 
Step 3. A canalicular transporter was added to account for secretion of micafungin from 
the hepatocyte into bile. The known fraction excreted in bile was used to optimize a Vmax 
and Km for this transporter. Because no metabolism was included in the model at this 
point, the apparent fraction excreted in the bile was the total fraction including parent 
and metabolites, assumed to be ~50-60% of the dose at 168h.8  
 
Step 4. Metabolism was added to the model by assigning an unbound intrinsic 
clearance (CLI’) to the three primary metabolizing enzymes. The CLI’ was optimized so 
that fraction excreted in the bile now represented only the parent (~44% at 168h). The 
CLI’ was partitioned between the three enzymes, assuming a ratio of 5:1:6 for 
arylsulfatase, catechol-O-methyltransferase, and CYP3A4, respectively, based on mass 
balance data.8  
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Based on these data, the model was used to generate plasma and liver 
concentration versus time curves and fraction excreted in the bile and urine for the 
standard healthy adult described above. Model parameters were optimized based on 
the observed data (Adult Development Dataset) using the Nelder-Mead algorithm in the 
MoBi® Toolbox for Matlab and methods described by Stader.25,27 The optimized model 
was used to generate drug concentration versus time profiles for a virtual population of 
healthy adults (n=1000) created using the PK Sim® population module.28 Drug 
concentration versus time profiles for the virtual population were compared with 
observed data obtained from studies that were not used in model development (Adult 
Validation Dataset, Table 6.2). The optimized model was considered acceptable if it met 
the PBPK Model Acceptance Criteria detailed below.  
 
Pediatric PBPK Model 
In order to scale from adults to children, drug-specific inputs were held constant 
and system-specific inputs were scaled by including age-dependencies in physiological 
parameters (e.g., body weight, organ weight, blood flow).16 The PK Sim® population 
module was used to generate populations (n=1000) of neonates (0d-<29d), infants 
(30d-<2y), children (2y-<6y), school age children (6y-<12y), and adolescents (12y-
<18y).28 Based on age and gender, each individual was assigned a weight and height 
according to the distribution in population datasets.18 The weight and height of each 
simulated individual was used to assign organ weights, volumes, and blood flows based 
on mean values reported in the ICRP database.19  
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 In the Adult PBPK Model, the equilibrium compartment (Step 1) and the biliary 
efflux clearance (Step 3) parameters were optimized using in vivo adult data; it was 
assumed for the Pediatric PBPK Model that there was no ontogeny to these processes. 
In addition, because limited data exist describing ontogeny of OATP1B1 activity, the 
OATP1B1 uptake used in the Adult PBPK Model was held constant in the Pediatric 
PBPK Model (Step 2). 
Other clearance processes were scaled using the mechanistic drug clearance 
method described by Edginton et al.29 GFR was scaled by calculating the ratio of 
expected GFR for unbound drug in a child to that in an adult; 
ܥܮீிோሺ௖௛௜௟ௗሻ ൌ
ܩܨܴሺ௖௛௜௟ௗሻ
ܩܨܴሺ௔ௗ௨௟௧ሻ ൈ
௨݂ ሺ௖௛௜௟ௗሻ
௨݂ ሺ௔ௗ௨௟௧ሻ
ൈ ܥܮீிோ ሺ௔ௗ௨௟௧ሻ (eq. 4)
Where CLGFR(child) is the child’s clearance due to GFR, GFR(child) is the estimated GFR of 
the child, GFR(adult) is the GFR in adults (assumed to be 110 mL/min29), and CLGFR(adult) 
is the clearance due to GFR  in adults. GFR(child)  was calculated using a postmenstrual 
age model30 and the fu (child) was estimated using methods described by McNamara and 
Alcorn.29,31  
To scale hepatic clearance (CLH) to children, CLI’ was calculated using adult 
plasma CL; 
ܥܮூ′ ൌ ܥܮு ൈ ܳுܳு െ ܥܮு ൈ
1
௨݂
 (eq. 5)
Adult CLI’ was then scaled to children using an ontogeny factor; 
ܥܮூ	′஼௒௉ଷ஺ସሺ௖௛௜௟ௗ	௚	௟௜௩௘௥ሻ ൌ ܱܵܨ஼௒௉ଷ஺ସ ൈ ܥܮூ′஼௒௉ଷ஺ସሺ௔ௗ௨௟௧ ௚ ௟௜௩௘௥ሻ (eq. 6)
Where CLI’CYP3A4(child g liver) is the scaled CLI’ due to CYP3A4 per gram of liver, OSFCYP3A4 
is the ontogeny scaling factor for CYP3A4,29 and CLI’CYP3A4(adult g liver) is the adult CLI’ due 
to CYP3A4. No ontogeny data were available for arylsulfatase and catechol-O-
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methyltransferase, so the OSFarylsulfatase and OSFcatechol-O-methyltransferase were assumed to 
equal one.  
Finally, child CLH was estimated using the equation for the well-stirred model 
after adjusting for liver weight (LWchild) and the blood/plasma (B/P) concentration ratio;  
ܥܮூ′ሺ௖௛௜௟ௗ	௧௢௧௔௟	௟௜௩௘௥ሻ ൌ ܥܮூ′஼௒௉ଷ஺ସሺ௖௛௜௟ௗ ௚ ௟௜௩௘௥ሻ ൈ ܮ ௖ܹ௛௜௟ௗ (eq. 7)
ܥܮு	ሺ௖௛௜௟ௗሻ ൌ
ܳு	ሺ௖௛௜௟ௗሻ ൈ	 ௨݂ ሺ௖௛௜௟ௗሻ ௧௢௧௔௟ ௟௜௩௘௥ ൈ ܥܮூ′ ሺ௖௛௜௟ௗሻ௧௢௧௔௟ ௟௜௩௘௥
ܳு	ሺ௖௛௜௟ௗሻ ൅ ሺ ௨݂ ሺ௖௛௜௟ௗሻ ൈ ܥܮூ′ሺ௖௛௜௟ௗሻ௧௢௧௔௟ ௟௜௩௘௥ሻ/ ܤܲሺ௖௛௜௟ௗሻ
 
(eq. 8)
In order to evaluate the Pediatric PBPK Model, model predictions were compared 
with observed data. Multiple pediatric datasets encompassing a range of ages and 
doses were available for model evaluation (Pediatric Validation Datasets, Table 6.2). 
Once acceptance criteria were met, an ECMO compartment was linked to the Pediatric 
PBPK Model.   
 
ECMO PBPK Model  
The Pediatric PBPK Model was exported into MoBi® where an ECMO 
compartment was added (Figure 6.1). The ECMO compartment was set in parallel with 
the Lung compartment and pulmonary blood flow was partitioned, with 80% assigned to 
the ECMO compartment and 20% assigned to the lungs. 
݀ܺா஼ெை
݀ݐ ሺ݌݈ܽݏ݉ܽሻ ൌ ܳ௅௨௡௚ ∗ ܨݎܽܿݐ݅݋݊2ܧܥܯܱ ∗ ܥ௣௟௦ ∗ ሺ1 െ ܪܿݐሻ 
(eq. 9)
݀ܺா஼ெை
݀ݐ ሺܾ݈݋݋݀	݈݈ܿ݁ݏሻ ൌ ܳ௅௨௡௚ ∗ ܨݎܽܿݐ݅݋݊2ܧܥܯܱ ∗ ܥ௕௖ ∗ ܪܿݐ 
(eq. 10)
Where dXECMO represents the change in the amount of drug in the ECMO compartment; 
QLung is the lung blood flow, Fraction2ECMO is the fraction of the lung blood flow that is 
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partitioned to the ECMO circuit (0.80); Cpls is the plasma concentration; Hct is the 
hematocrit, and Cbc is the concentration in red blood cells. 
The volume of the ECMO compartment was 400mL based on the standard volume of 
blood used to prime the ECMO circuit.  
Because the ex vivo results from Chapter 2 showed that micafungin was 
extracted extensively by the circuit, a first-order elimination rate constant (kECMO, min-1) 
was added to the ECMO compartment to describe the extraction determined in the ex 
vivo experiments; 
݀ܺா஼ெை
݀ݐ ሺ݌݈ܽݏ݉ܽሻ ൌ െ݇ா஼ெை ∗ ௨݂ ∗ ሺܳ௅௨௡௚ ∗ ܨݎܽܿݐ݅݋݊2ܧܥܯܱ ∗ ܥ௣௟௦ ∗ ሺ1 െ ܪܿݐሻሻ 
(eq. 11)
݀ܺா஼ெை
݀ݐ ሺܾ݈݋݋݀	݈݈ܿ݁ݏሻ ൌ െ݇ா஼ெை ∗ ௨݂ ∗ ሺܳ௅௨௡௚ ∗ ܨݎܽܿݐ݅݋݊2ܧܥܯܱ ∗ ܥ௕௖ ∗ ܪܿݐሻ 
(eq. 12)
The ex vivo experiments showed that circuit extraction resulted in a median decrease in 
AUC0-24 of 29%. The median decrease in AUC was determined by subtracting the actual 
AUC for each circuit from the AUC assuming no adsorption (Figure 6.3, Appendix 4). 
This calculation also was performed for the control samples and the circuit adsorption 
was corrected for loss in the control samples. Because 80% of the blood flow was 
exposed to the ECMO circuit, the kECMO term was optimized so that the PBPK-predicted 
AUC0-24 prior to adding the ECMO compartment decreased by 23% (29% x 0.8) after 
adding the ECMO compartment. 
An Edema disease state was added to the model to reflect the anasarca 
observed in children on ECMO. The Edema disease state assumed a 50% increase in 
body weight; that increase was assigned to the interstitial space of all organ 
compartments.32,33 The ECMO PBPK Model with Edema was considered the final 
ECMO PBPK Model and was used for all subsequent ECMO PBPK simulations.  
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The PK Sim® population module was used to generate an infant population (n=1000) 
based on the demographics of infants in the Micafungin ECMO Trial. The ECMO PBPK 
Model was used to predict concentration versus time curves for this population of 
infants. Model predicted concentrations were compared with observed data from the 
Micafungin ECMO Trial described in Chapter 5.  
 
Assessment of Dose-Exposure Relationship 
After meeting acceptance criteria, the ECMO PBPK Model was used to 
determine the micafungin dose needed to achieve target exposures in 90% of children 
on ECMO.34,35 Simulations of 1000 individuals were performed for neonates, infants, 
children, school age children, and adolescents. Efficacy was assessed based on the 
number of individuals who attained a target AUC from 0-24 hours (AUC0-24)  of at least 
75 mg*h/L.34,35 This surrogate endpoint matches the minimum micafungin exposure 
achieved by adult participants who cleared their fungal infection in the primary efficacy 
trial.36 Safety of the proposed dosing regimens was assessed by comparing predicted 
maximum AUC0-24 for each individual with maximum tolerated AUC0-24 (600 mg*h/L).20,37 
 
PBPK Model Acceptance Criteria  
Population predictability was evaluated by visual inspection of the observed data 
captured within the model’s 90% prediction interval. Because dosing is based on AUC, 
the primary method of assessing model precision was to evaluate the fold error between 
the PBPK-predicted AUC and observed AUC 
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ܨ݋݈݀	ܧݎݎ݋ݎ ൌ ܣܷܥ଴ିଶସܲܤܲܭܣܷܥ଴ିଶସܱܾݏ݁ݎݒ݁݀ 
(eq. 13)
A fold error between 0.7–1.3 was considered acceptable. For Adult and Pediatric 
Development and Validation Datasets, each reported AUC was compared with a PBPK-
predicted AUC for the same dosing interval. For the Micafungin ECMO Trial, the 
observed AUC0-24 was compared with PBPK-predicted AUC0-24. 
 
RESULTS 
Adult model 
Figure 6.4 shows the results of each step of the adult model building process. 
The model was optimized by assigning fu 0.006 (Table 6.1). The base model shows that 
with only GFR as a clearance process, there was virtually no clearance of micafungin, 
and predicted concentrations in liver tissue were low (less than plasma concentrations) 
relative to reported concentrations (greater than plasma concentration) at 6 hours 
(Figure 6.4).9 In Step 1, the interstitial:plasma partition coefficient for all organs was 
increased by a factor of 4, and the endothelial permeability was decreased to 0.03 
cm/min except for the brain compartment, which was kept at 1.26x10-09 cm/min. These 
adjustments provided a better description of the α-distribution phase, but concentrations 
in liver tissue remained low, plasma clearance was not accurately characterized, and all 
elimination occurred via the kidneys. In Step 2, OATP1B1 uptake was added to the 
model, which improved the description of the terminal elimination of micafungin from the 
plasma based on the observed data. However, all elimination was still via kidneys and 
liver tissue concentrations showed continued accumulation. In Step 3, a biliary efflux 
process was added, dividing elimination between bile and urine. At 168h the predicted 
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micafungin fraction eliminated via bile was 61% and urine was 5% compared with the 
observed fraction eliminated of 44% and 7% in feces and urine, respectively.8 Finally, in 
Step 4, metabolism was incorporated into the micafungin ECMO PBPK Model by adding 
CLI’, which was partitioned between arylsulfatase, catechol-O-methyltransferase, and 
CYP3A4 metabolic pathways. After addition of metabolism into the model, the predicted 
fraction of micafungin excreted via bile decreased to 45% and the fraction excreted in 
urine remained at 5%. These fractions were in close agreement with mass balance 
data. Concentrations in the liver exceeded those in plasma after 4 hours, consistent with 
observed animal data.9 
The final model showed excellent agreement between observed versus predicted 
data from the Adult Development Dataset (Figure 6.4, Step 4). The predicted AUC0-24 
after dose 1 was 108 mg*h/L compared to the observed AUC0-24 of 104 mg*h/L for the 
same dosing interval (1.04 fold error, Table 6.4). When optimized model predictions 
were compared with observed data from Model Validation Datasets (i.e., data not used 
to build the model), over 90% of the mean observed data fell within the 90% prediction 
interval of the model (Figure 6.5). The PBPK-predicted AUC0-24 values were within 3% 
of observed AUC0-24 values after multiple doses (Table 6.4). Based on this excellent 
predictive performance, this optimized Adult PBPK Model was scaled to children. 
 
Scaling to Children 
Pediatric simulations were performed for multiple dosing regimens and showed 
good agreement with corresponding observed exposures from the Pediatric Validation 
Datasets. For children ≥ 2 years of age, 97% (29/30) of the observed mean 
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concentrations from the Benjamin et al. study38, and 96% (52/54) from the Seibel et al. 
study35, were within the 90% prediction interval of the Pediatric PBPK Model (Figure 
6.6). Additionally, median fold errors between observed versus predicted AUC values 
were 1.04 and 1.05 for Benjamin et al. and Seibel et al., respectively (Table 6.5). In 
infants < 2 years of age, observed data from Undre et al.39 were over-predicted in the 
initial phase of distribution (5-15 minutes), but subsequent data were well described 
(Figure 6.7). In contrast, observed data from Benjamin et al. were under-predicted. 
Nonetheless, PBPK-predicted AUC values had acceptable fold errors of 1.11 for Undre 
et al. and 0.72 for Benjamin et al (Table 6.5). Based on these results, the model was 
exported into MoBi® where the ECMO compartment was added. 
 
ECMO model 
Results of the ECMO PBPK Model building process are shown in Figure 6.8. 
Prior to adding the ECMO compartment, the Pediatric PBPK Model predictions were 
compared with observed data from the Micafungin ECMO trial, and only 55% (33/60) of 
the observed data fell within the 90% prediction interval (Figure 6.8.1) The model over-
predicted AUC (117 mg*h/L) compared to the observed AUC reported in Chapter 5 (74 
mg*h/L; 1.58 fold error). Addition of the ECMO compartment to the Pediatric PBPK 
Model improved model predictions; 70% (42/60) of the observed data fell within the 90% 
prediction interval (Figure 6.8.2). However, AUC0-24 was still over-predicted (97 mg*h/L; 
1.31 fold error). After incorporating edema into the Pediatric PBPK model, 95% (57/60) 
of the observed data fell within the 90% model prediction interval (Figure 6.8.3), and the 
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median PBPK predicted AUC0-24 was 86 mg*h/L compared to the observed AUC of 74 
mg*h/L (1.16 fold error, Figure 6.9).  
Based on the precision of AUC estimates, the ECMO PBPK Model was used to 
simulate exposures for different dosing regimens for each pediatric age cohort. The 
following age-dependent dosing regimens were found to achieve the target AUC0-24 in ≥ 
90% of simulated children on ECMO in the first 24 hours of therapy: neonates (0-29d) 
10 mg/kg, infants (30d-<2y) 6 mg/kg, children (2y-<6y) 4 mg/kg, school-age children 
(6y-<12y) 3 mg/kg, and adolescents 2 mg/kg (Figure 6.10).  
Complicated dosing regimens such as the age-based regimen above are often 
difficult to implement. In order to simplify the dosing regimen, maximize efficacy, and 
minimize toxicity, the ECMO PBPK Model also was used to simulate exposures after a 
dose of 10 mg/kg for neonates and infants <2 years of age and 6 mg/kg for children 2 
years-<18 years of age (Figure 6.11). This approach achieved the target AUC0-24 in 
100% of simulated children on ECMO in the first 24 hours of therapy and 99.5% had an 
AUC0-24 (233 [76, 867]) below the safety threshold value of 600 mg*h/L. 
 
 
DISCUSSION 
This study used an established workflow to successfully develop a PBPK model 
in adults and scale it to children. By adding a novel ECMO compartment and accounting 
for disease state effects (i.e., edema), the model was able to generate dosing 
predictions in children on ECMO across the pediatric age spectrum. The adult model 
was successfully parameterized using drug specific and system specific data from the 
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literature. Because of the inherent complexity of PBPK models, it is challenging to know 
all parameters with certainty and invariably, assumptions must be made. In order to 
minimize bias introduced by these assumptions, the model was first parameterized 
according to the following known processes: 1) mass balance data,8 2) transporter-
mediated hepatic uptake,7 and 3) liver concentrations in excess of plasma 
concentrations.8,9 Anchored in these known processes, the model was parameterized 
assuming rapid distribution from the vascular space into the interstitial space and that 
unbound concentrations in the interstitial fluid exceeded those in plasma. This approach 
was justified based on the fact that micafungin binds to multiple proteins in addition to 
albumin, and could preferentially bind to proteins in the interstitial space.23 In addition, 
data for caspofungin showed that it distributed into interstitial space and reversibly 
adsorbed to the cellular membrane.10,11 This rapid equilibrium process has been used in 
PBPK models for other organic anions such as caspofungin25 and pravastatin.24 
Similarly, the micafungin CLI’ for the metabolizing enzymes of interest, and the rate of 
efflux, were optimized to achieve the appropriate fraction excreted in bile from mass 
balance data. The use of observed in vivo concentration versus time data to optimize 
PBPK model parameters is well described, the so-called “middle-out approach.”40 
However, this approach can limit generalizability. This was not the case for the 
micafungin model, where model predictions were in close agreement with both the Adult 
Development and Validation Datasets.  
After development of the adult model, the PBPK model was scaled to children 
based on known anatomic and physiologic data. Some of the processes had well-
described ontogeny data (e.g., maturation of GFR),41,42 but for many of the processes, 
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ontogeny data were lacking. For processes where ontogeny data were lacking (e.g., 
rapid equilibrium, transporter expression), the initial assumption was that there was no 
ontogeny, and this assumption held for the micafungin model. For children greater than 
two years of age, the model predictions were in close agreement with observed data. 
Both over- and under-predictions were observed, which makes population variability, 
rather than ontogeny, the more likely explanation. Variability would be expected as 
these children were all critically ill (e.g., cancer, invasive fungal infection). Model 
predictions for infants were less accurate, but again over- and under-predictions were 
observed. Failure to incorporate ontogeny data could play a role in model mis-
specification, especially considering that many maturation processes occur before two 
years of age.43 However, these processes were not explored because the small sample 
sizes in the infant studies would make evaluation impossible.  
The observed data from the Micafungin ECMO Trial showed that micafungin 
exposure was lower in children on ECMO. Based on the ex vivo experiments in Chapter 
2, this was due, in part, to the impact of the ECMO circuit, specifically  hemodilution 
from the exogenous blood required to prime the circuit and  extraction by the circuit. The 
impact of ECMO on micafungin PK was incorporated into the Pediatric PBPK Model by 
linking an ECMO compartment to the model with assigned  flows, a volume reflecting 
the exogenous blood, and an elimination rate constant accounting for extraction by the 
circuit that was measured in the ex vivo experiments described in Chapter 2. The total 
extraction by the ex vivo ECMO circuits was corrected for extraction observed in the 
control samples. This assumed that the extraction observed in the control samples was 
not occurring in vivo, which was a reasonable assumption if extraction in the control 
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samples was due to adsorption by the control tubes. However, if extraction in the control 
samples was due to light degradation or plasma metabolism, it is possible that these 
processes also could be observed in vivo. However, if total circuit extraction was not 
corrected for the extraction in the controls, then the AUC would be expected to 
decrease by ~40% after adding the ECMO compartment. A 40% decrease would result 
in substantial under-prediction of exposure compared to observed exposures. The 
excellent agreement between the ECMO PBPK Model-predicted and observed 
concentrations in children on ECMO supports the assumptions used in model 
development, and the use of circuit extraction corrected for extraction in controls. 
However, additional ex vivo experiments are planned to determine the mechanism(s) of 
extraction in the control tubes, and this model could be modified based on those results. 
Two important assumptions in the ECMO PBPK Model were the partitioning of 
pulmonary blood flow and the extent of edema. The pulmonary blood flow was 
partitioned such that 80% flowed through the ECMO circuit and 20% returned to the 
lungs. A sensitivity analysis was performed to evaluate the physiologically plausible 
range of blood flowing through the ECMO circuit (70-95%) and found a minimal effect 
on AUC (+/- 5%). The model was more sensitive to changes in the extent of edema. 
The Edema disease state in the final ECMO PBPK Model assumed a 50% increase in 
body weight due to edema with the resulting volume assigned to the interstitial 
compartment of each virtual organ. When a 10% increase in body weight was assumed, 
the resulting AUC was 20% higher. Future studies should quantify the extent of edema 
(e.g., daily weights) in order to more accurately estimate this parameter. Capturing other 
   
190 
 
treatments such as blood transfusions and crystalloid administration could provide 
additional detail about alterations in PK. 
The ECMO PBPK Model-predicted dosing was consistent with dosing trends 
observed in children not on ECMO. In general, neonates require higher doses to 
achieve comparable micafungin exposure to that observed in infants and older 
children.44 Work by Yanni et al. suggests that higher micafungin clearance in neonates 
and infants is due to age-dependent serum protein binding.45 For a low extraction drug 
like micafungin, clearance is directly proportional to fu. Micafungin is highly protein 
bound in adults (>99%), and small changes in fu can markedly change clearance. Yanni 
et al. measured the fu of micafungin in 6 neonates and reported a mean fu of 0.033 
compared to 0.004 measured in adults. The ECMO PBPK Model used the method 
developed by McNamara to scale fu from adults to children.31 Based on this model, the 
mean fu in neonates was 0.003 compared to the optimized fu in adults of 0.006, and this 
was likely responsible for the higher clearance and higher dose requirements in this 
population.  Because the model accuracy was excellent using the scaling method 
reported by McNamara et al., a distinct ontogeny function was not developed to 
describe the Yanni data.  
Optimized dosing based on the ECMO PBPK Model in all age cohorts except 
adolescents exceeded the recommended dose of 2 mg/kg.46  Although age-based 
predictions optimized dosing to achieve the minimum necessary exposure, a simplified 
dosing regimen of 10 mg/kg in neonates and infants < 2 years of age and 6 mg/kg in 
children 2 years-<18 years of age is more appropriate for several reasons: 1) clinical 
feasibility; 2) higher exposures may be needed to clear biofilms; and 3) micafungin is 
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safe even at high exposures. Micafungin is known to be safe at doses up to 15 mg/kg 
and AUC0-24 exposures exceeding 600 mg*h/L.37,47 The adult efficacy trial that linked an 
exposure of AUC0-24 75-139 mg*h/L to eradication of candidemia also included a 
recommendation that intravascular catheters be removed. Because catheter removal on 
ECMO is difficult, if not impossible, micafungin exposures need to be adequate to clear 
biofilms. In vitro work suggests that maintaining micafungin concentrations ≥ 2 mg/L 
may be sufficient to eradicate biofilms, but these results have not been confirmed in 
vivo.48 The simplified dosing recommendations in Figure 6.11 achieve a trough 
concentration of ≥ 2 mg/L in 96% of simulated children (data not shown). Based on 
these results, micafungin 10 mg/kg is recommended for neonates and infants <2 years 
of age and 6 mg/kg is recommended for children 2 years-<18 years of age. 
For neonates who are at risk for hematogenous candida meningoencephalitis, 10 
mg/kg is the recommended micafungin dose to achieve appropriate penetration of the 
cerebrospinal fluid, resulting in a plasma AUC0-24 of ~300 mg*h/L.47 Based on this 
information, assuming linear kinetics, a dose of > 20 mg/kg would be necessary to 
achieve appropriate CSF penetration in neonates on ECMO. Until a dose this high can 
be evaluated prospectively, fluconazole, with its better CSF penetration and limited 
interaction with the ECMO circuit should be considered in neonates on ECMO where 
candida meningoencephalitis is suspected.  
In conclusion, the ECMO PBPK Model developed in this study demonstrates 
proof of concept for translation of ex vivo ECMO results into dosing recommendations 
for children on ECMO. The Adult PBPK Model of micafungin was developed using data 
from the literature and physiologically justified assumptions. Although some parameters 
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were optimized using observed adult data, the model accurately predicted observed 
data in independent adult populations and after scaling to children. The addition of an 
ECMO compartment and incorporation of edema, consistent with that observed in 
children on ECMO, resulted in excellent agreement between PBPK predicted and 
observed data (ECMO PBPK Model-predicted AUC within 0.7-1.3 fold error of observed 
AUC). Consequently, the ECMO PBPK Model was used to determine the optimal dose 
of micafungin needed to treat invasive candidiasis in children supported with ECMO.  
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Table 6.1. Micafungin physicochemical properties and elimination pathways 
Parameter Reported value Optimized value 
Physicochemical properties   
Lipophilicity (LogP) -0.396  
Protein binding partner Albumin6  
Fraction unbound (%) <1%6 0.6% 
Molecular weight (g/mol) 1292.2649  
Compound type/pKa Weak acid/9.156  
Charge Negative  
B/P Ratio 0.98  
Metabolism and elimination   
Hepatic Uptake   
Vmax liver tissue (pmol/min/g tissue) 366307  
Vmax (µmol/L/min) 45.58  
Km (µmol/L) 407  
Hepatic Efflux   
Vmax liver tissue (pmol/min/g tissue) NR 300 
Vmax (µmol/L/min) NR 0.37 
Km (µmol/L) NR 10 
Fraction excreted via bile (168h) 44%6 45% 
Fraction excreted via urine (168h) 7%6 5% 
Ayrlsulfatase CLI’ (L/min) NR 0.003 
Catechol-O-methyltrasnsferase CLI’ (L/min) NR 0.0007 
CYP3A4 CLI’ (L/min) NR 0.004 
KECMO (1/min) NR 0.45 
NR – not reported 
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Table 6.2. Studies used in model development and evaluation 
Population N Age Dosing interval Dose Reference 
Adult Development Dataset      
Healthy volunteers 12 44 (4) Single dose 150 mg Hiemenz et al. 200520 
Adult Validation Datasets      
Healthy volunteers 23 NR q24 hours 150 mg Keirns et al. 200721 
Healthy volunteers 34 23 (3) q24 hours 200 mg Undre et. al 201422 
Pediatric Validation Datasets      
Immunocompromised children 84 4mo-<18y q24 hours 3-4.5 mg/kg Benjamin et al. 201338 
Immunocompromised children 77 2y-<18y q24 hours 0.5-4 mg/kg Seibel et al. 200535 
Children with fungal infection 7 0-2y q24 hours 2 mg/kg Undre et al. 201239 
ECMO Validation Dataset      
Critically ill infants on ECMO 11 59d (0-574d) q24 hours 4 mg/kg Autmizguine et al. 201650 
Age is reported as mean (standard deviation) or range except for the ECMO Validation Dataset where age is median 
(range); NR – not reported
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Table 6.3. Assumptions used in the model building process 
Factor Assumption Reference 
Mass balance 
90% eliminated in feces via bile and 10% in urine 
Fraction of the dose excreted at 168 hours: 44% in bile and 7% in urine 
EMA Summary6 
 
fu 0.006 with a normal distribution and SD of 0.002 Yanni et al. 201145 
OATP1B1 Vmax 
Vmax [pmol/(min*mg protein)] 814 with a normal distribution and SD of 248 and no 
ontogeny 
Yanni et al. 20107 
OATP1B1 Km Km (µM) 40 with a normal distribution and SD of 5 and no ontogeny Yanni et al. 20107 
Edema Body weight in children on ECMO can be increased by over 50% due to edema Anderson et al 199232 
SD – standard deviation
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Table 6.4. Observed versus predicted area under the concentration time curve for a 24 hour dosing interval (AUC0-24) for adult 
studies used in model development and evaluation 
Study Population N Dose 
AUCOBS 
(mg*h/L) 
AUCPBPK 
(mg*h/L) 
Fold 
Error 
Adult Development Datasets       
Hiemenz et al.20  Healthy Adult 12 150 mg 104a 108 1.04 
       
Adult Validation Datasets       
Keirns et al.21 Healthy Adult 23 150 mg 181b 178 0.98 
Undre et al.22 Healthy Adult 34 200 mg 236c 233 0.99 
AUCOBS observed AUC0-24 
AUCPBPK predicted AUC0-24 
a AUC0-24 measured after dose 1 
b AUC0-24 measured after dose 20 
c AUC0-24 measured after dose 5 
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Table 6.5. Observed versus predicted area under the concentration time curve for a 24 hour 
dosing interval (AUC0-24) for pediatric studies used in model evaluation 
Study Population N Dose 
AUCOBS 
(mg*h/L) 
AUCPBPK 
(mg*h/L) 
Fold 
Error 
Benjamin et al.38 12-<18y 1 4.5 mg/kg 339a 351 1.04 
 12-<18y 12 3 mg/kg 184 185 1.01 
 6-<12y 20 4.5 mg/kg 264 340 1.29 
 6-<12y 13 3 mg/kg 249 227 0.91 
 2-<6y 31 4.5 mg/kg 248 292 1.18 
 0-<2y 9 4.5 mg/kg 264 189 0.72 
 median     1.04d 
Seibel et al.35 2-<18y 15 0.5 mg/kg 28b 31 1.11 
 2-<18y 16 1 mg/kg 52 63 1.21 
 2-<18y 16 1 mg/kg 52 63 1.21 
 2-<18y 13 1.5 mg/kg 101 94 0.93 
 2-<18y 11 2 mg/kg 94 126 1.34 
 2-<18y 9 3 mg/kg 191 189 0.99 
 2-<18y 9 3 mg/kg 191 189 0.99 
 median     1.05 
Undre et al.39 0-2y 7 2 mg/kg 53c 59 1.11 
AUCOBS observed AUC 
AUCPBPK predicted AUC 
a Benjamin et al. measured AUC0-24 after dose 8 
b Seibel et al. measured AUC0-24 after dose 5 
c Undre et al. measured AUC0-24 after dose 1 
d Median for Benjamin et al. excludes the results from Infants (0-<2y) as they are 
considered separately  
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Figure 6.1. PBPK model structure.  
Standard model structure Model structure with ECMO compartment 
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Figure 6.2. PBPK workflow 
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Figure 6.3. Steps to calculate a change in AUC due to extraction by the ECMO circuit. Median change in AUC for circuits corrected 
for change in AUC in controls is used to parameterize micafungin extraction in the ECMO compartment of the ECMO PBPK Modelhe 
Adult Development Dataset. 
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Figure 6.4. Adult PBPK Model Development. PBPK model predictions for a dose of 50 mg compared with observed concentrations 
from the Adult Development Dataset.  
Base Adult PBPK Model assuming only passive distribution based on Rodgers and Rowland generated partition coefficients and 
elimination via GFR. 
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Step 1. Rapid equilibrium process compared to observed data in early distribution phase. 
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Step 2. Addition of hepatic uptake by OATP1B1. 
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Step 3. Addition of hepatic efflux into bile optimized to fraction excreted in bile equal to fraction excreted for parent and 
metabolite. Predicted fraction excreted in bile of micafungin at 168h (61%) exceeded observed fraction (44%) from 
mass balance study. 
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Step 4. Addition of metabolism via arylsulfatase, catechol-O-methyltransferase, and CYP3A4. The predicted fraction excreted in 
bile (45%) approximated the observed fraction excreted in feces (44%) at 168h. The predicted fraction excreted in urine (5%) 
approximated the observed fraction excreted in urine (7%) at 168h. The predicted and observed AUC0-24 (mg*h/L) were 104 and 
108, respectively (1.04 fold error). 
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Figure 6.5. Adult model validation. PBPK predicted exposures versus observed data from 
Adult Validation Datasets. Solid black line represents median predicted concentration; grey 
shaded area represents the 90% prediction interval; observed data (mean +/- 90% 
confidence interval) are represented by symbols. 
 
A. Keirns et al. 200721 Observed vs predicted exposure after 20 doses of 150 mg every 24 
hours 
 
 
AUC0-24 Observed 
181 mg*h/L 
AUC0-24 Predicted 
178 mg*h/L 
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B. Undre et al. 201422 Observed vs predicted exposure after 5 doses of 200 mg every 24 
hours 
 
 
AUC0-24 Observed 
236 mg*h/L 
AUC0-24 Predicted 
233 mg*h/L 
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Figure 6.6. Pediatric PBPK Model predictions versus observed data for children (2-<18y). 
PBPK model predictions for a dose of 1 mg/kg versus dose-normalized observed mean 
concentrations from children 2-<18y included in the Pediatric Validation Datasets. Solid 
black line represents the median predicted concentration; grey shaded area represents the 
90% prediction interval; symbols represent observed mean data for Benjamin et al.38 () and 
for Seibel et al.35 ().  
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Figure 6.7. Pediatric PBPK Model predictions versus observed data for infants (0-2y). PBPK 
model predictions for a dose of 1 mg/kg versus dose-normalized observed mean 
concentrations from infants 0-2y included in the Pediatric Validation Datasets. Solid black 
line represents the median predicted concentration; grey shaded area represents the 90% 
prediction interval; symbols represent observed data for Benjamin et al.38 (; mean +/- 90% 
confidence interval) are represented by and for Undre et al.39 (; mean).Inset shows first 14 
hours; initial concentration from Undre et al over-predicted. 
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Figure 6.8. ECMO PBPK Model development. Model predictions and observed data from 
infants on ECMO following a single dose of 4 mg/kg. Solid black line represents the median 
predicted concentration; grey shaded area represents the 90% prediction interval; observed 
data from each patient is represented by a unique color. PBPK-predicted AUC0-24 shown 
below each plot. 
 
1. Base PBPK model: Pediatric PBPK Model predictions versus observed 
concentrations in infants on ECMO 
 
 
AUC0-24 117 mg*h/L 
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2. Addition of ECMO compartment to the Pediatric PBPK Model 
 
 
AUC0-24 97 mg*h/L 
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3. Addition of the ECMO compartment and incorporation of Edema to the Pediatric 
PBPK Model to form final ECMO PBPK Model 
 
 
AUC0-24 86 mg*h/L 
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Figure 6.9. ECMO PBPK Model-predicted versus observed micafungin AUC0-24 in infants on 
ECMO after a dose of 4 mg/kg. Solid black horizontal line is median, box represents 
interquartile range and whiskers are 90% confidence interval. Dashed blue horizontal line 
represents target AUC0-24. Median AUC0-24 and percentage of children achieving target 
AUC0-24 shown below each plot. 
AUC0-24 74 mg*h/L 
55% ≥ 76 
AUC0-24 86 mg*h/L 
66% ≥ 76 
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Figure 6.10. ECMO PBPK Model-predicted optimized micafungin dosing and exposure in 
children on ECMO across the pediatric age spectrum. Solid line represents the median, box 
represents interquartile range, and whiskers represent 90% prediction interval.  Dosing 
achieved the target AUC0-24 (>75 mg*h/L, blue dashed line) in ≥ 90% of simulated children 
on ECMO in the first 24 hours of therapy. 
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Figure 6.11. ECMO PBPK Model-predicted micafungin exposure in children on ECMO 
across the pediatric age spectrum. Solid line represents the median, box represents 
interquartile range, and whiskers represent 90% prediction interval.  Dosing achieved the 
target AUC0-24 (>75 mg*h/L, blue dashed line) in 100% of simulated children on ECMO in the 
first 24 hours of therapy.  
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CHAPTER 7. SUMMARY AND FUTURE DIRECTIONS 
Extracorporeal membrane oxygenation (ECMO) is used to support 
cardiorespiratory failure in critically ill infants, children, and increasingly, in adults. In 
these vulnerable populations, the effect of ECMO on drug disposition leaves 
clinicians with uncertainty about dosing. Historically, drug dosing on ECMO was 
determined with dedicated pharmacokinetics (PK) trials in patients supported with 
ECMO, and based on these trials, dosing recommendations for some antibiotics and 
sedatives were adjusted.1-3 However, there are three limitations to this approach. 
First, the effect of ECMO on exposure is drug specific, necessitating a trial for each 
drug of interest.4 Second, the impact of ECMO can vary by age of the patient.5 Most 
ECMO PK trials were done in infants; and it is unclear whether the results can be 
extrapolated to older children and adults. Third, ECMO technology changes over 
time, and with it, the impact on drug disposition.6 Given the differences reported in 
drug extraction between older components (e.g., silicone membrane oxygenators) 
and newer technology (e.g., polymethylepentane hollow-fiber oxygenators), it is 
unknown whether dosing recommendations derived from trials using the older 
technology can be extrapolated to patients supported with modern ECMO circuits. In 
order to better understand circuit-drug interactions, multiple ex vivo studies of drug 
extraction in isolated ECMO circuits have been performed. These studies allow 
quantification of drug extraction, and have resulted in general recommendations.4,7-9 
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However, the ability to directly translate results from ECMO ex vivo 
experiments into dosing recommendations has been challenging. Until recently, 
ECMO PK studies and ex vivo experiments lacked a systematic approach. The 
ECMO PK project initiated in 2013 attempted to address this problem through an 
approach that combined ex vivo studies with PK trials and population PK analyses 
for commonly used drugs.10 This approach will provide greater insight into the 
mechanism of drug extraction and should determine dosing for the targeted drugs. 
However, the number of drugs proposed for study (n=19) makes it unlikely that 
mechanisms causing drug interaction with the circuit will be determined. Further, the 
work with fluconazole in this dissertation shows the limitations of population PK 
analysis in the ECMO system. Based on the fluconazole population PK analysis of 
the Fluconazole ECMO Trial (n=40, 88% were infants) and the ECMO ex vivo 
experiments with fluconazole, the effect of ECMO on volume of distribution and 
clearance was quantified. There is confidence in the dosing recommendations 
submitted to the FDA for fluconazole in infants on ECMO. There is less confidence 
in how to dose in children and adults. As new ECMO circuit equipment evolves, it is 
unknown whether the dosing recommendations will still be valid. 
The research described in this dissertation used an alternative approach that 
translated ECMO ex vivo results to bedside dosing recommendations using 
Physiologically Based Pharmacokinetic (PBPK) modeling. Studies focused on 
antifungal drugs in children on ECMO because invasive candidiasis is common, and 
often fatal, in this population.11,12 Candida infections are difficult to treat on ECMO 
due to the organism’s ability to form biofilms on the ECMO cannulas that connect the 
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child to the ECMO circuit. Thus, treatment relies on optimal antifungal dosing. To 
determine optimal dosing, the impact of the ECMO circuit on antifungal disposition 
was first assessed in isolation through ex vivo studies. Then, PBPK models for 
fluconazole and micafungin were developed in adults and scaled to children. Finally, 
the ECMO circuit was incorporated as a virtual organ into the PBPK models to 
predict dosing in this population. The PBPK models were evaluated with prospective 
clinical trials of fluconazole and micafungin in children on ECMO. Fluconazole and 
micafungin were chosen because they are used commonly to treat candidiasis in 
children on ECMO, and they have different physicochemical properties and 
clearance processes, which facilitated testing the generalizability of this approach. 
This approach demonstrated proof of concept for an ECMO PBPK Model that 
was developed using existing data from the literature, scaled to special populations 
(e.g., children, disease), and modified to include the effects of extracorporeal 
support. The PBPK Model-predicted dosing in infants on ECMO was in close 
agreement with the dosing recommendations from the Fluconazole and Micafungin 
ECMO PK Trials that were generated using traditional compartmental modeling. 
However, the real utility of the ECMO PBPK Model is its flexibility. By including 
information about organ ontogeny, the PBPK models can predict dosing in 
populations across the pediatric age spectrum, including populations that were not 
studied in the trials. In addition, the PBPK models can be modified to account for 
different disease states to provide disease-specific dosing. This was demonstrated 
in the present studies by incorporation of edema into the Pediatric ECMO PBPK 
Model, which adequately described the data in infants on ECMO. Most importantly 
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for ECMO, as ECMO technology evolves, the PBPK models can be modified to 
reflect the impact of the new circuit components on drug disposition. More broadly, 
these methods can be applied to other forms of extracorporeal support such as 
dialysis. 
As this work goes forward, a number of important questions remain 
unanswered. An overview of the key findings and future directions are discussed 
below. 
 
Understanding ECMO circuit-drug interactions through ex vivo experiments 
(Chapter 2) 
The ex vivo experiments in this dissertation were the first to focus on the 
ECMO circuit extraction of antifungals, and to isolate the circuit component 
responsible for extraction. At the time of study design, ECMO ex vivo studies had 
been performed for 27 drugs,4,8,13-20 primarily antibiotics and sedatives, but only one 
antifungal—voriconazole.19 During the course of this dissertation, ECMO ex vivo 
results were published for fluconazole using a circuit configuration similar to the 
Oxygenator Circuit in the present study.4 Results were nearly identical in showing 
that fluconazole was not extracted by the ECMO circuit. In general, extraction by the 
circuit is driven by hydrophobic and ionic adsorption. Neither of these processes 
were likely to affect fluconazole because it has a neutral charge and low lipophilicity. 
Similar to fluconazole, amphotericin B deoxycholate was not extracted by the 
circuit. Amphotericin B deoxycholate is slightly lipophilic but is a zwitterion, which 
may have limited its ionic adsorption by the circuit materials. However, the present 
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experiments only evaluated the extraction of the amphotericin B deoxycholate 
formulation. Further work is needed to understand whether amphotericin disposition 
in the ECMO circuit is different for other formulations. Several lipid-coated 
amphotericin formulations exist and are used commonly because they are 
associated with less renal toxicity.21-26 Decreased toxicity is thought to occur 
because the lipid coating limits the drug’s interaction with the renal tubular cells.27 
The lipid coatings are hydrophobic and, in some cases, charged. It is possible that 
these properties will lead to hydrophobic and/or ionic interactions resulting in 
adsorption by the ECMO circuit. If adsorption occurs, it is unknown whether the 
active drug will be removed from circulation, or if only the coating will be removed. If 
the coating is adsorbed but the active drug is released into plasma, it is possible that 
the renal-protective effects of lipid formulations will be negated. The current ex vivo 
experimental design can be used in future studies to determine whether overall 
exposure of amphotericin is decreased. However, in order to determine the 
differential impact on renal toxicity, ECMO animal studies would be necessary. 
Micafungin interacted with the ECMO circuit in both a time- and albumin 
concentration-dependent manner. Micafungin extraction was substantial over the 
first four hours of the experiment in a Complete Circuit, but not in the Oxygenator or 
Pump Circuits, or the control samples. Further, micafungin was extracted to a 
greater extent when albumin concentrations were <1 g/dL. There are two possible 
explanations. First, because albumin is the primary protein binding partner for 
micafungin, low albumin concentrations led to a higher fraction of unbound drug and 
unbound drug was bound by the circuit. The alternative is that albumin binds to the 
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circuit and occupies binding sites, thereby preventing micafungin adsorption. This 
raises an interesting clinical question about strategies to limit binding – can 
preloading the circuit with albumin limit drug interactions with a circuit? The answer 
is that the interaction is likely drug and circuit specific, but should be explored in 
future studies.  
While micafungin extraction during the first 4 hours was most likely due to 
adsorption by the hemofilter membrane, these results are in contrast to in vivo 
studies of micafungin in patients supported with continuous venovenous 
hemofiltration (CVVH). The CVVH studies used hemofilters of similar materials, but 
no significant difference in concentrations pre- and post-membrane was 
reported.28,29 Further research is necessary to understand the mechanism(s) by 
which the hemofilter extracts micafungin. Future experiments should sample pre- 
and post- hemofilter in the ECMO ex vivo system under a variety of conditions 
including different flow and filtration rates. The most accurate measure would be to 
extract drug from the hemofilter itself. However, methods would need to be 
developed that could effectively displace micafungin from the hemofilter membrane 
and accurately quantify it under those conditions. Alternatively, a mass balance 
study using radiolabeled drug and imaging (e.g., gamma camera) could isolate the 
sites of extraction. 
Micafungin is dosed clinically once every 24 hours. Therefore, it is important 
to understand disposition in the ex vivo system over an entire dosing interval. 
Unexpectedly, after 24 hours, all of the micafungin circuits and controls showed 
substantial extraction. The fact that extraction occurred in the controls suggested 
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one of three mechanisms: 1) slow adsorption by the materials of both the circuits 
and control tubes, 2) metabolism in the plasma (e.g., peptidases), or 3) drug 
degradation (e.g., micafungin is degraded by light30). Further studies are needed to 
understand the mechanism because both adsorption and light degradation could 
have important dosing implications. Adsorption can be quantified by measuring 
micafungin concentrations in sample tubes of different materials (e.g., 
polyvinylchloride versus silanized glass). The impact of plasma metabolism can be 
determined using different media such as whole blood versus crystalloid. Finally, the 
effect of light degradation can be assessed by measuring micafungin concentrations 
in tubes that were protected from light compared to those exposed to light. These 
experiments are planned and the methods currently are being refined.  
Alternatively, mass balance studies with radiolabeled micafungin also can be 
used to answer this question. There are certain methods that make mass balance 
studies more challenging in ECMO (e.g., how to remove all of the blood in the 
ECMO circuit? Will flushing the ECMO circuit displace micafungin adsorbed to 
ECMO components? Is this impacted by the type of flush selected?). Mass balance 
studies will be more expensive because they require radiolabeled micafungin and 
construction of multiple ECMO circuits as opposed to inexpensive control tubes of 
various materials. The mass balance approach will be employed if the above control 
tube experiments do not explain why micafungin concentrations decreased in the 
control samples.  
Future ECMO ex vivo studies should focus on two areas: 1) specific drug-
circuit interactions and 2) understanding broadly how drugs interact with the circuit. 
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There will always be a need to conduct dedicated studies for clinically important 
drugs. Ex vivo experiments are a quick, relatively inexpensive method to quantify the 
extraction in a specific ECMO circuit configuration. For a given circuit configuration, 
knowing how much extraction occurs can help clinicians decide whether higher 
doses might be necessary. Further, as demonstrated in this dissertation, the 
extraction can be translated directly to dosing recommendations using the ECMO 
PBPK Model. These experiments can also help determine if the extraction is 
saturable and/or reversible for specific drugs. Multiple dose experiments, dosing 
over a range of concentrations, and conducting experiments for prolonged times can 
help determine the saturability and reversibility of extraction by the ECMO circuit. 
The latter have important dosing ramifications, and could be used to develop dosing 
algorithms based on the age of the circuit. 
The ultimate goal of ECMO ex vivo research is to achieve an accurate a priori 
prediction of which drug(s) interact with different ECMO components, and to what 
extent. The traditional ECMO ex vivo system is ill-suited to answer this question. 
While inexpensive compared to clinical trials, each circuit can cost thousands of 
dollars. When perfusion experiments are conducted in triplicate with all of the 
different combinations of circuit components, the costs quickly become prohibitive. 
Based on the studies that have been conducted so far, even with the traditional 
ECMO ex vivo approach, the ability to broadly generalize is difficult. This is 
evidenced by the fact that over the past 40 years, less than 30 drugs have been 
studied in an ex vivo ECMO system, and there is no definitive understanding of what 
causes drugs to interact with the ECMO circuit, and certainly no quantitative 
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prediction of the extent of extraction. To accurately predict extraction by the ECMO 
circuit, data will need to be gathered for 100’s of drugs. This argues for a high 
throughput system that draws on expertise from the fields of materials science and 
quantitative structure-activity relationship (QSAR) modeling.  
There is extensive expertise and literature in the field of materials science 
with regard to drug sorption. Much of this literature describes the relationship 
between a drug and a storage container (e.g., vial, IV bag),31-34 and models 
predicting this interaction between a drug and storage material have been 
developed.35 Although, this approach has never been applied to ECMO, the 
principles remain the same. Similarly QSAR modeling uses computational methods 
to predict drug action based on physicochemical properties. QSAR modeling has 
been applied to predict drug-enzyme interactions and drug-protein binding.36,37 If the 
mechanism of circuit-drug interactions is known for a sufficient number of drugs and 
circuit materials, the same QSAR methods should be applicable to ECMO. By using 
materials science to understand the mechanism(s) by which drugs interact with the 
ECMO circuit, and using QSAR modeling to predict the degree of interaction 
between a drug and a surface, ECMO researchers should be able to predict whether 
a drug will interact with an ECMO circuit based on the physicochemical properties of 
the drug and the materials of the circuit. It is unlikely that many ECMO scientists will 
have expertise in both fields, so future research will rely on collaboration.  
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Physiologically based pharmacokinetics in critically ill children (Chapters 4 
and 6) 
The PBPK models develop in this dissertation were the first PBPK models for 
fluconazole and micafungin, the first to include an extracorporeal compartment, and 
the first to predict the effect of edema on drug exposure. The models for both 
fluconazole and micafungin followed an established work flow whereby an adult 
PBPK model was developed first to determine the appropriate model structure using 
robust adult data.38 Once there was confidence in the model structure, the adult 
model was scaled to children using known ontogeny of anatomy and physiology. 
Because dosing of both drugs is based on area under the concentration vs. time 
curve (AUC), performance of the models was evaluated by comparing both 
observed versus predicted concentrations and precision of the AUC estimates.  
The fluconazole Adult PBPK Model was relatively straightforward. 
Fluconazole is a small molecule with distribution that is perfusion-rate limited, has 
minimal metabolism, and is eliminated almost exclusively by the kidneys. Extensive 
drug-specific data existed for fluconazole, and only a few assumptions were made 
that were critical to the model structure. Optimized adult model predictions versus 
observed data from the literature showed good agreement, and PBPK-predicted 
AUC estimates were within 10% of the observed AUC. The adult model was 
successfully scaled to children by including age-dependencies in physiological 
parameters. Because the Pediatric PBPK Model was scaled from healthy adults, it 
did not capture the variability seen in critically ill children. However, the median 
PBPK-predicted AUC was within 5% of observed. Successful scaling to children 
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likely reflects the fact that fluconazole clearance is driven primarily by glomerular 
filtration rate (GFR),39 and GFR ontogeny is well described in children.40 One of the 
advantages of PBPK modeling is the ability to predict drug concentrations at the site 
of action. There are extensive data describing fluconazole concentrations in multiple 
organs.39 Future work should focus on refining the model to validate concentration 
predictions in sites other than the plasma. In this way, fluconazole dosing can be 
optimized for specific fungal infections.  
The same process of PBPK model development was applied to micafungin. 
Micafungin plasma disposition exhibited a pronounced distribution phase, and 
clearance was influenced by transporter-mediated hepatic uptake and biliary 
excretion. Because of uncertainty in the multiple processes involved in micafungin 
disposition, the micafungin model included several assumptions. One of the goals of 
this dissertation was to develop PBPK models using existing data, and the 
micafungin model provided proof of concept for this approach. When the known PK 
processes were combined with physiologically reasonable assumptions, the Adult 
PBPK Model showed excellent agreement between model predictions and observed 
data. The assumption in scaling to children was that the parameters for which 
ontogeny data were limited (e.g., transporter function) were similar between adults 
and children. When the system specific inputs were adjusted with known ontogeny 
(e.g. organ weights, GFR), the pediatric PBPK model also showed excellent 
agreement with observed data. Concerns that optimizing certain parameters with in 
vivo data might limit generalizability were mitigated for this molecule as PBPK 
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predictions showed excellent agreement with several independent validation 
datasets.  
The major focus and novel contribution of this dissertation research was 
inclusion of the ECMO compartment in the PBPK model. Extracorporeal devices 
such as ECMO are known to alter PK. This effect is drug dependent, and as noted 
above, not easily predicted based on physicochemical properties. The ECMO PBPK 
Models demonstrated that an ECMO compartment could be added to the Pediatric 
PBPK Model to accurately describe fluconazole and micafungin concentration 
versus time profiles. When the ECMO compartment was informed by the ECMO ex 
vivo experiments, the model was able to quantify the effect of ECMO on disposition 
of a particular drug. Because exposure to ECMO results in a profound inflammatory 
reaction, which leads to edema,41-44 an edema physiologic state also was added to 
the ECMO model. After accounting for both circuit and disease, the ECMO PBPK 
Models successfully predicted exposure for both fluconazole and micafungin in 
infants on ECMO. Going forward it will be important to capture clinical factors that 
can explain alterations in PK (e.g., extent of edema, volume of transfusions) so that 
these parameters can be more accurately estimated in the models.  
Validation of PBPK models remains an area of debate. The top-down 
approach (e.g., population PK) has well defined criteria for validation both in the 
literature and from a regulatory standpoint.45,46 A recent meeting at the FDA 
discussed validation criteria for PBPK models but there was no consensus on 
criteria.47 Because of the bottom-up approach, PBPK models are built on certain 
assumptions. If these assumptions are inaccurate, the models are vulnerable to 
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multiplicity of errors. In order to account for these errors, model bias can be 
assessed by calculating the average fold error (AFE) between predicted and 
observed concentrations: AFE=10[1/N∑log(predicted/observed)].38,48 The AFE indicates model 
under- (AFE<1) or over-prediction (AFE>1) when compared with observed values. 
Model precision can be assessed by calculating the absolute average fold error: 
AAFE= 10[1/N∑|log(predicted/observed)|] for each individual curve.48 The cutoff that is 
acceptable for AFE and AAFE depends on the molecule and purpose of the model. 
Population predictability can be assessed by generating a prediction interval (5th to 
95th percentile) of drug concentrations for the population and quantifying the number 
of observed concentrations that fall outside of the prediction interval. In general, the 
model is acceptable if 90% of observed concentrations fall within the prediction 
interval, but, again, this depends on the molecule and purpose of the model.38 
However, in order to apply these approaches, it is necessary to have observed data 
at the individual level. Many of the datasets used to evaluate models in this 
dissertation were obtained from the literature and only included summary data (e.g., 
mean concentration +/- standard deviation). As a result, in this dissertation 
population predictability was evaluated by visual inspection of the observed data 
captured within the model’s 90% prediction interval and comparing the fold error 
between the PBPK-predicted AUC and observed AUC. 
Because the PBPK models are mechanistic and can predict dosing for any 
age, the ECMO PBPK Models were used to define optimal dosing regimens in 
children of all ages.  In the future, this concept could be extended to adults. The 
majority of ECMO research has been focused on infants and ex vivo systems. With 
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adult ECMO programs expanding, this ECMO PBPK modeling approach can reverse 
the paradigm of scaling down to children, and scale up to predict optimal dosing in 
adults. 
 
 
Modeling and simulation to support clinical trials (Chapters 3 and 5) 
Modeling and simulation is a powerful tool in pediatric drug development. 
However, pediatric clinical drug trials remain the gold standard, and in the 
foreseeable future will continue to be necessary to evaluate model predictions. As 
part of this dissertation, two clinical PK trials of fluconazole and micafungin were 
performed in children on ECMO. Both of these trials were performed under Food 
and Drug Administration (FDA) Investigational New Drug applications so that data 
collected could be submitted to the FDA for consideration of amended product 
labeling. Dosing recommendations were derived for both drugs using traditional 
compartmental modeling. The dosing recommendations for fluconazole were 
submitted to the FDA in 2015 and currently are under review. The time from initial 
study design to FDA submission was more than 5 years, and there remains a 
concern that if ECMO technology changes, the submitted dosing recommendations 
may no longer be valid. Dosing recommendations for micafungin will be submitted to 
the FDA in 2016 but face the same challenges. These challenges were the impetus 
for the PBPK methodology developed in this dissertation.  
Going forward, the ECMO PBPK modeling approach will be used to develop 
dosing recommendations focusing on drugs that are prioritized by the Best 
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Pharmaceuticals for Children Act (BPCA).49 Dosing recommendations will need to 
be evaluated using PK data from children for the drugs of interest. The NIH-
sponsored Pediatric Trials Network supports an opportunistic PK study in children, 
whereby PK samples are collected for BPCA-prioritized drugs that are prescribed 
per standard of care to certain target populations. One target population is children 
on ECMO. Currently, 279 PK samples from 148 children for 20 drugs have been 
collected and enrollment is ongoing. The ECMO PBPK modeling approach can be 
used to leverage these data to develop optimal dosing recommendations for patients 
on ECMO, and label changes for dosing, if needed.   
PBPK modeling has tremendous potential beyond ECMO to understand drug 
disposition and to predict dosing in children. In children, PBPK models have been 
used to scale adult data to children. If scaling a validated adult model fails to 
accurately describe the observed pediatric data, this suggests that a mechanism 
regulating drug disposition is either missing or inaccurately described. Knowing 
where model inaccuracies affect PK (e.g., clearance) can point to future studies to 
elucidate the mechanism. PBPK models also hold potential to extrapolate from 
animals to humans. For example, most of the studies on transporter ontogeny come 
from developmental studies in animals. Relevant tissue samples are hard to obtain 
in children, and even when tissue is available, multiple confounders (e.g., disease 
state, tissue handling) can limit generalizability. Studies in developing animals allow 
for more control but it is frequently unknown whether the ontogeny determined in 
animals directly translates to children. PBPK provides a tool to explore those 
relationships. 
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For these reasons, PBPK models are recommended increasingly by 
regulators for pediatric drug development.50 Both the European Medicines Agency 
and Office of Clinical Pharmacology at the FDA have seen an increase in pediatric 
development plans incorporating PBPK modeling.51,52 Regulator’s from the FDA’s 
Office of Clinical Pharmacology published a summary of the regulatory experience 
with PBPK modeling for pediatric drug development detailing the potential 
advantages, but also noting the current weaknesses.53 In general, the authors list 
several of the advantages noted in this dissertation. PBPK modeling can facilitate 
optimal trial design by determining optimal sample times and decreasing the number 
of children needed to have confidence in model predictions. PBPK models can be 
scaled from animals to humans as mentioned above, although this approach is 
primarily applicable in early phases of drug development when limited data exist in 
humans. PBPK-PD models can leverage the burgeoning field of pediatric biomarkers 
by linking mechanisms of drug disposition with surrogate markers of effect. In order 
to facilitate submission of PBPK models to support pediatric drug development, the 
FDA has published a pediatric decision tree that describes the required clinical 
studies, criteria for extrapolation, and the number of children required in clinical 
trials.53-55 
However, PBPK models have important limitations, primarily the lack of data 
to inform PBPK models, particularly in infants and neonates.53 In order to 
successfully scale to children, the PBPK models must be informed by data 
describing the ontogeny of relevant anatomic and physiologic processes. Anatomic 
data (e.g., organ weights) are available from large databases;56,57 and ontogeny for 
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GFR and common metabolizing enzymes (e.g., CYP3A4) are described reasonably 
well in the literature.40,58 However, huge knowledge gaps remain about the ontogeny 
of non-CYP enzymes and drug transporters. In the recent Pediatric Transporter 
White Paper, the Pediatric Transporter Working Group outlines these knowledge 
gaps, and proposes methods to determine transporter ontogeny.59 As these gaps 
are filled, PBPK models will be better able to capture the developmental changes 
affecting drug absorption, distribution, metabolism, and elimination. 
The pediatric intensive care unit (PICU) provides unique resources for the 
study of age- and disease-related changes in expression and function of drug 
metabolizing enzymes and membrane transporters. These children tend to have 
invasive lines and tubes that mitigate the sample collection challenges common in 
pediatric trials. In addition to easy collection of blood samples, duodenal and jejunal 
feeding tubes are common and allow for collection of bile. Many children in the PICU 
also will have urinary catheters that make collection of 24 hour urine specimens 
straightforward. Further many of the established probe substrates (e.g., CYP3A4-
midazolam) are prescribed per standard of care. There remains a large body of 
foundational work that needs to be done (e.g. bile acid profiling in different disease 
states). However, more exciting are studies such as that by Ferslew and Brouwer of 
the disease effects on drug disposition.60  They identified a disease state (non-
alcoholic steatohepatitis) associated with a known alteration in transporter function 
and compared the PK and bile acid profiles between healthy and diseased subjects. 
Such studies could be easily translated to the PICU to assess the functional 
changes of transporters and drug metabolizing enzymes in different disease states. 
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In conclusion, this dissertation was the first to establish antifungal dosing 
recommendations for children on ECMO. The dosing recommendations from this 
research have been, or will be, submitted to the FDA for inclusion in the label, and 
were incorporated in antifungal dosing guidelines for children on ECMO.61 Although 
determining optimal dosing for these two commonly used drugs in children on 
ECMO was important, more importantly, the PBPK modeling developed in this 
dissertation demonstrated the utility of this approach to understand and quantify the 
physiologic alterations driving drug disposition in critically ill children. The modeling 
will also provide the necessary construct for using data from PBPK modeling to 
support dosing recommendations and inform study design for future PK trials. A 
more precise, refined, integrated approach for drug dosing in this pediatric sub-
population will improve both the safety and efficacy of drug therapy in critically ill 
children supported. 
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APPENDIX 1 
ECMO ex vivo data 
 
circuit drug samp site date time nom_time doseno amt flow dv 
32 B 0 A 2/23/2015 9:15 0   1.0 0 
32 B   2/23/2015 9:30 0 1 3   
32 B 1 A 2/23/2015 9:31 0.02   1.0 3.01 
32 B 2 A 2/23/2015 9:35 0.08   1.0 2.86 
32 B 3 A 2/23/2015 9:45 0.25   1.0 2.7 
32 B 4 A 2/23/2015 10:00 0.5   1.0 2.64 
32 B 5 A 2/23/2015 10:30 1   1.0 2.6 
32 B 6 A 2/23/2015 11:30 2   1.0 2.72 
32 B 7 A 2/23/2015 12:30 3   1.0 2.57 
32 B 8 A 2/23/2015 13:30 4   1.0 2.69 
32 B 9 A 2/23/2015 17:30 8   1.0 2.55 
32 B 10 A 2/23/2015 21:30 12   1.0 2.69 
32 B 11 A 2/24/2015 9:30 24   1.0 2.71 
32 B 12 A 2/25/2015 9:30 48   0.9 2.27 
32 B 13 A 2/26/2015 9:30 72   0.9 1.47 
33 B 0 A 2/23/2015 9:42 0   1.0 0 
33 B   2/23/2015 9:50 0 1 3   
33 B 1 A 2/23/2015 9:51 0.02   1.0 2.6 
33 B 2 A 2/23/2015 9:55 0.08   1.0 2.57 
33 B 3 A 2/23/2015 10:05 0.25   1.0 2.43 
33 B 4 A 2/23/2015 10:20 0.5   1.0 2.47 
33 B 5 A 2/23/2015 10:50 1   1.0 2.44 
33 B 6 A 2/23/2015 11:50 2   1.0 2.69 
33 B 7 A 2/23/2015 12:50 3   1.0 2.68 
33 B 8 A 2/23/2015 13:50 4   1.0 2.79 
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33 B 9 A 2/23/2015 17:50 8   1.0 2.74 
33 B 10 A 2/23/2015 21:50 12   1.0 2.82 
33 B 11 A 2/24/2015 9:50 24   1.0 0.87 
33 B 12 A 2/25/2015 9:50 48   1.0 0.87 
33 B 13 A 2/26/2015 9:50 72   1.0 0.95 
34 B 0 A 2/23/2015 10:20 0   1.0 0 
34 B   2/23/2015 10:20 0 1 3   
34 B 1 A 2/23/2015 10:21 0.02   1.0 2.99 
34 B 2 A 2/23/2015 10:25 0.08   1.0 3.06 
34 B 3 A 2/23/2015 10:35 0.25   1.0 2.88 
34 B 4 A 2/23/2015 10:50 0.5   1.0 2.89 
34 B 5 A 2/23/2015 11:20 1   1.0 2.75 
34 B 6 A 2/23/2015 12:20 2   1.0 2.87 
34 B 7 A 2/23/2015 13:20 3   1.0 3.01 
34 B 8 A 2/23/2015 14:20 4   1.0 2.99 
34 B 9 A 2/23/2015 18:20 8   1.0 3.04 
34 B 10 A 2/23/2015 22:20 12   1.0 2.99 
34 B 11 A 2/24/2015 10:20 24   1.0 0.73 
34 B 12 A 2/25/2015 10:20 48   1.0 0.69 
34 B 13 A 2/26/2015 10:20 72   1.0 0.49 
301 B 1 C 2/23/2015 9:31 0.02   1.0 2.25 
301 B 2 C 2/23/2015 9:35 0.08   1.0 2.55 
301 B 3 C 2/23/2015 9:45 0.25   1.0 2.5 
301 B 4 C 2/23/2015 10:00 0.5   1.0 2.67 
301 B 5 C 2/23/2015 10:30 1   1.0 2.79 
301 B 6 C 2/23/2015 11:30 2   1.0 2.96 
301 B 7 C 2/23/2015 12:30 3   1.0 2.8 
301 B 8 C 2/23/2015 13:30 4   1.0 3.15 
301 B 9 C 2/23/2015 17:30 8   1.0 3.08 
301 B 10 C 2/23/2015 21:30 12   1.0 3.19 
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301 B 11 C 2/24/2015 9:30 24   1.0 2.4 
301 B 12 C 2/25/2015 9:30 48   0.9 2.23 
301 B 13 C 2/26/2015 9:30 72   0.9 1.04 
302 B 1 C 2/23/2015 9:51 0.02   1.0 2.57 
302 B 2 C 2/23/2015 9:55 0.08   1.0 2.72 
302 B 3 C 2/23/2015 10:05 0.25   1.0 2.91 
302 B 4 C 2/23/2015 10:20 0.5   1.0 2.93 
302 B 5 C 2/23/2015 10:50 1   1.0 3.08 
302 B 6 C 2/23/2015 11:50 2   1.0 3.65 
302 B 7 C 2/23/2015 12:50 3   1.0 3.81 
302 B 8 C 2/23/2015 13:50 4   1.0 3.86 
302 B 9 C 2/23/2015 17:50 8   1.0 3.92 
302 B 10 C 2/23/2015 21:50 12   1.0 3.86 
302 B 11 C 2/24/2015 9:50 24   1.0 3.76 
302 B 12 C 2/25/2015 9:50 48   1.0 2.78 
302 B 13 C 2/26/2015 9:50 72   1.0 2.8 
303 B 1 C 2/23/2015 10:21 0.02   1.0 2.89 
303 B 2 C 2/23/2015 10:25 0.08   1.0 3.1 
303 B 3 C 2/23/2015 10:35 0.25   1.0 3.32 
303 B 4 C 2/23/2015 10:50 0.5   1.0 3.49 
303 B 5 C 2/23/2015 11:20 1   1.0 3.85 
303 B 6 C 2/23/2015 12:20 2   1.0 4.04 
303 B 7 C 2/23/2015 13:20 3   1.0 4.08 
303 B 8 C 2/23/2015 14:20 4   1.0 4.08 
303 B 9 C 2/23/2015 18:20 8   1.0 4.28 
303 B 10 C 2/23/2015 22:20 12   1.0 4.16 
303 B 11 C 2/24/2015 10:20 24   1.0 4.24 
303 B 12 C 2/25/2015 10:20 48   1.0 3.48 
303 B 13 C 2/26/2015 10:20 72   1.0 2.83 
351 B 1 H 2/23/2015 9:31 0.02   1.0 0 
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351 B 5 H 2/23/2015 10:30 1   1.0 0 
351 B 11 H 2/24/2015 9:30 24   1.0 0.17 
351 B 12 H 2/25/2015 9:30 48   0.9 0.23 
351 B 13 H 2/26/2015 9:30 72   0.9 0.15 
352 B 1 H 2/23/2015 9:51 0.02   1.0 0 
352 B 5 H 2/23/2015 10:50 1   1.0 0 
352 B 11 H 2/24/2015 9:50 24   1.0 0.17 
352 B 12 H 2/25/2015 9:50 48   1.0 0.09 
352 B 13 H 2/26/2015 9:50 72   1.0 0.11 
353 B 1 H 2/23/2015 10:21 0.02   1.0 0 
353 B 5 H 2/23/2015 11:20 1   1.0  
353 B 11 H 2/24/2015 10:20 24   1.0 0.11 
353 B 12 H 2/25/2015 10:20 48   1.0  
353 B 13 H 2/26/2015 10:20 72   1.0 0.07 
1 F 0 A 4/25/2012 16:50 0   1.1 0 
1 F   4/25/2012 16:52 0 1 250   
1 F 1 A 4/25/2012 16:53 0.02   1.1 296 
1 F 1 V 4/25/2012 16:53 0.02   1.1 211 
1 F 2 A 4/25/2012 16:57 0.08   1.1 308 
1 F 2 V 4/25/2012 16:57 0.08   1.1 319 
1 F 3 A 4/25/2012 17:07 0.25   1.1 329 
1 F 3 V 4/25/2012 17:07 0.25   1.1 293 
1 F 4 A 4/25/2012 17:22 0.5   1.1 297 
1 F 4 V 4/25/2012 17:22 0.5   1.1 294 
1 F 5 A 4/25/2012 17:53 1   1.1 264 
1 F 5 V 4/25/2012 17:53 1   1.1 256 
1 F 6 A 4/25/2012 18:52 2   1.1 283 
1 F 6 V 4/25/2012 18:52 2   1.1 289 
1 F 7 A 4/25/2012 19:52 3   1.1 293 
1 F 7 V 4/25/2012 19:52 3   1.1 263 
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1 F 8 A 4/25/2012 20:52 4   1.1 262 
1 F 8 V 4/25/2012 20:52 4   1.1 299 
2 F 0 A 4/30/2012 16:07 0   1.0 0 
2 F   4/30/2012 16:22 0 1 250   
2 F 1 A 4/30/2012 16:23 0.02   1.1 400 
2 F 1 V 4/30/2012 16:23 0.02   1.1 369 
2 F 2 A 4/30/2012 16:27 0.08   1.1 387 
2 F 2 V 4/30/2012 16:27 0.08   1.1 338 
2 F 3 A 4/30/2012 16:37 0.25   1.1 337 
2 F 3 V 4/30/2012 16:37 0.25   1.1 365 
2 F 4 A 4/30/2012 16:52 0.5   1.1 366 
2 F 4 V 4/30/2012 16:52 0.5   1.1 353 
2 F 5 A 4/30/2012 17:24 1   1.1 401 
2 F 5 V 4/30/2012 17:24 1   1.1 390 
2 F 6 A 4/30/2012 18:24 2   1.1 398 
2 F 6 V 4/30/2012 18:24 2   1.1 419 
2 F 7 A 4/30/2012 19:30 3   1.1 397 
2 F 7 V 4/30/2012 19:30 3   1.1 410 
2 F 8 A 4/30/2012 20:32 4   1.1 325 
2 F 8 V 4/30/2012 20:32 4   1.1 401 
3 F 0 A 4/30/2012 17:32 0   1.0 0 
3 F   4/30/2012 17:56 0 1 250   
3 F 1 A 4/30/2012 17:57 0.02   1.0 219 
3 F 1 V 4/30/2012 17:57 0.02   1.0 208 
3 F 2 A 4/30/2012 18:02 0.08   1.0 203 
3 F 2 V 4/30/2012 18:02 0.08   1.0 200 
3 F 3 A 4/30/2012 18:10 0.25   1.0 200 
3 F 3 V 4/30/2012 18:10 0.25   1.0 203 
3 F 4 A 4/30/2012 18:28 0.5   1.0 194 
3 F 4 V 4/30/2012 18:28 0.5   1.0 191 
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3 F 5 A 4/30/2012 19:00 1   1.0 195 
3 F 5 V 4/30/2012 19:00 1   1.0 187 
3 F 6 A 4/30/2012 20:01 2   1.0 208 
3 F 6 V 4/30/2012 20:01 2   1.0 203 
3 F 7 A 4/30/2012 21:11 3   1.0 205 
3 F 7 V 4/30/2012 21:11 3   1.0 211 
3 F 8 A 4/30/2012 22:07 4   1.0 216 
3 F 8 V 4/30/2012 22:07 4   1.0 212 
12 F 0 A 4/25/2012 14:40 0   1.0 0 
12 F   4/25/2012 14:43 0 1 13   
12 F 1 A 4/25/2012 14:44 0.02   1.0 18.2 
12 F 1 V 4/25/2012 14:44 0.02   1.0 18.8 
12 F 2 A 4/25/2012 14:48 0.08   1.0 17.1 
12 F 2 V 4/25/2012 14:48 0.08   1.0 17.8 
12 F 3 A 4/25/2012 14:58 0.25   1.0 18.3 
12 F 3 V 4/25/2012 14:58 0.25   1.0 12.5 
12 F 4 A 4/25/2012 15:13 0.5   1.0 19.7 
12 F 4 V 4/25/2012 15:13 0.5   1.0 18.7 
12 F 5 A 4/25/2012 15:43 1   1.0 18.8 
12 F 5 V 4/25/2012 15:43 1   1.0 18.7 
12 F 6 A 4/25/2012 16:43 2   1.0 16.4 
12 F 6 V 4/25/2012 16:43 2   1.0 16.4 
12 F 7 A 4/25/2012 17:43 3   1.0 18.1 
12 F 7 V 4/25/2012 17:43 3   1.0 18.1 
12 F 8 A 4/25/2012 18:43 4   1.0 17.6 
12 F 8 V 4/25/2012 18:43 4   1.0 18.5 
16 F 0 A 4/30/2012 14:29 0   1.1 0 
16 F   4/30/2012 14:30 0 1 8   
16 F 1 A 4/30/2012 14:31 0.02   1.1 15.4 
16 F 1 V 4/30/2012 14:31 0.02   1.1 15.8 
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16 F 2 A 4/30/2012 14:35 0.08   1.1 15 
16 F 2 V 4/30/2012 14:35 0.08   1.1 15.3 
16 F 3 A 4/30/2012 14:45 0.25   1.1 14.9 
16 F 3 V 4/30/2012 14:45 0.25   1.1 16.2 
16 F 4 A 4/30/2012 15:00 0.5   1.1 16.9 
16 F 4 V 4/30/2012 15:00 0.5   1.1 16.2 
16 F 5 A 4/30/2012 15:30 1   1.1 16.9 
16 F 5 V 4/30/2012 15:30 1   1.1 15.7 
16 F 6 A 4/30/2012 16:30 2   1.1 16.9 
16 F 6 V 4/30/2012 16:30 2   1.1 16.8 
16 F 7 A 4/30/2012 17:30 3   1.1 16.4 
16 F 7 V 4/30/2012 17:30 3   1.1 16.5 
16 F 8 A 4/30/2012 18:30 4   1.1 16.3 
16 F 8 V 4/30/2012 18:30 4   1.1 17.1 
23 F 0 A 9/22/2014 10:20 0   1.0 0.007
23 F  A 9/22/2014 10:30 0 1 19 1.0  
23 F 1 A 9/22/2014 10:31 0.02   1.0 17.61
23 F 2 A 9/22/2014 10:35 0.08   1.0 17.48
23 F 3 A 9/22/2014 10:45 0.25   1.0 17.61
23 F 4 A 9/22/2014 11:00 0.5   1.0 17.33
23 F 5 A 9/22/2014 11:30 1   1.0 17.2 
23 F 6 A 9/22/2014 12:30 2   1.0 17.16
23 F 7 A 9/22/2014 13:30 3   1.0 17.12
23 F 8 A 9/22/2014 14:30 4   1.0 17.33
23 F 9 A 9/22/2014 18:30 8   1.0 17.37
23 F 10 A 9/22/2014 22:30 12   1.0 17.61
23 F 11 A 9/23/2014 10:30 24   1.0 17.28
23 F 12 A 9/24/2014 10:30 48   1.0 17.37
23 F 13 A 9/25/2014 10:30 72   1.0 17.18
24 F  A 9/22/2014 10:50 0 1 18 1.0  
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24 F 1 A 9/22/2014 10:51 0.02   1.0 19.05
24 F 2 A 9/22/2014 10:55 0.08   1.0 18.01
24 F 3 A 9/22/2014 11:05 0.25   1.0 18.49
24 F 4 A 9/22/2014 11:20 0.5   1.0 18.51
24 F 5 A 9/22/2014 11:50 1   1.0 18.79
24 F 6 A 9/22/2014 12:50 2   1.0 18.04
24 F 7 A 9/22/2014 13:50 3   1.0 18.63
24 F 8 A 9/22/2014 14:50 4   1.0 18.33
24 F 9 A 9/22/2014 18:50 8   1.0 17.78
24 F 10 A 9/22/2014 22:50 12   1.0 17.49
24 F 11 A 9/23/2014 10:50 24   1.0 17.59
24 F 12 A 9/24/2014 10:50 48   1.0 17.32
24 F 13 A 9/25/2014 10:50 72   1.0 17.59
25 F 0 A 9/22/2014 11:10 0   1.0 0.004
25 F  A 9/22/2014 11:10 0 1 17 1.0  
25 F 1 A 9/22/2014 11:11 0.02   1.0 17.75
25 F 2 A 9/22/2014 11:15 0.08   1.0 17.29
25 F 3 A 9/22/2014 11:25 0.25   1.0 17.7 
25 F 4 A 9/22/2014 11:40 0.5   1.0 17.64
25 F 5 A 9/22/2014 12:10 1   1.0 18.07
25 F 6 A 9/22/2014 13:10 2   1.0 17.94
25 F 7 A 9/22/2014 14:10 3   1.0 16.91
25 F 8 A 9/22/2014 15:10 4   1.0 18.22
25 F 9 A 9/22/2014 19:10 8   1.0 17.88
25 F 10 A 9/22/2014 23:10 12   1.0 17.01
25 F 11 A 9/23/2014 11:10 24   1.0 17.47
25 F 12 A 9/24/2014 11:10 48   1.0 17.87
25 F 13 A 9/25/2014 11:10 72   1.0 17.44
101 F   4/25/2012 16:52 0 1 5   
101 F 1 C 4/25/2012 16:54 0.02   1.1 337 
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101 F 5 C 4/25/2012 17:54 1   1.1 311 
101 F 6 C 4/25/2012 18:53 2   1.1 298 
101 F 7 C 4/25/2012 19:53 3   1.1 299 
101 F 8 C 4/25/2012 20:53 4   1.1 314 
102 F   4/30/2012 16:22 0 1 5   
102 F 1 C 4/30/2012 16:26 0.02   1.1 260 
102 F 5 C 4/30/2012 17:26 1   1.1 205 
102 F 6 C 4/30/2012 18:25 2   1.1 249 
102 F 7 C 4/30/2012 19:31 3   1.1 250 
102 F 8 C 4/30/2012 20:33 4   1.1 237 
103 F   4/30/2012 17:56 0 1 5   
103 F 1 C 4/30/2012 17:59 0.02   1.0 256 
103 F 5 C 4/30/2012 19:01 1   1.0 260 
103 F 6 C 4/30/2012 20:03 2   1.0 275 
103 F 7 C 4/30/2012 21:12 3   1.0 262 
103 F 8 C 4/30/2012 22:08 4   1.0 264 
104 F   4/25/2012 14:43 0 1 0.1   
104 F 1 C 4/25/2012 14:44 0.02   1.0 14.6 
104 F 5 C 4/25/2012 15:43 1   1.0 14.3 
104 F 6 C 4/25/2012 16:43 2   1.0 14.7 
104 F 7 C 4/25/2012 17:43 3   1.0 15 
104 F 8 C 4/25/2012 18:43 4   1.0 15.7 
105 F  C 9/22/2014 10:22 0 1 0.6 1.0  
105 F 1 C 9/22/2014 10:31 0.02   1.0 18.73
105 F 2 C 9/22/2014 10:35 0.08   1.0 17.9 
105 F 3 C 9/22/2014 10:45 0.25   1.0 19.04
105 F 4 C 9/22/2014 11:00 0.5   1.0 19.71
105 F 5 C 9/22/2014 11:30 1   1.0 19.74
105 F 6 C 9/22/2014 12:30 2   1.0 18.62
105 F 7 C 9/22/2014 13:30 3   1.0 19.01
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105 F 8 C 9/22/2014 14:30 4   1.0 19.83
105 F 9 C 9/22/2014 18:30 8   1.0 19.68
105 F 10 C 9/22/2014 22:30 12   1.0 18.88
105 F 11 C 9/23/2014 10:30 24   1.0 19.24
105 F 12 C 9/24/2014 10:30 48   1.0 19.34
105 F 13 C 9/25/2014 10:30 72   1.0 19.71
106 F  C 9/22/2014 10:43 0 1 0.6 1.0  
106 F 1 C 9/22/2014 10:51 0.02   1.0 20.59
106 F 2 C 9/22/2014 10:55 0.08   1.0 19.82
106 F 3 C 9/22/2014 11:05 0.25   1.0 20.07
106 F 4 C 9/22/2014 11:20 0.5   1.0 20.55
106 F 5 C 9/22/2014 11:50 1   1.0 18.99
106 F 6 C 9/22/2014 12:50 2   1.0 19.9 
106 F 7 C 9/22/2014 13:50 3   1.0 19.39
106 F 8 C 9/22/2014 14:50 4   1.0 20.08
106 F 9 C 9/22/2014 18:50 8   1.0 19.46
106 F 10 C 9/22/2014 22:50 12   1.0 19.71
106 F 11 C 9/23/2014 10:50 24   1.0 20.61
106 F 12 C 9/24/2014 10:50 48   1.0 20.18
106 F 13 C 9/25/2014 10:50 72   1.0 20.03
107 F  C 9/22/2014 11:03 0 1 0.6 1.0  
107 F 1 C 9/22/2014 11:11 0.02   1.0 18.95
107 F 2 C 9/22/2014 11:15 0.08   1.0 18.92
107 F 3 C 9/22/2014 11:25 0.25   1.0 18.78
107 F 4 C 9/22/2014 11:40 0.5   1.0 18.09
107 F 5 C 9/22/2014 12:10 1   1.0 19.76
107 F 6 C 9/22/2014 13:10 2   1.0 19.4 
107 F 7 C 9/22/2014 14:10 3   1.0 17.69
107 F 8 C 9/22/2014 15:10 4   1.0 19.51
107 F 9 C 9/22/2014 19:10 8   1.0 18.93
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107 F 10 C 9/22/2014 23:10 12   1.0 19.12
107 F 11 C 9/23/2014 11:10 24   1.0 18.78
107 F 12 C 9/24/2014 11:10 48   1.0 19.42
107 F 13 C 9/25/2014 11:10 72   1.0 19.23
151 F 1 H 9/22/2014 10:31 0.02   1.0 3.419
151 F 5 H 9/22/2014 11:30 1   1.0 3.927
151 F 11 H 9/23/2014 10:30 24   1.0 14.88
151 F 13 H 9/25/2014 10:30 72   1.0 14.64
152 F 1 H 9/22/2014 10:51 0.02   1.0 0.501
152 F 5 H 9/22/2014 11:50 1   1.0 5.229
152 F 11 H 9/23/2014 10:50 24   1.0 14.04
152 F 13 H 9/25/2014 10:50 72   1.0 14.03
6 M 0 V 8/13/2012 14:13    1.0 0 
6 M   8/13/2012 14:17 0 1 13 1.0  
6 M 1 V 8/13/2012 14:18 0.02   1.0 10.06
6 M 1 A 8/13/2012 14:18 0.02   1.0 11.35
6 M 2 V 8/13/2012 14:22 0.08   1.0 11.29
6 M 2 A 8/13/2012 14:22 0.08   1.0 11.77
6 M 3 A 8/13/2012 14:32 0.25   1.0 10.54
6 M 3 V 8/13/2012 14:32 0.25   1.0 10.69
6 M 4 V 8/13/2012 14:47 0.5   1.0 10.69
6 M 4 A 8/13/2012 14:47 0.5   1.0 10.78
6 M 5 A 8/13/2012 15:17 1   1.0 10.99
6 M 5 V 8/13/2012 15:17 1   1.0 11.14
6 M 6 V 8/13/2012 16:17 2   1.0 10.05
6 M 6 A 8/13/2012 16:17 2   1.0 10.13
6 M 7 V 8/13/2012 17:17 3   1.0 10.14
6 M 7 A 8/13/2012 17:17 3   1.0 9.91 
6 M 8 A 8/13/2012 18:17 4   1.0 10.54
6 M 8 V 8/13/2012 18:17 4   1.0 10.57
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7 M   8/13/2012 14:53 0 1 13 1.0  
7 M 0 V 8/13/2012 14:48    1.0 0 
7 M 1 V 8/13/2012 14:54 0.02   1.0 9.76 
7 M 1 A 8/13/2012 14:54 0.02   1.0 10.92
7 M 2 A 8/13/2012 14:58 0.08   1.0 10.2 
7 M 2 V 8/13/2012 14:58 0.08   1.0 9.41 
7 M 3 A 8/13/2012 15:08 0.25   1.0 8.69 
7 M 3 V 8/13/2012 15:08 0.25   1.0 8.46 
7 M 4 V 8/13/2012 15:23 0.5   1.0 7.83 
7 M 4 A 8/13/2012 15:23 0.5   1.0 7.47 
7 M 5 V 8/13/2012 15:53 1   1.0 7.25 
7 M 5 A 8/13/2012 15:53 1   1.0 7.22 
7 M 6 A 8/13/2012 16:53 2   1.0 5.01 
7 M 6 V 8/13/2012 16:53 2   1.0 5.61 
7 M 7 A 8/13/2012 17:53 3   1.0 4.53 
7 M 7 V 8/13/2012 17:53 3   1.0 4.35 
7 M 8 A 8/13/2012 18:53 4   1.0 4.71 
7 M 8 V 8/13/2012 18:53 4   1.0 4.68 
8 M 0 V 8/16/2012 13:31    1.0 0 
8 M   8/16/2012 13:36  1 12 1.0  
8 M 1 V 8/16/2012 13:37 0.02   1.0 17.44
8 M 1 A 8/16/2012 13:37 0.02   1.0 17.82
8 M 2 A 8/16/2012 13:41 0.08   1.0 16.5 
8 M 2 V 8/16/2012 13:41 0.08   1.0 16.58
8 M 3 V 8/16/2012 13:51 0.25   1.0 17.52
8 M 3 A 8/16/2012 13:51 0.25   1.0 18.11
8 M 4 V 8/16/2012 14:06 0.5   1.0 16.41
8 M 4 A 8/16/2012 14:06 0.5   1.0 18.97
8 M 5 V 8/16/2012 14:36 1   1.0 16.68
8 M 5 A 8/16/2012 14:36 1   1.0 18.12
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8 M 6 A 8/16/2012 15:36 2   1.0 16.54
8 M 6 V 8/16/2012 15:36 2   1.0 17.98
8 M 7 A 8/16/2012 16:36 3   1.0 16.56
8 M 7 V 8/16/2012 16:36 3   1.0 17.12
8 M 8 A 8/16/2012 17:36 4   1.0 16.24
8 M 8 V 8/16/2012 17:36 4   1.0 16.7 
17 M   3/28/2013 15:15  1 8 1.0  
17 M 0 V 3/28/2013 15:13    1.0 0 
17 M 1 A 3/28/2013 15:16 0.02   1.0 10.2 
17 M 1 V 3/28/2013 15:16 0.02   1.0 10.49
17 M 2 V 3/28/2013 15:20 0.08   1.0 10.33
17 M 2 A 3/28/2013 15:20 0.08   1.0 10.33
17 M 3 A 3/28/2013 15:30 0.25   1.0 10.34
17 M 3 V 3/28/2013 15:30 0.25   1.0 10.41
17 M 4 A 3/28/2013 15:45 0.5   1.0 11.04
17 M 4 V 3/28/2013 15:45 0.5   1.0 9.91 
17 M 5 A 3/28/2013 16:15 1   1.0 8.93 
17 M 5 V 3/28/2013 16:15 1   1.0 9.94 
17 M 6 V 3/28/2013 17:15 2   1.0 10.15
17 M 6 A 3/28/2013 17:15 2   1.0 9.99 
17 M 7 V 3/28/2013 18:15 3   1.0 10.34
17 M 7 A 3/28/2013 18:15 3   1.0 9.33 
17 M 8 A 3/28/2013 19:15 4   1.0 10.01
17 M 8 V 3/28/2013 19:15 4   1.0 9.56 
18 M 0 V 6/17/2014 10:00    1.0 0 
18 M   6/17/2014 10:02  1 1.2   
18 M 1 A 6/17/2014 10:03 0.02   1.0 16.68
18 M 1 V 6/17/2014 10:03 0.02   1.0 17.55
18 M 2 V 6/17/2014 10:08 0.08   1.0 15.92
18 M 2 A 6/17/2014 10:08 0.08   1.0 14.84
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18 M 3 A 6/17/2014 10:18 0.25   1.0 13.31
18 M 3 V 6/17/2014 10:18 0.25   1.0 13.17
18 M 4 V 6/17/2014 10:32 0.5   1.0 10.19
18 M 4 A 6/17/2014 10:32 0.5   1.0 10.57
18 M 5 V 6/17/2014 11:02 1   1.0 7.76 
18 M 5 A 6/17/2014 11:02 1   1.0 7.85 
18 M 6 V 6/17/2014 12:02 2   1.0 5.32 
18 M 6 A 6/17/2014 12:02 2   1.0 5.44 
18 M 7 V 6/17/2014 13:02 3   1.0 3.89 
18 M 7 A 6/17/2014 13:02 3   1.0 4.1 
18 M 8 A 6/17/2014 14:02 4   1.0 3.48 
18 M 8 V 6/17/2014 14:02 4   1.0 3.31 
18 M 9 V 6/17/2014 18:02 8   1.0 2.37 
18 M 9 A 6/17/2014 18:02 8   1.0 2.11 
18 M 10 A 6/17/2014 22:02 12   1.0 1.85 
18 M 10 V 6/17/2014 22:02 12   1.0 1.39 
18 M 11 V 6/18/2014 10:02 24   1.0 0.63 
18 M 11 A 6/18/2014 10:02 24   1.0 0.62 
18 M 12 A 6/19/2014 10:04 48   1.0 0.56 
18 M 12 V 6/19/2014 10:04 48   1.0 0.58 
18 M 13 A 6/20/2014 10:02 72   1.0 0.74 
18 M 13 V 6/20/2014 10:02 72   1.0 0.62 
19 M   6/17/2014 11:17 0 1 1.2   
19 M 1 V 6/17/2014 11:18 0.02   1.0 19.94
19 M 1 A 6/17/2014 11:18 0.02   1.0 21.7 
19 M 2 A 6/17/2014 11:22 0.08   1.0 19.29
19 M 2 V 6/17/2014 11:22 0.08   1.0 18.5 
19 M 3 V 6/17/2014 11:32 0.25   1.0 15.73
19 M 3 A 6/17/2014 11:32 0.25   1.0 15.99
19 M 4 A 6/17/2014 11:47 0.5   1.0 13.84
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19 M 4 V 6/17/2014 11:47 0.5   1.0 13.22
19 M 5 A 6/17/2014 12:17 1   1.0 10.68
19 M 5 V 6/17/2014 12:17 1   1.0 10.37
19 M 6 A 6/17/2014 13:17 2   1.0 7.05 
19 M 6 V 6/17/2014 13:17 2   1.0 7.02 
19 M 7 A 6/17/2014 14:17 3   1.0 5.05 
19 M 7 V 6/17/2014 14:17 3   1.0 3.61 
19 M 8 V 6/17/2014 15:17 4   1.0 2.97 
19 M 8 A 6/17/2014 15:17 4   1.0 2.61 
19 M 9 V 6/17/2014 19:17 8   1.0 1.6 
19 M 9 A 6/17/2014 19:17 8   1.0 1.61 
19 M 10 V 6/17/2014 23:17 12   1.0 0.93 
19 M 10 A 6/17/2014 23:17 12   1.0 1.04 
19 M 11 V 6/18/2014 11:17 24   1.0 0.71 
19 M 11 A 6/18/2014 11:17 24   1.0 0.67 
19 M   6/18/2014 11:20 24 2 1.2   
20 M   9/11/2014 14:30  1 1.2   
20 M 1 A 9/11/2014 14:31 0.02   1.0 15.45
20 M 2 A 9/11/2014 14:35 0.08   1.0 16.61
20 M 3 A 9/11/2014 14:45 0.25   1.0 15.42
20 M 4 A 9/11/2014 15:00 0.5   1.0 14.35
20 M 5 A 9/11/2014 15:30 1   1.0 13.08
20 M 6 A 9/11/2014 16:30 2   1.0 11.64
20 M 7 A 9/11/2014 17:30 3   1.0 10.47
20 M 8 A 9/11/2014 18:30 4   1.0 10.19
20 M 9 A 9/11/2014 22:30 8   1.0 7.55 
20 M 10 A 9/12/2014 2:30 12   1.0 7.92 
20 M 11 A 9/12/2014 14:30 24   1.0 8.14 
20 M 12 A 9/13/2014 14:30 48   1.0 6.76 
20 M 13 A 9/14/2014 14:30 72   1.0 4.89 
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21 M 0 A 9/11/2014 15:34 0.02   1.0 0 
21 M   9/11/2014 15:35  1 1.2   
21 M 1 A 9/11/2014 15:36 0.02   1.0 16.68
21 M 2 A 9/11/2014 15:40 0.08   1.0 17.23
21 M 3 A 9/11/2014 15:48 0.25   1.0 17.45
21 M 4 A 9/11/2014 16:05 0.5   1.0 17.47
21 M 5 A 9/11/2014 16:35 1   1.0 17.1 
21 M 6 A 9/11/2014 17:35 2   1.0 17.24
21 M 7 A 9/11/2014 18:35 3   1.0 16.72
21 M 8 A 9/11/2014 19:35 4   1.0 16.25
21 M 9 A 9/11/2014 23:35 8   1.0 14.73
21 M 10 A 9/12/2014 3:35 12   1.0 13.1 
21 M 11 A 9/12/2014 15:35 24   1.0 8.07 
21 M 12 A 9/13/2014 15:35 48   1.0 5.02 
21 M 13 A 9/14/2014 15:35 72   1.0 4.16 
22 M   9/11/2014 16:00  1 1.2   
22 M 1 A 9/11/2014 16:01 0.02   1.0 17.25
22 M 2 A 9/11/2014 16:05 0.08   1.0 17.97
22 M 3 A 9/11/2014 16:15 0.25   1.0 18.24
22 M 4 A 9/11/2014 16:30 0.5   1.0 18 
22 M 5 A 9/11/2014 17:00 1   1.0 16.96
22 M 6 A 9/11/2014 18:00 2   1.0 16.57
22 M 7 A 9/11/2014 19:00 3   1.0 15.6 
22 M 8 A 9/11/2014 20:00 4   1.0 14.31
22 M 9 A 9/12/2014 0:00 8   1.0 12.55
22 M 10 A 9/12/2014 4:00 12   1.0 10.15
22 M 11 A 9/12/2014 16:00 24   1.0 6.36 
22 M 12 A 9/13/2014 16:04 48   1.0 3.64 
22 M 13 A 9/14/2014 16:00 72   1.0 1.35 
22 M 0 A 9/11/2014  0.02   1.0  
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26 M 0 A 1/26/2015 11:58 0   1.0 0 
26 M   1/26/2015 12:00  1 1.2   
26 M 1 A 1/26/2015 12:01 0.02   1.0 20.85
26 M 2 A 1/26/2015 12:05 0.08   1.0 20.63
26 M 3 A 1/26/2015 12:15 0.25   1.0 19.76
26 M 4 A 1/26/2015 12:30 0.5   1.0 18.49
26 M 5 A 1/26/2015 13:00 1   1.0 15.49
26 M 6 A 1/26/2015 14:00 2   1.0 15.14
26 M 7 A 1/26/2015 15:00 3   1.0 13.39
26 M 8 A 1/26/2015 16:00 4   1.0 12.56
26 M 9 A 1/26/2015 20:00 8   1.0 11.52
26 M 10 A 1/27/2015 0:00 12   1.0 5.24 
26 M 11 A 1/27/2015 12:00 24   1.0 4.39 
26 M 12 A 1/28/2015 12:00 48   1.0 5.29 
26 M 13 A 1/29/2015 12:00 72   1.0 4.34 
27 M 0 A 1/26/2015 12:19 0   1.0 0 
27 M   1/26/2015 12:20  1 1.2   
27 M 1 A 1/26/2015 12:21 0.02   1.0 16.96
27 M 2 A 1/26/2015 12:25 0.08   1.0  
27 M 3 A 1/26/2015 12:35 0.25   1.0 17.94
27 M 4 A 1/26/2015 12:50 0.5   1.0 17.74
27 M 5 A 1/26/2015 13:20 1   1.0 14.84
27 M 6 A 1/26/2015 14:20 2   1.0 11.87
27 M 7 A 1/26/2015 15:20 3   1.0 11.71
27 M 8 A 1/26/2015 16:20 4   1.0 8.98 
27 M 9 A 1/26/2015 20:20 8   1.0 9.65 
27 M 10 A 1/27/2015 0:20 12   1.0 6 
27 M 11 A 1/27/2015 12:20 24   1.0 6.15 
27 M 12 A 1/28/2015 12:20 48   1.0 6.79 
27 M 13 A 1/29/2015 12:20 72   1.0 5.32 
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28 M 0 A 1/26/2015 12:49 0   1.0 0 
28 M   1/26/2015 12:50  1 1.2   
28 M 1 A 1/26/2015 12:51 0.02   1.0 19.4 
28 M 2 A 1/26/2015 12:55 0.08   1.0 18.91
28 M 3 A 1/26/2015 13:05 0.25   1.0 17.29
28 M 4 A 1/26/2015 13:20 0.5   1.0 16.08
28 M 5 A 1/26/2015 13:50 1   1.0 15.1 
28 M 6 A 1/26/2015 14:50 2   1.0 13.49
28 M 7 A 1/26/2015 15:50 3   1.0 11.78
28 M 8 A 1/26/2015 16:50 4   1.0 11.33
28 M 9 A 1/26/2015 20:50 8   1.0 8.98 
28 M 10 A 1/27/2015 0:50 12   1.0 9.11 
28 M 11 A 1/27/2015 12:50 24   1.0 4.09 
28 M 12 A 1/28/2015 12:50 48   1.0 4.61 
28 M 13 A 1/29/2015 12:50 72   1.0 5.38 
29 M   2/2/2015 9:30  1 1.2   
29 M 0 A 2/2/2015 8:15 0   1.0  
29 M 1 A 2/2/2015 9:31 0.02   1.0 20.71
29 M 2 A 2/2/2015 9:35 0.08   1.0 20.21
29 M 3 A 2/2/2015 9:45 0.25   1.0 18.41
29 M 4 A 2/2/2015 10:00 0.5   1.0 17.11
29 M 5 A 2/2/2015 10:30 1   1.0 14.2 
29 M 6 A 2/2/2015 11:30 2   1.0 13.39
29 M 7 A 2/2/2015 12:30 3   1.0 11.68
29 M 8 A 2/2/2015 13:30 4   1.0 10.41
29 M 9 A 2/2/2015 17:30 8   1.0 7.84 
29 M 10 A 2/2/2015 21:30 12   1.0 6.27 
29 M 11 A 2/3/2015 9:30 24   1.0 3.92 
29 M 12 A 2/4/2015 9:30 48   1.0 3.35 
30 M 0 A 2/2/2015 8:15 0   1.0 0 
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30 M   2/2/2015 9:50  1 1.2   
30 M 1 A 2/2/2015 9:51 0.02   1.0 18.07
30 M 2 A 2/2/2015 9:55 0.08   1.0 18.08
30 M 3 A 2/2/2015 10:05 0.25   1.0 17.25
30 M 4 A 2/2/2015 10:20 0.5   1.0 15.85
30 M 5 A 2/2/2015 10:50 1   1.0 14.43
30 M 6 A 2/2/2015 11:50 2   1.0 12.83
30 M 7 A 2/2/2015 12:50 3   1.0 11.25
30 M 8 A 2/2/2015 13:50 4   1.0 10.67
30 M 9 A 2/2/2015 17:50 8   1.0 8.65 
30 M 10 A 2/2/2015 21:50 12   1.0  
30 M 11 A 2/3/2015 9:50 24   1.0 6.41 
30 M 12 A 2/4/2015 9:50 48   1.0 5.05 
30 M 13 A 2/5/2015 9:50 72   1.0 4.42 
31 M   2/2/2015 10:20  1 1.2   
31 M 0 A 2/2/2015 8:15 0   1.0 0 
31 M 1 A 2/2/2015 10:21 0.02   1.0 10.31
31 M 2 A 2/2/2015 10:25 0.08   1.0 12.53
31 M 3 A 2/2/2015 10:35 0.25   1.0 9.99 
31 M 4 A 2/2/2015 10:50 0.5   1.0 8.89 
31 M 5 A 2/2/2015 11:20 1   1.0 5.5 
31 M 6 A 2/2/2015 12:20 2   1.0 5.21 
31 M 7 A 2/2/2015 13:20 3   1.0 4.75 
31 M 8 A 2/2/2015 14:20 4   1.0 4.14 
31 M 9 A 2/2/2015 18:20 8   1.0 3.3 
31 M 10 A 2/2/2015 22:20 12   1.0 2.75 
31 M 11 A 2/3/2015 10:20 24   1.0 4.28 
31 M 12 A 2/4/2015 10:20 48   1.0 3.6 
31 M 13 A 2/5/2015 10:20 72   1.0 4.23 
201 M 1 C 8/13/2012 14:18 0.02   1.0 12.54
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201 M 5 C 8/13/2012 15:17 1   1.0 12.74
201 M 6 C 8/13/2012 16:17 2   1.0 11.83
201 M 7 C 8/13/2012 17:17 3   1.0 11.4 
201 M 8 C 8/13/2012 18:17 4   1.0 11.93
202 M 1 C 9/11/2014 14:31 0.02   1.0 57.6 
202 M 2 C 9/11/2014 14:35 0.08   1.0 58.85
202 M 3 C 9/11/2014 14:45 0.25   1.0 57.37
202 M 4 C 9/11/2014 15:00 0.5   1.0 55.72
202 M 5 C 9/11/2014 15:30 1   1.0 55.17
202 M 6 C 9/11/2014 16:30 2   1.0 55.34
202 M 7 C 9/11/2014 17:30 3   1.0 53.64
202 M 8 C 9/11/2014 18:30 4   1.0 52.64
202 M 9 C 9/11/2014 22:30 8   1.0 38.76
202 M 10 C 9/12/2014 2:30 12   1.0 38.1 
202 M 11 C 9/12/2014 14:30 24   1.0 33.56
202 M 12 C 9/13/2014 14:30 48   1.0 18.8 
202 M 13 C 9/14/2014 14:30 72   1.0 19.44
203 M 1 C 9/11/2014 15:36 0.02   1.0 67.01
203 M 2 C 9/11/2014 15:40 0.08   1.0 65.65
203 M 3 C 9/11/2014 15:48 0.25   1.0 67.25
203 M 4 C 9/11/2014 16:05 0.5   1.0 66.28
203 M 5 C 9/11/2014 16:35 1   1.0 68.35
203 M 6 C 9/11/2014 17:35 2   1.0 67 
203 M 7 C 9/11/2014 18:35 3   1.0 63.7 
203 M 8 C 9/11/2014 19:35 4   1.0 61.62
203 M 9 C 9/11/2014 23:35 8   1.0 53.13
203 M 10 C 9/12/2014 3:35 12   1.0 46.91
203 M 11 C 9/12/2014 15:35 24   1.0 33.12
203 M 12 C 9/13/2014 15:35 48   1.0 18.42
203 M 13 C 9/14/2014 15:35 72   1.0 10.52
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204 M 1 C 1/26/2015 12:01 0.02   1.0 36.75
204 M 2 C 1/26/2015 12:05 0.08   1.0 35.96
204 M 3 C 1/26/2015 12:15 0.25   1.0 35.05
204 M 4 C 1/26/2015 12:30 0.5   1.0 35.17
204 M 5 C 1/26/2015 13:00 1   1.0 35.56
204 M 6 C 1/26/2015 14:00 2   1.0 36.23
204 M 7 C 1/26/2015 15:00 3   1.0 32.08
204 M 8 C 1/26/2015 16:00 4   1.0 31.26
204 M 9 C 1/26/2015 20:00 8   1.0 28.29
204 M 10 C 1/27/2015 0:00 12   1.0 26.42
204 M 11 C 1/27/2015 12:00 24   1.0 23.01
204 M 12 C 1/28/2015 12:00 48   1.0 20.35
204 M 13 C 1/29/2015 12:00 72   1.0 17.17
251 M 1 H 9/11/2014 14:33 0.02   1.0 0.07 
251 M 5 H 9/11/2014 15:30 1   1.0 0.06 
251 M 6 H 9/11/2014 16:30 2   1.0 0.21 
251 M 11 H 9/13/2014 14:30 24   1.0 0.16 
251 M 13 H 9/14/2014 14:30 72   1.0 0.34 
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Define 
 
circuit Circuit number 
drug B – amphotericin B deoxycholate 
F – fluconazole 
M - micafungin 
samp sample number 
site A – arterial 
C – control 
H - hemofiltrate 
V- venous 
date MM/DD/YYY 
time HH:MM 
nom_time Nominal sampling time (h) 
dose_no Done number 
amt Amount of dose (mg) 
flow ECMO flow rate (l/min) 
dv Concentration (mg/L) 
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APPENDIX 2 
Fluconazole data 
 
ORDN  ID  ECMO  WT  PNA  GA RACE SEX SCRE ALBE ASTE  ALTE  HMFLTRE
1  1  0  3.48  19 36 0 0 1.2 2.3 82  32  0
2  1  0  3.48  19 36 0 0 1.2 2.3 82  32  0
3  1  0  3.48  19 36 0 0 1.2 2.3 82  32  0
4  1  0  3.48  19 36 0 0 1.2 2.3 82  32  0
5  1  0  3.48  19 36 0 0 0.9 2.3 39  27  0
6  1  0  3.48  19 36 0 0 0.9 2.3 39  27  0
7  1  0  3.48  19 36 0 0 0.9 2.3 39  27  0
8  1  0  3.48  19 36 0 0 0.9 2.3 39  27  0
9  1  0  3.48  19 36 0 0 0.9 2.3 39  27  0
10  1  0  3.48  19 36 0 0 0.9 2.3 39  27  0
11  1  0  3.48  19 36 0 0 0.9 2.3 29  16  0
12  1  0  3.48  19 36 0 0 0.9 2.3 29  16  0
13  1  0  3.48  19 36 0 0 0.8 2.3 29  16  0
14  1  0  3.48  19 36 0 0 0.8 2.3 29  16  0
15  1  0  3.48  19 36 0 0 0.8 2.3 29  16  0
16  1  0  3.48  19 36 0 0 0.8 2.3 29  16  0
17  2  0  3.00  14 39 0 1 0.5 2.0 35  79  0
18  2  0  3.00  14 39 0 1 0.5 2.0 35  79  0
19  2  0  3.00  14 39 0 1 0.5 2.0 35  79  0
20  2  0  3.00  14 39 0 1 0.5 2.0 35  79  0
21  2  0  3.00  14 39 0 1 0.4 2.0 35  79  0
22  2  0  3.00  14 39 0 1 0.4 2.0 35  79  0
23  2  0  3.00  14 39 0 1 0.4 2.0 35  79  0
24  2  0  3.00  14 39 0 1 0.3 2.0 35  79  0
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25  2  0  3.00  14 39 0 1 0.3 2.0 35  79  0
26  2  0  3.00  14 39 0 1 0.3 2.0 35  79  0
27  2  0  3.00  14 39 0 1 0.3 2.0 35  79  0
28  2  0  3.00  14 39 0 1 0.3 2.0 35  79  0
29  3  0  1.00  5 28 0 1 0.7 2.7 16  5  0
30  3  0  1.00  5 28 0 1 0.7 2.7 16  5  0
31  3  0  1.00  5 28 0 1 0.7 2.7 16  5  0
32  3  0  1.00  5 28 0 1 0.7 2.7 16  5  0
33  3  0  1.00  5 28 0 1 0.7 2.7 16  5  0
34  4  0  2.69  13 37 0 0 1.3 2.2 25  10  0
35  4  0  2.69  13 37 0 0 1.3 2.2 25  10  0
36  4  0  2.69  13 37 0 0 1.3 2.2 25  10  0
37  4  0  2.69  13 37 0 0 1.3 2.2 25  10  0
38  4  0  2.69  13 37 0 0 1.3 2.4 12  8  0
39  4  0  2.69  13 37 0 0 1.3 2.4 12  8  0
40  4  0  2.69  13 37 0 0 1.3 2.4 12  8  0
41  4  0  2.69  13 37 0 0 0.8 2.4 12  8  0
42  4  0  2.69  13 37 0 0 1.0 2.0 12  8  0
43  4  0  2.69  13 37 0 0 1.0 2.0 12  8  0
44  4  0  2.69  13 37 0 0 1.0 2.0 12  8  0
45  4  0  2.69  13 37 0 0 1.0 2.0 12  8  0
46  4  0  2.69  13 37 0 0 1.0 2.0 12  8  0
47  4  0  2.69  13 37 0 0 0.7 2.0 12  8  0
48  4  0  2.69  13 37 0 0 0.8 2.8 12  8  0
49  4  0  2.69  13 37 0 0 0.8 2.8 12  8  0
50  4  0  2.69  13 37 0 0 0.8 2.8 12  8  0
51  4  0  2.69  13 37 0 0 0.8 2.8 12  8  0
52  5  0  2.83  55 33 1 0 0.3 2.7 50  65  0
53  5  0  2.83  55 33 1 0 0.3 2.7 50  65  0
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54  5  0  2.83  55 33 1 0 0.3 2.7 50  65  0
55  5  0  2.83  55 33 1 0 0.3 2.7 50  65  0
56  5  0  2.83  55 33 1 0 0.4 2.7 50  65  0
57  5  0  2.83  55 33 1 0 0.4 2.7 50  65  0
58  5  0  2.83  55 33 1 0 0.4 2.7 50  65  0
59  5  0  2.83  55 33 1 0 0.4 2.4 62  69  0
60  5  0  2.83  55 33 1 0 0.4 2.4 62  69  0
61  5  0  2.83  55 33 1 0 0.4 2.4 62  69  0
62  5  0  2.83  55 33 1 0 0.4 2.4 62  69  0
63  5  0  2.83  55 33 1 0 0.4 2.4 62  69  0
64  5  0  2.83  55 33 1 0 0.4 2.8 53  71  0
65  5  0  2.83  55 33 1 0 0.4 2.8 53  71  0
66  5  0  2.83  55 33 1 0 0.4 2.8 53  71  0
67  5  0  2.83  55 33 1 0 0.4 2.8 53  71  0
68  6  0  8.00  262 34 1 0 0.4 3.1 26  21  0
69  6  0  8.00  262 34 1 0 0.4 3.1 26  21  0
70  6  0  8.00  262 34 1 0 0.4 3.1 26  21  0
71  6  0  8.00  262 34 1 0 0.4 3.1 26  21  0
72  6  0  8.00  262 34 1 0 0.5 3.1 26  21  0
73  6  0  8.00  262 34 1 0 0.5 3.1 26  21  0
74  6  0  8.00  262 34 1 0 0.5 3.1 26  21  0
75  6  0  8.00  262 34 1 0 0.6 3.1 20  21  0
76  6  0  8.00  262 34 1 0 0.6 3.1 20  21  0
77  6  0  8.00  262 34 1 0 0.6 3.1 20  21  0
78  6  0  8.00  262 34 1 0 0.6 3.1 20  21  0
79  6  0  8.00  262 34 1 0 0.6 3.1 20  21  0
80  6  0  8.00  262 34 1 0 0.6 3.1 20  21  0
81  6  0  8.00  262 34 1 0 0.6 3.1 20  21  0
82  6  0  8.00  262 34 1 0 0.6 3.1 20  21  0
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83  7  0  2.06  6 34 1 1 1.0 2.0 18  9  0
84  7  0  2.06  6 34 1 1 1.0 2.0 18  9  0
85  7  0  2.06  6 34 1 1 1.0 2.0 18  9  0
86  7  0  2.06  6 34 1 1 1.0 2.0 18  9  0
87  7  0  2.06  6 34 1 1 1.0 2.0 18  9  0
88  7  0  2.06  6 34 1 1 1.0 2.0 18  9  0
89  7  0  2.06  6 34 1 1 1.0 2.0 18  9  0
90  7  0  2.06  6 34 1 1 0.8 2.0 18  9  0
91  7  0  2.06  6 34 1 1 0.8 2.0 18  9  0
92  7  0  2.06  6 34 1 1 0.8 2.0 18  9  0
93  7  0  2.06  6 34 1 1 0.6 2.2 15  8  0
94  7  0  2.06  6 34 1 1 0.6 2.2 15  8  0
95  7  0  2.06  6 34 1 1 0.6 2.2 15  8  0
96  7  0  2.06  6 34 1 1 0.6 2.2 15  8  0
97  8  0  7.16  257 39 1 0 0.2 2.8 35  16  0
98  8  0  7.16  257 39 1 0 0.2 2.8 35  16  0
99  8  0  7.16  257 39 1 0 0.2 2.8 35  16  0
100  8  0  7.16  257 39 1 0 0.2 2.8 35  16  0
101  8  0  7.16  257 39 1 0 0.2 2.8 35  16  0
102  8  0  7.16  257 39 1 0 0.2 2.8 35  16  0
103  8  0  7.16  257 39 1 0 0.2 2.8 27  12  0
104  8  0  7.16  257 39 1 0 0.2 2.8 27  12  0
105  8  0  7.16  257 39 1 0 0.2 2.8 27  12  0
106  8  0  7.16  257 39 1 0 0.2 2.8 27  12  0
107  8  0  7.16  257 39 1 0 0.2 2.8 27  12  0
108  8  0  7.16  257 39 1 0 0.2 2.8 27  12  0
109  8  0  7.16  257 39 1 0 0.2 2.8 27  12  0
110  8  0  7.16  257 39 1 0 0.2 2.8 27  12  0
111  9  0  1.88  155 24 1 1 1.3 1.1 159  126  0
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112  9  0  1.88  155 24 1 1 1.3 1.1 159  126  0
113  9  0  1.88  155 24 1 1 1.3 1.1 159  126  0
114  9  0  1.88  155 24 1 1 1.3 1.1 159  126  0
115  9  0  1.88  155 24 1 1 1.3 1.1 159  126  0
116  9  0  1.88  155 24 1 1 1.3 1.1 159  126  0
117  9  0  1.88  155 24 1 1 1.3 1.1 159  126  0
118  9  0  1.88  155 24 1 1 1.3 1.1 159  126  0
119  9  0  1.88  155 24 1 1 1.3 1.1 159  126  0
120  9  0  1.88  155 24 1 1 1.3 1.1 159  126  0
121  9  0  1.88  155 24 1 1 1.3 1.1 159  126  0
122  9  0  1.88  155 24 1 1 1.3 1.1 159  126  0
123  9  0  1.88  155 24 1 1 1.3 1.1 159  126  0
124  10  0  4.30  59 37 0 1 0.2 2.7 35  19  0
125  10  0  4.30  59 37 0 1 0.2 2.7 35  19  0
126  10  0  4.30  59 37 0 1 0.2 2.7 35  19  0
127  10  0  4.30  59 37 0 1 0.2 2.7 35  19  0
128  10  0  4.30  59 37 0 1 0.2 2.7 35  19  0
129  10  0  4.30  59 37 0 1 0.2 2.7 35  19  0
130  10  0  4.30  59 37 0 1 0.2 2.7 35  19  0
131  10  0  4.30  59 37 0 1 0.2 2.7 35  19  0
132  10  0  4.30  59 37 0 1 0.2 2.7 35  19  0
133  10  0  4.30  59 37 0 1 0.2 2.7 35  19  0
134  10  0  4.30  59 37 0 1 0.2 2.7 35  19  0
135  10  0  4.30  59 37 0 1 0.2 2.7 35  19  0
136  10  0  4.30  59 37 0 1 0.2 2.7 35  19  0
137  11  0  2.93  18 38 1 1 0.2 2.7 16  11  0
138  11  0  2.93  18 38 1 1 0.2 2.7 16  11  0
139  11  0  2.93  18 38 1 1 0.2 2.7 16  11  0
140  11  0  2.93  18 38 1 1 0.2 2.7 16  11  0
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141  11  0  2.93  18 38 1 1 0.2 2.7 16  11  0
142  11  0  2.93  18 38 1 1 0.2 2.7 16  11  0
143  11  0  2.93  18 38 1 1 0.2 2.7 16  11  0
144  11  0  2.93  18 38 1 1 0.2 2.7 16  11  0
145  11  0  2.93  18 38 1 1 0.2 2.7 16  11  0
146  11  0  2.93  18 38 1 1 0.2 2.7 16  11  0
147  11  0  2.93  18 38 1 1 0.2 2.7 16  11  0
148  11  0  2.93  18 38 1 1 0.2 2.7 16  11  0
149  12  0  4.59  36 39 1 0 0.5 3.1 24  14  0
150  12  0  4.59  36 39 1 0 0.5 3.1 24  14  0
151  12  0  4.59  36 39 1 0 0.5 3.1 24  14  0
152  12  0  4.59  36 39 1 0 0.5 3.1 24  14  0
153  12  0  4.59  36 39 1 0 0.5 3.1 24  14  0
154  12  0  4.59  36 39 1 0 0.5 3.1 24  14  0
155  12  0  4.59  36 39 1 0 0.5 3.1 24  14  0
156  12  0  4.59  36 39 1 0 0.5 3.1 24  14  0
157  12  0  4.59  36 39 1 0 0.5 3.1 24  14  0
158  12  0  4.59  36 39 1 0 0.5 3.1 24  14  0
159  12  0  4.59  36 39 1 0 0.5 3.1 24  14  0
160  13  1  3.11  14 38 1 1 0.8 1.7 22  10  1
161  13  1  3.11  14 38 1 1 0.8 1.7 22  10  1
162  13  1  3.11  14 38 1 1 0.8 1.7 22  10  1
163  13  1  3.11  14 38 1 1 0.8 1.7 22  10  1
164  13  1  3.11  14 38 1 1 1.1 2.6 32  9  1
165  13  1  3.11  14 38 1 1 1.1 2.6 32  9  1
166  13  1  3.11  14 38 1 1 1.1 2.6 32  9  1
167  13  1  3.11  14 38 1 1 1.6 2.6 32  9  1
168  13  1  3.11  14 38 1 1 1.6 2.6 32  9  1
169  13  1  3.11  14 38 1 1 1.6 2.6 32  9  1
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170  13  1  3.11  14 38 1 1 1.6 2.6 32  9  1
171  14  0  7.13  64 40 0 1 0.4 2.7 35  19  0
172  14  0  7.14  64 40 0 1 0.1 2.7 35  19  0
173  14  0  7.14  64 40 0 1 0.4 2.7 35  19  0
174  15  0  2.96  9 37 0 1 0.1 2.7 35  19  0
175  15  0  2.90  9 37 0 1 0.1 2.7 35  19  0
176  15  0  2.90  9 37 0 1 0.1 2.7 35  19  0
177  15  0  2.90  9 37 0 1 0.1 2.7 35  19  0
178  15  0  2.90  9 37 0 1 0.1 2.7 35  19  0
179  15  0  2.86  9 37 0 1 0.1 2.7 35  19  0
180  15  0  2.86  9 37 0 1 0.1 2.7 35  19  0
181  15  0  2.86  9 37 0 1 0.1 2.7 35  19  0
182  15  0  3.10  9 37 0 1 0.1 2.7 35  19  0
183  15  0  3.10  9 37 0 1 0.1 2.7 35  19  0
184  15  0  2.93  9 37 0 1 0.5 2.7 35  19  0
185  15  0  3.04  9 37 0 1 0.1 2.7 35  19  0
186  15  0  2.97  9 37 0 1 0.1 2.7 35  19  0
187  15  0  3.02  9 37 0 1 0.1 2.7 35  19  0
188  15  0  3.02  9 37 0 1 0.1 2.7 35  19  0
189  15  0  3.33  9 37 0 1 0.1 2.7 35  19  0
190  15  0  3.33  9 37 0 1 0.1 2.7 35  19  0
191  15  0  3.27  9 37 0 1 0.1 2.7 35  19  0
192  15  0  3.46  9 37 0 1 0.1 2.7 35  19  0
193  15  0  3.50  9 37 0 1 0.1 2.7 35  19  0
194  15  0  3.53  9 37 0 1 0.1 2.7 35  19  0
195  15  0  3.56  9 37 0 1 0.1 2.7 35  19  0
196  15  0  3.56  9 37 0 1 0.1 2.7 35  19  0
197  16  0  2.30  25 36 1 1 0.1 2.7 35  19  0
198  16  0  2.30  25 36 1 1 0.1 2.7 35  19  0
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199  16  0  2.30  25 36 1 1 0.1 2.7 35  19  0
200  16  0  2.30  25 36 1 1 0.1 2.7 35  19  0
201  16  0  2.30  25 36 1 1 0.1 2.7 35  19  0
202  16  0  2.30  25 36 1 1 0.1 2.7 35  19  0
203  16  0  2.30  25 36 1 1 0.1 2.7 35  19  0
204  16  0  2.15  25 36 1 1 0.1 2.7 35  19  0
205  16  0  2.26  25 36 1 1 0.1 2.7 35  19  0
206  16  0  2.28  25 36 1 1 0.1 2.7 35  19  0
207  16  0  2.55  25 36 1 1 0.1 2.7 35  19  0
208  16  0  2.22  25 36 1 1 0.1 2.7 35  19  0
209  16  0  2.53  25 36 1 1 0.1 2.7 35  19  0
210  16  0  2.40  25 36 1 1 0.1 2.7 35  19  0
211  16  0  2.51  25 36 1 1 0.1 2.7 35  19  0
212  16  0  2.51  25 36 1 1 0.1 2.7 35  19  0
213  16  0  2.51  25 36 1 1 0.1 2.7 35  19  0
214  16  0  2.51  25 36 1 1 0.1 2.7 35  19  0
215  16  0  2.59  25 36 1 1 0.1 2.7 35  19  0
216  16  0  2.59  25 36 1 1 0.1 2.7 35  19  0
217  16  0  2.59  25 36 1 1 0.1 2.7 35  19  0
218  16  0  2.72  25 36 1 1 0.1 2.7 35  19  0
219  16  0  2.72  25 36 1 1 0.1 2.7 35  19  0
220  16  0  2.97  25 36 1 1 0.1 2.7 35  19  0
221  16  0  2.80  25 36 1 1 0.6 2.7 35  19  0
222  16  0  2.75  25 36 1 1 0.1 2.7 35  19  0
223  16  0  2.94  25 36 1 1 0.1 2.7 35  19  0
224  16  0  2.94  25 36 1 1 0.1 2.7 35  19  0
225  16  0  2.89  25 36 1 1 0.1 2.7 35  19  0
226  16  0  2.89  25 36 1 1 0.1 2.7 35  19  0
227  16  0  2.89  25 36 1 1 0.1 2.7 35  19  0
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228  16  0  2.89  25 36 1 1 0.1 2.7 35  19  0
229  16  0  3.16  25 36 1 1 0.4 2.7 35  19  0
230  16  0  3.36  25 36 1 1 0.1 2.7 35  19  0
231  16  0  3.39  25 36 1 1 0.4 2.7 35  19  0
232  16  0  3.39  25 36 1 1 0.4 2.7 35  19  0
233  16  0  3.65  25 36 1 1 0.1 2.7 35  19  0
234  16  0  3.67  25 36 1 1 0.1 2.7 35  19  0
235  16  0  3.17  25 36 1 1 0.1 2.7 35  19  0
236  16  0  3.17  25 36 1 1 0.1 2.7 35  19  0
237  16  0  3.15  25 36 1 1 0.4 2.7 35  19  0
238  16  0  3.29  25 36 1 1 0.4 2.7 35  19  0
239  16  0  3.29  25 36 1 1 0.1 2.7 35  19  0
240  17  0  3.18  6 39 0 1 0.7 2.7 35  19  0
241  17  0  3.18  6 39 0 1 0.7 2.7 35  19  0
242  17  0  3.18  6 39 0 1 0.7 2.7 35  19  0
243  17  0  3.18  6 39 0 1 0.7 2.7 35  19  0
244  17  0  3.41  6 39 0 1 0.1 2.7 35  19  0
245  17  0  3.50  6 39 0 1 0.6 2.7 35  19  0
246  17  0  3.50  6 39 0 1 0.6 2.7 35  19  0
247  17  0  3.80  6 39 0 1 0.4 2.7 35  19  0
248  17  0  4.38  6 39 0 1 0.1 2.7 35  19  0
249  17  0  4.38  6 39 0 1 0.1 2.7 35  19  0
250  18  0  3.55  78 36 2 1 0.1 2.7 35  19  0
251  18  0  3.35  78 36 2 1 0.1 2.7 35  19  0
252  18  0  3.35  78 36 2 1 0.1 2.7 35  19  0
253  18  0  3.55  78 36 2 1 0.1 2.7 35  19  0
254  18  0  3.55  78 36 2 1 0.1 2.7 35  19  0
255  18  0  3.88  78 36 2 1 0.1 2.7 35  19  0
256  18  0  3.88  78 36 2 1 0.1 2.7 35  19  0
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257  18  0  3.89  78 36 2 1 0.1 2.7 35  19  0
258  18  0  3.89  78 36 2 1 0.1 2.7 35  19  0
259  18  0  3.89  78 36 2 1 0.1 2.7 35  19  0
260  18  0  3.89  78 36 2 1 0.1 2.7 35  19  0
261  18  0  3.89  78 36 2 1 0.1 2.7 35  19  0
262  19  0  3.39  16 38 2 1 0.1 2.7 35  19  0
263  19  0  3.38  16 38 2 1 0.1 2.7 35  19  0
264  19  0  3.31  16 38 2 1 0.1 2.7 35  19  0
265  19  0  3.32  16 38 2 1 0.1 2.7 35  19  0
266  19  0  3.21  16 38 2 1 0.1 2.7 35  19  0
267  19  0  3.12  16 38 2 1 0.1 2.7 35  19  0
268  19  0  3.19  16 38 2 1 0.1 2.7 35  19  0
269  19  0  3.19  16 38 2 1 0.1 2.7 35  19  0
270  20  0  3.89  20 39 0 1 0.1 2.7 35  19  0
271  20  0  3.87  20 39 0 1 0.1 2.7 35  19  0
272  20  0  3.79  20 39 0 1 0.1 2.7 35  19  0
273  20  0  3.70  20 39 0 1 0.1 2.7 35  19  0
274  20  0  3.68  20 39 0 1 0.1 2.7 35  19  0
275  20  0  3.68  20 39 0 1 0.1 2.7 35  19  0
276  20  0  3.68  20 39 0 1 0.1 2.7 35  19  0
277  20  0  3.68  20 39 0 1 0.1 2.7 35  19  0
278  20  0  3.68  20 39 0 1 0.1 2.7 35  19  0
279  20  0  3.58  20 39 0 1 0.1 2.7 35  19  0
280  20  0  3.58  20 39 0 1 0.1 2.7 35  19  0
281  20  0  3.50  20 39 0 1 0.1 2.7 35  19  0
282  20  0  3.50  20 39 0 1 0.1 2.7 35  19  0
283  20  0  3.53  20 39 0 1 0.1 2.7 35  19  0
284  20  0  3.43  20 39 0 1 0.3 2.7 35  19  0
285  20  0  3.43  20 39 0 1 0.3 2.7 35  19  0
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286  20  0  3.48  20 39 0 1 0.1 2.7 35  19  0
287  20  0  3.32  20 39 0 1 0.1 2.7 35  19  0
288  20  0  3.38  20 39 0 1 0.1 2.7 35  19  0
289  20  0  3.30  20 39 0 1 0.1 2.7 35  19  0
290  20  0  3.26  20 39 0 1 0.1 2.7 35  19  0
291  20  0  3.46  20 39 0 1 0.1 2.7 35  19  0
292  20  0  3.48  20 39 0 1 0.3 2.7 35  19  0
293  20  0  3.48  20 39 0 1 0.3 2.7 35  19  0
294  21  0  3.91  40 37 0 1 0.1 2.7 35  19  0
295  21  0  3.91  40 37 0 1 0.1 2.7 35  19  0
296  21  0  3.91  40 37 0 1 0.1 2.7 35  19  0
297  21  0  3.62  40 37 0 1 0.3 2.7 35  19  0
298  21  0  3.62  40 37 0 1 0.3 2.7 35  19  0
299  22  0  2.23  4 38 2 0 0.1 2.7 35  19  0
300  22  0  2.23  4 38 2 0 0.9 2.7 35  19  0
301  22  0  2.35  4 38 2 0 0.7 2.7 35  19  0
302  22  0  2.35  4 38 2 0 0.7 2.7 35  19  0
303  22  0  2.35  4 38 2 0 0.7 2.7 35  19  0
304  22  0  2.35  4 38 2 0 0.7 2.7 35  19  0
305  22  0  2.35  4 38 2 0 0.7 2.7 35  19  0
306  22  0  2.35  4 38 2 0 0.7 2.7 35  19  0
307  22  0  2.35  4 38 2 0 0.5 2.7 35  19  0
308  22  0  2.35  4 38 2 0 0.5 2.7 35  19  0
309  22  0  2.37  4 38 2 0 0.5 2.7 35  19  0
310  22  0  2.37  4 38 2 0 0.5 2.7 35  19  0
311  22  0  2.36  4 38 2 0 0.4 2.7 35  19  0
312  22  0  2.36  4 38 2 0 0.4 2.7 35  19  0
313  22  0  2.25  4 38 2 0 0.4 2.7 35  19  0
314  22  0  2.21  4 38 2 0 0.1 2.7 35  19  0
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315  22  0  2.21  4 38 2 0 0.1 2.7 35  19  0
316  22  0  2.20  4 38 2 0 0.4 2.7 35  19  0
317  22  0  2.22  4 38 2 0 0.1 2.7 35  19  0
318  23  1  3.16  24 38 1 0 0.6 4.0 113  38  1
319  23  1  3.16  24 38 1 0 0.6 4.0 113  38  1
320  23  1  3.16  24 38 1 0 0.6 4.0 113  38  1
321  23  1  3.16  24 38 1 0 0.6 4.0 113  38  1
322  23  1  3.16  24 38 1 0 0.6 4.0 113  38  1
323  23  1  3.16  24 38 1 0 0.6 4.0 131  44  1
324  23  1  3.16  24 38 1 0 0.6 4.0 131  44  1
325  23  1  3.16  24 38 1 0 0.6 4.0 131  44  1
326  23  1  3.16  24 38 1 0 0.4 4.0 155  58  1
327  23  1  3.16  24 38 1 0 0.4 4.0 155  58  1
328  23  1  3.16  24 38 1 0 0.4 4.0 155  58  1
329  23  1  3.16  24 38 1 0 0.4 4.0 155  58  1
330  23  1  3.16  24 38 1 0 0.6 4.0 208  79  1
331  23  1  3.16  24 38 1 0 0.6 4.0 208  79  1
332  23  1  3.16  24 38 1 0 0.6 4.0 208  79  1
333  23  1  3.16  24 38 1 0 0.6 4.0 208  79  1
334  23  1  3.16  24 38 1 0 0.6 4.0 208  79  1
335  23  1  3.16  24 38 1 0 0.6 4.0 208  79  1
336  23  1  3.16  24 38 1 0 0.6 4.0 208  79  1
337  23  1  3.16  24 38 1 0 0.6 4.0 208  79  1
338  23  1  3.16  24 38 1 0 0.6 4.0 208  79  1
339  23  1  3.16  24 38 1 0 0.6 4.0 208  79  1
340  23  1  3.16  24 38 1 0 0.5 4.0 192  80  1
341  23  1  3.16  24 38 1 0 0.6 4.0 208  79  1
342  23  1  3.16  24 38 1 0 0.5 4.0 192  80  1
343  23  1  3.16  24 38 1 0 0.5 4.0 192  80  1
   
277 
 
344  23  1  3.16  24 38 1 0 0.5 4.0 192  80  1
345  23  1  3.16  24 38 1 0 0.5 4.0 198  90  1
346  23  1  3.16  24 38 1 0 0.5 4.0 198  90  1
347  23  1  3.16  24 38 1 0 0.5 4.0 198  90  1
348  24  1  3.40  20 40 0 1 0.4 1.2 452  62  1
349  24  1  3.40  20 40 0 1 0.4 1.2 452  62  1
350  24  1  3.40  20 40 0 1 0.4 1.2 452  62  1
351  24  1  3.40  20 40 0 1 0.4 1.2 452  62  1
352  24  1  3.40  20 40 0 1 0.4 1.2 452  62  1
353  24  1  3.40  20 40 0 1 0.4 1.4 452  45  1
354  24  1  3.40  20 40 0 1 0.4 1.4 452  45  1
355  24  1  3.40  20 40 0 1 0.4 1.4 452  45  1
356  24  1  3.40  20 40 0 1 0.4 1.4 452  45  1
357  24  1  3.40  20 40 0 1 0.4 1.4 452  45  1
358  24  1  3.40  20 40 0 1 0.4 1.6 452  43  1
359  24  1  3.40  20 40 0 1 0.4 1.6 452  43  1
360  24  1  3.40  20 40 0 1 0.4 1.6 452  43  1
361  24  1  3.40  20 40 0 1 0.6 1.6 452  80  1
362  24  1  3.40  20 40 0 1 0.9 1.6 455  80  1
363  24  1  3.40  20 40 0 1 0.5 1.8 781  103  1
364  24  1  3.40  20 40 0 1 0.7 2.2 781  103  1
365  24  1  3.40  20 40 0 1 0.8 2.2 1602  164  1
366  24  1  3.40  20 40 0 1 1.2 1.9 1386  156  1
367  24  1  3.40  20 40 0 1 1.5 2.2 996  145  1
368  24  1  3.40  20 40 0 1 1.5 2.2 996  145  1
369  24  1  3.40  20 40 0 1 1.5 2.2 996  145  1
370  24  1  3.40  20 40 0 1 1.5 2.2 996  145  1
371  24  1  3.40  20 40 0 1 1.5 2.2 996  145  1
372  24  1  3.40  20 40 0 1 1.5 2.2 996  145  1
   
278 
 
373  24  1  3.40  20 40 0 1 1.5 2.2 996  145  1
374  24  1  3.40  20 40 0 1 1.5 2.2 996  145  1
375  24  1  3.40  20 40 0 1 1.5 2.2 996  145  1
376  24  1  3.40  20 40 0 1 1.5 2.2 996  145  1
377  24  1  3.40  20 40 0 1 1.7 2.2 870  155  1
378  24  1  3.40  20 40 0 1 1.7 2.2 870  155  1
379  24  1  3.40  20 40 0 1 1.7 2.2 870  155  1
380  24  1  3.40  20 40 0 1 2.2 2.6 731  149  1
381  24  1  3.40  20 40 0 1 2.2 2.6 731  149  1
382  24  1  3.40  20 40 0 1 2.2 2.6 731  149  1
383  24  1  3.40  20 40 0 1 2.3 2.6 409  107  1
384  24  1  3.40  20 40 0 1 2.7 2.6 284  105  1
385  24  1  3.40  20 40 0 1 2.8 2.6 284  105  1
386  24  1  3.40  20 40 0 1 3.2 3.0 175  93  1
387  24  1  3.40  20 40 0 1 3.2 3.0 175  93  1
388  24  1  3.40  20 40 0 1 3.2 3.0 175  93  1
389  25  1  7.00  165 39 1 1 0.3 3.5 51  18  0
390  25  1  7.00  165 39 1 1 0.3 3.5 51  18  0
391  25  1  7.00  165 39 1 1 0.3 3.5 51  18  0
392  25  1  7.00  165 39 1 1 0.2 3.5 34  14  0
393  25  1  7.00  165 39 1 1 0.2 3.5 34  14  0
394  25  1  7.00  165 39 1 1 0.2 3.5 34  14  0
395  25  1  7.00  165 39 1 1 0.2 3.5 34  14  0
396  25  1  7.00  165 39 1 1 0.2 3.5 34  14  0
397  25  1  7.00  165 39 1 1 0.2 3.5 34  14  0
398  25  1  7.00  165 39 1 1 0.2 3.5 34  14  0
399  25  1  7.00  165 39 1 1 0.2 3.5 34  14  0
400  25  1  7.00  165 39 1 1 0.2 3.5 30  14  0
401  25  1  7.00  165 39 1 1 0.2 3.5 30  14  0
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402  25  1  7.00  165 39 1 1 0.2 3.5 30  14  0
403  25  1  7.00  165 39 1 1 0.2 3.5 30  14  0
404  25  1  7.00  165 39 1 1 0.3 3.5 36  14  0
405  25  1  7.00  165 39 1 1 0.3 3.5 36  14  0
406  25  1  7.00  165 39 1 1 0.1 3.5 15  9  0
407  25  1  7.00  165 39 1 1 0.3 3.5 24  11  0
408  25  1  7.00  165 39 1 1 0.3 3.5 24  11  0
409  25  1  7.00  165 39 1 1 0.3 3.5 24  11  0
410  26  1  2.01  18 38 0 1 0.9 2.2 23  14  0
411  26  1  2.01  18 38 0 1 0.9 2.2 23  14  0
412  26  1  2.01  18 38 0 1 0.9 2.2 23  14  0
413  26  1  2.01  18 38 0 1 0.9 2.2 23  14  0
414  26  1  2.01  18 38 0 1 0.9 2.2 23  14  0
415  26  1  2.01  18 38 0 1 0.9 2.2 23  14  0
416  26  1  2.01  18 38 0 1 0.9 2.2 23  14  0
417  26  1  2.01  18 38 0 1 0.9 2.2 23  14  0
418  26  1  2.01  18 38 0 1 0.9 2.2 23  14  0
419  26  1  2.01  18 38 0 1 0.9 2.2 23  14  0
420  26  1  2.01  18 38 0 1 0.9 2.2 23  14  0
421  26  1  2.01  18 38 0 1 0.9 2.2 23  14  0
422  26  1  2.01  18 38 0 1 0.8 2.2 23  14  0
423  26  1  2.01  18 38 0 1 0.8 2.2 23  14  0
424  26  1  2.01  18 38 0 1 0.8 2.2 23  14  0
425  26  1  2.01  18 38 0 1 0.8 2.2 23  14  0
426  26  1  2.01  18 38 0 1 0.7 2.2 23  14  0
427  26  1  2.01  18 38 0 1 0.7 2.2 23  14  0
428  27  1  2.44  32 34 0 1 0.7 2.1 59  10  0
429  27  1  2.44  32 34 0 1 0.7 2.1 59  10  0
430  27  1  2.44  32 34 0 1 0.7 2.1 59  10  0
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431  27  1  2.44  32 34 0 1 0.7 2.1 59  10  0
432  27  1  2.44  32 34 0 1 0.7 2.1 59  10  0
433  27  1  2.44  32 34 0 1 0.7 2.1 59  10  0
434  27  1  2.44  32 34 0 1 0.7 2.1 59  10  0
435  27  1  2.44  32 34 0 1 0.7 2.1 59  10  0
436  27  1  2.44  32 34 0 1 0.7 2.1 59  10  0
437  27  1  2.44  32 34 0 1 0.7 2.1 59  10  0
438  27  1  2.44  32 34 0 1 0.7 2.1 73  33  0
439  27  1  2.44  32 34 0 1 0.7 2.1 73  33  0
440  27  1  2.44  32 34 0 1 0.7 2.1 73  33  0
441  28  1  2.70  1 36 0 0 1.0 1.9 39  12  0
442  28  1  2.70  1 36 0 0 1.0 2.4 42  5  0
443  28  1  2.70  1 36 0 0 1.0 2.4 42  5  0
444  28  1  2.70  1 36 0 0 1.0 2.4 42  5  0
445  28  1  2.70  1 36 0 0 1.0 2.4 42  5  0
446  28  1  2.70  1 36 0 0 1.0 2.4 42  5  0
447  28  1  2.70  1 36 0 0 1.0 2.4 42  5  0
448  28  1  2.70  1 36 0 0 1.0 2.4 42  5  0
449  28  1  2.70  1 36 0 0 1.0 2.4 42  5  0
450  28  1  2.70  1 36 0 0 1.0 2.4 42  5  0
451  28  1  2.70  1 36 0 0 1.0 2.4 42  5  0
452  28  1  2.70  1 36 0 0 0.9 2.8 42  5  0
453  28  1  2.70  1 36 0 0 0.9 2.8 42  5  0
454  28  1  2.70  1 36 0 0 0.9 2.8 42  5  0
455  28  1  2.70  1 36 0 0 0.8 2.5 85  11  0
456  28  1  2.70  1 36 0 0 0.9 2.5 85  11  0
457  28  1  2.70  1 36 0 0 0.9 2.2 112  15  0
458  28  1  2.70  1 36 0 0 0.9 2.2 112  15  0
459  28  1  2.70  1 36 0 0 0.9 2.2 35  9  0
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460  28  1  2.70  1 36 0 0 0.9 2.2 35  9  0
461  28  1  2.70  1 36 0 0 0.9 2.2 35  9  0
462  28  1  2.70  1 36 0 0 0.9 2.2 35  9  0
463  28  1  2.70  1 36 0 0 0.9 2.2 35  9  0
464  28  1  2.70  1 36 0 0 0.9 2.2 35  9  0
465  28  1  2.70  1 36 0 0 0.9 2.2 35  9  0
466  28  1  2.70  1 36 0 0 0.9 2.2 35  9  0
467  28  1  2.70  1 36 0 0 0.9 2.2 35  9  0
468  28  1  2.70  1 36 0 0 0.9 2.2 35  9  0
469  28  1  2.70  1 36 0 0 0.8 3.0 35  9  0
470  28  1  2.70  1 36 0 0 0.8 3.0 35  9  0
471  28  1  2.70  1 36 0 0 0.8 3.0 35  9  0
472  28  1  2.70  1 36 0 0 0.8 2.6 35  9  0
473  28  1  2.70  1 36 0 0 0.8 2.6 35  9  0
474  28  1  2.70  1 36 0 0 0.8 2.6 35  9  0
475  29  1  3.20  7 38 2 0 0.5 2.0 31  15  0
476  29  1  3.20  7 38 2 0 0.5 2.0 31  15  0
477  29  1  3.20  7 38 2 0 0.5 2.0 31  15  0
478  29  1  3.20  7 38 2 0 0.5 2.0 31  15  0
479  29  1  3.20  7 38 2 0 0.5 2.0 31  15  0
480  29  1  3.20  7 38 2 0 0.5 2.0 31  15  0
481  29  1  3.20  7 38 2 0 0.5 2.7 31  15  0
482  29  1  3.20  7 38 2 0 0.5 2.7 31  15  0
483  29  1  3.20  7 38 2 0 0.5 2.7 31  15  0
484  29  1  3.20  7 38 2 0 0.6 2.7 31  15  0
485  29  1  3.20  7 38 2 0 0.6 2.7 31  15  0
486  29  1  3.20  7 38 2 0 0.6 2.7 31  15  0
487  29  1  3.20  7 38 2 0 0.6 2.7 25  16  0
488  29  1  3.20  7 38 2 0 0.6 2.7 25  16  0
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489  29  1  3.20  7 38 2 0 0.5 2.7 25  16  0
490  29  1  3.20  7 38 2 0 0.5 2.7 25  14  0
491  29  1  3.20  7 38 2 0 0.5 2.7 25  14  0
492  29  1  3.20  7 38 2 0 0.5 2.7 25  14  0
493  29  1  3.20  7 38 2 0 0.5 2.7 25  14  0
494  29  1  3.20  7 38 2 0 0.5 2.7 25  14  0
495  29  1  3.20  7 38 2 0 0.5 2.7 25  14  0
496  29  1  3.20  7 38 2 0 0.5 2.7 25  14  0
497  29  1  3.20  7 38 2 0 0.5 2.7 25  14  0
498  29  1  3.20  7 38 2 0 0.5 2.7 25  14  0
499  29  1  3.20  7 38 2 0 0.5 2.7 25  14  0
500  29  1  3.20  7 38 2 0 0.5 2.7 25  14  0
501  29  1  3.20  7 38 2 0 0.6 2.7 25  14  0
502  29  1  3.20  7 38 2 0 0.6 2.7 25  14  0
503  29  1  3.20  7 38 2 0 0.6 2.7 25  14  0
504  29  1  3.20  7 38 2 0 0.6 2.7 25  14  0
505  29  1  3.20  7 38 2 0 0.6 2.7 25  14  0
506  29  1  3.20  7 38 2 0 0.6 2.7 25  14  0
507  29  1  3.20  7 38 2 0 0.4 2.7 25  14  0
508  29  1  3.20  7 38 2 0 0.4 2.7 25  14  0
509  29  1  3.20  7 38 2 0 0.4 2.7 25  14  0
510  29  1  3.20  7 38 2 0 0.5 2.7 25  14  0
511  29  1  3.20  7 38 2 0 0.4 2.7 19  14  0
512  29  1  3.20  7 38 2 0 0.4 2.7 19  14  0
513  29  1  3.20  7 38 2 0 0.4 2.7 19  14  0
514  30  1  12.50  1072 40 1 1 0.6 2.3 111  17  0
515  30  1  12.50  1072 40 1 1 0.6 2.3 111  17  0
516  30  1  12.50  1072 40 1 1 0.6 2.3 111  17  0
517  30  1  12.50  1072 40 1 1 0.6 2.3 111  17  0
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518  30  1  12.50  1072 40 1 1 0.6 2.3 111  17  0
519  30  1  12.50  1072 40 1 1 0.6 2.3 111  17  0
520  30  1  12.50  1072 40 1 1 0.4 2.3 111  17  0
521  30  1  12.50  1072 40 1 1 0.6 2.3 111  17  0
522  30  1  12.50  1072 40 1 1 0.4 2.3 111  17  0
523  30  1  12.50  1072 40 1 1 0.4 2.3 111  17  0
524  30  1  12.50  1072 40 1 1 0.4 2.3 111  17  0
525  30  1  12.50  1072 40 1 1 0.7 2.3 111  17  0
526  30  1  12.50  1072 40 1 1 0.7 2.3 111  17  0
527  31  1  6.22  113 37 1 1 0.6 2.9 59  25  0
528  31  1  6.22  113 37 1 1 0.6 2.9 59  25  0
529  31  1  6.22  113 37 1 1 0.6 2.9 59  25  0
530  31  1  6.22  113 37 1 1 0.6 2.9 59  25  0
531  31  1  6.22  113 37 1 1 0.6 2.9 59  25  0
532  31  1  6.22  113 37 1 1 0.4 2.9 59  25  0
533  31  1  6.22  113 37 1 1 0.4 2.9 59  25  0
534  31  1  6.22  113 37 1 1 0.4 2.9 59  25  0
535  31  1  6.22  113 37 1 1 0.4 2.9 59  25  0
536  31  1  6.22  113 37 1 1 0.4 2.9 59  25  0
537  31  1  6.22  113 37 1 1 0.6 2.9 35  24  0
538  31  1  6.22  113 37 1 1 0.7 3.6 32  23  0
539  31  1  6.22  113 37 1 1 0.7 3.6 32  23  0
540  31  1  6.22  113 37 1 1 0.7 3.6 32  23  0
541  31  1  6.22  113 37 1 1 0.7 3.6 32  23  0
542  31  1  6.22  113 37 1 1 0.7 3.6 32  23  0
543  32  1  2.52  96 30 0 1 0.3 2.9 31  14  0
544  32  1  2.52  96 30 0 1 0.3 2.9 31  14  0
545  32  1  2.52  96 30 0 1 0.3 2.9 31  14  0
546  32  1  2.52  96 30 0 1 0.3 2.9 31  14  0
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547  32  1  2.52  96 30 0 1 0.3 2.9 31  14  0
548  32  1  2.52  96 30 0 1 0.3 2.9 31  14  0
549  32  1  2.52  96 30 0 1 0.3 2.9 31  14  0
550  32  1  2.52  96 30 0 1 0.2 2.9 31  14  0
551  32  1  2.52  96 30 0 1 0.2 2.9 31  14  0
552  32  1  2.52  96 30 0 1 0.2 2.9 31  14  0
553  32  1  2.52  96 30 0 1 0.2 2.9 31  14  0
554  32  1  2.52  96 30 0 1 0.2 2.9 31  14  0
555  32  1  2.52  96 30 0 1 0.2 2.9 31  14  0
556  32  1  2.52  96 30 0 1 0.2 2.9 31  14  0
557  32  1  2.52  96 30 0 1 0.2 2.9 31  14  0
558  32  1  2.52  96 30 0 1 0.2 2.9 31  14  0
559  32  1  2.52  96 30 0 1 0.2 2.9 31  14  0
560  32  1  2.52  96 30 0 1 0.2 2.9 31  14  0
561  32  1  2.52  96 30 0 1 0.2 2.9 31  14  0
562  32  1  2.52  96 30 0 1 0.2 2.9 31  14  0
563  32  1  2.52  96 30 0 1 0.2 2.9 31  14  0
564  32  1  2.52  96 30 0 1 0.2 2.9 31  14  0
565  32  1  2.52  96 30 0 1 0.2 2.9 31  14  0
566  32  1  2.52  96 30 0 1 0.2 2.9 31  14  0
567  32  1  2.52  96 30 0 1 0.2 2.9 31  14  0
568  32  1  2.52  96 30 0 1 0.2 2.9 31  14  0
569  32  1  2.52  96 30 0 1 0.2 2.9 31  14  0
570  32  1  2.52  96 30 0 1 0.2 2.9 31  14  0
571  32  1  2.52  96 30 0 1 0.2 2.9 31  14  0
572  32  1  2.52  96 30 0 1 0.2 2.9 31  14  0
573  32  1  2.52  96 30 0 1 0.3 3.7 46  23  0
574  32  1  2.52  96 30 0 1 0.3 3.7 46  23  0
575  32  1  2.52  96 30 0 1 0.3 3.7 46  23  0
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576  33  1  22.00  2084 40 1 0 0.4 2.8 46  34  0
577  33  1  22.00  2084 40 1 0 0.4 2.8 46  34  0
578  33  1  22.00  2084 40 1 0 0.4 2.8 46  34  0
579  33  1  22.00  2084 40 1 0 0.4 2.8 46  34  0
580  33  1  22.00  2084 40 1 0 0.4 2.8 46  34  0
581  33  1  22.00  2084 40 1 0 0.4 2.8 46  34  0
582  33  1  22.00  2084 40 1 0 0.4 2.8 46  34  0
583  33  1  22.00  2084 40 1 0 0.4 2.8 89  64  0
584  33  1  22.00  2084 40 1 0 0.4 2.8 89  64  0
585  33  1  22.00  2084 40 1 0 0.4 2.8 89  64  0
586  33  1  22.00  2084 40 1 0 0.5 2.8 42  56  0
587  33  1  22.00  2084 40 1 0 0.5 2.8 42  56  0
588  33  1  22.00  2084 40 1 0 0.5 2.8 42  56  0
589  33  1  22.00  2084 40 1 0 0.5 2.8 42  56  0
590  33  1  22.00  2084 40 1 0 0.5 2.8 23  28  0
591  33  1  22.00  2084 40 1 0 0.6 2.8 23  28  0
592  33  1  22.00  2084 40 1 0 0.5 2.8 23  28  0
593  33  1  22.00  2084 40 1 0 0.6 2.8 23  28  0
594  33  1  22.00  2084 40 1 0 0.6 3.1 77  57  0
595  33  1  22.00  2084 40 1 0 0.6 3.1 77  57  0
596  33  1  22.00  2084 40 1 0 0.6 3.1 77  57  0
597  34  1  3.32  18 40 0 1 0.1 2.9 34  17  0
598  34  1  3.32  18 40 0 1 0.1 2.9 34  17  0
599  34  1  3.32  18 40 0 1 0.1 2.9 34  17  0
600  34  1  3.32  18 40 0 1 0.1 2.9 34  17  0
601  34  1  3.32  18 40 0 1 0.1 2.9 34  17  0
602  34  1  3.32  18 40 0 1 0.1 2.9 34  17  0
603  34  1  3.32  18 40 0 1 0.1 2.9 34  17  0
604  34  1  3.32  18 40 0 1 0.1 2.9 34  17  0
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605  34  1  3.32  18 40 0 1 0.1 2.9 34  17  0
606  34  1  3.32  18 40 0 1 0.1 2.9 34  17  0
607  34  1  3.32  18 40 0 1 0.1 2.9 29  15  0
608  34  1  3.32  18 40 0 1 0.1 2.9 29  15  0
609  34  1  3.32  18 40 0 1 0.1 2.9 29  15  0
610  34  1  3.32  18 40 0 1 0.1 2.9 29  14  0
611  34  1  3.32  18 40 0 1 0.1 2.9 29  14  0
612  34  1  3.32  18 40 0 1 0.1 2.9 29  14  0
613  34  1  3.32  18 40 0 1 0.1 2.9 29  14  0
614  34  1  3.32  18 40 0 1 0.1 2.9 29  14  0
615  34  1  3.32  18 40 0 1 0.1 2.9 29  14  0
616  34  1  3.32  18 40 0 1 0.1 2.9 29  14  0
617  34  1  3.32  18 40 0 1 0.1 2.9 29  14  0
618  34  1  3.32  18 40 0 1 0.1 2.9 29  14  0
619  34  1  3.32  18 40 0 1 0.1 2.9 29  14  0
620  34  1  3.32  18 40 0 1 0.1 2.9 29  14  0
621  34  1  3.32  18 40 0 1 0.1 2.9 29  14  0
622  34  1  3.32  18 40 0 1 0.1 2.9 29  14  0
623  34  1  3.32  18 40 0 1 0.1 2.9 29  14  0
624  34  1  3.32  18 40 0 1 0.1 2.9 23  13  0
625  34  1  3.32  18 40 0 1 0.1 2.9 23  13  0
626  34  1  3.32  18 40 0 1 0.1 2.9 23  13  0
627  34  1  3.32  18 40 0 1 1.0 2.9 23  13  0
628  34  1  3.32  18 40 0 1 1.0 2.9 23  13  0
629  34  1  3.32  18 40 0 1 1.0 2.9 23  13  0
630  34  1  3.32  18 40 0 1 0.1 2.9 23  13  0
631  34  1  3.32  18 40 0 1 0.2 2.9 23  13  0
632  34  1  3.32  18 40 0 1 0.2 2.9 23  13  0
633  34  1  3.32  18 40 0 1 0.1 2.9 23  13  0
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634  34  1  3.32  18 40 0 1 0.2 2.9 23  13  0
635  34  1  3.32  18 40 0 1 0.2 2.9 23  13  0
636  34  1  3.32  18 40 0 1 0.2 2.9 23  13  0
637  34  1  3.32  18 40 0 1 0.2 2.9 23  13  0
638  34  1  3.32  18 40 0 1 0.2 2.9 23  13  0
639  34  1  3.32  18 40 0 1 0.2 2.9 23  13  0
640  34  1  3.32  18 40 0 1 0.2 2.9 23  13  0
641  36  1  3.90  7 41 2 1 0.6 0.8 68  69  1
642  36  1  3.90  7 41 2 1 0.6 0.8 68  69  1
643  36  1  3.90  7 41 2 1 0.6 0.8 68  69  1
644  36  1  3.90  7 41 2 1 0.6 0.8 68  69  1
645  36  1  3.90  7 41 2 1 0.6 0.8 68  69  1
646  36  1  3.90  7 41 2 1 0.6 0.8 68  69  1
647  36  1  3.90  7 41 2 1 0.6 0.8 68  69  1
648  36  1  3.90  7 41 2 1 1.0 0.8 68  69  1
649  36  1  3.90  7 41 2 1 1.0 0.8 68  69  1
650  36  1  3.90  7 41 2 1 1.0 0.8 68  69  1
651  36  1  3.90  7 41 2 1 1.2 2.5 54  51  1
652  36  1  3.90  7 41 2 1 1.2 2.5 54  51  1
653  36  1  3.90  7 41 2 1 1.2 2.5 54  51  1
654  36  1  3.90  7 41 2 1 1.4 2.5 54  51  1
655  36  1  3.90  7 41 2 1 1.5 1.9 44  28  1
656  36  1  3.90  7 41 2 1 1.6 3.1 44  28  1
657  36  1  3.90  7 41 2 1 2.0 3.1 44  28  1
658  36  1  3.90  7 41 2 1 1.8 3.1 36  19  1
659  36  1  3.90  7 41 2 1 1.8 3.1 36  19  1
660  36  1  3.90  7 41 2 1 1.8 3.1 36  19  1
661  36  1  3.90  7 41 2 1 1.8 3.1 36  19  1
662  36  1  3.90  7 41 2 1 1.8 3.1 36  19  1
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663  36  1  3.90  7 41 2 1 1.8 3.1 36  19  1
664  36  1  3.90  7 41 2 1 1.8 3.1 36  19  1
665  36  1  3.90  7 41 2 1 1.8 3.1 36  19  1
666  36  1  3.90  7 41 2 1 1.8 3.1 36  19  1
667  36  1  3.90  7 41 2 1 1.8 3.1 36  19  1
668  36  1  3.90  7 41 2 1 1.6 3.1 36  19  1
669  36  1  3.90  7 41 2 1 1.6 3.1 36  19  1
670  36  1  3.90  7 41 2 1 1.6 3.1 36  19  1
671  36  1  3.90  7 41 2 1 1.3 3.1 36  19  1
672  36  1  3.90  7 41 2 1 1.3 3.1 36  19  1
673  36  1  3.90  7 41 2 1 1.3 3.1 36  19  1
674  36  1  3.90  7 41 2 1 1.3 3.1 36  19  1
675  36  1  3.90  7 41 2 1 1.2 3.1 36  19  1
676  36  1  3.90  7 41 2 1 1.3 3.1 36  19  1
677  36  1  3.90  7 41 2 1 1.3 3.1 36  19  1
678  36  1  3.90  7 41 2 1 1.6 2.2 38  10  1
679  36  1  3.90  7 41 2 1 1.6 2.2 38  10  1
680  36  1  3.90  7 41 2 1 1.9 2.2 33  8  1
681  36  1  3.90  7 41 2 1 2.1 2.2 33  8  1
682  36  1  3.90  7 41 2 1 1.8 2.2 33  8  1
683  36  1  3.90  7 41 2 1 1.3 2.2 33  8  1
684  36  1  3.90  7 41 2 1 1.0 2.2 33  8  1
685  36  1  3.90  7 41 2 1 0.8 2.2 38  9  1
686  36  1  3.90  7 41 2 1 0.8 2.2 38  9  1
687  37  1  37.00  4160 40 1 1 0.9 2.3 102  117  0
688  37  1  37.00  4160 40 1 1 1.2 3.0 94  91  0
689  37  1  37.00  4160 40 1 1 1.2 3.0 94  91  0
690  37  1  37.00  4160 40 1 1 1.2 3.0 94  91  0
691  37  1  37.00  4160 40 1 1 1.2 3.0 94  91  0
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692  37  1  37.00  4160 40 1 1 1.1 3.0 94  91  0
693  37  1  37.00  4160 40 1 1 1.2 3.0 94  91  0
694  37  1  37.00  4160 40 1 1 1.1 3.0 94  91  0
695  37  1  37.00  4160 40 1 1 1.1 3.0 94  91  0
696  37  1  37.00  4160 40 1 1 1.1 3.0 94  91  0
697  37  1  37.00  4160 40 1 1 1.1 3.0 94  91  0
698  37  1  37.00  4160 40 1 1 1.1 3.0 94  91  0
699  37  1  37.00  4160 40 1 1 1.1 3.0 94  91  0
700  37  1  37.00  4160 40 1 1 1.1 3.0 94  91  0
701  37  1  37.00  4160 40 1 1 1.1 3.0 94  91  0
702  37  1  37.00  4160 40 1 1 1.1 3.0 94  91  0
703  37  1  37.00  4160 40 1 1 1.1 3.0 94  91  0
704  37  1  37.00  4160 40 1 1 1.1 3.0 94  91  0
705  37  1  37.00  4160 40 1 1 1.1 3.0 94  91  0
706  37  1  37.00  4160 40 1 1 1.1 3.0 94  91  0
707  37  1  37.00  4160 40 1 1 1.1 3.0 94  91  0
708  37  1  37.00  4160 40 1 1 1.1 3.0 94  91  0
709  37  1  37.00  4160 40 1 1 1.1 3.0 94  91  0
710  37  1  37.00  4160 40 1 1 1.1 3.0 94  91  0
711  37  1  37.00  4160 40 1 1 1.1 3.0 94  91  0
712  37  1  37.00  4160 40 1 1 1.1 3.0 94  91  0
713  37  1  37.00  4160 40 1 1 1.1 3.0 94  91  0
714  37  1  37.00  4160 40 1 1 0.6 2.8 50  46  0
715  37  1  37.00  4160 40 1 1 1.1 3.0 94  91  0
716  38  1  77.00  6498 40 1 0 0.5 2.4 31  37  0
717  38  1  77.00  6498 40 1 0 0.5 2.4 31  37  0
718  38  1  77.00  6498 40 1 0 0.5 2.4 31  37  0
719  38  1  77.00  6498 40 1 0 0.5 2.4 31  37  0
720  38  1  77.00  6498 40 1 0 0.5 2.4 31  37  0
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721  38  1  77.00  6498 40 1 0 0.5 2.4 31  37  0
722  38  1  77.00  6498 40 1 0 0.5 2.4 31  37  0
723  38  1  77.00  6498 40 1 0 0.6 3.0 31  37  0
724  38  1  77.00  6498 40 1 0 0.6 3.0 31  37  0
725  38  1  77.00  6498 40 1 0 0.7 3.0 31  37  0
726  38  1  77.00  6498 40 1 0 0.7 3.0 31  37  0
727  38  1  77.00  6498 40 1 0 0.7 3.0 31  37  0
728  38  1  77.00  6498 40 1 0 0.7 3.0 31  37  0
729  38  1  77.00  6498 40 1 0 0.7 3.0 31  37  0
730  38  1  77.00  6498 40 1 0 0.7 3.0 31  37  0
731  38  1  77.00  6498 40 1 0 0.7 3.0 31  37  0
732  38  1  77.00  6498 40 1 0 0.6 3.0 31  37  0
733  38  1  77.00  6498 40 1 0 0.7 3.0 31  37  0
734  38  1  77.00  6498 40 1 0 0.6 3.0 31  37  0
735  38  1  77.00  6498 40 1 0 0.6 3.0 31  37  0
736  38  1  77.00  6498 40 1 0 0.5 3.0 31  37  0
737  38  1  77.00  6498 40 1 0 0.5 3.0 31  37  0
738  38  1  77.00  6498 40 1 0 0.5 3.0 31  37  0
739  38  1  77.00  6498 40 1 0 0.5 3.0 31  37  0
740  38  1  77.00  6498 40 1 0 0.5 3.0 31  37  0
741  38  1  77.00  6498 40 1 0 0.5 3.0 31  37  0
742  38  1  77.00  6498 40 1 0 0.5 3.0 31  37  0
743  38  1  77.00  6498 40 1 0 0.5 3.0 31  37  0
744  38  1  77.00  6498 40 1 0 0.4 2.6 42  61  0
745  38  1  77.00  6498 40 1 0 0.4 2.6 42  61  0
746  38  1  77.00  6498 40 1 0 0.4 2.6 42  61  0
747  38  1  77.00  6498 40 1 0 0.4 2.6 42  61  0
748  38  1  77.00  6498 40 1 0 0.4 2.6 42  61  0
749  38  1  77.00  6498 40 1 0 0.4 2.6 42  61  0
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750  39  1  4.20  131 31 0 1 1.2 2.5 1238  411  1
751  39  1  4.20  131 31 0 1 1.2 2.5 1238  411  1
752  39  1  4.20  131 31 0 1 1.2 2.5 1238  411  1
753  39  1  4.20  131 31 0 1 1.2 2.5 1238  411  1
754  39  1  4.20  131 31 0 1 1.2 2.5 1238  411  1
755  39  1  4.20  131 31 0 1 1.2 2.5 1238  411  1
756  39  1  4.20  131 31 0 1 1.2 2.5 1238  411  1
757  39  1  4.20  131 31 0 1 1.6 2.1 731  262  1
758  39  1  4.20  131 31 0 1 1.6 2.1 731  262  1
759  39  1  4.20  131 31 0 1 1.6 2.1 731  262  1
760  39  1  4.20  131 31 0 1 1.7 2.4 354  193  1
761  39  1  4.20  131 31 0 1 1.7 2.4 354  193  1
762  39  1  4.20  131 31 0 1 1.7 2.4 354  193  1
763  39  1  4.20  131 31 0 1 1.5 2.1 170  129  1
764  39  1  4.20  131 31 0 1 1.6 2.5 115  91  1
765  39  1  4.20  131 31 0 1 1.6 2.5 115  91  1
766  39  1  4.20  131 31 0 1 1.7 2.7 99  68  1
767  39  1  4.20  131 31 0 1 1.7 2.7 99  68  1
768  39  1  4.20  131 31 0 1 1.7 2.7 99  68  1
769  39  1  4.20  131 31 0 1 1.7 2.6 69  47  1
770  39  1  4.20  131 31 0 1 1.7 2.6 69  47  1
771  39  1  4.20  131 31 0 1 1.8 3.3 92  66  1
772  39  1  4.20  131 31 0 1 1.8 3.3 92  66  1
773  39  1  4.20  131 31 0 1 1.8 3.3 92  66  1
774  39  1  4.20  131 31 0 1 1.8 3.3 92  66  1
775  39  1  4.20  131 31 0 1 1.8 3.3 92  66  1
776  39  1  4.20  131 31 0 1 1.8 3.3 92  66  1
777  39  1  4.20  131 31 0 1 1.8 3.3 92  66  1
778  39  1  4.20  131 31 0 1 1.8 3.3 92  66  1
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779  39  1  4.20  131 31 0 1 1.8 3.3 92  66  1
780  39  1  4.20  131 31 0 1 1.8 3.3 92  66  1
781  39  1  4.20  131 31 0 1 2.0 2.9 92  62  1
782  39  1  4.20  131 31 0 1 2.0 2.9 92  62  1
783  39  1  4.20  131 31 0 1 2.0 2.9 92  62  1
784  39  1  4.20  131 31 0 1 1.7 3.4 91  55  1
785  39  1  4.20  131 31 0 1 1.7 3.4 91  55  1
786  39  1  4.20  131 31 0 1 1.7 3.4 91  55  1
787  39  1  4.20  131 31 0 1 1.3 3.2 81  54  1
788  39  1  4.20  131 31 0 1 1.1 3.3 68  44  1
789  39  1  4.20  131 31 0 1 1.3 3.2 81  54  1
790  39  1  4.20  131 31 0 1 1.0 3.2 60  39  1
791  39  1  4.20  131 31 0 1 1.0 3.2 60  39  1
792  39  1  4.20  131 31 0 1 0.9 3.0 55  34  1
793  39  1  4.20  131 31 0 1 0.9 3.0 55  34  1
794  39  1  4.20  131 31 0 1 0.9 3.0 64  33  1
795  39  1  4.20  131 31 0 1 0.9 3.0 64  33  1
796  39  1  4.20  131 31 0 1 0.9 3.0 64  33  1
797  39  1  4.20  131 31 0 1 0.9 3.0 64  33  1
798  39  1  4.20  131 31 0 1 0.9 3.0 64  33  1
799  39  1  4.20  131 31 0 1 1.1 3.1 38  29  1
800  40  1  5.60  125 38 1 0 0.4 3.7 35  14  0
801  40  1  5.60  125 38 1 0 0.4 3.7 35  14  0
802  40  1  5.60  125 38 1 0 0.4 3.7 35  14  0
803  40  1  5.60  125 38 1 0 0.4 3.7 35  14  0
804  40  1  5.60  125 38 1 0 0.4 3.7 35  14  0
805  40  1  5.60  125 38 1 0 0.4 3.7 35  14  0
806  40  1  5.60  125 38 1 0 0.4 3.7 35  14  0
807  40  1  5.60  125 38 1 0 0.4 3.7 35  14  0
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808  40  1  5.60  125 38 1 0 0.4 3.7 35  14  0
809  40  1  5.60  125 38 1 0 0.5 3.7 37  14  0
810  40  1  5.60  125 38 1 0 0.9 3.7 28  13  0
811  40  1  5.60  125 38 1 0 0.9 3.7 28  13  0
812  40  1  5.60  125 38 1 0 0.9 3.7 28  13  0
813  40  1  5.60  125 38 1 0 0.6 3.9 28  13  0
814  40  1  5.60  125 38 1 0 0.6 4.0 30  13  0
815  40  1  5.60  125 38 1 0 0.6 4.0 30  13  0
816  40  1  5.60  125 38 1 0 0.6 4.0 30  13  0
817  40  1  5.60  125 38 1 0 0.6 4.0 30  13  0
818  40  1  5.60  125 38 1 0 0.6 4.0 30  13  0
819  40  1  5.60  125 38 1 0 0.6 4.0 30  13  0
820  40  1  5.60  125 38 1 0 0.6 4.0 30  13  0
821  40  1  5.60  125 38 1 0 0.6 4.0 30  13  0
822  40  1  5.60  125 38 1 0 0.6 4.0 30  13  0
823  40  1  5.60  125 38 1 0 0.6 4.0 30  13  0
824  40  1  5.60  125 38 1 0 0.6 4.0 30  13  0
825  40  1  5.60  125 38 1 0 0.6 4.0 30  13  0
826  40  1  5.60  125 38 1 0 0.6 4.0 30  13  0
827  40  1  5.60  125 38 1 0 0.6 4.0 30  13  0
828  40  1  5.60  125 38 1 0 0.6 4.0 30  13  0
829  40  1  5.60  125 38 1 0 0.6 4.0 30  13  0
830  40  1  5.60  125 38 1 0 0.5 3.6 30  12  0
831  40  1  5.60  125 38 1 0 0.5 3.6 30  12  0
832  40  1  5.60  125 38 1 0 0.5 3.6 30  12  0
833  41  1  10.00  392 40 1 1 0.2 2.2 29  11  0
834  41  1  10.00  392 40 1 1 0.2 2.2 29  11  0
835  41  1  10.00  392 40 1 1 0.2 2.2 29  11  0
836  41  1  10.00  392 40 1 1 0.2 2.2 29  11  0
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837  41  1  10.00  392 40 1 1 0.2 2.2 29  11  0
838  41  1  10.00  392 40 1 1 0.2 2.2 29  11  0
839  41  1  10.00  392 40 1 1 0.3 2.2 29  11  0
840  41  1  10.00  392 40 1 1 0.3 2.2 29  11  0
841  41  1  10.00  392 40 1 1 0.3 2.2 29  11  0
842  41  1  10.00  392 40 1 1 0.3 2.2 29  11  0
843  41  1  10.00  392 40 1 1 0.3 2.2 29  11  0
844  41  1  10.00  392 40 1 1 0.5 2.2 29  11  0
845  41  1  10.00  392 40 1 1 0.5 2.2 29  11  0
846  41  1  10.00  392 40 1 1 0.5 2.2 29  11  0
847  41  1  10.00  392 40 1 1 0.3 2.2 29  11  0
848  41  1  10.00  392 40 1 1 0.6 2.5 37  26  0
849  41  1  10.00  392 40 1 1 0.5 2.5 37  26  0
850  41  1  10.00  392 40 1 1 0.5 2.5 37  26  0
851  41  1  10.00  392 40 1 1 0.5 2.5 37  26  0
852  41  1  10.00  392 40 1 1 0.5 2.5 37  26  0
853  41  1  10.00  392 40 1 1 0.5 2.5 37  26  0
854  41  1  10.00  392 40 1 1 0.4 2.9 25  17  0
855  41  1  10.00  392 40 1 1 0.4 2.9 25  17  0
856  41  1  10.00  392 40 1 1 0.4 2.9 25  17  0
857  41  1  10.00  392 40 1 1 0.4 2.9 25  17  0
858  41  1  10.00  392 40 1 1 0.4 2.9 25  17  0
859  41  1  10.00  392 40 1 1 0.4 2.9 25  17  0
860  41  1  10.00  392 40 1 1 0.4 2.9 25  17  0
861  41  1  10.00  392 40 1 1 0.4 2.9 25  17  0
862  41  1  10.00  392 40 1 1 0.4 2.9 25  17  0
863  41  1  10.00  392 40 1 1 0.4 2.9 25  17  0
864  41  1  10.00  392 40 1 1 0.4 2.9 25  17  0
865  41  1  10.00  392 40 1 1 0.4 2.9 25  17  0
   
295 
 
866  41  1  10.00  392 40 1 1 0.4 2.9 25  17  0
867  41  1  10.00  392 40 1 1 0.4 2.9 25  17  0
868  41  1  10.00  392 40 1 1 0.3 2.9 25  17  0
869  41  1  10.00  392 40 1 1 0.3 2.9 25  17  0
870  41  1  10.00  392 40 1 1 0.3 2.9 25  17  0
871  42  1  15.00  938 40 0 0 0.4 2.8 46  33  0
872  42  1  15.00  938 40 0 0 0.4 2.8 46  33  0
873  42  1  15.00  938 40 0 0 0.4 2.8 46  33  0
874  42  1  15.00  938 40 0 0 0.4 2.8 46  33  0
875  42  1  15.00  938 40 0 0 0.4 2.8 46  33  0
876  42  1  15.00  938 40 0 0 0.4 2.8 46  33  0
877  42  1  15.00  938 40 0 0 0.4 2.8 46  33  0
878  42  1  15.00  938 40 0 0 0.5 2.8 46  33  0
879  42  1  15.00  938 40 0 0 0.5 2.8 46  33  0
880  42  1  15.00  938 40 0 0 0.5 2.8 46  33  0
881  42  1  15.00  938 40 0 0 0.5 2.8 46  33  0
882  42  1  15.00  938 40 0 0 0.5 2.8 46  33  0
883  42  1  15.00  938 40 0 0 0.5 2.7 46  33  0
884  42  1  15.00  938 40 0 0 0.5 2.7 46  33  0
885  42  1  15.00  938 40 0 0 0.4 2.7 46  33  0
886  42  1  15.00  938 40 0 0 0.3 2.7 46  33  0
887  42  1  15.00  938 40 0 0 0.3 2.7 46  33  0
888  42  1  15.00  938 40 0 0 0.3 2.7 46  33  0
889  42  1  15.00  938 40 0 0 0.3 2.7 46  33  0
890  42  1  15.00  938 40 0 0 0.3 2.7 46  33  0
891  42  1  15.00  938 40 0 0 0.3 2.7 46  33  0
892  42  1  15.00  938 40 0 0 0.3 2.7 46  33  0
893  42  1  15.00  938 40 0 0 0.3 2.4 24  27  0
894  42  1  15.00  938 40 0 0 0.3 2.4 24  27  0
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895  42  1  15.00  938 40 0 0 0.3 2.4 24  27  0
896  42  1  15.00  938 40 0 0 0.3 2.4 24  27  0
897  42  1  15.00  938 40 0 0 0.3 2.4 24  27  0
898  42  1  15.00  938 40 0 0 0.3 2.4 24  27  0
899  42  1  15.00  938 40 0 0 0.3 2.4 24  27  0
900  42  1  15.00  938 40 0 0 0.3 2.4 24  27  0
901  42  1  15.00  938 40 0 0 0.3 2.4 24  27  0
902  42  1  15.00  938 40 0 0 0.3 2.4 24  27  0
903  42  1  15.00  938 40 0 0 0.3 2.4 24  27  0
904  43  1  10.00  391 40 0 1 0.2 3.1 23  15  0
905  43  1  10.00  391 40 0 1 0.2 3.1 23  15  0
906  43  1  10.00  391 40 0 1 0.2 3.1 23  15  0
907  43  1  10.00  391 40 0 1 0.2 3.1 23  15  0
908  43  1  10.00  391 40 0 1 0.2 3.1 23  15  0
909  43  1  10.00  391 40 0 1 0.2 3.1 23  15  0
910  43  1  10.00  391 40 0 1 0.2 3.1 23  15  0
911  43  1  10.00  391 40 0 1 0.3 3.1 23  15  0
912  43  1  10.00  391 40 0 1 0.3 3.1 23  15  0
913  43  1  10.00  391 40 0 1 0.3 3.1 23  15  0
914  43  1  10.00  391 40 0 1 0.3 3.1 23  15  0
915  43  1  10.00  391 40 0 1 0.3 3.1 23  15  0
916  43  1  10.00  391 40 0 1 0.3 3.1 23  15  0
917  43  1  10.00  391 40 0 1 0.3 3.1 23  15  0
918  43  1  10.00  391 40 0 1 0.2 3.1 23  15  0
919  43  1  10.00  391 40 0 1 0.3 3.1 23  15  0
920  43  1  10.00  391 40 0 1 0.2 3.1 23  15  0
921  43  1  10.00  391 40 0 1 0.2 3.1 23  15  0
922  43  1  10.00  391 40 0 1 0.2 3.3 23  15  0
923  43  1  10.00  391 40 0 1 0.2 3.3 23  15  0
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CVVHDE  SCAVENGE  TAFD  TALD AMT DUR RATE DV EVID
0    0.00  0.00 87.0 2.0 43.5 1
0  0  2.12  2.10 25.2 0
0  0  4.37  4.35 20.4 0
0  0  8.42  8.40 22.2 0
0    16.97  16.95 2
0  0  20.03  20.02 20.5 0
0    23.97  0.00 40.0 1.0 40.0 1
0  0  44.80  20.83 26.0 0
0    48.55  0.00 40.0 1.0 40.0 1
0  0  53.05  4.50 31.3 0
0    60.38  11.84 2
0    72.07  0.00 40.0 1.0 40.0 1
0    88.97  16.90 2
0  0  92.97  20.90 34.5 0
0    96.03  0.00 40.0 1.0 40.0 1
0  0  98.97  2.94 39.0 0
0    0.00  0.00 75.0 2.0 37.5 1
0  0  2.10  2.11 24.6 0
0  0  4.25  4.26 22.3 0
0  0  8.42  8.43 21.4 0
0    16.08  16.09 2
0  0  23.33  23.34 17.2 0
0    24.08  0.00 35.0 1.0 35.0 1
0    40.08  15.99 2
0  0  46.42  22.32 18.5 0
0    48.08  0.00 35.0 1.0 35.0 1
0    64.08  16.00 2
0  0  71.08  23.00 19.6 0
   
298 
 
0    0.00  0.00 26.5 2.5 10.6 1
0  0  2.83  2.84 10.6 0
0  0  4.75  4.76 26.4 0
0  1  14.50  14.51 26.7 0
0  0  26.00  26.01 21.2 0
0    0.00  0.00 67.5 2.0 33.8 1
0  0  2.33  2.32 20.8 0
0  0  4.17  4.15 15.3 0
0  0  11.92  11.90 15.1 0
0    12.67  12.65 2
0  0  20.67  20.65 14.2 0
0    22.67  0.00 30.0 1.0 30.0 1
0    36.67  14.00 2
0    36.67  14.00 2
0    47.42  0.00 30.0 1.0 28.6 1
0  0  47.42  24.75 16.6 0
0  0  51.17  3.74 23.8 0
0    68.17  0.00 30.0 1.0 30.0 1
0    84.67  16.49 2
0    84.67  16.49 2
0  0  92.67  24.49 24.4 0
0    92.67  0.00 30.0 1.0 30.0 1
0  0  97.67  4.99 28.0 0
0    0.00  0.00 70.0 2.0 35.0 1
0  0  2.17  2.17 29.7 0
0  0  5.97  5.97 24.2 0
0  0  8.32  8.32 23.2 0
0    17.25  17.26 2
0  0  21.17  21.17 18.2 0
   
299 
 
0    23.25  0.00 30.0 1.0 30.0 1
0    41.25  17.99 2
0  0  47.25  23.99 16.0 0
0    47.25  0.00 30.0 1.0 30.0 1
0  0  51.33  4.08 19.2 0
0    71.75  0.00 30.0 1.0 30.0 1
0    89.25  17.49 2
0  0  95.92  24.16 15.3 0
0    96.33  0.00 30.0 1.0 30.0 1
0  0  100.58  4.25 26.8 0
0    0.00  0.00 212.5 2.0 106.3 1
0  0  2.00  2.01 36.9 0
0  0  4.50  4.51 34.0 0
0  0  10.50  10.51 25.8 0
0    17.75  17.76 2
0  0  21.75  21.76 27.8 0
0    23.75  0.00 100.0 1.0 100.0 1
0    41.75  18.02 2
0  0  45.75  22.02 32.4 0
0    47.75  0.00 100.0 1.0 100.0 1
0  0  53.75  5.99 42.4 0
0    71.75  0.00 100.0 1.0 100.0 1
0  0  93.75  21.99 37.1 0
0    95.75  0.00 100.0 1.0 100.0 1
0  0  98.75  3.00 46.8 0
0    0.00  0.00 48.5 2.0 24.3 1
0  0  2.67  2.68 26.2 0
0  0  4.33  4.34 26.0 0
0  0  10.42  10.43 22.2 0
   
300 
 
0  0  22.92  22.93 17.7 0
0    23.75  0.00 24.0 1.0 24.0 1
0  1  34.17  10.40 17.8 0
0    38.25  14.49 2
0    47.25  0.00 24.0 1.0 24.0 1
0    71.25  0.00 24.0 1.0 24.0 1
0    86.25  15.01 2
0  0  92.83  21.59 9.5 0
0    95.25  0.00 24.0 1.0 24.0 1
0  0  101.83  6.60 30.9 0
0    0.00  0.00 175.0 2.0 87.5 1
0  0  2.58  2.58 27.3 0
0  0  4.50  4.49 23.7 0
0  0  10.00  9.99 18.3 0
0  0  23.00  22.99 11.3 0
0    24.00  0.00 80.0 2.0 40.0 1
0    41.58  17.58 2
0  0  46.25  22.25 15.3 0
0    48.00  0.00 80.0 1.0 80.0 1
0  0  51.75  3.76 24.6 0
0    73.25  0.00 80.0 2.0 40.0 1
0  0  93.28  20.02 8.1 0
0    96.00  0.00 80.0 1.0 80.0 1
0  0  101.50  5.48 20.8 0
0    0.00  0.00 43.0 2.0 21.5 1
0  0  2.67  2.67 32.7 0
0  0  7.50  7.50 29.1 0
0    10.00  10.00 2
0  0  11.50  11.50 23.2 0
   
301 
 
0    23.00  0.00 21.0 1.0 21.0 1
0  0  31.92  8.91 42.8 0
0  1  31.92  8.91 39.4 0
0  0  38.50  15.49 37.5 0
0  1  38.50  15.49 20.3 0
0  1  41.83  18.82 34.7 0
0    47.00  0.00 21.0 1.0 21.0 1
0  1  51.83  4.83 47.2 0
0    0.00  0.00 75.0 2.0 37.5 1
0  1  6.25  6.23 17.6 0
0  0  7.00  6.98 13.6 0
0  1  11.00  10.98 12.8 0
0    15.00  0.00 35.0 1.0 35.0 1
0  0  35.50  20.48 19.0 0
0    40.50  0.00 35.0 1.0 35.0 1
0  0  42.50  2.00 22.9 0
0  0  44.50  4.00 22.6 0
0    63.00  0.00 35.0 1.0 35.0 1
0  0  83.00  20.00 24.6 0
0    85.00  0.00 35.0 1.0 35.0 1
0  0  88.00  3.01 26.5 0
0    0.00  0.00 38.7 2.0 19.4 1
0  0  2.63  2.63 12.9 0
0  0  4.13  4.13 10.7 0
0  0  13.55  13.55 9.0 0
0  0  19.63  19.63 6.9 0
0  0  23.13  23.13 8.1 0
0    23.88  0.00 35.0 1.0 35.0 1
0  0  43.88  20.00 10.9 0
   
302 
 
0    49.05  0.00 35.0 1.0 35.0 1
0  0  51.13  2.09 20.5 0
0    72.88  0.00 35.0 1.0 35.0 1
0  0  93.72  20.82 17.4 0
0    0.00  0.00 115.0 2.0 57.5 1
0  0  2.08  2.09 33.3 0
0  0  4.25  4.26 32.1 0
0    6.42  6.43 2
0  0  8.33  8.34 29.2 0
0  0  18.85  18.86 21.3 0
0    23.08  0.00 55.0 1.0 55.0 1
0    46.42  0.00 55.0 1.0 55.0 1
0  1  57.17  10.75 26.3 0
0    70.42  0.00 55.0 1.0 55.0 1
0  0  91.75  21.34 18.1 0
0    0.00  0.00 80.0 2.0 40.0 1
0  0  2.42  2.41 18.0 0
0  0  6.42  6.41 17.7 0
0  0  11.92  11.91 14.8 0
0    16.92  16.91 2
0  0  22.92  22.91 11.3 0
0    23.92  0.00 40.0 1.0 40.0 1
0    40.92  16.99 2
0  0  46.75  22.82 22.0 0
0    47.92  0.00 40.0 1.0 40.0 1
0  0  54.92  6.99 25.9 0
0    0.00  0.00 85.0 2.0 42.5 1
0    24.08  0.00 85.0 2.0 42.5 1
0  1  47.10  23.02 14.4 0
   
303 
 
0    0.00  0.00 8.7 2.0 4.3 1
0  0  22.33  22.33 1.9 0
0    22.67  0.00 8.7 2.2 4.0 1
0  0  25.00  2.33 4.3 0
0  0  27.92  5.25 4.5 0
0  0  34.83  12.16 3.4 0
0  0  46.50  23.83 3.1 0
0    46.67  0.00 8.7 2.0 4.3 1
0  0  70.33  23.66 3.3 0
0    70.42  0.00 8.7 2.0 4.3 1
0    94.33  0.00 8.7 2.0 4.3 1
0    119.33  0.00 8.7 2.0 4.3 1
0    143.33  0.00 8.7 2.0 4.3 1
0  0  166.33  23.00 3.7 0
0    166.50  0.00 8.7 2.0 4.3 1
0    190.33  0.00 8.7 2.0 4.3 1
0    214.33  0.00 8.7 2.0 4.3 1
0    238.33  0.00 8.7 2.0 4.3 1
0    262.83  0.00 8.7 2.2 4.0 1
0    286.33  0.00 8.7 2.2 4.0 1
0    310.33  0.00 8.7 2.2 4.0 1
0    334.17  0.00 8.7 2.2 4.0 1
0  1  353.83  19.66 2.3 0
0    0.00  0.00 7.0 1.0 7.0 1
0    23.50  0.00 7.0 1.0 7.0 1
0    47.00  0.00 7.0 1.0 7.0 1
0    72.17  0.00 7.0 1.0 7.0 1
0    95.17  0.00 7.0 1.0 7.0 1
0    119.83  0.00 7.0 1.0 7.0 1
   
304 
 
0    143.25  0.00 7.0 1.0 7.0 1
0    167.50  0.00 7.0 1.0 7.0 1
0    191.75  0.00 7.0 1.0 7.0 1
0    215.50  0.00 7.0 1.0 7.0 1
0    239.50  0.00 7.0 1.0 7.0 1
0    263.50  0.00 7.0 1.0 7.0 1
0    287.50  0.00 7.0 1.0 7.0 1
0    311.50  0.00 7.0 2.5 2.8 1
0  1  328.33  16.83 6.7 0
0    336.17  0.00 7.0 2.6 2.7 1
0  0  338.83  2.66 7.8 0
0  0  341.75  5.58 7.6 0
0  0  348.75  12.58 6.2 0
0  0  359.50  23.33 5.5 0
0    360.50  0.00 7.0 1.7 4.2 1
0  0  383.92  23.42 5.6 0
0    384.08  0.00 7.0 2.0 3.5 1
0    408.17  0.00 7.0 1.2 5.8 1
0    431.70  0.00 7.0 1.1 6.2 1
0    456.00  0.00 7.0 2.0 3.5 1
0  0  479.50  23.50 4.7 0
0    480.33  0.00 7.0 1.0 7.0 1
0    503.75  0.00 7.0 1.0 7.0 1
0    527.67  0.00 7.0 2.0 3.5 1
0    553.00  0.00 7.0 2.0 3.4 1
0    576.33  0.00 7.0 1.3 5.6 1
0    599.00  0.00 7.0 1.5 4.7 1
0    624.08  0.00 7.0 1.2 6.0 1
0  0  647.50  23.42 4.4 0
   
305 
 
0    647.58  0.00 7.0 2.2 3.2 1
0    671.50  0.00 7.0 2.1 3.4 1
0    695.57  0.00 7.0 2.0 3.5 1
0    719.00  0.00 7.0 1.8 4.0 1
0    743.25  0.00 7.0 1.2 6.0 1
0    767.75  0.00 7.0 2.0 3.5 1
0    791.67  0.00 7.0 2.0 3.5 1
0  0  815.50  23.83 3.8 0
0    0.00  0.00 17.0 2.0 8.5 1
0  0  2.00  2.00 9.8 0
0  0  3.00  3.00 9.0 0
0  0  8.00  8.00 8.5 0
0  0  23.00  23.00 6.7 0
0  0  47.00  47.00 5.5 0
0    47.75  0.00 17.0 2.0 8.5 1
0    96.00  0.00 17.0 2.2 7.8 1
0  0  143.00  47.00 1.8 0
0    143.50  0.00 17.0 2.0 8.5 1
0    0.00  0.00 22.0 2.0 11.0 1
0  1  7.83  7.83 5.5 0
0    24.00  0.00 22.0 2.0 11.0 1
0  1  32.25  8.25 6.8 0
0    48.00  0.00 22.0 2.0 11.0 1
0  1  56.50  8.50 6.2 0
0    72.00  0.00 22.0 2.0 11.0 1
0  1  79.17  7.17 6.1 0
0    95.75  0.00 22.0 2.0 11.0 1
0  1  127.67  31.92 2.9 0
0  1  148.83  53.08 1.4 0
   
306 
 
0  1  176.00  80.25 0.9 0
0    0.00  0.00 18.0 1.0 18.0 1
0    20.67  0.00 18.0 1.0 18.0 1
0    44.50  0.00 18.0 1.0 18.0 1
0    68.67  0.00 18.0 1.0 18.0 1
0    92.50  0.00 18.0 1.0 18.0 1
0    116.50  0.00 18.0 1.0 18.0 1
0    140.58  0.00 18.0 2.0 9.0 1
0  0  154.67  14.09 7.4 0
0    0.00  0.00 40.0 1.0 40.0 1
0    24.00  0.00 40.0 1.0 40.0 1
0    48.83  0.00 40.0 1.0 40.0 1
0    72.50  0.00 40.0 2.0 20.0 1
0  0  95.75  23.25 6.9 0
0    96.25  0.00 40.0 1.0 40.0 1
0  0  97.00  0.75 15.3 0
0  0  98.00  1.75 14.1 0
0  0  102.98  6.73 13.2 0
0  0  119.75  23.50 7.4 0
0    120.00  0.00 40.0 1.0 40.0 1
0  0  143.75  23.75 7.4 0
0    144.00  0.00 40.0 2.0 20.0 1
0    168.00  0.00 40.0 2.0 20.0 1
0  0  191.75  23.75 8.6 0
0    192.00  0.00 40.0 2.0 20.0 1
0    216.00  0.00 40.0 2.0 20.0 1
0    240.00  0.00 40.0 2.0 20.0 1
0    264.25  0.00 40.0 2.0 20.0 1
0    288.00  0.00 40.0 2.0 20.0 1
   
307 
 
0    312.25  0.00 40.0 2.0 20.0 1
0    336.00  0.00 40.0 2.0 20.0 1
0  0  359.75  23.75 9.7 0
0    360.08  0.00 40.0 2.0 20.0 1
0    0.00  0.00 42.0 1.0 42.0 1
0    23.42  0.00 21.0 1.0 21.0 1
0    47.33  0.00 21.0 1.0 21.0 1
0    71.25  0.00 21.0 1.0 21.0 1
0  0  71.87  0.62 13.1 0
0    0.00  0.00 6.0 1.0 6.0 1
0  1  44.25  44.25 1.8 0
0  1  66.95  66.95 1.3 0
0  0  71.25  71.25 1.0 0
0    71.50  0.00 6.0 1.0 6.0 1
0  0  72.75  1.25 4.0 0
0  0  75.75  4.25 3.5 0
0  0  82.75  11.25 3.1 0
0  1  90.25  18.75 2.5 0
0  0  97.50  26.00 2.2 0
0  1  114.00  42.50 1.3 0
0  0  121.75  50.25 1.2 0
0  1  139.50  68.00 0.7 0
0    144.00  0.00 6.0 0.5 12.0 1
0  1  161.50  17.50 2.4 0
0  0  239.00  95.00 0.3 0
0    240.00  0.00 6.0 0.5 12.0 1
0  1  284.07  44.07 0.8 0
0    312.00  0.00 6.0 0.5 12.0 1
0    0.00  0.00 37.9 1.0 37.9 1
   
308 
 
0    24.00  0.00 37.9 1.0 37.9 1
0    48.00  0.00 37.9 1.0 37.9 1
0    72.00  0.00 37.9 1.0 37.9 1
0    72.75  0.76 2
0    95.93  23.95 2
0    96.00  0.00 37.9 1.0 37.9 1
0    120.00  0.00 37.9 1.0 37.9 1
0    120.25  0.24 2
0  0  144.00  23.99 16.8 0
0  0  144.00  23.99 14.9 0
0    144.50  0.00 37.9 1.0 37.9 1
0    145.12  0.60 2
0  0  146.00  1.49 24.7 0
0  0  146.00  1.49 24.2 0
0  0  150.00  5.49 24.1 0
0  0  150.00  5.49 20.6 0
0  0  152.00  7.49 22.5 0
0  0  152.00  7.49 15.8 0
0    169.08  24.57 2
0  0  169.75  25.24 16.1 0
0  0  169.75  25.24 16.2 0
0    192.00  47.49 2
0  0  192.00  47.49 13.5 0
0  0  192.00  47.49 13.0 0
0  0  209.67  65.15 11.3 0
0  0  209.83  65.32 11.2 0
0    217.50  72.99 2
0  0  234.75  90.24 8.6 0
0  0  234.75  90.24 8.3 0
   
309 
 
0    0.00  0.00 85.0 2.0 42.5 1
0  0  2.00  2.01 16.0 0
0  0  2.00  2.01 21.3 0
0  0  5.83  5.84 14.1 0
0  0  5.83  5.84 16.9 0
0  0  13.50  13.51 14.4 0
0  0  13.50  13.51 13.2 0
0    13.50  13.51 2
0  0  26.08  26.09 6.1 0
0  0  26.08  26.09 11.8 0
0    38.00  38.01 2
0  0  49.83  49.84 8.1 0
0  0  49.83  49.84 8.1 0
0    62.00  62.01 2
0    68.08  68.09 2
0    74.92  74.92 2
0    85.92  85.92 2
0    110.17  110.17 2
0    134.00  134.01 2
0    158.00  158.01 2
0  0  164.67  164.67 3.8 0
0  0  164.67  164.67 3.7 0
0    168.00  0.00 85.0 2.0 42.5 1
0  0  170.33  2.35 21.6 0
0  0  170.33  2.35 21.8 0
0  0  173.75  5.77 15.2 0
0  0  173.75  5.77 19.7 0
0  0  182.05  14.07 13.0 0
0  0  182.05  14.07 17.0 0
   
310 
 
0    183.08  15.10 2
0  0  194.08  26.10 15.0 0
0  0  194.08  26.10 15.1 0
0    206.33  38.35 2
0  0  216.17  48.18 14.1 0
0  0  216.17  48.18 13.9 0
0    229.67  61.68 2
0    254.33  86.35 2
0    277.33  109.35 2
0    301.00  133.02 2
0  0  315.25  147.27 9.4 0
0  0  315.25  147.27 9.5 0
0    0.00  0.00 84.0 1.0 84.0 1
0  0  1.25  1.26 14.2 0
0  0  1.25  1.26 14.3 0
0    2.18  2.19 2
0  0  5.25  5.26 10.9 0
0  0  5.25  5.26 9.8 0
0  0  9.33  9.34 9.4 0
0  0  9.33  9.34 9.8 0
0  0  22.75  22.76 6.7 0
0  0  22.75  22.76 6.7 0
0    23.75  0.00 84.0 1.0 84.0 1
0    26.62  2.85 2
0  0  47.00  23.23 8.0 0
0  0  47.00  23.23 7.5 0
0    47.75  0.00 84.0 1.0 84.0 1
0    51.00  3.24 2
0    71.75  0.00 84.0 1.0 84.0 1
   
311 
 
0    74.75  3.00 2
0    98.92  27.16 2
0  0  117.25  45.50 4.6 0
0  0  117.25  45.50 3.3 0
0    0.00  0.00 50.3 2.0 25.1 1
0  0  2.25  2.24 17.1 0
0  0  2.42  2.41 20.3 0
0  0  4.25  4.24 14.9 0
0  0  4.25  4.24 18.6 0
0  0  10.25  10.24 7.0 0
0  0  10.25  10.24 17.3 0
0  0  28.50  28.49 12.9 0
0  0  28.50  28.49 12.9 0
0  0  52.33  52.32 10.4 0
0  0  52.33  52.32 11.6 0
0    63.92  63.91 2
0    87.83  87.82 2
0  0  95.08  95.07 4.8 0
0  0  95.08  95.07 5.1 0
0  0  102.33  102.32 3.9 0
0    111.83  111.82 2
0  0  120.33  120.32 3.8 0
0    0.00  0.00 61.0 2.0 30.5 1
0  0  2.25  2.25 15.7 0
0  0  2.25  2.25 15.7 0
0  0  6.00  6.00 15.1 0
0  0  6.00  6.00 14.3 0
0  0  8.00  8.00 14.5 0
0  0  8.00  8.00 13.7 0
   
312 
 
0    14.00  14.00 2
0  0  26.00  26.00 12.2 0
0  0  26.00  26.00 12.1 0
0    37.00  37.00 2
0  0  49.92  49.92 9.1 0
0  0  49.92  49.92 9.9 0
0    0.00  0.00 67.5 2.0 33.8 1
0    1.50  1.48 2
0  0  2.58  2.57 22.2 0
0  0  2.58  2.57 21.0 0
0  0  6.00  5.98 14.7 0
0  0  6.00  5.98 13.0 0
0  0  8.00  7.98 18.2 0
0  0  8.00  7.98 15.2 0
0    13.25  13.23 2
0  0  26.00  25.98 15.3 0
0  0  26.00  25.98 13.4 0
0    38.00  37.98 2
0  0  46.00  45.98 12.6 0
0  0  46.08  46.07 12.4 0
0    66.50  66.48 2
0    85.83  85.82 2
0    109.83  109.82 2
0    134.17  134.15 2
0    157.50  157.48 2
0  0  164.00  163.98 1.3 0
0  0  164.25  164.23 1.6 0
0    164.42  0.00 67.5 2.0 33.8 1
0  0  166.50  2.10 16.7 0
   
313 
 
0  0  166.50  2.10 18.5 0
0  0  170.50  6.10 15.3 0
0  0  170.50  6.10 17.7 0
0  0  174.08  9.68 13.5 0
0  0  174.08  9.68 16.5 0
0    181.75  17.35 2
0  0  188.00  23.60 14.1 0
0  0  188.00  23.60 13.8 0
0    205.50  41.10 2
0  0  211.83  47.43 9.3 0
0  0  212.00  47.60 8.7 0
0    0.00  0.00 80.0 2.0 40.0 1
0  0  2.17  2.16 18.3 0
0  0  4.08  4.08 14.4 0
0  0  4.08  4.08 15.3 0
0  0  8.08  8.08 15.8 0
0  0  8.08  8.08 13.2 0
0    18.92  18.91 2
0  0  25.83  25.83 11.0 0
0  0  25.83  25.83 12.3 0
0    42.83  42.83 2
0  0  49.80  49.79 9.1 0
0  0  49.80  49.79 6.8 0
0    67.58  67.58 2
0    91.58  91.58 2
0    115.58  115.58 2
0    151.83  151.83 2
0    163.67  163.66 2
0  0  163.83  163.83 2.1 0
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0  0  163.83  163.83 2.2 0
0    167.83  0.00 80.0 2.0 40.0 1
0  0  170.17  2.35 13.9 0
0  0  170.17  2.35 19.2 0
0  0  171.83  4.02 15.6 0
0  0  171.83  4.02 16.7 0
0  0  175.83  8.02 15.1 0
0  0  175.83  8.02 16.1 0
0    187.58  19.77 2
0  0  193.92  26.10 13.0 0
0  0  193.92  26.10 11.8 0
0    210.83  43.02 2
0  0  217.92  50.10 11.6 0
0  0  217.92  50.10 11.2 0
0    235.58  67.77 2
0    259.57  91.75 2
0    283.58  115.77 2
0    307.67  139.85 2
0    331.33  163.52 2
0  0  417.17  249.35 1.0 0
0  0  420.00  252.18 0.9 0
0    0.00  0.00 312.5 2.0 156.3 1
0  0  2.00  2.01 23.8 0
0  0  2.00  2.01 22.2 0
0  0  3.75  3.76 20.6 0
0  0  3.92  3.92 22.8 0
0  0  11.75  11.76 17.9 0
0    11.75  11.76 2
0  0  11.75  11.76 18.0 0
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0  0  21.00  21.01 18.5 0
0  0  23.75  23.76 17.6 0
0  0  27.67  27.67 15.2 0
0    34.92  34.92 2
0  0  59.33  59.34 11.3 0
0    0.00  0.00 155.5 2.0 77.8 1
0  0  2.75  2.77 22.6 0
0  0  2.75  2.77 16.9 0
0  0  4.00  4.02 20.7 0
0  0  4.00  4.02 22.0 0
0    9.33  9.35 2
0  0  9.50  9.52 21.6 0
0  0  9.50  9.52 20.8 0
0  0  25.50  25.52 16.8 0
0  0  25.50  25.52 17.0 0
0    32.50  32.52 2
0    39.75  39.77 2
0  0  40.75  40.77 12.7 0
0  0  40.75  40.77 14.0 0
0  0  51.50  51.52 12.4 0
0  0  51.50  51.52 11.9 0
0    0.00  0.00 63.0 2.0 31.5 1
0  0  2.00  1.99 18.9 0
0  0  2.00  1.99 17.8 0
0  0  4.00  3.99 14.4 0
0  0  4.00  3.99 16.8 0
0  0  8.00  7.99 14.5 0
0  0  8.00  7.99 14.8 0
0    19.33  19.32 2
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0  0  25.83  25.82 8.6 0
0  0  25.83  25.82 7.8 0
0    43.83  43.82 2
0  0  50.00  49.99 3.7 0
0  0  50.00  49.99 3.5 0
0    68.00  67.99 2
0    90.08  90.07 2
0    114.33  114.32 2
0    140.00  139.99 2
0  0  163.58  163.57 0.3 0
0  0  163.58  163.57 0.2 0
0    163.58  163.57 2
0    168.50  0.00 63.0 2.0 31.5 1
0  0  170.50  1.99 17.8 0
0  0  170.50  1.99 17.2 0
0  0  173.00  4.49 16.7 0
0  0  173.50  4.99 16.8 0
0  0  176.00  7.49 14.6 0
0  0  176.00  7.49 15.7 0
0    187.50  18.99 2
0  0  194.00  25.49 10.3 0
0  0  194.00  25.49 9.8 0
0    212.08  43.57 2
0  0  218.25  49.74 5.5 0
0  0  218.25  49.74 5.3 0
0    0.00  0.00 550.0 2.0 275.0 1
0  0  2.00  2.00 25.1 0
0  0  2.00  2.00 24.0 0
0  0  6.25  6.25 19.2 0
   
317 
 
0  0  6.25  6.25 17.7 0
0  0  10.25  10.25 17.9 0
0  0  10.25  10.25 15.4 0
0    18.42  18.42 2
0  0  26.00  26.00 13.0 0
0  0  26.00  26.00 13.5 0
0    42.50  42.50 2
0  0  50.25  50.25 8.0 0
0  0  50.25  50.25 8.6 0
0    66.00  66.00 2
0    69.70  69.70 2
0    89.58  89.59 2
0    113.50  113.50 2
0    138.00  138.00 2
0    162.00  162.00 2
0  0  166.42  166.42 0.6 0
0  0  166.42  166.42 0.6 0
0    0.00  0.00 83.0 2.0 41.5 1
0  0  2.08  2.07 16.5 0
0  0  2.08  2.07 10.8 0
0  0  3.92  3.91 16.6 0
0  0  3.92  3.91 9.8 0
0  0  7.92  7.91 11.4 0
0  0  7.92  7.91 15.5 0
0    19.67  19.66 2
0  0  25.92  25.91 11.3 0
0  0  25.92  25.91 8.9 0
0    43.67  43.66 2
0  0  49.92  49.91 0
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0  0  49.92  49.91 6.8 0
0    67.92  67.91 2
0    91.83  91.82 2
0    115.92  115.91 2
0    139.83  139.82 2
0    163.13  163.12 2
0  0  167.92  167.91 0.2 0
0    167.92  0.00 83.0 2.0 41.5 1
0  0  167.92  167.91 0.1 0
0  0  169.92  1.99 18.0 0
0  0  169.92  1.99 16.7 0
0  0  171.92  3.99 16.8 0
0  0  171.92  3.99 17.5 0
0  0  176.00  8.07 16.3 0
0  0  176.00  8.07 15.3 0
0    187.92  19.99 2
0  0  194.00  26.07 11.4 0
0  0  194.00  26.07 10.8 0
0    211.77  43.84 2
0  0  217.00  49.07 6.4 0
0  0  217.92  49.99 4.9 0
0    235.33  67.41 2
0    259.83  91.91 2
0    283.67  115.74 2
0    307.67  139.74 2
0    331.67  163.74 2
0  0  335.92  167.99 0.4 0
0  0  335.92  167.99 0.3 0
0  0  342.50  174.57 0.3 0
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0  0  343.92  175.99 0.2 0
0  0  349.42  181.49 0.3 0
0  0  353.42  185.49 0.2 0
1    0.00  0.00 97.5 2.0 48.8 1
1  0  2.00  2.02 17.0 0
1  0  2.00  2.02 13.7 0
1  0  5.50  5.52 14.5 0
1  0  5.50  5.52 16.5 0
1  0  12.17  12.18 15.7 0
1  0  12.17  12.18 15.2 0
1    18.08  18.10 2
1  0  23.83  23.85 13.1 0
1  0  23.83  23.85 10.8 0
1    41.23  41.25 2
1  0  48.00  48.02 11.3 0
1  0  48.00  48.02 12.4 0
1    65.50  65.52 2
1    89.92  89.93 2
1    114.00  114.02 2
1    137.75  137.77 2
1    161.75  161.77 2
1  0  161.75  161.77 6.7 0
1  0  161.75  161.77 5.4 0
1    166.75  0.00 97.5 2.0 48.8 1
1  0  169.00  2.26 19.2 0
1  0  169.00  2.26 16.9 0
1  0  171.00  4.26 14.4 0
1  0  171.00  4.26 17.9 0
1  0  174.00  7.26 15.9 0
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1  0  174.00  7.26 19.2 0
1    185.83  19.10 2
1  0  192.00  25.26 17.7 0
1  0  192.00  25.26 17.4 0
1    209.87  43.13 2
1  0  215.83  49.10 14.0 0
1  0  215.83  49.10 14.5 0
1    233.50  66.76 2
1    257.50  90.76 2
1    282.08  115.35 2
1    306.08  139.35 2
1    330.00  163.26 2
1    334.00  0.00 97.5 2.0 48.8 1
1    354.00  20.00 2
1    378.17  44.17 2
1    401.42  67.42 2
1    425.83  91.84 2
1    449.92  115.92 2
1    473.75  139.75 2
1  0  510.50  176.50 6.1 0
0    0.00  0.00 444.0 1.0 444.0 1
0    13.75  13.74 2
0  1  13.75  13.74 12.6 0
0  1  21.00  20.99 10.9 0
0    24.00  0.00 222.0 1.0 222.0 1
0    37.33  13.33 2
0  1  37.33  13.33 16.3 0
0  1  45.00  21.00 16.2 0
0    48.00  0.00 222.0 1.0 222.0 1
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0  1  55.13  7.14 16.7 0
0  1  59.95  11.96 15.2 0
0  1  60.78  12.79 15.6 0
0    60.78  12.79 2
0  1  64.58  16.59 14.3 0
0  1  68.67  20.67 12.7 0
0    72.00  0.00 222.0 1.0 222.0 1
0  0  72.00  24.01 14.7 0
0  0  72.00  24.01 14.2 0
0  1  73.50  1.51 17.0 0
0  0  73.50  1.51 23.6 0
0  0  73.50  1.51 22.8 0
0  0  76.00  4.01 22.0 0
0  0  76.00  4.01 19.8 0
0  0  80.00  8.01 20.9 0
0  0  80.00  8.01 19.6 0
0  0  91.67  19.68 14.9 0
0  0  91.67  19.68 12.9 0
0  0  94.00  22.01 11.9 0
0  0  94.00  22.01 12.3 0
0    0.00  0.00 800.0 4.0 200.0 1
0  0  4.00  4.02 11.7 0
0  0  7.92  7.93 11.5 0
0  0  14.00  14.02 11.5 0
0  0  23.33  23.35 6.9 0
0    24.00  0.00 400.0 2.0 200.0 1
0  1  26.42  2.40 11.7 0
0    26.42  2.40 2
0  1  38.00  13.99 13.2 0
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0    38.00  13.99 2
0  0  43.75  19.74 10.3 0
0    48.00  0.00 400.0 2.0 200.0 1
0  1  62.53  14.53 14.6 0
0    62.53  14.53 2
0  1  75.33  27.33 11.2 0
0    76.00  0.00 400.0 2.0 200.0 1
0    85.92  9.91 2
0  1  85.92  9.91 17.2 0
0    96.00  0.00 400.0 2.0 200.0 1
0  1  98.25  2.26 20.1 0
0    110.00  14.01 2
0  1  110.00  14.01 15.1 0
0  1  119.92  23.92 11.2 0
0    120.00  0.00 400.0 2.0 200.0 1
0  1  122.63  2.65 15.6 0
0  0  143.58  23.60 9.9 0
0    144.00  0.00 400.0 2.0 200.0 1
0  0  146.33  2.32 19.2 0
0    146.50  2.48 2
0  0  150.25  6.23 14.3 0
0    158.00  13.98 2
0  0  158.00  13.98 13.3 0
0  0  164.08  20.07 12.0 0
0  0  191.33  47.32 10.8 0
1    0.00  0.00 105.0 2.0 52.5 1
1  0  2.33  2.35 20.1 0
1  0  2.33  2.35 21.2 0
1  0  5.25  5.27 18.3 0
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1  0  5.25  5.27 18.4 0
1  0  11.00  11.02 15.8 0
1  0  11.00  11.02 14.7 0
1    16.00  16.02 2
1  0  23.00  23.02 13.4 0
1  0  23.00  23.02 16.2 0
1    40.08  40.10 2
1  0  47.00  47.02 13.1 0
1  0  47.00  47.02 13.0 0
1    65.17  65.18 2
1    88.67  88.68 2
1  1  112.42  112.43 9.3 0
1    112.42  112.43 2
1  1  122.08  122.10 8.2 0
1  1  130.33  130.35 7.4 0
1    136.67  136.68 2
1  1  149.00  149.02 7.0 0
1    160.50  160.52 2
1  0  162.50  162.52 6.4 0
1  0  162.50  162.52 5.2 0
1    166.50  0.00 105.0 2.0 52.5 1
1  0  169.00  2.48 7.2 0
1  0  169.00  2.48 7.9 0
1  0  173.08  6.57 15.9 0
1  0  173.08  6.57 16.2 0
1  0  179.17  12.65 17.9 0
1  0  179.17  12.65 15.6 0
1    184.00  17.48 2
1  0  191.00  24.48 17.8 0
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1  0  191.00  24.48 17.3 0
1    207.92  41.40 2
1  0  215.00  48.48 14.7 0
1  0  215.00  48.48 14.7 0
1    232.98  66.47 2
1    256.50  89.98 2
1  1  256.50  89.98 10.8 0
1    280.83  114.32 2
1  1  280.83  114.32 8.3 0
1    304.25  137.73 2
1  1  304.25  137.73 9.1 0
1  1  328.83  162.32 6.4 0
1    328.83  162.32 2
1    334.00  0.00 105.0 2.0 52.5 1
1  1  337.00  3.00 19.2 0
1  1  340.00  6.00 21.6 0
1  1  352.17  18.17 21.5 0
0    0.00  0.00 140.0 3.3 43.1 1
0  0  3.25  3.25 25.9 0
0  0  3.25  3.25 21.7 0
0  0  6.00  6.00 25.2 0
0  0  6.00  6.00 22.3 0
0  0  12.17  12.17 19.4 0
0  0  12.17  12.17 23.2 0
0  0  26.00  26.00 16.8 0
0  0  26.00  26.00 17.8 0
0    28.58  28.59 2
0    42.17  42.17 2
0  0  54.00  54.00 12.3 0
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0  0  54.00  54.00 14.0 0
0    70.92  70.92 2
0    89.50  89.50 2
0    113.17  113.17 2
0    137.92  137.92 2
0    161.25  161.25 2
0  0  168.00  168.00 6.0 0
0  0  168.00  168.00 6.0 0
0    168.17  0.00 140.0 2.1 67.3 1
0  0  170.25  2.08 29.4 0
0  0  170.25  2.08 16.2 0
0  0  174.00  5.83 23.1 0
0  0  174.00  5.83 22.7 0
0  0  180.08  11.91 23.7 0
0  0  180.08  11.91 23.2 0
0    185.67  17.50 2
0  0  197.00  28.83 17.4 0
0  0  197.00  28.83 17.3 0
0    209.42  41.25 2
0  0  215.83  47.66 13.3 0
0  0  215.83  47.66 13.5 0
0    0.00  0.00 250.0 2.3 111.1 1
0    2.08  2.09 2
0  0  2.28  2.29 21.2 0
0  0  2.28  2.29 21.8 0
0  0  5.58  5.59 15.7 0
0  0  5.58  5.59 17.7 0
0    13.42  13.42 2
0  0  13.58  13.59 16.3 0
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0  0  13.58  13.59 12.7 0
0  0  25.48  25.49 13.0 0
0  0  25.48  25.49 10.9 0
0    37.58  37.59 2
0  0  49.42  49.42 9.0 0
0  0  49.42  49.42 9.2 0
0    61.58  61.59 2
0    97.92  97.92 2
0    109.33  109.34 2
0  1  127.42  127.42 29.0 0
0    131.92  0.00 250.0 2.0 125.0 1
0    133.50  1.60 2
0    154.92  0.00 120.0 1.0 120.0 1
0    157.33  2.42 2
0  0  179.33  24.42 16.4 0
0  0  179.33  24.42 18.5 0
0    179.42  0.00 120.0 1.0 120.0 1
0  0  180.50  1.08 29.1 0
0  0  180.50  1.08 31.8 0
0    180.58  1.17 2
0  0  183.42  4.00 31.0 0
0  0  183.42  4.00 26.8 0
0  0  187.42  8.00 23.3 0
0  0  187.42  8.00 26.8 0
0  0  203.42  24.00 18.6 0
0  0  203.42  24.00 18.5 0
0    203.42  0.00 120.0 1.0 120.0 1
0    205.58  2.17 2
0  0  227.42  24.01 16.2 0
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0  0  227.42  24.01 18.2 0
0    0.00  0.00 375.0 2.1 180.3 1
0  0  2.17  2.16 18.4 0
0  0  2.17  2.16 13.2 0
0  0  3.92  3.91 16.7 0
0  0  3.92  3.91 16.3 0
0  0  7.92  7.91 15.7 0
0  0  7.92  7.91 15.5 0
0    19.83  19.83 2
0  0  25.92  25.91 11.3 0
0  0  25.92  25.91 10.8 0
0  0  49.92  49.91 7.3 0
0  0  49.92  49.91 8.6 0
0    55.92  55.91 2
0    68.17  68.16 2
0    92.00  92.00 2
0    115.92  115.91 2
0    138.92  138.91 2
0  0  167.88  167.88 0.8 0
0  0  167.92  167.91 0.5 0
0    168.17  0.00 375.0 2.1 176.1 1
0  0  170.38  2.21 19.7 0
0  0  170.38  2.21 5.1 0
0    170.42  2.24 2
0  0  172.12  3.94 14.3 0
0  0  172.12  3.94 19.1 0
0  0  175.88  7.71 16.2 0
0  0  175.92  7.74 13.5 0
0    187.67  19.49 2
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0  0  193.92  25.74 9.5 0
0  0  193.92  25.74 8.2 0
0    211.67  43.49 2
0  0  212.17  43.99 6.1 0
0  0  212.17  43.99 5.5 0
0    0.00  0.00 250.0 2.1 120.2 1
0  0  2.17  2.18 17.6 0
0  0  2.17  2.18 20.5 0
0  0  4.08  4.10 14.2 0
0  0  4.08  4.10 16.4 0
0  0  7.58  7.60 16.8 0
0  0  7.58  7.60 16.0 0
0    20.08  20.10 2
0  0  25.58  25.60 10.7 0
0  0  25.58  25.60 9.9 0
0    43.58  43.60 2
0  0  49.58  49.60 4.2 0
0  0  49.58  49.60 4.0 0
0  1  55.42  55.43 3.1 0
0    67.92  67.93 2
0  1  67.92  67.93 2.6 0
0    77.58  0.00 120.0 1.0 120.0 1
0  1  79.58  2.01 14.5 0
0    91.28  13.71 2
0  0  98.08  20.51 8.8 0
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Define 
 
ORDN Unique number for each record 
ID Subject ID 
ECMO 1 = ECMO support 
0 = No ECMO support 
WT Weight (kg) 
PNA Postnatal age (days) 
GA Gestational age (weeks) 
RACE 0 = White 
1 = Black 
2 = Other 
SEX 0 = Female 
1 = Male 
SCRE Serum creatinine 
ALBE Serum albumin 
ASTE Serum aspartate aminotransferase 
ALTE Serum alanine aminotransferase 
HMFLTRE 0 = No hemofilter support 
1 = Hemofilter support 
CVVHDE 0 = No continuous venovenous hemodialysis support 
1 = Continuous venovenous hemodialysis support 
SCAVENGE 0 = timed sample 
1 = scavenge sample 
TAFD Time after first dose (h) 
TALD Time after last dose (h) 
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AMT Amount (mg) 
DUR Duration of infusion (h) 
RATE Rate of infusion (mg/h) 
DV Concentration (mg/L) 
EVID 0 = Concentration record 
1 = Dosing record 
2 = Lab record 
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APPENDIX 3 
Micafungin data 
 
id  wt  pna  ga  race  sex scr alb ast alt tafd Tald amt  rate dv
1  3.30  2  39  black  0 0.00    
1  3.30  0  39  black  0 0.00    
1  3.30  4  39  black  0 0.00     0.00
1  3.30  4  39  black  0 0.3 0.00    
1  3.30  4  39  black  0 0.00     0.00
1  3.30  1  39  black  0 2.5 29 9 0.00    
1  3.30  4  39  black  0 0.01 13.2  13.2
1  3.30  4  39  black  0 1.09 1.08      4.81
1  3.30  4  39  black  0 1.09 1.08      4.70
1  3.30  4  39  black  0 2.01 2.00      3.66
1  3.30  4  39  black  0 2.01 2.00      3.56
1  3.30  5  39  black  0 3.09 3.08      3.63
1  3.30  5  39  black  0 3.09 3.08      4.25
1  3.30  5  39  black  0 10.76 10.75      3.51
1  3.30  5  39  black  0 10.76 10.75      3.49
1  3.30  5  39  black  0 13.01 13.00      2.96
1  3.30  5  39  black  0 13.01 13.00      3.20
1  3.30  5  39  black  0 23.84 23.83      1.82
1  3.30  5  39  black  0 23.84 23.83      1.63
1  3.30  5  39  black  0 24.01 24.00  13.2  13.2
1  3.30  6  39  black  0 48.01 24.00  13.2  13.2
1  3.30  7  39  black  0 71.92 23.92      2.17
1  3.30  7  39  black  0 71.92 23.92      2.43
1  3.30  7  39  black  0 72.01 24.00  13.2  13.2
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1  3.30  7  39  black  0 73.17 1.17      6.39
1  3.30  7  39  black  0 73.17 1.17      3.95
1  3.30  7  39  black  0 74.09 2.08      5.34
1  3.30  7  39  black  0 74.09 2.08      1.43
1  3.30  8  39  black  0 75.09 3.08      3.17
1  3.30  8  39  black  0 75.09 3.08      5.05
1  3.30  8  39  black  0 83.01 11.00      5.22
1  3.30  8  39  black  0 83.01 11.00      5.25
1  3.30  8  39  black  0 84.84 12.83      5.57
1  3.30  8  39  black  0 84.84 12.83      5.27
1  3.30  8  39  black  0 96.66 24.65      2.01
1  3.30  8  39  black  0 96.66 24.65      3.03
1  3.30  8  39  black  0 96.67 24.67  13.2  13.2
1  3.30  9  39  black  0 121.01 24.33  13.2  13.2
1  3.30  10  39  black  0 144.01 23.00  13.2  13.2
1    11  39  black  0 3.7 30 14 151.01    
1    11  39  black  0 0.3 158.26    
1  3.30  11  39  black  0 168.01 24.00  13.2  13.2
1    11  39  black  0 169.26    
1    12  39  black  0 174.92    
1    15  39  black  0    
2  85.60  6024  37  White  0 0.00    
2  85.60  6024  37  White  0 0.00 150.0  150.0
2  85.60  6025  37  White  0 2.5 27 42 12.00    
2  85.60  6025  37  White  0 24.00 24.00  150.0  150.0
2  85.60  6026  37  White  0 0.4 36.00    
2  85.60  6026  37  White  0 48.09    
2  85.60  6026  37  White  0 48.19 24.18      2.04
2  85.60  6026  37  White  0 48.34 24.33  150.0  128.2
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2  85.60  6026  37  White  0 49.59 1.25      10.09
2  85.60  6026  37  White  0 53.00 4.67      6.98
2  85.60  6027  37  White  0 59.00 10.67      4.19
2  85.60  6027  37  White  0 0.5 2.3 19 25 59.75    
2  85.60  6027  37  White  0 62.00 13.67      3.52
2  85.60  6027  37  White  0 71.92    
2  85.60  6027  37  White  0 71.92 23.58      2.17
2  85.60  6027  37  White  0 72.00 23.67  150.0  150.0
2  85.60  6028  37  White  0 96.00 24.00  150.0  150.0
2  85.60  6029  37  White  0 120.17 24.17      2.40
2  85.60  6029  37  White  0 120.37 24.37  150.0  150.0
2  85.60  6029  37  White  0 121.50 1.13      13.79
2  85.60  6029  37  White  0 122.50 2.13      10.18
2  85.60  6029  37  White  0 123.92 3.55      9.84
2  85.60  6030  37  White  0 130.00 9.63      6.70
2  85.60  6030  37  White  0 134.17 13.80      4.56
2  85.60  6030  37  White  0 144.17 23.80      2.62
2  85.60  6030  37  White  0 144.19 23.82  150.0  150.0
2  85.60  6031  37  White  0 168.00 23.82  150.0  150.0
2  85.60  6033  37  White  0 204.00    
2  85.60  6033  37  White  0 0.4 215.84    
2  85.60  6034  37  White  0 2.1 120 177 245.00    
2  85.60  6043  37  White  0 2.1 62 113 443.50    
2  85.60  6426  37  White  0 41 42 9642.50    
3  9.60  575  37  White  1 0.2 3.5 210 479 0.00    
3  9.60  574  37  White  1 0.00    
3  9.60  575  37  White  1 0.00 39.0  39.0
3  9.60  574  37  White  1 0.00    
3  9.60  575  37  White  1 1.16 1.17      7.47
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3  9.60  575  37  White  1 1.16 1.17      8.93
3  9.60  575  37  White  1 2.04 2.05      5.36
3  9.60  575  37  White  1 2.08 2.08      6.25
3  9.60  575  37  White  1 3.13 3.13      5.84
3  9.60  575  37  White  1 3.13 3.13      5.72
3  9.60  575  37  White  1 10.96 10.97      3.32
3  9.60  575  37  White  1 10.98 10.98      2.92
3  9.60  575  37  White  1 13.04 13.05      2.57
3  9.60  575  37  White  1 13.04 13.05      3.67
3  9.60  576  37  White  1 23.91 23.92      1.76
3  9.60  576  37  White  1 29.49 29.50  39.0  39.0
3  9.60  577  37  White  1 55.08 25.58  39.0  39.0
3  9.60  578  37  White  1 78.99 23.92      2.90
3  9.60  578  37  White  1 78.99 23.92      3.53
3  9.60  578  37  White  1 0.2 78.99    
3  9.60  578  37  White  1 79.16 24.08  39.0  39.0
3  9.60  578  37  White  1 80.16 1.00      17.02
3  9.60  578  37  White  1 80.16 1.00      14.26
3  9.60  578  37  White  1 81.24 2.08      14.91
3  9.60  578  37  White  1 81.24 2.08      8.94
3  9.60  578  37  White  1 84.91 5.75      11.66
3  9.60  578  37  White  1 84.91 5.75      12.45
3  9.60  579  37  White  1 88.08 8.92      8.89
3  9.60  579  37  White  1 88.08 8.92      6.47
3  9.60  579  37  White  1 91.49 12.33      6.77
3  9.60  579  37  White  1 91.49 12.33      6.94
3  9.60  579  37  White  1 103.11 23.95      4.03
3  9.60  579  37  White  1 103.19 24.03      2.94
3  9.60  579  37  White  1 103.56 24.40  39.0  39.0
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3  9.60  580  37  White  1 115.58    
3  9.60  580  37  White  1 126.99 23.43  39.0  39.0
3  9.60  581  37  White  1 3.9 45 72 138.36    
3  9.60  581  37  White  1 0.1 150.83    
3  9.60  581  37  White  1 152.33 25.33  39.0  33.3
4  3.90  124  27  black  0 0.00    
4  3.90  124  27  black  0 0.2 0.00    
4  3.90  124  27  black  0 0.00     0.00
4  3.90  122  27  black  0 2.7 40 17 0.00    
4  3.90  124  27  black  0 0.00    
4  3.90  122  27  black  0 0.00    
4  3.90  124  27  black  0 0.01 15.6  15.6
4  3.90  124  27  black  0 1.51 1.50      8.87
4  3.90  124  27  black  0 1.51 1.50      5.09
4  3.90  124  27  black  0 2.76 2.75      5.22
4  3.90  124  27  black  0 2.76 2.75      6.57
4  3.90  124  27  black  0 5.10 5.08      5.38
4  3.90  124  27  black  0 5.10 5.08      5.20
4  3.90  125  27  black  0 11.21 11.20      3.30
4  3.90  125  27  black  0 11.21 11.20      3.20
4  3.90  125  27  black  0 11.35    
4  3.90  125  27  black  0 13.10 13.08      3.14
4  3.90  125  27  black  0 13.10 13.08      2.84
4  3.90  125  27  black  0 0.2 22.60    
4  3.90  125  27  black  0 23.65 23.63      1.52
4  3.90  125  27  black  0 23.65 23.63      1.44
4  3.90  125  27  black  0 24.50 24.48  15.6  15.6
4  3.90  126  27  black  0 48.01 23.52  15.6  13.3
4  3.90  127  27  black  0 0.2 58.35    
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4  3.90  127  27  black  0 59.23    
4  3.90  127  27  black  0 70.43 22.42      1.88
4  3.90  127  27  black  0 70.43 22.42      1.92
4  3.90  127  27  black  0 72.01 24.00  15.6  15.6
4  3.90  127  27  black  0 73.43 1.42      8.80
4  3.90  127  27  black  0 73.43 1.42      7.68
4  3.90  127  27  black  0 74.51 2.50      7.01
4  3.90  127  27  black  0 74.51 2.50      7.10
4  3.90  127  27  black  0 77.10 5.08      6.00
4  3.90  127  27  black  0 77.10 5.08      4.27
4  3.90  128  27  black  0 0.2 82.93    
4  3.90  128  27  black  0 82.98 10.97      3.63
4  3.90  128  27  black  0 82.98 10.97      3.12
4  3.90  128  27  black  0 85.13 13.12      2.89
4  3.90  128  27  black  0 85.13 13.12      3.51
4  3.90  128  27  black  0 95.10 23.08      2.29
4  3.90  128  27  black  0 95.10 23.08      2.13
4  3.90  128  27  black  0 96.01 24.00  15.6  15.6
4  3.90  129  27  black  0 120.30 24.28  15.6  15.6
4  3.90  130  27  black  0 0.3 130.68    
4  3.90  136  27  black  0 0.2 274.83    
4  3.90          76 31 8987.11    
4  3.90  126  27  black  0    
4    122           
4  3.90  130  27  black  0    
4  3.90  131  27  black  0    
5  2.94  10  39  black  1 0.00    
5  2.94  1  39  black  1 48 9 0.00    
5  2.94  1  39  black  1 32 5 0.00    
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5  2.94  7  39  black  1 3.6 0.00    
5  2.94  1  39  black  1 0.00    
5  2.94  11  39  black  1 0.00 23.6  23.5
5  2.94  12  39  black  1 0.6 11.08    
5  2.94  12  39  black  1 11.38    
5  2.94  12  39  black  1 22.83 22.83      5.05
5  2.94  12  39  black  1 22.83 22.83      4.47
5  2.94  12  39  black  1 23.75 23.75  23.6  23.5
5  2.94  12  39  black  1 25.03 1.28      16.88
5  2.94  12  39  black  1 25.10 1.35      20.64
5  2.94  12  39  black  1 26.37 2.62      14.43
5  2.94  12  39  black  1 26.37 2.62      12.91
5  2.94  12  39  black  1 28.75 5.00      12.53
5  2.94  12  39  black  1 28.75 5.00      12.86
5  2.94  13  39  black  1 0.5 34.83    
5  2.94  13  39  black  1 34.83 11.08      8.10
5  2.94  13  39  black  1 34.83 11.08      7.19
5  2.94  13  39  black  1 40.75 17.00      5.57
5  2.94  13  39  black  1 40.83 17.08      7.23
5  2.94  13  39  black  1 46.73 22.98      5.21
5  2.94  13  39  black  1 46.73 22.98      4.51
5  2.94  13  39  black  1 47.78 24.03  23.6  23.5
5  2.94  14  39  black  1 0.4 66.62    
5  2.94  14  39  black  1 71.68 23.90  23.6  23.5
5  2.94  15  39  black  1 0.4 83.00    
5  2.94  15  39  black  1 94.82 23.13      5.60
5  2.94  15  39  black  1 94.92 23.23      4.19
5  2.94  15  39  black  1 96.13 24.45  23.6  23.5
5  2.94  15  39  black  1 97.33 1.20      16.72
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5  2.94  15  39  black  1 97.33 1.20      14.92
5  2.94  15  39  black  1 98.38 2.25      9.95
5  2.94  15  39  black  1 98.40 2.27      11.09
5  2.94  15  39  black  1 101.23 5.10      7.18
5  2.94  15  39  black  1 101.23 5.10      9.40
5  2.94  16  39  black  1 0.5 106.75    
5  2.94  16  39  black  1 106.92 10.78      8.53
5  2.94  16  39  black  1 106.92 10.78      7.37
5  2.94  16  39  black  1 112.88 16.75      6.19
5  2.94  16  39  black  1 112.88 16.75      5.33
5  2.94  16  39  black  1 118.73 22.60      4.42
5  2.94  16  39  black  1 118.73 22.60      4.28
5  2.94  16  39  black  1 119.87 23.73  23.6  23.5
5  2.94  17  39  black  1 130.75    
5  2.94  8  39  black  1    
5  2.94  14  39  black  1    
6  3.47  6  39  White  1 0.00     0.00
6  3.47  4  39  White  1 0.00    
6  3.47  6  39  White  1 0.00     0.00
6  3.47  6  39  White  1 0.00    
6  3.47  4  39  White  1 0.00    
6  3.47  5  39  White  1 2.3 103 25 0.00    
6  3.47  6  39  White  1 1.2 0.00    
6  3.47  6  39  White  1 0.01 13.9  13.9
6  3.47  6  39  White  1 1.34 1.33      6.13
6  3.47  6  39  White  1 1.34 1.33      5.10
6  3.47  6  39  White  1 2.76 2.75      4.99
6  3.47  6  39  White  1 2.76 2.75      3.67
6  3.47  6  39  White  1 5.38 5.37      0.44
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6  3.47  6  39  White  1 5.46 5.45      3.88
6  3.47  6  39  White  1 11.43 11.42      0.99
6  3.47  6  39  White  1 11.43 11.42      2.67
6  3.47  7  39  White  1 148 41 17.18    
6  3.47  7  39  White  1 17.43 17.42      1.69
6  3.47  7  39  White  1 17.43 17.42      1.11
6  3.47  7  39  White  1 23.18 23.17      0.88
6  3.47  7  39  White  1 23.21 23.20      1.84
6  3.47  7  39  White  1 23.71 23.70  13.9  13.9
6  3.47  7  39  White  1 1.5 29.84    
6  3.47  8  39  White  1 48.93 25.22  13.9  13.9
6  3.47  9  39  White  1 1.6 65.68    
6  3.47  9  39  White  1 71.16 22.23      2.37
6  3.47  9  39  White  1 71.21 22.28      2.28
6  3.47  9  39  White  1 72.83 23.90  13.9  13.9
6  3.47  9  39  White  1 73.68    
6  3.47  10  39  White  1 89.18    
6  3.47  11  39  White  1 3.3 15 22 113.68    
7  2.90  2  39  black  1 59 17 0.00    
7  2.90  6  39  black  1 0.00     0.00
7  2.90  6  39  black  1 0.00     0.00
7  2.90  1  39  black  1 2.5 0.00    
7  2.90  6  39  black  1 0.00 11.6  11.6
7  2.90  6  39  black  1 0.6 0.00    
7  2.90  7  39  black  1 1.13 1.15      7.74
7  2.90  7  39  black  1 1.13 1.15      7.81
7  2.90  7  39  black  1 2.00 2.02      5.50
7  2.90  7  39  black  1 2.00 2.02      5.57
7  2.90  7  39  black  1 4.98 5.00      4.03
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7  2.90  7  39  black  1 4.98 5.00      3.98
7  2.90  7  39  black  1 10.82 10.83      2.66
7  2.90  7  39  black  1 10.82 10.83      3.02
7  2.90  7  39  black  1 16.97 16.98      2.25
7  2.90  7  39  black  1 16.98 17.00      2.19
7  2.90  7  39  black  1 24.47 24.48  11.6  11.6
7  2.90  8  39  black  1 29.07    
7  2.90  8  39  black  1 48.90 24.43  11.6  11.6
7  2.90  9  39  black  1 0.8 61.70    
7  2.90  4  39  black  1    
8  6.20  138    black  0 0.3 0.00    
8  6.20  138    black  0 0.00     0.00
8  6.20  138    black  0 0.00    
8  6.20  135    black  0 3.1 53 27 0.00    
8  6.20  138    black  0 0.01 24.8  24.8
8  6.20  139    black  0 0.96 0.95      10.23
8  6.20  139    black  0 1.96 1.95      7.69
8  6.20  139    black  0 5.21 5.20      6.50
8  6.20  139    black  0 0.3 5.26    
8  6.20  139    black  0 11.01 11.00      4.32
8  6.20  139    black  0 17.04 17.03      2.74
8  6.20  139    black  0 23.16 23.15      2.22
8  6.20  139    black  0 23.78 23.77  24.8  24.8
8  6.20  140    black  0 0.2 40.68    
8  6.20  141    black  0 49.06 25.28  24.8  24.8
8  6.20  141    black  0 53.46    
8  6.20  144    black  0 22 22 136.71    
8  6.20  141    black  0    
8  6.20  134    black  0    
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9  65.00  6254    black  0 3.1 96 103 0.00    
9  65.00  6257    black  0 1.1 0.00    
9  65.00  6257    black  0 0.00    
9  65.00  6257    black  0 0.02 100.0  100.0
9  65.00  6258    black  0 1.3 14.85    
9  65.00  6258    black  0 20.60 20.58      1.41
9  65.00  6258    black  0 23.38 23.37  100.0  100.0
9  65.00  6258    black  0 24.88 1.50      5.75
9  65.00  6258    black  0 26.88 3.50      5.12
9  65.00  6258    black  0 32.77 9.38      3.71
9  65.00  6259    black  0 38.52 15.13      2.82
9  65.00  6259    black  0 44.52 21.13      2.33
9  65.00  6259    black  0 47.65 24.27  100.0  100.0
9  65.00  6260    black  0 1.9 63.65    
9  65.00  6261    black  0 86.27    
9  65.00  6265    black  0 3.4 56 42 182.82    
9  65.00  6257    black  0    
10  3.90  111  39  black  0 0.7 0.00    
10  3.90  111  39  black  0 0.00     0.00
10  3.90  109  39  black  0 265 27 0.00    
10  3.90  108  39  black  0 2.5 0.00    
10  3.90  111  39  black  0 0.00     0.00
10  3.90  111  39  black  0 0.5 0.00    
10  3.90  111  39  black  0 2.5 0.00    
10  3.90  111  39  black  0 0.01 15.6  13.3
10  3.90  112  39  black  0 1.21 1.20      8.66
10  3.90  112  39  black  0 1.21 1.20      5.72
10  3.90  112  39  black  0 2.13 2.12      6.58
10  3.90  112  39  black  0 2.13 2.12      4.65
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10  3.90  112  39  black  0 5.08 5.07      4.95
10  3.90  112  39  black  0 5.08 5.07      5.45
10  3.90  112  39  black  0 0.6 5.11    
10  3.90  112  39  black  0 11.01 11.00      2.80
10  3.90  112  39  black  0 11.01 11.00      2.73
10  3.90  112  39  black  0 0.6 14.78    
10  3.90  112  39  black  0 17.46 17.45      1.32
10  3.90  112  39  black  0 17.48 17.47      1.41
10  3.90  112  39  black  0 23.00 22.98      0.94
10  3.90  112  39  black  0 23.01 23.00      1.13
10  3.90  112  39  black  0 24.40 24.38  15.6  15.6
10  3.90  113  39  black  0 47.28 22.88  15.6  14.4
10  3.90  114  39  black  0 53.11    
10  3.90  114  39  black  0 0.4 64.91    
10  3.90  114  39  black  0 71.13 23.85      1.97
10  3.90  114  39  black  0 71.15 23.87      1.68
10  3.90  114  39  black  0 72.10 24.82  15.6  15.6
10  3.90  115  39  black  0 73.25 1.15      11.35
10  3.90  115  39  black  0 73.25 1.15      7.51
10  3.90  115  39  black  0 74.16 2.07      9.93
10  3.90  115  39  black  0 74.16 2.07      6.74
10  3.90  115  39  black  0 77.20    
10  3.90  115  39  black  0 78.10 6.00      6.61
10  3.90  115  39  black  0 78.10 6.00      6.13
10  3.90  115  39  black  0 82.90 10.80      4.94
10  3.90  115  39  black  0 83.11 11.02      4.74
10  3.90  115  39  black  0 88.83 16.73      3.43
10  3.90  115  39  black  0 88.85 16.75      3.36
10  3.90  115  39  black  0 0.4 88.86    
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10  3.90  115  39  black  0 95.28 23.18      1.75
10  3.90  115  39  black  0 95.28 23.18      1.84
10            18 13 137.45    
10  3.90  107  39  black  0    
11  3.00  18    White  0 0.00     0.00
11  3.00  16    White  0 2.5 41 16 0.00    
11  3.00  18    White  0 0.00 12.0  12.0
11  3.00  18    White  0 0.6 0.00    
11  3.00  18    White  0 1.47 1.48      3.59
11  3.00  18    White  0 1.47 1.48      3.40
11  3.00  18    White  0 3.47 3.48      4.33
11  3.00  18    White  0 9.46 9.47      2.57
11  3.00  18    White  0 13.47 13.48      0.00
11  3.00  19    White  0 23.31 23.32      0.89
11  3.00  19    White  0 24.22 24.23  12.0  12.0
11            24 14 100.39    
12  3.40  46  37  White  1 0.00     0.00
12  3.40  46  37  White  1 0.00 13.6  13.6
12  3.40  44  37  White  1 2.1 0.00    
12  3.40  46  37  White  1 0.3 77 93 0.00    
12  3.40  46  37  White  1 1.37 1.38      7.37
12  3.40  46  37  White  1 2.35 2.37      5.19
12  3.40  46  37  White  1 4.44 4.45      4.14
12  3.40  46  37  White  1 10.45 10.47      2.18
12  3.40  47  37  White  1 16.05 16.07      1.52
12  3.40  47  37  White  1 22.62 22.63      0.98
12  3.40  47  37  White  1 23.17 23.18  13.6  13.6
12  3.40  50  37  White  1 20 70 88.29    
13  4.90  187  34  White  0 0.00    
   
344 
 
13  4.90  187  34  White  0 0.00     0.00
13  4.90  187  34  White  0 0.6 31 13 0.00    
13  4.90  187  34  White  0 0.01 19.6  19.6
13  4.90  187  34  White  0 1.21 1.20      9.84
13  4.90  187  34  White  0 2.29 2.28      7.24
13  4.90  187  34  White  0 4.88 4.87      5.88
13            3.8 4.94    
13  4.90  187  34  White  0 11.71 11.70      2.76
13  4.90  188  34  White  0 17.04 17.03      2.06
13  4.90  188  34  White  0 22.79 22.78      1.37
13  4.90  188  34  White  0 23.93 23.92  19.6  19.6
13  4.90  189  34  White  0 47.96 24.03  19.6  19.6
13            33 15 52.34    
13            56.38    
14  5.50  74    White  0 0.00    
14  5.50  74    White  0 2.6 3.2 35 79 0.00    
14  5.50  74    White  0 0.00     0.00
14  5.50  74    White  0 0.00 22.0  22.0
14  5.50  74    White  0 1.60 1.60      7.25
14  5.50  74    White  0 2.60 2.60      6.04
14  5.50  74    White  0 4.90 4.90      4.86
14  5.50  74    White  0 11.26 11.27      3.95
14  5.50  75    White  0 16.93 16.93      3.25
14  5.50  75    White  0 23.01 23.02      2.48
14  5.50  75    White  0 24.01 24.02  22.0  22.0
14  5.50  76    White  0 47.26 23.25  22.0  22.0
14  5.50  77    White  0 70.85 23.58      4.13
14  5.50  77    White  0 71.83 24.57  22.0  22.0
14  5.50  77    White  0 73.43 1.60      12.34
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14  5.50  77    White  0 74.26 2.43      10.48
14  5.50  77    White  0 76.93 5.10      9.69
14  5.50  77    White  0 82.91 11.08      7.71
14  5.50  78    White  0 88.93 17.10      5.29
14  5.50  78    White  0 95.18 23.35      2.71
14  5.50  78    White  0 95.75 23.92  22.0  22.0
14  5.50  79    White  0 118.10 22.35  22.0  22.0
14  5.50  80    White  0 145.58 27.48  22.0  22.0
14  5.50  81    White  0 0.6 160.63    
14  5.50  81    White  0 167.03 21.45  22.0  22.0
14  5.50  82    White  0 5.1 88 31 189.75    
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Define 
 
id Subject ID 
wt Weight (kg) 
pna Postnatal age (days) 
ga Gestational age (weeks) 
race Race 
sex 0 = Female 
1 = Male 
scr Serum creatinine 
alb Serum albumin 
ast Serum aspartate aminotransferase 
alt Serum alanine aminotransferase 
tafd Time after first dose (h) 
tald Time after last dose (h) 
amt Amount (mg) 
rate Rate of infusion (mg/h) 
dv Concentration (mg/L) 
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APPENDIX 4 
Ex vivo Extraction Calculations 
4.1 AUC0-24 Calculations for micafungin ex vivo circuits 
Circuit Time Conc lnConc AUC 
Log 
AUC 
Circuit 
18 0.02 16.68 2.81421 0  
18 0.08 14.84 2.697326 0.944525  
18 0.25 13.31 2.588516 2.390392  
18 0.5 10.57 2.35802 2.971854  
18 1 7.85 2.060514 4.571332  
18 2 5.44 1.693779 6.571512  
18 3 4.1 1.410987 4.738464  
18 4 3.48 1.247032 3.781533  
18 8 2.11 0.746688 10.95246  
18 12 1.85 0.615186 7.908606  
18 24 0.62 -0.47804 13.50138 58.33206
19 0.02 21.7 3.077312 0  
19 0.08 19.29 2.959587 1.228282  
19 0.25 15.99 2.771964 2.990034  
19 0.5 13.84 2.627563 3.722284  
19 1 10.68 2.368373 6.095912  
19 2 7.05 1.953028 8.739718  
19 3 5.05 1.619388 5.994497  
19 4 2.61 0.95935 3.696757  
19 8 1.61 0.476234 8.279584  
19 12 1.04 0.039221 5.21723  
19 24 0.67 -0.40048 10.09783 56.06213
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20 0.02 15.45 2.737609 0  
20 0.08 16.61 2.810005 0.96138  
20 0.25 15.42 2.735665 2.721297  
20 0.5 14.35 2.66375 3.719647  
20 1 13.08 2.571084 6.852597  
20 2 11.64 2.454447 12.34601  
20 3 10.47 2.348514 11.04467  
20 4 10.19 2.321407 10.32937  
20 8 7.55 2.021548 35.21652  
20 12 7.92 2.069391 30.9341  
20 24 8.14 2.09679 96.35397 210.4796
22 0.02 17.25 2.847812 0  
22 0.08 17.97 2.888704 1.056453  
22 0.25 18.24 2.903617 3.077793  
22 0.5 18 2.890372 4.529934  
22 1 16.96 2.830858 8.737421  
22 2 16.57 2.807594 16.76424  
22 3 15.6 2.747271 16.08012  
22 4 14.31 2.660959 14.94572  
22 8 12.55 2.529721 53.64303  
22 12 10.15 2.317474 45.23033  
22 24 6.36 1.850028 97.2948 261.3599
26 0.02 20.85 3.037354 0  
26 0.08 20.63 3.026746 1.244388  
26 0.25 19.76 2.98366 3.432619  
26 0.5 18.49 2.91723 4.779493  
26 1 15.49 2.740195 8.472882  
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26 2 15.14 2.71734 15.31433  
26 3 13.39 2.594508 14.24709  
26 4 12.56 2.530517 12.97057  
26 8 11.52 2.444085 48.13004  
26 12 5.24 1.656321 31.88776  
26 24 4.39 1.479329 57.62964 198.1088
27 0.02 16.96 2.830858 0  
27 0.25 17.94 2.887033 4.012445  
27 0.5 17.74 2.875822 4.459953  
27 1 14.84 2.697326 8.123443  
27 2 11.87 2.474014 13.29978  
27 3 11.71 2.460443 11.78982  
27 4 8.98 2.195 10.28468  
27 8 9.65 2.266958 37.24393  
27 12 6 1.791759 30.72401  
27 24 6.15 1.816452 72.8963 192.8344
28 0.02 19.4 2.965273 0  
28 0.08 18.91 2.939691 1.149237  
28 0.25 17.29 2.850128 3.074945  
28 0.5 16.08 2.777576 4.169421  
28 1 15.1 2.714695 7.792433  
28 2 13.49 2.601949 14.27988  
28 3 11.78 2.466403 12.61569  
28 4 11.33 2.427454 11.55354  
28 8 8.98 2.195 40.43807  
28 12 9.11 2.209373 36.17938  
28 24 4.09 1.408545 75.22217 206.4748
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29 0.02 20.71 3.030617 0  
29 0.08 20.21 3.006178 1.227539  
29 0.25 18.41 2.912894 3.280322  
29 0.5 17.11 2.839663 4.438017  
29 1 14.2 2.653242 7.80491  
29 2 13.39 2.594508 13.79104  
29 3 11.68 2.457878 12.51554  
29 4 10.41 2.342767 11.03282  
29 8 7.84 2.059239 36.25744  
29 12 6.27 1.835776 28.10315  
29 24 3.92 1.366092 60.04028 178.491 
30 0.02 18.07 2.894253 0  
30 0.08 18.08 2.894806 1.0845  
30 0.25 17.25 2.847812 3.002497  
30 0.5 15.85 2.76317 4.135032  
30 1 14.43 2.669309 7.564447  
30 2 12.83 2.551786 13.61433  
30 3 11.25 2.420368 12.0227  
30 4 10.67 2.367436 10.95744  
30 8 8.65 2.157559 38.49879  
30 24 6.41 1.857859 119.5862 210.466 
31 0.02 10.31 2.333114 0  
31 0.08 12.53 2.528126 0.683037  
31 0.25 9.99 2.301585 1.906055  
31 0.5 8.89 2.184927 2.357327  
31 1 5.5 1.704748 3.529934  
31 2 5.21 1.65058 5.353691  
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31 3 4.75 1.558145 4.976457  
31 4 4.14 1.420696 4.438015  
31 8 3.3 1.193922 14.81656  
31 12 2.75 1.011601 12.06659  
31 24 4.28 1.453953 41.5054 91.63307
 
Define 
 
Circuit Circuit/Control ID 
Time Time (h) 
Conc Concentration (mg/L) 
lnConc Natural log of concentration 
AUC log Logarithmic calculation of AUC for each time interval 
= (t2-t1) * (C2-C1) / ln (C2 / C1) 
Where t = time, C = concentration 
AUC Circuit Total AUC for each Circuit at 24h  
=sum of AUC for each time interval 
 
4.2 Relative decrease in AUC0-24 for micafungin circuits 
Circuit Time Conc lnConc AUC Log AUC 
Base 
AUC Circuit Relative 
Decrease in 
AUC 
18 0.02 16.68 2.81421 0    
 0.08 16.67 2.813611 1.00049997    
 0.25 16.66 2.813011 2.833049915    
 0.5 16.65 2.81241 4.163749875    
 1 16.64 2.811809 8.32249975    
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 2 16.63 2.811208 16.6349995    
 3 16.62 2.810607 16.6249995    
 4 16.61 2.810005 16.6149995    
 8 16.6 2.809403 66.41999799    
 12 16.59 2.8088 66.37999799    
 24 16.58 2.808197 199.019994 398.0148 58.33205672 0.853442489 
19 0.02 21.7 3.077312 0    
 0.08 21.69 3.076851 1.301699977    
 0.25 21.68 3.07639 3.686449935    
 0.5 21.67 3.075929 5.418749904    
 1 21.66 3.075467 10.83249981    
 2 21.65 3.075005 21.65499962    
 3 21.64 3.074543 21.64499961    
 4 21.63 3.074081 21.63499961    
 8 21.62 3.073619 86.49999846    
 12 21.61 3.073156 86.45999846    
 24 21.6 3.072693 259.2599954 518.3944 56.06213081 0.891854287 
20 0.02 15.45 2.737609 0    
 0.08 15.44 2.736962 0.926699968    
 0.25 15.43 2.736314 2.623949908    
 0.5 15.42 2.735665 3.856249865    
 1 15.41 2.735017 7.70749973    
 2 15.4 2.734368 15.40499946    
 3 15.39 2.733718 15.39499946    
 4 15.38 2.733068 15.38499946    
 8 15.37 2.732418 61.49999783    
 12 15.36 2.731767 61.45999783    
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 24 15.35 2.731115 184.2599935 368.5194 210.4795624 0.428850775 
22 0.02 17.25 2.847812 0    
 0.08 17.24 2.847232 1.034699971    
 0.25 17.23 2.846652 2.929949918    
 0.5 17.22 2.846071 4.306249879    
 1 17.21 2.845491 8.607499758    
 2 17.2 2.844909 17.20499952    
 3 17.19 2.844328 17.19499952    
 4 17.18 2.843746 17.18499952    
 8 17.17 2.843164 68.69999806    
 12 17.16 2.842581 68.65999806    
 24 17.15 2.841998 205.8599942 411.6834 261.3598502 0.36514356 
26 0.02 20.85 3.037354 0    
 0.08 20.84 3.036874 1.250699976    
 0.25 20.83 3.036394 3.541949932    
 0.5 20.82 3.035914 5.2062499    
 1 20.81 3.035434 10.4074998    
 2 20.8 3.034953 20.8049996    
 3 20.79 3.034472 20.7949996    
 4 20.78 3.033991 20.7849996    
 8 20.77 3.03351 83.0999984    
 12 20.76 3.033028 83.05999839    
 24 20.75 3.032546 249.0599952 498.0114 198.1088135 0.602200236 
27 0.02 16.96 2.830858 0    
 0.08 16.95 2.830268 1.017299971    
 0.25 16.94 2.829678 2.880649916    
 0.5 16.93 2.829087 4.233749877    
   
354 
 
 1 16.92 2.828496 8.462499754    
 2 16.91 2.827905 16.91499951    
 3 16.9 2.827314 16.90499951    
 4 16.89 2.826722 16.89499951    
 8 16.88 2.826129 67.53999803    
 12 16.87 2.825537 67.49999802    
 24 16.86 2.824944 202.3799941 404.7292 192.8343521 0.523547207 
28 0.02 19.4 2.965273 0    
 0.08 19.39 2.964757 1.163699974    
 0.25 19.38 2.964242 3.295449927    
 0.5 19.37 2.963725 4.843749892    
 1 19.36 2.963209 9.682499785    
 2 19.35 2.962692 19.35499957    
 3 19.34 2.962175 19.34499957    
 4 19.33 2.961658 19.33499957    
 8 19.32 2.961141 77.29999828    
 12 19.31 2.960623 77.25999827    
 24 19.3 2.960105 231.6599948 463.2404 206.4747637 0.554281603 
29 0.02 20.71 3.030617 0    
 0.08 20.7 3.030134 1.242299976    
 0.25 20.69 3.02965 3.518149932    
 0.5 20.68 3.029167 5.171249899    
 1 20.67 3.028683 10.3374998    
 2 20.66 3.028199 20.6649996    
 3 20.65 3.027715 20.6549996    
 4 20.64 3.027231 20.6449996    
 8 20.63 3.026746 82.53999838    
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 12 20.62 3.026261 82.49999838    
 24 20.61 3.025776 247.3799951 494.6542 178.4910445 0.639159946 
30 0.02 18.07 2.894253 0    
 0.08 18.06 2.8937 1.083899972    
 0.25 18.05 2.893146 3.069349922    
 0.5 18.04 2.892592 4.511249885    
 1 18.03 2.892037 9.017499769    
 2 18.02 2.891482 18.02499954    
 3 18.01 2.890927 18.01499954    
 4 18 2.890372 18.00499954    
 8 17.99 2.889816 71.97999815    
 12 17.98 2.88926 71.93999815    
 24 17.97 2.888704 215.6999944 431.347 210.4659732 0.512072696 
31 0.02 10.31 2.333114 0    
 0.08 10.3 2.332144 0.618299951    
 0.25 10.29 2.331173 1.750149862    
 0.5 10.28 2.3302 2.571249797    
 1 10.27 2.329227 5.137499594    
 2 10.26 2.328253 10.26499919    
 3 10.25 2.327278 10.25499919    
 4 10.24 2.326302 10.24499919    
 8 10.23 2.325325 40.93999674    
 12 10.22 2.324347 40.89999674    
 24 10.21 2.323368 122.5799902 245.2622 91.6330655 0.6263873 
      MEAN AUC 
DECREASE 
0.59969401 
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      MEDIAN 
AUC 
DECREASE  
0.538914405 
 
Define 
 
Circuit Circuit/Control ID 
Time Time (h) 
Conc Concentration (mg/L) 
lnConc Natural log of concentration 
AUC log Logarithmic calculation of AUC for each time interval 
= (t2-t1) * (C2-C1) / ln (C2 / C1) 
Where t = time, C = concentration 
AUC Base Total AUC assuming no extraction at 24h 
=sum of AUC for each time interval 
AUC Circuit Total AUC for each Circuit at 24h 
=sum of AUC for each time interval (from Appendix 4.1) 
Relative 
Decrease in 
AUC 
Decrease in AUC in circuit relative to AUC if no extraction 
=(AUC Base – AUC Circuit) / AUC Base) 
Circuit Subject ID 
Time Time (h) 
Conc Concentration (mg/L) 
lnConc Natural log of concentration 
AUC log Logarithmic calculation of AUC for each time interval 
= (t2-t1) * (C2-C1) / ln (C2 / C1) 
Where t = time, C = concentration 
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AUC Circuit Total AUC for each Circuit at 24h 
=sum of AUC for each time interval 
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4.3 AUC0-24 Calculations for micafungin ex vivo controls 
 
Circuit Time Conc lnConc AUC 
Log 
AUC 
Control 
202 0.02 57.6 4.053523 0  
202 0.08 58.85 4.074992 3.493366  
202 0.25 57.37 4.049521 9.878166  
202 0.5 55.72 4.020339 14.13525  
202 1 55.17 4.010419 27.72227  
202 2 55.34 4.013496 55.25496  
202 3 53.64 3.982295 54.48558  
202 4 52.64 3.963476 53.13843  
202 8 38.76 3.657389 181.386  
202 12 38.1 3.640214 153.7162  
202 24 33.56 3.513335 429.3841 982.5944
203 0.02 67.01 4.204842 0  
203 0.08 65.65 4.184338 3.979661  
203 0.25 67.25 4.208417 11.29595  
203 0.5 66.28 4.193888 16.69096  
203 1 68.35 4.224642 33.65485  
203 2 67 4.204693 67.67276  
203 3 63.7 4.154185 65.33611  
203 4 61.62 4.120986 62.65425  
203 8 53.13 3.972742 229.0806  
203 12 46.91 3.848231 199.8219  
203 24 33.12 3.500137 475.3894 1165.577
204 0.02 36.75 3.604138 0  
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204 0.08 35.96 3.582407 2.181214  
204 0.25 35.05 3.556776 6.03552  
204 0.5 35.17 3.560193 8.777491  
204 1 35.56 3.571221 17.68232  
204 2 36.23 3.589888 35.89396  
204 3 32.08 3.468233 34.11294  
204 4 31.26 3.442339 31.66823  
204 8 28.29 3.342508 119.0012  
204 12 26.42 3.274121 109.3774  
204 24 23.01 3.135929 296.1089 660.8391
 
 
Define 
 
Circuit Circuit/Control ID 
Time Time (h) 
Conc Concentration (mg/L) 
lnConc Natural log of concentration 
AUC log Logarithmic calculation of AUC for each time interval 
= (t2-t1) * (C2-C1) / ln (C2 / C1) 
Where t = time, C = concentration 
AUC Control for each Control at 24h  
=sum of AUC for each time interval 
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4.4 Relative decrease in AUC0-24 for micafungin controls 
 
Circuit Time Conc lnConc AUC 
Log 
AUC 
Base 
AUC Control Relative 
Decrease 
in AUC 
202 0.02 57.6 4.053523 0    
202 0.08 57.59 4.053349 3.4557    
202 0.25 57.58 4.053175 9.78945    
202 0.5 57.57 4.053002 14.39375    
202 1 57.56 4.052828 28.7825    
202 2 57.55 4.052654 57.555    
202 3 57.54 4.05248 57.545    
202 4 57.53 4.052307 57.535    
202 8 57.52 4.052133 230.1    
202 12 57.51 4.051959 230.06    
202 24 57.5 4.051785 690.06 1379.276 982.5944 0.287602 
203 0.02 67.01 4.204842 0    
203 0.08 67 4.204693 4.0203    
203 0.25 66.99 4.204543 11.38915    
203 0.5 66.98 4.204394 16.74625    
203 1 66.97 4.204245 33.4875    
203 2 66.96 4.204095 66.965    
203 3 66.95 4.203946 66.955    
203 4 66.94 4.203797 66.945    
203 8 66.93 4.203647 267.74    
203 12 66.92 4.203498 267.7    
203 24 66.91 4.203348 802.98 1604.928 1165.577 0.273752 
204 0.02 36.75 3.604138 0    
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204 0.08 36.74 3.603866 2.2047    
204 0.25 36.73 3.603594 6.24495    
204 0.5 36.72 3.603322 9.18125    
204 1 36.71 3.603049 18.3575    
204 2 36.7 3.602777 36.705    
204 3 36.69 3.602504 36.695    
204 4 36.68 3.602232 36.685    
204 8 36.67 3.601959 146.7    
204 12 36.66 3.601686 146.66    
204 24 36.65 3.601413 439.86 879.2934 660.8391 0.248443 
      MEAN AUC 
DECREASE 
0.269932 
      MEDIAN 
AUC 
DEACREASE  
0.248443 
 
Define 
 
Circuit Circuit/Control ID 
Time Time (h) 
Conc Concentration (mg/L) 
lnConc Natural log of concentration 
AUC log Logarithmic calculation of AUC for each time interval 
= (t2-t1) * (C2-C1) / ln (C2 / C1) 
Where t = time, C = concentration 
AUC Base Total AUC assuming no extraction at 24h 
=sum of AUC for each time interval 
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AUC Circuit Total AUC for each Control at 24h 
=sum of AUC for each time interval (from Appendix 4.1) 
Relative 
Decrease in 
AUC 
Decrease in AUC in control relative to AUC if no extraction 
=(AUC Base – AUC Control) / AUC Base) 
 
 
 
